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ABSTRACT 
B-ceU chronic lymphocytic leukaemia (B-CLL) results from a clonal accumulation of 
CD5+ve B- lymphocytes. This expansion of B-lymphocytes is due to increased proliferation 
and extended survival secondary to decreased apoptosis. Both proliferation and apoptosis are 
regulated by a group of soluble proteins, termed cytokines, which are secreted by cells and 
play a key role in the regulation of immunological responses. In view of this, the role of 
cytokines in the pathogenesis ofB-CLL was studied. 
Interleukin 4 (IL-4) is an anti-apoptotic cytokine which up-regulates bcl-2 in malignant B-
lympbocytes. Peripheral blood samples, from untreated B-CLL patients were investigated, 
together with a group of ten heaJtby controls. Flow cytometric analysis was used to quantify 
(i) the expression of intracellular IL-4 by CD19+ and CD3+ lymphocytes, and (ii) IL-4R 
expression of CD 19+ and CD3+ lymphocytes. The proportion of CD 19+ve lymphocytes 
expressing intracellular IL-4 was significantly higher in patients with B-CLL than in controls 
(p=0.03). Simi larly, the proportion of CD3+ve lymphocytes expressing intracellular IL-4 was 
significantly higher in B-CLL patients than controls (p=O.Ol). No significant difference was 
found in the overall proportion of CD 19+ve lymphocytes expressing IL-4R between patients 
and controls. However, the proportion of CD3+ve lymphocytes . expressing IL-4R was 
significantly greater in patients than in controls (p=O.OO 1 ). 
A number of anti-apoptotic cytokines, including IL-2, IL-4, IL-7, IL-9 and IL-15 share a sub-
unit known as the common gamma chain (ye). A nested RT-PCR technique was used to 
analyse fi1ll-length ye receptor RT-PCR products in B and T-lymphocytes fro m patients with 
B-CLL and controls. The presence and concentration of full size IL-2, IL-4, IL-7, IL-9, IL- 15, 
ye, IL-4R a chain, as well as IL-2 delta 2 (IL-282) and IL-4 delta 2 (JL-282) spliced RT-PCR 
products were measured. IL-2 full-length RT-PCR products (using exon 1-4 amplifiers) were 
present ta a significantly more present at higher concentration in patient when compared to 
control B-lymphocyte samples (p=0.04). No significant difference was found between IL-4 
full -length RT-PCR products in patients than in controls. IL-7 RT-PCR products were present 
at higher concentration in patient B- and T-lymphocytes than in controls (p=0.034 and 
p=0.041 respectively). IL-15 RT-PCR products were present at a lower concentration in 
patient than in control T-lymphocytes (p=O.OOI). IL-2 and IL-4 wild RT-PCR products (using 
exon 1-3 amplifiers) were present at significantly higher concentration in patient B-
lymphocytes (p=O.OOOI and p=0.026 respectively). The concentration of IL-482 and the IL-
4Ra RT-PCR products were significantly lower in patient than in control T-lymphocytes 
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(p=O.OOOI for both). There was a significant difference in the concentration of the IL-2 82 
RT-PCR products between patient and control B-lymphocytes (p=0.029). 
fn view of the above results, the apoptotic effect of the addition of IL-2 and IL-4 antisense 
oligonucleotides (ONs) to B-CLL and control cells was investigated. ONs were designed to 
block wild type IL-2 and IL-4 mRNA transcript expression as well as their spliced variants IL-
282, and IL-482. The percentages of CD19+/Annexin V+, CD3+/Annexin V+ or Propidium 
iodide (PI)+/Annexin V+ cells, as well as the percentage of CD19+ve and CD3+ve cells 
expressing intracellular IL-2, was measured by flow cytometry. The results demonstrated that, 
when B-CLL cells were incubated with IL-2 ONs, the percentage of CD19+/Annexin V+, as 
well as PI+/Annexin V+, lymphocytes were significantly increased (p=0.002). The addition of 
IL-4 and control antisense ONs had a similar, but not statistically significant effect. This pro-
apoptotic effect was not seen in B-CLL CD3+ve lymphocytes. ELISA analysis showed that 
addition of JL-2 ONs decreased the level of IL-2 protein secreted by PI-lA-stimulated B-CLL 
cells but the addition of IL-4 antisense ONs increased the level of IL-4 protein. Finally, 
addition of ONs decreased the percentage of CD 19+ve and CD3+ve B-CLL lymphocytes 
expressing intraceUular IL-2 and IL-4. 
In summary, the results obtained in this study imply that IL-2, IL-4, IL-7 and IL-15 may play a 
role in the survival of malignant B-lymphocytes in B-CLL. 
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CHAPTER 1: INTRODUCTION 
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1.1. NATURE OF HAEMATOLOGICAL MALIGNANCIES 
Blood is the very essence of life, the "circulatory computer tape" that carries various coded 
cellular and humoral messages in order to protect the organs and tissues of the body against 
foreign antigens (Page, 1972). However for a very long time, nothing was known about its 
real purpose and function, until the construction of the first microscope by Antonj van 
Leeuwenhoek (1632-1723), when red blood cells were described as "ruddy globules". 
Subsequently, William Hewson (1739-1774) discovered lacteal and lymphatic vessels in birds 
and reptiles, and he was the first to discover red blood cells and leukocytes. In addition, he 
noticed that the cellular content of the lymph was nucleated and believed that these cells were 
formed in the lymph nodes. He also showed that the thymus discharges huge numbers of cells 
into a thoracic duct and into the blood (Hewson, 1774). 
Using the newly discovered microscope, various types ofwhite cells in the blood were further 
described. This is attributed to Paul Ehrlich (Ehrlich, 1880). He drew the distinction between 
lymphocytes and other leukocytes by emphasising their different origins and proposed that 
lymphocytes originate in lymph nodes and spleen while other classes of leukocyte are 
produced in the bone marrow. He also developed a theory of antibody production (Ehrlich, 
1900). However, the rather uniform appearence of lymphocytes did not reveal their 
astonishing diversity until the mid-1960s, when they were described as thymus derived T-
lymphocytes and ···bursa equivalent .. or thymus independent 8-lymphocytes (Roitt et al. 1964). 
Equally long and laborious is the story of haematological malignancies. Initially, described as 
a pathological curiosity, leukaemia was almost simultaneously discovered by Virchow in 
Berlin (Virchow, 1845) and Bennett in Edinburgh (Bennett, 1845), although others reported 
seeing patients with large spleens and characteristic blood changes. Both saw the changes in 
the blood of leukaemic patients but described them differently. Bennett called the condition, 
"pyemia", meaning blood containing pus. Virchow however, could find no inflammation that 
might lead to the formation of the pus. He described the cell as "white cells" which, 
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translated to Greek later became known as leukaemia. It was soon apparent that leukaemia is 
not one disease. Virchow himself proposed to subdivide leukaemia into two forms. One was 
"splenic" or "lienal" leukaemia, characterised by great swelling of the spleen and the other 
form characterised by the enlargement of the lymph nodes was called "lymphatic" leukaemia. 
Ebstein in 1889 (Ebstein, 1889) proposed to further subdivide leukaemia into acute and 
chronic forms. The term acute and chronic lymphatic is still in use for the classification of 
leukaemias. Leukaemia is a malignant neoplasm, the term used to describe abnorrnaJ cellular 
growth. The term ' malignant' is used because ofthe ability of the abnormally dividing cells to 
invade normal tissues and spread to distant sites in the host. Malignant neoplasms have 
abnormal nuclear divisions and chromosomes. 
Cancer can be divided into three broad subgroups: carcinomas, sarcomas and leukaemias and 
lymphomas. The leukaemias and lymphomas arise in the blood-forming cells in the lymph 
nodes and bone marrow and then invade the mononuclear phagocytic system and remaining 
body structures. The development of many cancers is a co-ordinated and logical process with 
a multi-factorial aetiology. 
1.2. CLASSIFICATION OF HAEMATOLOGICAL MALIGNANCIES 
Chronic lymphoproliferative diseases include different entities characterised by distinct 
clinico-pathological features (Bennet et al. 1989). Over the past 30 years, the classification 
of haematological malignancies has undergone continuous change. Described below is a 
Revised European-American Classification of Lymphoid Neoplasms (R.E.A.L) of the 
lymphoproliferative disorders (Harris et al. 1994). 
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1.2.1. Lymphoproliferative disorders 
• Lymphoblastic leukaemias 
• Mature (peripheral) 8-ceU tumours 
• Mature (peripheral) T -cell disorders 
• Hodgkin's lymphoma 
1.2.1.1. Sub-division of lymphoproliferative disorders 
Lymphoproliferative disorders can be further sub-divided. With the revolution of molecular 
biological techniques as well as the application of multiparametric and quantitative flow 
cytometry, which has improved the diagnostic utility of immunophenotypic analysis, more 
thorough analyses ofT- and B-lymphocyte monoclonality, chromosomal abnormalities and 
phenotypes are possible (Rothe et al. 1996). 
Mature (peripheral) 8-cell tumours: 
• Chronic lymphocytic leukaemia 
• Atypical CLL 
• Mantle Cell Lymphoma 
• 8-prolymphocytic Leukaemia 
• Marginal Zone B-cell Lymphoma 
• Large cell transformation of CLL 
• Follicular Lymphoma 
• Non-endemic Burkitt's Lymphoma 
• Diffuse Large 8 -cell Lymphoma 
• Plasma Cell Myeloma, Plasmacytoma 
• Hairy Cell Leukaemia 
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1.3. B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) 
1.3.1. General description 
B cell chronic lymphocytic leukaemia (B-CLL) was first described in 1903 by Turk (Turk, 
1903). Minot and Isaacs wrote about its clinical features in 1924 and Dameshek further 
described it in 1967 (Minot et al. 1924 and Dameshek, 1967). Since then knowledge of this 
disease has expanded considerably. B-CLL is the most common single haematological 
malignancy, accounting for more than 25% of all leukaemias in the Western world. It is far 
less common in the Far East. Its incidence among all adult leukaemias ranges from 2.5% in 
Japan to 38% in Denmark (Brinker, 1982). In West Africa, two peaks among the low rates of 
B-CLL are observed in women aged 40-44 and in males aged 70 and over. In general, B-CLL 
is rare before the age of 40, peaks around 60 and affects twice as many males than females. 
Elderly patients tend to have a more advanced form of the disease. 
The cause of the disease is unknown, but viruses and environmental factors are suspected. B-
CLL has been linked to several occupations and exposures. Increase in B-CLL incidence has 
been reported among farmers engaged in soybean production, cattle raising and herbicide use 
(Burmeister et al. 1982 and Blair et al. 1985). Rubber manufacturers as well as asbestos 
workers also have an increased incidence of B-CLL (Kagan et al. 1983). Many cases are 
diagnosed following a routine blood test. Of all the leukaemias, B-CLL has the highest 
familial incidence, with first-degree relatives having a 2 to 7-fold higher chance of developing 
the disease (Capalbo et al. 2000). Since Japanese individuals, including those who migrated to 
Hawaii, have a much lower incidence of the disease there is speculation that genetic 
influences are stronger than environmental influences (Capalbo et al. 2000). 
Although classified as a proliferative disorder, in the majority of patients, B-CLL is a disease 
with little evidence of an aggressive proliferation of the abnormal lymphocytes at least in 
early stage (Binet et al. 1981 , Baccarini et al. 1982, and Catovsky et al. 1989). The malignant 
lymphocytes are the result of a clonal expansion which has been arrested at an early stage of 
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differentiation and as a result appears cytologically mature but biologically immature 
(Dameshek et al. 1967, Dighiero et al. 1991 ). The cells are an expansion of a rare CD5+ve B-
lymphocyte population, normally seen in the mantle zone of normal peripheral lymph nodes 
(Bannerji, 2000). This leads to an accumulation of lymphocytes, a progressive enlargement of 
tumour burden and eventually the death of the host. The progressive accumulation of 
lymphocytes starts in lymph nodes and/or bone marrow gradually expands to most of the 
haemopoietic organs (Dameshek et al. 1967). Involvement of other organs such as central 
nervous system or peripheral nerves, skin (Bonvalet et al. 1984), lungs (Palosarri et al. 1986) 
kidneys (Dabbs et al. 1986), and bones and lachrymal glands (Hansen, 1973) is also possible 
but rare at diagnosis. 
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Figure 1.1: Morphology of normal and 8-CLL lymphocytes 
A) Normal blood film B) B-CLL blood film 
C) Normal bone marrow stain D) B-CLL bone marrow stain 
Normal and B-CLL peripheral blood and trephine biopsy stain. A) Normal peripbtnl blood May-Grunwald-
Giemse (MGG) stain: Gran=granulocytes, Eo=eosinophi~ Mono=mmocytes, Lymph, lymphocytes B) B-CLL 
stain: periphtnl blood film shows lymphocytes with rims of cytoplasm, coarse condensed nuclear chromatin and 
rare nucleoli C) Normal bone marrow stain: Nor-normoblast, Gran=granulocyte, My=myelocyte, PC=plasma 
cell, Meta=metarnyelocyte D) Bone marrow trephine biopsy: infiltration by small leukaemic 8-CLL cells. 
Adapted from Hoftbrand et al. l993 and Haematological malignancy Diagnostic Service (HMDS) classification, 
Website. 
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1.3.2. Clinical features of B-CLL 
In many patients, symmetrical enlargement of superficial cervical and axilliary lymph nodes 
is found, but the nodes are usually discrete, smooth, mobile and non-tender and vary from 1 
to 2 cm. It is possible to document lymph enlargement in the hilar regions on routine 
radiography, or in the retroperitoneal regions by ultrasound or CT scanning. Increasing 
tiredness and excessive sweating or night sweats are present with malaise and weight loss. 
Splenomegaly and hepatomegaly are found in 50% of the patients and an enlarging abdomen 
could be the primary complaint. Due to reduced humoral and cellular responses, patients 
experience a greater tendency to bacterial and viral (mainly herpes zoster and simplex) but 
also mycobacterial and fungal infections than normal healthy individuals (Bannerji, 2000). 
Hypogammaglobulinaemia, specific antibody deficiency, depleted cell-mediated immunity, 
neutropenia and poor opsonisation are the main causes of immunodeficiency (Chapel et al. 
1987). A severe chest infection or pneumonia could be the first manifestation of B-CLL 
(Bannerji, 2000). 
Associated autoimmune phenomena are related to the presence of autoantibodies directed 
mainly against blood components (Hamblin et al. 1986). This can lead to the development of 
autoimmune haemolytic anaemia or thrombocytopenia. Autoimmune haemolytic anaemia 
occurs in I 0-25% of patients at some time during the course of the disease (Sthoeger et al. 
1993). With time, anaemia, thrombocytopenia and neutropenia develop as a result of bone 
marrow failure. 
1.3.3. Laboratory findings 
The diagnosis should be considered in any patient in whom the lymphocyte count consistently 
exceeds 4.5 x I 09 / I. The peripheral blood film reveals a lymphocytosis, predominantly due to 
a population of small lymphocytes with a high nuclear to cytoplasmic ratio similar in 
appearance to normal, mature peripheral blood lymphocytes. The autoantibodies described 
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are warm reactive polyclonal IgG and display activity against monomorphic antigens of the 
rhesus system (Dighiero et al. 1988). Reduced concentrations of immunoglobulins are found 
and this becomes more marked with advancement of the disease. This decline starts with lgA 
levels. Monoclonal bands, often I gM (M band) are seen in less than 1 0% of cases. The 
appearance of an M band and discovery of free light chains in the urine (Bence-Jones 
proteinuria) may be an indication of transformation of the disease. Bone marrow examination 
is an essential investigation in B-CLL. The aspirate is useful to confirm morphological 
features particularly in-patients with low white blood cells (WBC) counts and to assess 
haematopoiesis. B-CLL does not transform into acute leukaemia, although immunoblastic 
transformation may occur as a terminal lymphoma (Richter syndrome) (Bannerji, 2000). 
1.3.4. Diagnosis of B-CLL 
B-CLL is diagnosed by the presence of an absolute and persistent lymphocytosis greater than 
5xl09 lymphocytes per Litre with bone marrow infiltration by these cells equal to or greater 
than 30% of all nucleated cells (Bennet et al. 1987, Cheson et al. 1988, Bannerji, 2000). 
Morphologically, the lymphocytes in the blood films are smal~ showing scanty cytoplasm and 
a characteristic pattern of nuclear chromatin clumping (Bannerji, 2000). Some variation in 
size and shape may be seen and occasionally cells with immature or even blast cell 
characteristics may be noted. A feature of the blood film is also the appearance of 'smear 
cells' . Smear cells are artefacts due to rupture of the nuclear and cell membranes during 
preparation ofthe blood film (Figure 1.1). However, the proportion of smear cells in the blood 
film correlates directly with the lymphocyte count. Lymphoid infiltration described as 
nodular, interstitial mixed (nodular and interstitial) and diffuse coincides with disease 
progression (Rozman et al. 1984, Pangalis et al. 1988). 
At least 70% of cases presenting with lymphocytosis are identified as B-CLL (Catovsky, 
1997). Their irnmunophenotype typically shows a low expression of surface lgM and lgD 
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with clonal restricted Light chains (Bannerji, 2000). B-lymphocyte antigens like CD 19, CD20 
and CD23 (the hallmark ofthe disease with expression correlating with the disease prognosis) 
are eo-expressed with CD5 in almost all cases (Kneitz et al. 2000). CD 10 and CD22 are 
negative, whereas CD 11 c and CD25 may be expressed but in most cases are only weakly 
positive (Dameshek et al. 1967, Knapp et al. 1989, Ginaldi et al. 1998). In general, antigen 
density is weaker than on normal lymphocytes. The surface immunoglobulin (slg) is often 
IgM with frequent eo-expression of IgD. Infrequently IgD predominates. Tbis is shown to be 
monoclonal because of the expression of one form of light chain, either kappa (K) or lambda 
(A.) (Dighiero et al. 1993). 
CD38 is a transmembrane glycoprotein expressed on the surface of leukaemic cells m a 
signjficant percentage of patients with B-CLL (40% of the patients). Patients with high 
expression (20% or more) have significantly shorter survival times (Ibrahim et al. 2001 ). 
Malignant B-lymphocytes were considered antigen-inexperienced 'virgin' lymphocytes but 
there is some evidence that at least half of these cases represent expansion of previously 
triggered, post germinal centre (GC) 'memory' B-lymphocytes. This is based on the presence 
of somatic mutations in the heavy (H) chain variable region (V) genes (Darnle et al. 1999). 
1.3.5. Malignant 8 -lymphocyte markers and adhesion molecules 
1.3.5.1. CD5 
This is a marker expressed on the majority of peripheral blood T-lymphocytes and a sub-
population of B-lymphocytes. In 1991 , a new nomenclature for CD5+ve B-lymphocytes was 
suggested. B-lymphocytes expressing the CD5 antigen were defmed as B 1 lymphocytes and 
conventional B-lymphocytes as 8 2 (Kantor, 199 1 ). 
The CD5 molecule is tyrosine phosphorylated and eo-precipitates fo llowing cross linking of 
the 8-cell receptor (Lankester et al. 1994). In adult humans, 5% to 30% of the circulating B-
lymphocytes are B 1, with fewer than 1 0% in the spleen and less than 30% in lymph nodes 
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(Ladyard et al. 1987). The population of CD5+ve B-lymphocytes use a restricted set of lg 
genes and produce natural auto antibodies (mostly IgM) against single stranded (ss) DNA or 
IgG (Hardy et al. 1994). CD27 has been shown to be the native ligand for CD5 and is 
expressed on normal and leukaernic cells (Garllard et al. 1994). It was hypothesised that 
CD5+ve B-lymphocyte antigen presenting cells could interact with CD27 on the B2 
lymphocytes and this would augment the signal delivered through the specific antigen 
receptor by thymus-independent antigens (Gordon, 1994). Mice deficient in CD5+ve B-
lymphocytes are not able to mount responses to thymus independent antigens (Gordon, 1994). 
1.3.5.2. CD19 
CD19 is expressed during all stages ofB-cell differentiation and maturation, except on plasma 
cells (Tedder et al. 1989 and Zhou et al. 1 995). It is also present on follicular dendritic cells, 
but is not found on T -lymphocytes or normal granulocytes. CD 19 plays a role in regulation of 
B-lymphocyte proliferation. It associates with the complement receptor 2 (CD21), CD81 , 
Leu-13 and I or MHC class 11 to form a signal transduction complex on the surface of B-
lymphocytes (Bradbury et al. 1992 and Tedder et al. 1994). CD19 closely resembles the T -ceU 
receptor and belongs to the Ig superfamily. 
1.3.5.3. CD20 
CD20 is expressed on pre-B-lymphocytes, resting and activated B-Iymphocytes but not on 
plasma cells. Low level of expression is observed on a small subset of normal circulating T-
lymphocytes (Genot et al. 1991). The CD20 mo lecule is involved in the regulation of B 
lymphocyte activation. In malignant B-CLL cells, CD20 is hyperphosphorylated when 
compared to CD20 on normal resting B-lymphocytes. However, its expression on malignant 
B-lymphocytes is relatively less intense (Genot et al. 1991). 
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1.3.5.4. CD21 
CD21 is a receptor for the C3d complement fragment and for Ebstein-Barr virus. It is 
expressed on mature B-lymphocytes, follicular dendritic cells and some epithelial cells. It is 
also weakly expressed on a subset ofT lymphocytes and thymocytes. CD21 plays a role in B-
lymphocyte activation and proliferation (Timems et al. 1995). Normal and malignant B 
lymphocyte when activated via CD21 increase their DNA synthesis and the level of soluble 
CD 19 is increased in B-CLL (Lowe et al. 1989). 
1.3.5.5. CD23 
CD23 is identical to the low affmity receptor for IgE (FceRII). It is mainly expressed on 
mature B-lymphocytes, mantle zone B-lymphocytes and follicular dendritic cells, but not on 
proliferating cells in the germinal centre. In fact its expression is rapidly lost upon isotype 
switching (Sarfati et al. 1989). CD23 plays a role in the regulation of JgE responses. Two 
spliced variants of CD23 (CD23 A and CD23 B) exist (Y okota et al. 1988). CD23 A is 
expressed on B-lymphocytes and CD23 B on a variety of cell types and its expression is IL-4 
dependent. The level of soluble CD23 antigen is increased in B-CLL (Lowe et al. 1989) and 
its expression is most probably dependent on other cell types (Fournier et al. 1995 and 
Fournier et al. 1992). 
1.3.5.6. CD24 
CD24 is expressed on the surface of B-lymphocytes, granulocytes and most B-cell lines. 
CD24 may play a role in the regu lation ofB-cell proliferation and maturation. 
1.3.5.7. CD25 
CD25 is expressed on activated T and B-lymphocytes. CD25 associates with the p75 pchain 
(CD122) and the common y chain (CD123) to form the high affinity IL-2 receptor complex. 
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1.3.5.8. Adhesion molecules 
It was found that the expression of L-selectin (CD62) is significantly increased in B-CLL but 
not in other cases. Also, the beta-1 integrin VLA-4 (CD49d-CD29) is expressed only in a 
minority of B-CLL cases and the beta-2 integrin LFA-1 (CD11a/CD18) was shown to be a 
marker ofbad prognosis (Baldini et al. 1992). The presence ofhigh CD44 density predicts for 
longer survival compared to cases with low CD44 density (Csanaki et al. 1998). An increased 
serum level of intracellular adhesion molecule 1 (ICAM-1) identifies stage B patients with 
poorer survival and stage A patients with higher risk of progression (Molica et al. 1997). 
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Figure 1.2: 8-lymphocyte differentiation 
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chain 
A. light 
chain 
TdT 
MHC I I 11 
CD19 
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CD23 
The sequence of immunoglobulin gene rearrangement, antigen and immunoglobulin expression during B-
lymphocyte development. The immunoglobulin heavy-chain and K and 1.. light-chain genes occur on 
chromosomes 14, 2 and 22 respectively. CD 19 is expressed during all stages of B-lymphocyte differentiation and 
maturation but not on plasma cells. CD20 is expressed on pre-B-Iymphocytes, resting and activated B-
lymphocytes but no on plasma cells. CD23 is mainly expressed on mature B-lymphocytes and mantle zone B-
lymphocytes. CD22 is also a feature of very early B-lymphocytes. TdT=terminal deoxynucleotidyl transferase, 
K= kappa, A.=lan1bda 
Adapted from Hoffbrand et al. 1993. 
41 
1.3.6. Animal models of B-CLL 
An animal model for B-cell chronic lymphocytic leukaemia is the aged H-2 congenic NZB 
(New Zealand Black), NZW (New Zealand White) and (NZB x NZW) Fl mouse strain (Marti 
et al. 1995). The spleens of all the congenic strains, homozygous for H-2z locus, contain 
extremely high frequencies of CD5+ve B-lymphocytes. These cells proliferate in a 
monoclonal and polyclonal fashion and B-CLL develops in some cases. The high CD5+ve B-
lymphocytes frequencies are apparently controlled by the homozygosity of a locus or cluster 
of loci closely linked to the H-2z complex (Okada et al. 1991 ). B-CLL in these mice has a 
surface phenotype typical of CD5+ve B lineage cells, which express high levels of proto-
oncogene bcl-2. This was also observed in pre-malignant B-lymphocytes in the aged mice 
(Okamoto et al. 1993). 
A similar condition to human B-CLL was described in cattle. Bovine leukaemia virus (BL V) 
infection causes persistent lymphocytosis in cows (True blood et al. 1998). BL V -induced 
persistent lymphocytosis (PL) is characterised by a polyclonal expansion of CD5+ve 
lymphocytes (Trueblood et al. 1998). In this condition, increased T -lymphocyte expression of 
IL-2 contributes to the development and possibly maintenance of a persistent lymphocytosis. 
There is also some evidence suggesting that abnormal expression of GM-CSF receptor could 
play an important role in PL (Murakami et al. 1999). 
Permanent, EBV -negative, B-CLL lines were also established from the peripheral blood of 
patients with B-CLL. These cells can grow as suspensions in liquid culture, express lgG 
lambda and other B lymphocyte markers and show Ig heavy chain and light chain 
rearrangements. The lymphocytes have been injected subcutaneously into severe combined 
immune deficient (SCID) mice and the growing tumour used as a xenograft model to test new 
chemotherapeutic agents (Mohammad et al. 1996). 
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1.3.7. Normal counterpart of the malignant 8-CLL B-lymphocytes 
B-lymphocytes found at the edge of germinal centres and within the mantle zone of secondary 
follicles are considered to be normal counterparts of malignant B-lymphocytes (Caligaris-
Capio et al. 1985). However further work has shown that many specific differences exist 
between normal CD5+ve lymphocytes and malignant B-lymphocytes. Furthermore, a 
substantial number of B-lymphocytes in 20-week-o ld foetal lymph nodes and spleen express 
the CD5 marker (Bofil et al. 1985, Antin et al. 1986). They share with malignant B-
lymphocytes lectin non-responsiveness and the inability to cap slg. 
1.3.8. Chromosomal abnormalities 
Different neoplasms are characterised by karyotypic changes in tumour cells that are unevenly 
distributed throughout different chromosomes, regions and bands. After the discovery of the 
Philadelphia chromosome in CML in 1960 by Novell and Hungeford it became apparent that 
chromosomal changes in human cancers are well organised events. 
Conventional cytogenic techniques demonstrate clonal chromosome abnormalities in about 
50% of patients and molecular cytogenetic techniques in 80% of the patients (Monserrat et al. 
1997, Dohner et al. 1998). Before 1993, the main recurrent cytogenetic alteration described in 
B-CLL was trisomy of chromosome 12 (Bienz et al. 1993). Karyotypic abnormalities have 
been described most of them involving chromosomes 6, 11 , 12, 13 and 14. These are now 
found in 50% of cases studied. Trisomy of the chromosome 12 (10-15% of cases) is 
associated with a poor prognosis and atypical B-CLL (Han et al. 1984a, Juliusson et al. 
1990a, Juliusson et aJ. 1990b). Several oncogenes are found on chromosome 12 (ATFI, 
ETV6, K-ras, and MGF) but none seem to be important in the pathogenesis of 8-CLL. 
Trisomy 12 is found only in malignant B-lymphocytes suggesting the change occurred after 
commitment to B-lymphocyte lineage (Han et al. 1984 b, Knuutila et al. 1986, Escudier et al. 
1993). Structural modifications ofthe long arm of chromosome 13 at or near band 13q14 (15-
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20% of cases) are the most common. In many patients, an abnormality involving band 13q14 
was the only chromosomal alteration (Peterson et al. 1992). Chromosome 14 t( 11; 14) 
abnormalities are associated with a poor prognosis (Que et al. 1993). Other chromosomal 
abnormalities include chromosome 6 deletions, where breakpoints are very heterogeneous, 
although q 15, q23 and q25-27 are the most frequently reported. Monosomies of chromosome 
17 and 18 are seen rarely. 
1.3.9. Staging ofB-CLL 
Based on the assumption of slow progression, the disease has been divided into five stages 
(Rai et al 1975) (Table 1.1 ). Rai staging system takes the view that malignant lymphocytes 
first accumulate in the blood and bone marrow then in lymph nodes and spleen, and finally 
result in bone marrow failure. 
Table 1.1: Rai system of staging 8-CLL 
Stage 0 
Stage I 
Lymphocytosis (greater than 5xl06/l) in blood and bone marrow, no 
anaemia or thrombocytopenia or physical signs 
Lymphocytosis with palpable adenopathy. No hepatosplenomegaly, 
anaemia or thrombocytopenia. 
Stage li Lymphocytosis with hepatic and/or splenic enlargement, with or without 
lymph node enlargement and without anaemia and thrombocytopenia 
Stage Ill Lymphocytosis with anaemia (haemoglobin < than 11 g/dl), irrespective of 
physical signs 
Stage IV Lymphocytosis with thrombocytopenia (platelets < 100x109/l) with or 
without lymphadenopathy, hepatomegaly, splenomegaly or anaemia 
Binet staging modified the Rai system (Table 1.2). The International Workshop on CLL 
accepted this latter proposal in 1981. Patients are staged according to the number of the organs, 
44 
involved, considering each of the following nodal areas as one: neck, axillae, inguinal regions 
spleen and liver. 
Table 1.2: Binet system of staging B-CLL 
Stage A 
Stage B 
Stage C 
No organ enlargement or up to two nodal areas, no anaemia or 
thrombocytopenia 
Patients have three involved areas, no anaemia or thrombocytopenia 
Anaemia (haemoglobin (Hb ), 1 Og/dl) and thrombocytopenia (platelets 
<100xl09/l) regardless ofthe number of areas oflymphoid enlargement 
The International Workshop proposed to retain the Rai stages as subgroups for A, as A(O), 
A(I) and A(Il). This is to identify the most benign group of Rai system, stage 0. There is a 
more favourable prognosis in stage A(O). These stages correlate with different prognosis. 
However about 20% of low risk patients will progress to more advanced disease and those 
staging systems are presently unable to predict these evolutions. 
1.3.1 0. B-CLL prognostic factors 
The most significant prognostic feature of the disease is staging by either system. The 
important individual features like Hb, spleen size, lymph nodes or platelet count are already 
incorporated in the staging system. Other factors such as sex (males), age (>70 years), poor 
response to initial therapy or some key laboratory findings, (initial lymphocyte count, 
doubling time ( < 12 months, trisomy 12) also indicate poor prognosis. 
1.3.11. Treatment ofB-CLL 
The National Institute of Health sponsored a Working Group, which has published guidel ines 
for the diagnosis and treatment of B-CLL (Cheson et al. 1996). Treatment depends on the 
stage ofthe disease, with no treatment needed at the stage A{O) (Kalil et al. 2000). For stages 
A(O), A(I) and for A(II) a period of observation may be necessary to establish the pattern of 
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the disease (stability or progression) (Keating, 1999). However, evidence of bone marrow 
failure, symptomatic involvement of lymph nodes or skin, autoimmune anaemia or 
splenomegaly may be indications to start treatment (Zwiebel et al. 1998). In the context of B-
CLL, complete remission (CR) is defined by normalisation of blood and bone marrow, partial 
remission (PR) by the regression of at least 50% of the physical signs, lyrnphocyte counts less 
than 15x I 09 /1 and normal Hb and platelet count. 
Autoimrnune haemolytic anaemia and I or thrombocytopenia are very often controlled by 
corticosteroids, before administering chemotherapy. Alternatively, patients may receive high 
dose immunoglobulins, cyclosporin, splenectomy or low-dose radiation to the spleen 
(Rozman et al. 1995). 
Due to lack of humoral defence against bacterial and viral agents, infectious complications 
are very common in advanced stages of B-CLL. Intravenous irnmunoglobulins (400 mg/kg 
every 3 weeks for 1 year) can significant ly reduce bacterial infections. 
Many drugs and combinations have been used in the treatment ofB-CLL: 
A) Corticosteroids are used as an initial treatment for stage C patients. However, prednisolone 
as a single agent has only a limited effect on B-CLL. Because prednisolone can produce a 
reduction in lymphocytic infiltration of bone marrow that can result in significant 
improvement in cytopenia, it is useful for treatment with advanced stage of disease (Catovsky 
et al. 1991). 
B) Chlorambucil is an alkylating agent, which remains one of the most commonly used drugs 
in B-CLL. It may be helpful for elderly patients with poor performance status and for patients 
who do not tolerate fludarabine (Kalil et al. 2000). It is well absorbed after oral administration 
and produces less side effects such as gastrointestinal upset or alopecia. However, it does 
have a cumulative toxicity. Chlorambucil delays the rate of disease progression but does not 
improve survival (Catovsky et al. 1991 ). 
46 
C) Combination chemotherapy has been attempted in advanced forms of the disease (Kalil et 
al. 2000). The first used was CHOP (cyclophosphamide, vincristine and prednisolone) which 
gave a response rate about 70%. French Co-operative Group studies found that modified 
CHOP therapy produces a higher response rate and better median survival (Hansen et al. 
1991). 
D) Purine analogues such as fludarabine, cladribine and deoxycoformycin have been used in 
B-CLL. Fludarabine inhibits DNA polymerase and ribonucleotide reductase and promotes 
apoptosis of malignant B as well as normal T-lymphocytes and is an acceptable option for 
frrst-line therapy in B-CLL (Kalil et al. 2000). 
E) Splenic irradiation has been used succesfully in B-CLL (Rubin et al. 1981 ). 
F) Splenectomy may be indicated in autoimmune haemolytic anaemia refractory to 
corticosteroids or thrombocytopenia and massive painful splenomegaly (Seymour et al. 
1997). 
G) Allogeneic bone marrow transplantation gives promising results, but is only available to 
patients with matched, related donors. Autologous transplantation of bone marrow purged by 
a mixture of anti-B-cell monoclonal antibodies, after conditioning with cyclophosphamide 
and total body irradiation, produced a high proportion of complete responses (Rabinowe et al. 
1993) 
H) Immune response modifiers are potential therapies of the future. Aberrant expression by 
malignant cells of genes that regulate growth and survival of cells can give rise to "altered-
self ' antigens that could potentially be targeted by the host immune system. In addition, 
tumour cells generally maintain expression of tissue-specific ''differentiation antigens''. Such 
antigens can be used to target tumour cells. 
-Using this passive immunotherapy, monoclonal antibodies specific for tumour associated 
"differentiation antigens" can be administered to patients. CD20 and CD52 are targets for 
such monoclonal antibody therapy (MoAb) (Rawstron et al. 1997 and Nguyen et al 1999). 
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The use of antibody may include unconjugated antibody (anti-CD20), chimeric anti-CD20 
antibody (Rituximab), radiolabelled antibody, and immunotoxins. CD20 expression is limited 
to B-lymphocytes but CD52 occurs on T and 8-lymphocytes as well as monocytes. 
Chimeric/humanised antibodies have been developed against these antigens using the human 
IgG 1 backbone for optimum complement fixation (Multani et al. 1 998). Campath 1-H is a 
humanised antibody directed at CD52. It binds to CD52 and induces antibody-dependent lysis 
of the target cells. Campath therapy has now been approved for patients with B-CLL who 
received alkylating agents, and who failed fludarabine therapy (Osterborg et al. 1997). 
-Interferon-a has no effect on patients with advanced disease and has only a minor effect on 
patients with early disease (O'Brien et al. 1995) 
-Therapeutic vaccination involves introducing modified cancer cells, cancer particles or 
antigen-modified cytotoxic T -lymphocytes to the patient, which in turn provoke an anti-
cancer response. Dendritic cell-based vaccines are gaining popularity and these cells have the 
particular ability to effectively present tumour-associated antigens (T AA) to the immune 
system. Dendritic cells can be loaded with T AA by their natural endocytic capability or by 
genetic modification (Morse et al. 2000). 
-Cancer is a genetic disease and thus gene transfer may correct genetic defects. It can be used 
to selectively kill tumour cells or it may be used to induce host anti-tumour immunity. This 
can be achieved by using vectors as genetic adjuvants. Vectors can encode stimulatory 
cytokines such us lL-2, IL-12 or granulocyte macrophage colony-stimulatory factor (GM-
CSF) or vectors encoding immune stimulatory surface molecules such as 87-1 (CD80) or 
CD40 ligand (CD 154) (8uhmann et al. 1999). Naked DNA vaccines represent an attractive 
approach for generating antigen-specific immunity because oftheir stability and simplicity of 
delivery. However, there are some concerns about DNA vaccines such as integration into host 
genome, cell transformation and limited potency (Hsu et al. 2001). The use of RNA as a 
tumour vaccine has also been proposed and has several potential advantages. Total cellular 
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RNA or mRNA can be utilised and it is not necessary to know the molecular nature of the 
putative tumour antigen(s) (Mitchell et al. 2000, Saens-Badillos et al. 2001). 
-Antisense oligonucleotides are short synthetic, single stranded stretches ofONA molecules that 
can interfere with complementary sequences within target mRNAs. Antisense mediated 
reduction in bcl-2 protein level has been shown to accelerate the rate of death in cultures of pre-
B cell leukaemia, T-ALL or non-Hodgkin B-cell lymphoma. Bcl-2 antisense therapeutics may 
find a role in the practice of clinical oncology (Reed et al. 1997). 
1.3.12. Differential diagnosis 
The differential diagnosis of lymphoproliferative disorders is based on many important 
factors. Physical signs of the disease as well as many laboratory finding have to be taken into 
consideration. Flow cytometry is commonly used to detect the percentage of cells positive or 
negative for a particular antigen as well as the intensity of the antigen on a particular cell 
type. For example, low expression of surface immunoglobulins (slg) in B-CLL is considered 
an important diagnostic criterion (Tefferi et al. 1996). In addition identification of markers 
such as TdT in the nucleus or C025 provide further information about cellular maturation and 
the activation state of the malignant cells (Jenings et al. 1997). Based on the most frequent B-
CLL antigenic profile (COS+, C023+, FMCT, low slg expression and weak or negative 
expression ofCD22), a scoring system was proposed (Matutes et al. 1994). Each ofthe above 
markers has I or 0 value (typical or atypical for CLL). According to the criteria used by the 
National Cancer Institute (NCI) typical cases of B-CLL are characterised by the following 
immunophenotypes: CD5+, C023+, COlla-, FMC7-, JgM+ and /or lgD+, and weak 
expression ofC020. All cases with this phenotype and lymphocyte count greater than 5xl09/l 
should be diagnosed as B-CLL. Table 1.3 describes the differential diagnosis of B-CLL. 
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Table 1.3: Differential diagnosis of B-CLL 
Disease 
Atypical CLL 
Mantle cell 
lymphoma 
Characterisation 
Atypical CLL is characterised by the presence of CD5+ve and CD23-ve 
cells. However, FISH results for t(ll ; l4) are needed to distinguish it 
from mantle cell lymphoma. Trisomy 12 and any 2 of the following: 
CD 11 a, FMC7, strong CD20, CD28 and Ig/CD79b are also seen m 
atypical CLL. 
Mantle cell lymphoma is characterised by the presence of CD5+ve and 
CD23-ve lymphocytes with moderate to strong slg/CD79b expression 
(Jennings et al. 1997). Evidence of t(l1 ;14) must be present, 
demonstrated by nuclear expression ofcyclin Dl gene (CCNDl). 
B-ceU In B-cell prolymphocytic leukaemia (B-PPL) the cells are large, with a 
prolymphocytic prominent nucleolus and lower nuclear/cytoplasmic ratio. They are also 
leukaemia strongly slg/ CD79b+ve but also CD5-ve, and FMC7 positive (Sole et al. 
1998, Ginaldi et al. 1998). 
Large This term is used when there is evidence of pre-existing B-CLL and 
transformation partial or complete replacement of lymph nodes and/or bone marrow by 
of CLL cohesive sheets of large B-lymphocytes. 
Marginal Marginal zone lymphoma is characterised by bone marrow infiltration 
zone lymphoma with small to medium sized lymphocytes with some evidence of plasma 
cell differentiation. The B-cell immunophenotype should be CD5-ve, 
CD 1 Q-ve, CD l9+ve, CD20+ve and CD23+ve. In extranodal marginal 
zone lymphoma cells are: slgM+ve, slgD-ve, CD5-ve, CDlQ-ve, 
CD20+ve, CD23-ve. 
FoiJicular 
lymphoma 
Follicular lymphoma is characterised by follicular growth pattern, as 
well as the presence of centrocytes and centroblasts. Cells are CD 1 O+ve, 
CD19+ve, CD20+ve, CD2Tve, CD45RA+ve and CD75+ve. T(14;18) 
and bcl-2 rearrangements are present in the majority of follicular 
lymphomas (Bordeleau et al. 2000). 
Myeloma Myeloma plasma cells can be distinguished by CD56 expression and/or 
low or absent CD19 expression (Mulligan 2000). 
Hairy cell Hairy cell leukaemia (HCL) requires cells with typical morphology in 
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leukaemia blood and in bone marrow). The immunophenotype of Hairy cell 
leukaemia includes clonal Ig with CDll, CD25, CD103 and strong 
CD22 expression (Bennett et al. 1989, Mulligan et al. 1990, Matutes et 
al. 1994). 
1.4. L YMPHOCYTES 
1.4.1. General introduction 
A variety of cells are important in mediating immune responses by directly interacting with 
each other and secreting soluble molecules. These cells include lymphocytes, phagocytes, 
auxiliary cells (basopbils, mast cells, platelets) and tissue cells. It is only in the last 40 years 
that it has become apparent that the lymphocyte is a crucial player in the immune system. 
Lymphocytes are immunologically competent cells that assist phagocytes in defence of the 
body against infection and other foreign antigens. To understand B-CLL, it is important to 
view the characteristics of the human lymphoid system. In primary lymphopoietic organs 
such as bone marrow and thymus, lymphocytes derived from stem cells undergo division in a 
manner which is not dependent on antigenic stimulation. These organs provide a unique 
microenvironment controlled in part by soluble factors (cytokines, growth hormones and 
hormones). After being released from their primary organs, lymphocytes migrate to 
secondary (or peripheral) lymphoid organs, such as the spleen, lymph nodes and tonsils. Here, 
from the resting state (Go phase of the cycle) after encounter with antigen, they undergo 
activation, leading to cell division and differentiation. T lymphopoiesis in the thymus 
continues until about the time of puberty but B-lymphocytes continue to be produced 
throughout life. The normal human body contains about 1012 lymphocytes. Under light 
microscopy they appear to have uniform appearance. Lymphocytes are small, round (5-12 urn 
in diameter) with a roughly spherical nucleus, and densely compacted nuclear chromatin. 
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However on the basis of their functional properties and the expression of specific proteins, 
they can be divided into several important groups. Two major types are B- and T-
lymphocytes. B- and T -lymphocytes lineage cells arise from a common subset of 
haematopoietic stem cells that become committed to the lymphoid pathway. They are 
responsible for the specific recognition of antigen. 
1.4.2. Normal B-lymphocytes 
All lymphocytes are derived from pluripotential haematopoietic bone marrow stem cells. B-
lymphocytes develop in the bone marrow, which provides a specialised microenvironment 
allowing B-lymphocytes to develop. The microenvironment achieves this by interacting with 
B-lymphocytes by means of adhesion molecules, and also by producing factors such as IL-7 
(Figure 1.3, Table 1.4). B-lymphocyte can be divided into two groups, which are 
distinguished by the presence of the CD5 antigen on the surface of the cell. B-lymphocytes 
expressing CD5 molecules are called B 1 cells and conventional CD5- ve B-lymphocytes are 
named B-2 cells. B-1 cells, which are present in B-CLL, are characterised by self-renewal, 
with spontaneous production of immunoglobulins, polyreactive specificity and low or no 
somatic hypermutation. With time, they are no longer produced by bone marrow but are 
maintained by division of existing B-1 cells (Kearney, 1993, Parham, 2000). 
Each B-lymphocyte is genetically programmed to encode a surface receptor for a specific 
antigen. After initial recognition of an antigen, B-lymphocytes multiply and differentiate into 
plasma cells and are able to produce and secrete antibody. Antibodies are divided into five 
classes or isotypes lgA, IgD, IgE, lgG and IgM consisting oftwo heavy chains (a, o, &, y or 
~) and two light chains (kappa (K) and lambda (A.). In humans, two-thirds of the antibody 
molecules contain K chain and one-third A. chains. Each antibody molecule contains either K 
or A. chains but not both. Cell surface IgM and lgD are the antigen receptors on circulating B-
lymphocytes that have yet to encounter antigen. The first antibody to be secreted in the 
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immune response is IgM (also IgD but in very small amounts). IgM, which is displayed on B-
CLL B-lymphocytes, is secreted as a circular pentamer of immunoglobulin monomers. IgM 
binds strongly to surface antigen but its effector mechanisms are Limited. 
The response of B-lymphocytes to pathogens and foreign substances is mediated through the 
cell-surface B-cell receptor (BCR). Signalling through this receptor can also lead to 
activation, tolerance and/or differentiation. Two ligand receptor systems have been identified 
that exert profound influence on the outcome of B-T lymphocyte interactions. The first 
system ligates CD28/CTLA-4 on T-lymphocytes to B7. 1 and B7.2 on B cell signals the TCR-
activated cell to produce cytokines and avoid anergy (Gimmi et al. 1991 , Razi-Wolf et al. 
1992, Freeman et al. 1993 ). In the second system the expression of CD40L by activated T 
helper cells triggers B-lymphocyte activation through binding to CD40 (Armitage et al. 1992) 
(Figure 1.4). 
The process of isotype switching or class switching produces antibodies of the lgG, lgA or 
IgE isotypes. These antibodies have more specialised effector functions than IgM. Antibodies 
secreted by plasma cells in secondary lymphoid tissues and bone marrow finds their way into 
the extracellular fluid where recognition of antigen takes place. Their binding sites interact 
with a component of the pathogen surface such as glycoproteins and proteoglycans. 
Antibodies can also coat bacteria (opsonisation) facilitating their ingestion and destruction by 
phagocytes or activation of complement prior to destruction by phagocytes. 
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Figure 1.3: Stages of B-lymphocyte development defined by the rearrangement and 
expression of immunoglobulin genes. 
H-chain genes 
Stem cell germ line 
© 
• Early pro-B cell D-J rearranged 
~ 
Late pro-B cell V-DJ rearranged 
© Pre-B cell receptor 
Large pre-B cell VDJ rearranged 
mu 
Small pre-B cell V JD rearranged (9) 
Immature B cell VDJ rearranged 
r' IgM (9) IgD 
Mature B cell VJD rearranged 
L-chain genes 
germ line 
germ line 
germJine 
germ line 
V-J rearrangement 
VJ rearranged 
VJ rearranged 
Surface lg 
absent 
absent 
absent 
J.l chain at the 
surface as part of 
the pre-B-«11 receptor 
J.1 chain in cytoplasm 
and at the surface 
as part of pre-B cell 
receptor 
IgM expressed on 
the cell surface 
IgD and IgM made 
from alternatively 
spliced H -chain 
transcripts 
ln the stem cell, the immunoglobulin (Ig) genes are in the gerrnline configuration. The fi rst rearrangements are 
heavy-chain (1-1-chain) genes. Joining DH to JH defines the early pro- cell, which becomes a late pro-B cell on 
joining VH to DJH. Expression of a functionaiJ.I chain and its expression at the cell surface as part of the pre-B 
receptor define the large pre-B lymphocyte. Successful light-chain gene rearrangement and expression of IgM on 
the cell surface define the immature B-lymphocyte. The mature B-lymphocyte is defined by the use of alternative 
splicing if heavy chain m RNA to place lgD on the cell surface as well as lgM. Adapted from : ' The Immune 
system' by P Parham, 2000. 
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1.4.3. Malignant B-lymphocytes 
B-CLL malignant B-lymphocytes express many cell surface antigens but their expression 
differs from normal B-lyrnphocytes. 95% of all B-CLL B-lyrnphocytes express CD5, a 6kDa 
antigenic determinant initially found on the surface ofT -lyrnphocytes (Boumsell et al. 1978). 
Almost all appear to react with CD19, CD20 (with low density), CD24, CD37 and CD21 
monoclonal antibodies (Ranheirn, 1995, Nadler, 1986). In addition most cases express CD 18, 
CD23, CD27, CD32, CD37, CD39, CD40, CD44, CD45RA and Ddw75. A minority of cases 
express other antigens such as CD1c, CD11a, b, and c, CD14, CD22, CD25, CD29, CD35, 
CD49c, CD54, CD61, CD62L, CD70, CD71 and CD72 (Morabito et al. 1987, Keller et al. 
1987, Delia et al. 1988, Merle-Beral et al. 1989, Worrnsley et al. 1990, Kipps, 1995). 
Their immunophenotype typically shows a low expression of surface I gM and lgD with clonal 
restricted light chains (Bannerji, 2000). The surface immunoglobulin (slg) is often IgM with 
frequent eo-expression of lgD. Infrequently lgD predominates. This is shown to be 
rnonoclonal because of the expression of one form of light chain, either kappa (K) or lambda 
(A.) (Dighiero et al. 1993). 
Malignant B-lymphocytes are inefficient antigen presenting cells because they lack 
expression of the T cell eo-stimulatory molecule B7-l (CD80) and B7-2 (CD86) (Van der 
Hove et al. 1997) although they may also down-regulate the expression of CD 154, the CD40 
ligand in T-lymphocytes (Cantwell et al. 1997). Leukaemic B-lymphocytes have been show 
to interfere with the interaction of normal T -lyrnphocytes with B-lyrnphocyte in B-CLL. 
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1.4.4. Normal T-lymphocytes 
T-lymphocytes are also derived from the bone marrow but then mature in the thymus. They have 
a variety of functions. One role is to interact with B-lymphocytes and to help them to mature into 
antibody secreting cells. The other is to interact with mononuclear phagocytes and help them 
destroy intracellular pathogens. T-lyrnphocytes recognize degraded proteins bound by major 
histocornpatibity complex (MHC). There are two types ofT lymphocytes, T-helper lymphocytes 
(Th) and T cytotoxic lymphocytes (Tc). Th cells have been further subdivided into Thl and Th2 
subtypes, depending on the profile of cytokines they secrete. Tc lymphocytes are responsible for 
the destruction of host cells, which have been infected with viruses or other intracellular 
pathogens (Mossman et al. 1996). 
Table 1.4: Distribution of B- and T -lymphocytes in normal human tissue 
Tissue 
Peripheral blood 
Bone marrow 
Thymus 
Lymph node 
Spleen 
1.4.4.1. The Thlffh2 paradigm 
B lymphocytes (%) 
10-15 
80-90 
<1 
20-30 
50-60 
T lymphocytes (%) 
70-80 
5-10 
99 
70-80 
30-40 
The Thlffh2 pattern of cytokine production was first described in mice (Mossman et al. 
1986) and later in man (del Prete et al. 1991 ). Th 1 lymphocytes are characterised by the 
secretion of cytokines such as interferon-gamma (IFN-y), IL-2 and tumour necrosis factor 
alpha (TNF-a.), and Th2 lymphocytes by the secretion of I L-4, IL-5, IL- l 0 and TL-1 3 
(Romagnamini et al. 1999). Thl and Th2 subsets secrete IL-3, TNFa., granulocyte-
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macrophage colony stimulating factor (GM-CSF) and members of the chemokine family. The 
functions of Thl and Th2 lymphocytes correlate with the pattern of their cytokines 
production. 
Thl lymphocytes are involved in cell-mediated immunity. Thl clones induce delayed type 
hypersensitivity (DTH) reaction, with IFN-y commonly expressed at the sites of DTH 
reactions (Y amamura et al. 1991 and Tsicopoulos et al. 1992). Th2 cytokines are involved in 
antibody production, particularly IgE responses by promoting class switching from IgM to 
lgG 1 and IgE, as well as enhancement of eosinophil production and function (Mossman et al. 
1989). Th 1 and Th2 lymphocytes are not pre-programmed as separate lineages in the thymus, 
instead they develop from a common peripheral precursor T -lymphocyte (Kamagava et al. 
1993). Th1 or Th2 commitment appears to be dependent on the cytokine milieu at the time of 
activation, antigen concentration (Hosken et al. 1995), strength of TCR binding by antigen-
MHC complex· (Constant et al. 1997) and the type of APC interacting with the T-lymphocyte 
(Langhorne et al. 1998). 
IL-4 stimulates differentiation of uncommitted T-lymphocyte precursors into Th2 
lymphocytes, whereas INF-y, IL- 12 and TGF-P enhance Th1 development. Once established, 
each of these patterns of response is able to suppress the other: INF-y secreted by Thl cells 
inhibits proliferation of Th2 lymphocytes, IL-l 0 secreted by Th2 lymphocytes inhibits 
cytokine secretion by Th 1 lymphocytes (Florentino et al. 1989). While Thl and Th2 
lymphocytes are the major sources of their respective cytokines, many other cells within and 
outside the immune system contribute to the production of these cytokines, e.g. NK cells can 
produce IFN-y while IL-4 can be produced by mast cells and basophils. 
1.4.5. T-lymphocytes in B-CLL 
Although the neoplastic process in B-CLL involves a clonal proliferation of B-lymphocytes, 
there are many functional defects within the T-lymphocyte population. These defects may be 
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primary or secondary and may play a role in the pathogenesis ofthe disease. The first of these 
changes involves an alteration in T-lymphocyte sub-populations. They include an increase in 
total T-lymphocyte numbers as well as an inverted CD4:CD8 ratio (Hautekeete et al. 1987). 
B-CLL T-lymphocytes also demonstrate a different pattern of activation and proliferation 
potential compared to normal controls. 
CD8 T-lymphocytes have been found in B-CLL to have a lower proliferation rate than their 
normal counterparts (Antica et al. 1993). Decreased T helper function and increased T 
suppressor function have also been reported (Chiorazzi et al. 1979, Hersey et al. 1980, Kay et 
al. 1981 ). The T -cell receptor repertoire in B-CLL was more frequently abnormal in CD4 T-
lymphocytes (Rezvany et al. 1999). 
Cytokine production by T-lymphocytes from B-CLL patients differs from normal individuals. 
Reduced IL -2 production as well as impaired IL-2 receptor production has been reported. 
However, some differences in IL-2 production kinetics by CD2 lymphocytes have been 
reported but no differences were found when the levels of both cytokines reach their peak 
(AyanJar-Baturnan et al. 1986). CD2-stimulated B-CLL T-lymphocytes produced higher 
levels ofiNF-y and TNF-a (TNFSF2) but not TNF-P (TNFSFl ) when compared to normal T-
lymphocytes (Reyes et al. 1998). Altered T-lymphocyte funct ion in B-CLL patients is also 
suggested by reduced levels of the activation markers CD28 and CTLA-4 (CD152) and the 
I L-2 receptor, when compared with T lymphocytes of healthy donors (Scrivener, et al. 200 I). 
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Figure 1.4: Interactions between normal B- and T -lymphocytes 
TCR MHC class ll 
LFA- 1 1CAM-l 
CD40 
CD28/CTLA-4 
IL-4 
Activated T cell Activated 8 cell 
Ligation of the T cell receptor complex with antigen-specific major histocompatibility complex (MHC) leads to 
sequential expression of CD40L, 87.1 and 87.2. This leads to up-regulation of CD40L expression on T-
lymphocytes and its sequential interaction with CD40 on B-lymphocytes. Signalling via CD40 up-regulates the 
expression of 87.1/87.2. At thi s stage 8-lymphocyte becomes an antigen-presenting cell (APC) and fully 
activates T-lymphocyte. 
1.5. CYTOKINES 
1.5.1. Introduction 
Over 30 years ago it was shown that antigen inhibited migration of neutrophils and 
macrophages in culture. Subsequently a variety of biological activities in lymphoid culture 
supematants were described and a cytotoxic lymphocyte-derived mediator caJled 
lymphotoxin was isolated in 1968 (Kolb, 1968). These biochernicaJly undefined, lymphocyte-
derived factors were thus called ' lymphokines' (Dumonde et al. 1969) and later becomed 
known as interleukins. To qualify as an interleukin, a cytokine must be shown to have a 
unique amino acid sequence and functional activities involving leukocytes. Whereas many 
cytokines are now termed interleukins, others continue to be known by their older names [e.g. 
interferon -alfalbeta (IFN alp), IFN- gamma (IFN-y), tumour necrosis factor (TNF)]. 
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Cytokines are peptide molecules, some with sugar attached (glycoproteins), that act as soluble 
cell-to-cell messengers. Many form high molecular weight oligomers and one cytokine (IL-
12) is a heterodimer. They have regulatory effects on haematopoietic and many other cell 
types that participate in host defence and repair systems. Cytokines include lymphocyte-
derived factors known as ' lymphokines', monocyte-derived factors called ' monokines', 
haematopoietic factors called ' colony stimulating factors ', connective tissue 'growth factors ' 
and chemotactic chemokines. They have relatively low molecular weights (8-25kDa), are 
distinguished by their overlapping activity and ability to act on many cell types and are 
produced by many different cells, so they can act in both an autocrine and a paracrine 
manner. Depending on their target cell type they can activate or supress gene in the target cell 
(Arai et al. 1990). Cytokines are involved in a variety of processes such as viral infections, 
inflammation, haemopoiesis, immunity, tissue repair and fibrosis. Some of them are now 
termed chemokines because of their chemotactic role for specific cell types. Rapid secretion 
in response to appropriate signals makes them very powerful cell-to-cell communicators. 
Despite been structurally distinct they can be organised into groups that exhibit functional 
similarities based on shared receptor utilisation. For instance, the IL-2 common gamma (ye) 
receptor chain is shared by interleukins 2, 4, 7, 9 and 15 (Kondo et al. 1993, Russell et al. 
1993, Noguchi et al. 1993, and Giri et al. 1994). IL-6, IL-11 , LIF and CNTF (Taga et al. 
1997) share the gp 130 chain of the IL-6 receptor. IL-3, IL-5 and colony stimulating factor 
share a common beta (p) chain receptor (Scott et al. 1999). 
1.5.2. Classification of cytokines 
Cytokines can be divided into different categories such as interferons, interleukins and 
colony stimulating factors. 
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-Interferons (IFNs) are particularly important in defence against viral infections, being the 
first line of resistance. These include IFN-a and IFN-~ that are produced by virally infected 
cells and IFN-y, which is responsible for the resistance to infection ofuninfected cells. 
-Interleukins (ILs) are mainly produced by T-lymphocytes but they can also be produced by 
B-lymphocytes, mononuclear phagocytes, mast cells and other tissue cells. They are involved 
in cell-to-cell interactions. 
-Colony stimulating factors play a role in directing the division and differentiation of bone 
marrow stem cells (Jakubowski et al. 1996). 
-Other cytokines include tumour necrosis factors {TNFa (TNFSF2), TNF~ (TNFSF1)} and 
transforming growth factor (TGF-~) with a variety of functions (Fortune! et al. 2000, R&D 
System mini review, 2001). 
1.5.3. Role of cytokines 
The interactions between cytokines can be described as synergistic or antagonistic and 
stimulatory or inhibitory. Cytokine action is also contextual, in other words, dependent on the 
microenvironment (other cytokines, hormones, growth factors, and prostaglandins) (Spom et 
al. 1988). The induction of IgM production by IL-2 and IL-5 (Matsui et al. 1989) and 
potentiation of the cytotoxic action of TNFSF2 on tumour cells by INF-y are examples of 
cytotine synergy (Lee et al. 1984) while lL-4 is antagonistic to INF-y influence on Jg 
subclasses synthesis by B cells (Snapper et al. 1988). 
Among the first examples of the ability of cytokines to stimulate the production of other 
cytokines was the discovery of IL-l that stimulates the production of IL-2 by murine 
thymocytes and effects their proliferation (Smith et al. 1980). Similarly, many examples of 
inhibitory actions of cytokines on the production of other cytokines are known. For example 
IL-4 inhibits the production ofTNFSF by monocytic cells (Hart et al. 1989). 
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However, the regulation of cytokine interactions is still not fully understood. Evidence 
suggests that transcriptional and post-transcriptional mechanisms are involved (Aman et al. 
1993 and Oliveira et al 1994). Cytokine receptor expression may also play an important role 
with reduced levels of cytokine receptor or the expression of higher affmity receptors 
(Holtman et al. 1987). 
The great variety of cytokines, their abundance in the organism and the complicated way they 
interact with each other help define their characteristics. These include pleiotropy (they tend 
to have multiple targets and multiple actions), redundancy (different cytokines may have 
similar actions), synergism/antagonism (different responses with more than one cytokines) 
and formation of cytokine cascades. 
1.5.4. The cytokine receptor family 
The common structural features of cytokine receptors allow them to be grouped into families and 
subfamilies. The class I cytokine receptor fumily includes receptors for many important 
cytokines including IL-2, IL-4, IL-12. Most ofthese receptors form heterodimers but some are 
monodirners or even heterotrimers (Heim et al., 1996). Some form subfamilies with the common 
receptor to all its members (Taga et al. 1995) (Table 1.5). 
62 
Table 1.5: Human cytokines and their receptors 
~ Moleculor Exons lntrons Gene Receotor Gene 
" 
weight location MW colation 
IL-Ia 17.5 kDa 5 4 2q(q12-21 ) 80 and 60 kDa 2q l2 
shared with 
IL-IP 
I L-IP 17.3 kDa 6 5 2q(ql3-q21) 80 to60 kDa 
IL-2 15.5 kDa 4 3 4q(q26-<j27) 55kDa, 70 a -Xp22.3 
kDa 
and 64-kDa y-Xql 3.1 
IL-3 14-30 kDa 5q(q23-3 1) 120 kDa 
IL-4 15-19 kDa 4 3 5q(q23-3 1) 50-<iOkDa and a-16pll.2-16pl 2 
64kDa y-Xq l3.1 
IL-5 2x22.5kDa 4 3 5q(q23-<j31) 46.5 kDa and 3p24-26 
(homodimcr) 114 kDa 
IL-<i 26 kDa 7p(p21-24) 80 kDa lq2 1 
IL-7 14.9 kDa 6 5 8q(q l2-<jl 3) 70kDa a -5pl 3 
y-Xql3 .1 
IL-8 8.5 kDa 4 3 4 58kDa and 2q35 
67kDa 
IL-9 32-39 kDa 5 4 5q3 1-<j35 64kDa Yq28 
y-Xql 3. 1 
IL-10 18kDa I 90-120kDa llq23.3 
IL-11 23kDa 5 4 19 
IL-12 35kDa and 5q3 1-<j33 IOOkDa lp31.2 
40kDa 3p12-pl 3.2 
(hctcrodimcr) 
IL-13 12kDa 4 3 5q3 1 140kDa Xq l3.1-<j28 
IL- 14 
IL-15 34kDa 8 7 4q31 a -1 Op 14-p 15 
y-Xq l3. 1 
IL-16 14-17kDa 15q26. 1 
IL-17 97.8kDa 
IL-18 22JkDa 3 4 
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1.5.5. Role of cytokines in the development and function of lymphoid cells 
Each cytokine has a unique function in homeostasis. The following is a short outline of their 
main characteristics, emphasising the role they play in Band T lymphocyte activities. 
Macrophages, endothelial cells, B-lymphocytes and fibroblasts, produce IL-l (Kasahara et al. 
1992). Its role is to induce inflammatory responses such as the production of prostaglandins 
and degenerative enzymes (collagenase) that take part in the destruction of cartilage and 
bone. During injury, IL-l induces production of acute phase proteins by the liver and is also 
responsible for inducing fever and augmenting release of corticosteroids. IL-l exerts its 
actions through IL-l receptors, which are present on most cells (Dover et al. 1990). 
IL-2 is known as T -cell growth factor because it activates and induces proliferation of T-
lymphocytes. It is also produced in response to activation ofT cells. IL-2 augments B cell 
growth and immunoglobulin production as well as IFN-y production. 
IL-3 is produced primarily by activated T lymphocytes, activated NK cells, activated mast 
cells and possibly epidermal cells (Luger et al. 1985). The activities of IL-3 include 
stimulating the proliferation of mast cell lines, differentiation of neutrophils, macrophages, 
basophils, eosinophils and mast cells, and potentiation of the activities of eosinophils, 
basophils and monocytes (Schrader et al. 1983). 
IL-4 is produced by mast cells, basophils, a subpopulation ofT -lymphocytes bearing NK 1.1 
markers and naive CD4, as well as CD8 T-lymphocytes and some IL-3 dependent bone 
marrow cell lines (Ho ward et al. 1982, Brown et al. 1987, Rodriques-Traduce et al. 1992 and 
Seder et al. 1992). 
IL-5 is a product of activated T-lymphocytes and acts on eosinophils, basophils, B-
lymphocytes and thymocytes. It has been shown that IL-5 enhances IgE synthesis and CD23 
expression in IL-4 stimulated cells (Pene et al. 1988). lL-5 exerts its activity by interacting 
with a specific multi-subunit receptor present on normal B-lymphocytes and eosinophils 
(Mita et al. 1989). 
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IL-6 is produced by activated monocytes, endothelial cells, a variety of tumour cells, 
activated T and B-lymphocytes and fibroblasts and acts on a variety of cell types including 
fibroblasts and hepatocytes (Wong et al. 1988 and Roodman et al. 1992). Among other roles, 
IL-6 increases B lymphocyte differentiation and stimulation of IgG secretion and induces 
cytotoxic T lymphocyte differentiation (Taga et al. 1987). 
IL-7 is a product of bone marrow stromal cells and thymic stromal cells (Goodwin et al. 
1989). It has some T cell growth factor activity with augmentation of T cell cytotoxicity 
(Hickrnan et al. 1990). 
IL-8 is a neutrophil chemotactic factor produced by LPS-stimulated mononuclear cells 
(Yoshimura et a l. 1987). It is released at the site of injury where there is recruitment of 
monocytes and neutrophils. It can be produced by stimulated normal eosinopruls and induced 
by histamine (Jeanllin et al. 1994). It is also able to inhibit IgE production by B-lyrnphocytes 
(Kimata et al. 1992). 
IL-9 is aT-cell-derived cytokine that interacts with a specific receptor associated with the IL-
2 receptor y chain. Interleukin-9 potentiates IL-4 induced immunoglobulin (lgG, IgM and 
IgE) production by normal human B-lymphocytes and shares common signal transduction 
pathways with IL-4 (Renauld et al. 1995a). 
IL-l 0 was initially named cytokine synthesis inhibitory factor (Fiorentino et al. 1989). It is 
produced by T helper clones, but also, by EBV -positive B cells lines and LPS transformed 
macrophages (Benjamin et al. 1992 and Vaal Melafyt et al. 1993). It has a range of activities, 
the most important being a growth and differentiation factor for activated B-lymphocytes, but 
also the induction of MHC 11 antigen expression and increased viabil ity of B cells (Rousset 
et a l. 1992). IL-10 also co-operates with TGF-~ to induce lgA production by naive B-
lymphocytes eo-cultured with anti-CD40 antibody. In vitro it can inhibit the production of 
IFN-y and JL-2, cytokines produced mainly by Th1 cells. 
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IL-12 is a key cytokine in immune regulation. IL-12 is produced by dendritic cells, 
macrophages, neutrophils and activated T-lymphocytes (Ma et al. 1998). It promotes both 
natural killer cell and cytotoxic T-lyrnphocyte activity and therefore is an important factor in 
the development of immune responses against tumours and infectious agents. Priming with 
IFN-y increases production ofiL-12 by PBMC (Harrison et al. 1997, Lee et al. 1998). 
IL-13 is produced by Th2 lyrnphocytes and together with IL-4 and IL-l 0 share the capacity to 
inhibit cytokine synthesis by monocytes. It is essential for B lyrnphocyte activation (Defrance 
et al. 1998), and induces CD23 expression and MHC class 11 expression, as well as playing a 
role in allergic reactions (Punnomen et al. 1993). IL-4 and IL-13 receptors share a common 
subunit involved in signal transduction (Vita et al. 1995). 
The major sources of IL-15 are monocytes, epithelial cells and fibroblast cell lines. It shares 
many biological activities with IL-2 but shows no homology to IL-2. These two cytokines, at 
least in part, use components of the IL-2R system, ~ and y chain, for binding and signalling. 
IL-16 was originally identified as a product of CD8+ve cells. CD4+ve cells, after mitogenic 
stimulation, can also produce IL-16 as well as eosinophils, bronchial epithelial cells, mast 
cells and fibroblasts. IL-16 is a potent chemotactic factor for CD4+ve cells and eosinophils 
but also induces cell surface expression of high affinity IL-2 receptors (Rand et al. 1991 and 
Center et al. 1995). 
Human IL-17 is secreted primarily by activated CD4+ve lymphocytes (predominantly by the 
memory cell subset) (Fossiez et al. 1996). Activities ofTL-17 include the ability to induce IL-
6, IL-8, G-CSF and PGE2 secretion, thus having pro-inflammatory as well as indirect 
haematopoietic activities (Fine et al. 1997). 
Finally, IL-18 has been shown to be a widely produced cytokine. IL-18 mRNA is detected in 
macrophages, adrenal epithelial cells, liver, lungs and unstimulated PBMC. It was originally 
designated as IFN-gamma inducing factor (IGIF), because it was cloned as a cytokine that 
strongly induces IFN-gamma production (Okamura et al 1995). 
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1.5.6. Splice variants of cytokine genes 
The function of individual cytokines and of the overall network is further complicated by 
alternative splicing. Spliced variants have been described for many cytokines (Atamas et al 
1997). These can be expressed as soluble or membrane bound proteins and can be tissue 
specific. Alternative splicing is a tightly controlled process by specific factors whose 
expression is highly restricted. 
Pre-mRNA splicing take place on the spliceosomes, a dynamic complex of small nuclear 
ribonucleoprotein particles (snRNPs) and extrinsic (nonsnRNP) protein factors assembled on 
the juxtaposed 5' and 3' splice sides (Figure 1.5). lntron excision proceeds in two successive 
transesterification reactions whereby the upstream exon is cleaved from the intron and ligated 
to the downstream exon (Lopez, 1998). First the 2 ' hydroxyl group of the adenosine residue 
of the branch site attacks the phosphate group linking the last nucleotide of the 5' exon with 
the guanosine residue of the GU intronic dinucleotide, thus forming the branched 
intermediate (lariat formation). Then the 3' hydroxyl group that has been formed at the last 
nucleotide of the 5' exon attacks the phosphate group that links the guanosine residue of the 
AG intronic dinucleotide with the first nucleotide of the 3' ex on, resulting in release of the 
lariat and joining the two exons (Madhani et al. 1992 and Nielson, 1994). Terminal exons, 
that are the first and last exon, require special mechanisms for their recognition that appear to 
involve cap and poly A+ binding proteins. In addition, the terminal exons are generally longer 
with the average size being 600 nucleotides. Under certain conditions exclusion of exons can 
occur, suggesting that the juxtaposition events do not necessarily have to occur between 
neighbouring exons. Tissue specific exons, may be excluded from mRNA by exon skipping, 
whereby the splice sites for the optional exon are ignored and the upstream and downstream 
exons are ligated to each other directly (Sorg et al. 1993, Korte et al. 1999). Splicing is 
regulated by sequence elements that are distant from a splice site. 
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Figure 1.5: Design of a splice variant 
First tnmsesterification 
Second transesterification 
~OH 
I I -p-GT---'1------A----AG-p-.----, 
.-----,1 -p- r-1 -----, 
Joined exons 
T 
G 
Two-transesterification steps involved in the splicing process. Pre-mRNA splicing takes place on the 
spliceosomes. lntron excision proceeds in two successive transesterification reactions. Exons are indicated as 
boxes and introns as solid lines. The conserved GT, A and AG nucleotides are shown. These variants can act as a 
natural inhjbitor of the wiJd type protein (Atarnas, 1997). 
Splice variants have been described for TGF ~1 , TGF~2, IL-1a.M-SSF, G-CSF, IL-2, IL-4, 
IL-5, IL-6, IL-7 and IL- 15 (Webb et al. 1988, Chiu et al. 1990, Sorg et al. 1991, Tanihara et 
al. 1993, Frishman et al. 1993, Kestler et al. 1995 and Onu et al. 1997). However in only a 
few cases has the actual translation of the spliced variant rn.RNA into protein been 
demonstrated. 
Such variants can be created for IL-2 and IL-4 by alternative splicing of certain exons that 
may in turn give rise to the generation of proteins with differential expression in tissue. IL-4 
and IL-2 splice variants, IL-482 and IL-282 and IL-283 respectively, are reported to function 
as natural inhibitors of the wild type protein (Alms et al. 1996). The IL-4 variant inhibits eo-
stimulation ofT cell proliferation through competitive binding to its receptors. Similarly, both 
IL-2 spliced variants inhibit IL-2 eo-stimulation of T-lymphocytes proliferation and cellular 
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binding of recombinant IL-2 to high affmity IL-2 receptors (Atamas et al. 1996). They may 
do so by engaging only p and y c chains but not the a chain. Thus the altered expression of a 
wild type and alternatively spliced variant protein may lead to disease (Glare et al. 1999 and 
Sakkas et al. 1999). 
Alternative splicing has also been described for IL-7 (Korte et al. 1999). Also spliced variants 
lacking exons 3 and 5 or both in combination with exon 4 have been described (Korte et al. 
1999). Similarly secretion of IL-15 is controlled via alternative splicing in the region of the 
signal peptide of the precursor protein, although both mature variants have the same amino 
acid composition (Onu et al. 1997). 
1.5.7. Structure and function oftheyc dependent cytokines and their receptors 
1.5. 7.1. Introduction 
As well as other receptor families, the ye chain family is an important example of the 
common features of cytokine receptors such us IL-2R, IL-4R, IL-7R, IL-9R and IL-15R 
(Kondo et al. 1993, Russell et al. 1993, Noguchi et al. 1993 and Giri et al. 1994) (Table 1.8). 
Each receptor has additional individual subunits, which add specificity to their signalling The 
ye chain was identified in 1990 and a complementary cDNA clone encoding this member of 
the cytokine receptor family was isolated (Takeshita et al. 1990). Co-irnmunoprecipitation 
studies performed in the presence of IL-2 led to the identification of a 64-kDa protein that 
was associated with IL-2R p. The ye chain is composed of a 255-amino-acid extracellular 
domain, a 29-amino-acid hydrophobic transmembrane region, and 86-amino-acid C-terminal 
cytoplasmic tail. 
The extracellular domain contains many features, which are common to receptors such as the 
IL-2 p, IL-4R a , IL-7R a and IL-9R a chains (Bazan et al. 1990) (Table 1.6). These include a 
region having four Cys residues located in theN-terminal half of the extracellular domain and 
a second WS motif (WSXWS) (Noguchi et al. 1993). This region also contains two 
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fibronectin type Ill-like domains of unknown significance. The y chain is necessary for the 
formation of high (equilibrium dissociation constant: K0 =10 11 M) and intermediate (K0 =10 10 
- 109 M) affinity receptors and increases receptor affinity by 3 to I 0 fold (Smith, 1980). It is 
required for the receptor-mediated internalisation ofiL-2. 
The ye chain receptor is constitutively expressed on essentially all cells of haematopoietic 
origin. However they display two types of ye transcripts, differing in their carboxyl terminal 
coding regions. The newly identified sequence display a deletion of 72 nucleotides close to 
the 3'-end ofthe open reading frame. The result is the loss of24 amino-acids, which include a 
conserved tyrosine residue shared by several members of the cytokine receptor family (Shi et 
al. 1997). The IL-2 receptor complex signals by rapidly increasing tyrosine phosphorylation 
of P and ye chains of the complex (Mills et al. 1990). Signalling is mediated through a group 
of receptor-associated tyrosine-kinases termed Janus or JAK kinases (Schindler et al. 1995). 
The importance of the y chain was identified in the study of X-linked combined 
immunodeficiency (XSCID) where a mutation of the ye chain leads to impaired T and NK 
lymphocyte function and consequently to impaired immune responses (Noguchi et al. 1993). 
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Table 1.6: Characteristics of cytokines belonging to ye chain receptor family 
Cytokine Mature Secreted Exons Size of Introns Chromosomal 
proteins peptide an exon location 
(kDa) (aa) (kb) 
IL-2 15 133 4 4 3 4q26-28 
IL-4 20 129 4 10 3 5q26-28 
IL-7 17 152 6 33 5 8ql2-13 
IL-9 14 126 5 4 4 5q31-q35 
IL-15 15 114 8 5 7 4q25-35 
aa=Amino-acid, kDa=kilodalton, kb=ki lo-bases 
1.5.7.2. Interleukin-2 (IL-2) 
fL-2 was first identified as an essential growth-promoter for bone marrow-derived T 
lymphocytes (Morgan et al. , 1976). IL-2 is a polypeptide of approximately 15.5 kDa. 
Cloning of IL-2 revealed that 153 amino-acid human IL-2 translation products undergo 
several post-translational processing events, including cleavage of a 20-residue signal 
peptide, addition of carbohydrate to the threonine residue at position 3 (Thr-3), and 
formation of a disulphide bond between cysteines 58 and I 05 (De V os et al. 1983, 
Taniguchi et al. 1983). The three-dimensional structure ofiL-2 predicts the existence of four 
core a helices and two crossover loops containing p strands (Bazan et al. 1992). The IL-2 
gene is located on chromosome 4 and contains four exons and three introns (Fujita et al. 
1983). Exon l encodes Ala1-Asn29, which forms a short strand plus helix A. Exon 2 encodes 
Asn30-Lys49, which forms a connecting strand with short a helix and p pleated sheet. Exon 3 
encodes Ala50-Lys97, which forms helix B+B', a short connecting strand and helix C. And 
fmally exon 4 encodes Gly98-Thy133, to make a short connecting strand, a P-pleated sheet 
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and helix D (Brandhuber et al, 1987). To exert its biological effects, IL-2 must interact with 
specific high-affinity receptors. Helix A contacts the P-chain receptor. The minor a helix 
and connecting strand encoded by exon 2 contact the a chain and then a loop around the ye 
chain. Helix B+B' Lie on top of the contact residue without connecting the IL-2R. Finally 
Helix D plays an important role in the engagement of the gamma c receptor and Lies in a 
groove between the beta and ye chain (Voss et al. 1993). 
Thl cells, in response to activation by mitogen, alloantigens or antigens presented in context 
with appropriate MHC molecules, produce IL-2. Its expression is controlled predominantly at 
the levels of mRNA transcription and message stabilisation (Lindstain et al. 1989 and Fraser 
et al. 1991). It can also be produced after stimulation by B-lymphocytes but in very small 
amounts (Mouzaki et al. 1993). The effect of IL-2 on different cell type of the immune 
system is shown in Table 1.7. 
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Table 1.7: llr-2 effect on the immune system 
On B-lymphocytes 
• Augments B lymphocyte growth and increases immunoglobulin production (Ceuppens et 
al. 1985) 
On T -lymphocytes 
• Autocrine growth factor for T -lymphocytes and supports the development of cytotoxic 
T -lymphocytes (Ruscetti et al. 1977) 
• Augments gamma interferon production (Ortaldo et al. 1984) 
• Modulates the expression of IL-2R (Smith et al. 1985) 
On other cells 
• Participates in the activation, tumoricidal activity and growth of NK I LAK cells 
(Grimm et al. 1983) 
• Induces IL-6 production by human monocytes (Musso et al. 1992) 
• Modulates histamine production by stimulated basophils (White et al. 1992) 
• Affects effector function of fibroblasts (Plaisance et al. 1992) and normal and 
malignant epithelial cells (Ciacci et al. 1993), myeloid cells including 
polymorphonuclear and monomorphonucler phagocytes as well as normal and 
myelopoietic progenitor cells (Pizzolo et al, 1993). 
1.5.7.2.1. IL-2 receptor (IL-2R) 
The effects of IL-2 on its target cell are mediated through specific cell surface receptors (IL-
2R). The IL-2R contains three distinct subunits, a 55-kDa a chain, (Tac, p55, CD25), a 70-
75kDa p chain (IL-2Rbeta, p70/p75, CD122) and a 64-kDa y chain (IL-2R gamma, gamma c, 
p64). The existence of three different chains allows the formation of different isoforms of IL-
2R: high, intermediate and low a:fftnity. The three chains are noncovalently bound to form a 
heterotrimeric high affinity receptor (Nakamura et al. 1993, Minami et al. 1993). 
The human IL-2 R a chain has been cloned and localised on chromosome 10 band 14-15 
(Leonard et al. 1985). The a chain is structurally related to the IL-15R a chain and resembles 
members of the component receptor fami ly (Bazan et al. 1992). The majority of the chain is 
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an extracellular domain and contains 11 cysteines and disruption of any of the cysteines 
reduces the ability of IL-2R a to bind (Rusk et al. 1988). There is also a suggestion that 
residues 158-160 may contribute to the interactions with the p and ye chain (Robb et al. 
1988). 
The human IL-2 R p chain has been mapped to chromosome 22 and the mature protein has 
525 amino acids (Bazan et al. 1990). Little is known about the regulation of the IL-2R p gene. 
Mature unstimulated CD8+ cells are able to express the p chain (Ohashi et al. 1989) and its 
expression on B-lympbocytes can be induced by IL-2 or by IL-4 (Loughnan et al. 1989 and 
Nakanishi et al. 1996). The third chain, ye, forms part of individual receptor of several 
cytokines belonging to common y chain receptor family (see chapter 1.6.6.1 0. Dimerisation of 
a , p, and ye chain induces IL-2 signal transduction (Figure 1.14). 
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Figure 1.6: IL-2 signalling pathway 
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Following stimulation LL-2R undergoes phosphorylation. Various kinases (p56lck' Syk. or JAK) phosphorylated 
specific substrates, triggering cascade of events organised in three major pathways; She activation and induction 
of the Ras pathway, the Pl-3 kinase pathway and JAK-STAT pathway. 
Abbreviations: TL-2=interleukin 2, a =alfa chain, ~=beta chain, y=gamma chain, JAK=Janus kinase, 
MAPK=mitogen-activated protein kinase, STAT=signal transducers and activators oftranscription 
Adapted from Theze et al. Immunology Today, p: 481-486,1996 
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1.5. 7 .3. Intcrlcukin-4 (IL-4) 
IL-4 was first shown to induce activation and immunoglobulin production by activated mouse 
B-lymphocytes (Swain et al. 1982, Sanderson et al. 1986). Molecular cloning of human IL-4 
cDNA demonstrated a single open reading frame of 153 amino acids (aa) yielding a secreted 
glycoprotein of 129 aa with a molecular weight of 15-19 kDa. The IL-4 gene is located on the 
long arm of chromosome 5 on band q23-31 and is composed of 4 exons and 3 introns (Yokota 
et al. 1986). In close proximity are the genes for other related cytokines IL-3, IL-5, IL-13 and 
GM-CSF (Morgan et al. 1992). X-ray diffraction of IL-4 crystals and magnetic resonance 
spectroscopy of IL-4 in solution revealed a left-handed boundle of four a-helices with short 
stretches of p sheets. It belongs to the short chain 4-helix bundle superfamily along with IL-2 
and IL-5 (Waiter et al. 1992, Powers et al. 1992) (Figure 1.5). The existence of alternative IL-
4 mRNA has been reported. This novel IL-4 spliced variant has been named IL-4 delta2 (IL-4 
o2), and is characterised by a lack of exon 2. This variant appears to be found naturally and is 
expressed at a higher level in thymocytes and bronchoalveolar lavage cells. The mechanism of 
action of IL-4 o2 is not as a costimulator of T-lymphocyte differentiation but rather as an 
inhibitor ofT -lymphocyte dependent differentiation (Atarnas et al. 1996). 
IL-4 can be produced by mast cells, basophils, a subpopulation of T -lymphocytes bearing 
NK1.1 markers and naive CD4, as well as CD8 T-lymphocytes and some IL-3 dependent 
bone marrow cell I ines (Ho ward et al. 1982, Brown et al. 1987, Rodriques-Traduce et al. 1992 
and Seder et al. 1992). The effect ofiL-4 on the immune system is shown in Table 1.8. 
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Table 1.8: IL-4 effect on the immune system 
On B-lymphocytes 
• Induces MHC Class 11 expression (de Vries et al 1998). 
• Induces proliferation in the presence of anti-I gM (Gordon et al. 1988) 
• Induces expression and release of low affinity IgE receptor (CD23) (V ercelli et al. 1988) 
• Stimulates IgE and IgG 1 synthesis (Snapper et al. 1988) 
On T -lymphocytes 
• Induces proliferation ofthymocytes (Murphy et al. 1992) 
• Enhances cytotoxic activity of CTLs (Spitz et al 1988) 
• Inhibits IL-2-induced CTL and LAK activity (Jin et al. 1989) 
On other cells 
• Stimulates mast cell growth (Wills-Karp, 1999) 
• Induces MHC Class I and 11 expression and tumoricidal activity of macrophages 
(Thomson A, Cytokine handbook, Academic Press, 1998) 
• Blocks IL-l , IL-6, JL-8, IL-l 0, IL-12 and TNFSF2 production by monocytes (Haro et 
al. 1989) 
1.5.7.3.1. IL-4 receptor (IL-4R) 
IL-4 acts via high affmity receptors expressed in low numbers on a wide range of cell types. 
They include B- and T -lymphocytes, granulocytes, monocytes, fibroblasts, epithelial and 
endothelial cells (Chomarat et al. 1997). The mature receptor represents a complex composed 
of at least two different proteins, the common y chain shared by several interleukin receptors 
(ldzerda et al. 1990) and a 140 kDa high affmity binding chain (IL-4 Ra.) (Russell et al. 1993) 
(Table 1.9). IL-4R a. is a glycoprotein composed of 800 amino acids (aa), with an 
extracellular domain of 207 containing two motifs. One is a single 24aa transmembrane 
domain, and the other a 569aa intracellular portion. The coding gene has been localised on the 
short arm of chromosome 16 ( 16p 12.1) (Prichard et al. 1991 ). The common ye chain is a 
65kDa protein, which after dimerisation with the IL-4Ra. chain, increases the affmity of the 
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IL-4R by 2-3 fold. This Dimerisation is also essential for IL-4 induced signal transduction 
(Figure 1.7). 
Table 1.9: Properties ofthe human IL-4 and IL-4Ra chain 
IL-4 IL-4Ra 
Mature protein: 
amino-acids 129 800 
Molecular weight kDa) 15-19 140 
Disulphide bonds 3 (6 Cys) 3 (6 Cys) 
Gene: 
Gene size (kilobase pairs) 10 3.6 
Introns 3 
Chromosome location 5q23-31 16 ( 16p 12. 1) 
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Figure 1. 7: lL-4 signalling pathway 
fL-4Ralfa ~ IL-4 
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IL-4 signalling cascade through the gp 140/yc IL-4R complex. (I) Binding of IL-4 to 140-kDa chain induces 
dimerisation of the IL-4Ra chain with ye chain. Tyrosine kinase associated to the receptor becomes activated. 
IL-4 binding allows also interaction of JAK-1 with boxl and box2 sequences located near the cellular 
membrane. (2) The IRS-2 protein interacts with the IL-4Ra and then becomes phosphorylated. (2') Monomers 
of STAT-6 binds to fL-4Ra chain. (3) Phosphorylated IRS-2 displays high affinity binding for SH2 domains of 
the p85 subunit ofthe phosphoinositol-3 kinase (PI-3 kinase). (3') STAT-6 is tyrosine phosphorylated by JAK-
1, allowing its dimerisation and its release from the IL-4Ra chain. (4) fRS-2 protein may interact also with other 
SH-2 domain. (4' ) STAT-6 dimers are moved to nucleus leading to the activation of IL-4 regulated genes. (5) 
lRS-2-PJ-3 kinase complex is released from the IL-4Ra. 
Adapted from : Choromat P, Thecytokine handbook, p 139, 1998 
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1.5.7.4. Interleukin-7 (IL-7) 
IL-7 was originally identified as a factor secreted by bone marrow (Welch et al. 1989) and 
contains six exons over 33 kilo bases (Lupton et al. 1990). Exon 5 of the human gene encodes 
the 18 amino-acid insert found only in human IL-7 (Goodwin et al. 1989). The molecular 
weight of IL-7 is 17.4 kDa. It is a single copy gene located on chromosome 8q 12-13 
(Southerland et al. 1989) in proximity to the p53/p56Lyn gene. IL-7 cDNA is composed of 
534 nucleotides encoding a protein of 177 amino-acid residues with a signal sequence of 25 
amino-acid residues and three potential N- linked glycosylation sites (Goodwin et al. 1989). 
Alternatively spliced human IL-7 mRNA lacking the entire exon 4 (44-amino-acid residues) 
has been isolated from SK-HeP-1 line (Korte et al. 1999). 
Both immune and non-immune cells secrete IL-7. Bone marrow stromal cells are able to 
produce IL-7 as well as thymic cells and keratinocytes (Goodwin et al. 1990) intestinal 
epithelial cells and follicular dendritic cells (Kroencke et al. 1996). The effect ofiL-7 on the 
immune system is shown in Table 1.1 0. 
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Table 1.10: IL-7 effect on the immune system 
On B-lymphocytes 
• It is able to induce the growth and differentiation of precursor B-lymphocytes. 
• IL-7 most likely acts at some point after commitment to B cell lineage and exerts 
growth effects primarily on CD220+ pre-B-lymphocytes (Namen et al. 1990 and 
Hayashi et al. 1990). 
• A number of genes involved in B-lymphocytes development may be upregulated by 
IL-7, including n-myc, c-myc (Morrow et al. 1992). 
On T -lymphocytes 
• T cell growth factor activity. IL-7 can influence both the proliferation and differentiation 
ofT-lympbocytes.lt may act directly on CD8+ve T-lymphocytes to augment 
cytotoxicity and may be a potent differentiation factor for the development of CTL. 
(Hickrnan et al. 1990) 
On other cells 
• Induction of pro-inflammatory cytokine production such as IL-l and IL-6 from 
monocytes (Costello et al. 1992) 
• Downregulates the expression ofTGF-P from macrophages (Dubinett et al. 1993) 
1.5.7.4.1. IL-7 receptor (TL-7R) 
The IL-7 receptor (CD127) is composed of at least two subunits including a IL-7R a. chain and 
the common y chain (Kondo et al. 1993). The IL-7R a. chain was identified by direct expression 
cloning (Goodwin et al. 1990) and is located on chromosome 5p13 (Lynch et al. 1992. The IL-
7Ra. forms a heterodimer with the ye chain, which is required for high affinity IL-7 binding 
(Noguchi et al. 1993). IL-7Ra. has been detected on pre-B-lymphocytes, human intestinal cells, 
and bone marrow macrophages but not on mature B-lymphocytes (Foxwell et al. 1992). It seems 
that in the B cell lineage, IL-7R a. expression is tightly regulated. In the thymus, double negative 
(CD4-ve, CD8-ve) and single positive (CD4+ve or CD8+ve) lymphocytes express this receptor. 
In contrast to the tightly regulated expression of the IL-7a. chain, the y chain is constitutively 
expressed on mature B-lymphocytes, fetal and neonatal thymocytes and mature T-lymphocytes. 
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Binding ofiL-7 to its receptor involves activation of the Janus tyrosine kinase proteins (JAK), 
JAK-1 and JAK-3 (Foxwe LI et al. 1995). The transduction ofthe signal into the nucleus is then 
mediated by the STAT proteins (STAT-1 and STAT-5) (Zeng et al. 1994). 
1.5.7.5. Ioterlcukin-9 (llr-9) 
IL-9 is a 30-40 kd glycoprotein. Its single copy gene is located on chromosome 5 near the loci 
for IL-3, IL-4, IL-5, granulocyte macrophage colony stimulating factor (GM-CSF) and IL-13 
(Modi et al. 1991 ). It contains 5 exons and 4 introns stretching over 4 kd (Renauld et al. 1990). 
TL-9 is produced preferentially by Th2lymphocytes. Unstimulated freshly isolated PBMC do not 
express TL-9 mRNA but stimulation with PHA or anti-CD3 antibody induced substantial 
expression ofiL-9 in CD4 T-lymphocytes (Renauld et al. 1990). After stimulation with CD3 and 
CD28 expression of IL-9 was restricted to CD45RO+ve T-lymphocyte subset (memory cells) 
(Houssiau et al. 1995). IL-9 expression is associated with HTL V -1, a retrovirus involved in adult 
T cell leukaemia (Kelleher et al. 1991). The effect oflL-9 on the immune system is shown in 
Table 1.11. 
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Table 1.11: IL-9 effect on the immune system 
On B-lymphocytes 
• IL-9 synergises with IL-4 for lgE and IgG production but not for IgM production. 
Generally IL-9 favors humoral autoimmunity but inhibits cell-mediated autoimmune 
processes. (Dugas et al. 1993) 
On T -lymphocytes 
• IL-9 exhibits growth-promoting activity for T -cell tumors (patients with Hodgkin and 
large cell anaplastic lymphoma constitutively produce IL-9) (Merz et al. 1991) 
On other cells 
• In murine model IL-9 promotes growth and differentiation of bone marrow derived mast 
cell lines (Moeller et al. 1989). It also increases IL -6 secretion by mast cell lines (Hutner 
et al. 1990). 
• IL-9 promotes some granulocytic as well as monocytic colony growth from 
CD34+CD2- progenitors (Schaafsma et al. 1993) 
• Addition ofiL-9 was found to increase proliferation of human myeloid leukaemic cells 
suggesting preferential activity on transformed cells as compared to their normal 
progenitors (Lemoli et al. 1996). 
1.5.7.5.1. IL-9 receptor (IL-9R) 
The human IL-9 receptor cDNA encodes a 522 amino acid protein. IL-9R is a member of the 
haematopoietin receptor superfamily. It interacts with they chain of the IL-2 receptor, which is 
required for signal transduction but not for IL-9 binding (Demoulin et al. 1998). 
1.5.7.6. Interleukin-15 (IL-15) 
The human IL-15 gene maps to chromosome 4q31 (Anderson et al. 1995). The proximity to the 
IL-2 gene suggests a common ancestry within the helical cytokine family. IL-15 is a cytokine of 
between 14 and 15 kDa. IL- 15 and IL-2 share little sequence homology, and it is possible to 
align their sequences on the basis of the helical structure of IL-2. There are 21 amino-acid 
identities between IL-15 and IL-2 (Pettit et al. 1997). 
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IL-15 mRNA is expressed constitutively in a wide variety of cells (monocytes and macrophages) 
and in many tissues (skeletal muscle, placenta, heart, lung, liver kidney and dermal layer of the 
skin), but is not expressed in normal T, B or natural killer (NK) cells (Grabstein et al. 1994, 
Doherty et al. 1996). The effect of IL-15 on the immune system is shown in table 1.12. 
Table 1.12: 0...,..15 effect on the immune system 
On B lymphocytes 
• IL-15 induces proliferation following preactivation with PMA or IgM but not in resting B-
lymphocytes. It is involved in the differentiation of normal B-lymphocytes and induces 
secretion of immunoglobulins in combination with anti-CD40 stimulation (Armitage et 
al.1995). 
• IL-15 regulates growth of B-CLL cells regardless of their preactivation (Trentin et al. 
1996). 
On T-lymphocytes 
• IL-15 is able to stimulate the growth of activated T lymphocytes, CD4+, CD8+ and y& T 
cells. (Grabstein et al. 1994) 
• IL-15 inhibits apoptosis of cytokine-deprived; activated T-lymphocytes (Akbar et al. 
1997). 
• It induces cytokine production by T -lymphocytes (Mori et al. 1996). 
On other ceUs 
• IL-15 may be a growth and differentiation factor for NK cells as well as inducing cytokine 
production by these cells (Mrozek et al. 1996). 
• It activates neutrophils and mast cells proliferate in response to IL-15 (Tagaya et al. 1996). 
1.5.7.6.1. IL-15 receptor (IL-15R) 
The IL-15 receptor is composed of at least three subunits: an IL-l5Ra chain, the IL-2Rf3 chain 
and the ye chain. This combination has similarities with the 1L-2-IL-2R system, in which the 
generation of the high affmity receptor for IL-2 requires the presence of all three subunits. 
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Antibodies recognizing the IL-2R~ and y chains inhibit IL-15 mediated responses. The IL-l5Ra 
chain is a type I membrane protein of 263 amino acids and it belongs to a larger family of 
proteins that contain protein-binding motifs known as 'sushi domains' (Giri et al. 1994). The 
gene coding the human IL-15R a chain is located on chromosome lOp 14-p 15. The a chain is 
required for high-affinity binding, but not for signaling by IL-15 (Anderson et al. 1995). IL-15R 
a chain mRNA is expressed in a wide variety of cells and tissues, including fibroblasts, 
epithelial cells, B-and T-lymphocytes, monocytes, prostate, liver, testis and ovary. The IL-2R~­
yc heterodimer forms the core signalling complex, wchich associetes with JAK.l and JAK3 and 
activates ST AT3 and STAT5. The downstream events that follow ligand binding include the 
activation of nuclear proteins, such as myc and fos and the upregulation of bcl-2 and bcl-xL 
levels, leading to resistance to apoptotic cell death leading to enhanced survival or proliferation 
(DiSanto, 1997). 
1.5.8. Immuooregulation of B-CLL cells 
In vitro experiments have indicated that many cytokines may be involved in the induction or 
regulation of B-CLL B-lymphocytes proliferation (Cordingley et al. 1988, Nerl et al. 1988, 
Touw et al 1992 and Mainou-Fowler et al. 1995) (Figure 1.8). These include 1NFSF2, IL-2, 
IFN-a, IL-4 and IL-7. It is still unclear which cytokines or cell-cell contacts are important to 
the survival of B-CLL cells in vivo, and whether the cytokines are produced by the tumour 
cells themselves or by accessory cells. However, it is now apparent that some cytokines play 
a role in the growth and differentiation of B-lymphocytes, while others may intervene in 
apoptosis. During immunological responses, normal B-lymphocytes secrete a number of 
cytokines such as GM-CSF, IFN-y, TGF-~, IL-Ia/~, IL-2 IL-7, IL-8 and IL-10 (Gause et al. 
1996). Production of IL-2 by normal B-lymphocytes is limited to the proliferating cells that 
also have increased expression of IL-2R. This suggests autocrine production of IL-2 (Schena 
et al. 1992b). 
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An autocrine/paracrine role in malignant B-lymphocytes has only been suggested for TNFa. 
(Cordingley et al. 1988). TNF-a. has been shown to induce cell proliferation in the majority of 
B-CLL patients, with or without prior stimulation. Soluble TNF-receptors have been 
demonstrated in the serum ofB-CLL patients (van Kooten et al. 1992 and Waage et al. 1992). 
IL-4 and IL-6 can inhjbit TNF-a.-induced proliferation in vitro (van Kooten, 1992). There is 
also evidence for the constitutive expression of IL-6 genes in B-CLL (Freeman et al. 1989) 
but it is not clear whether IL-6 is a growth or differentiation factor for B-CLL. Serum levels 
of IL-6 measured by ELISA are increased in B-CLL and IL-6 can inhibit apoptosis of 
malignant cells (Reittie et al. 1992 and 1996). 
Freshly isolated B-CLL cells or cells cultured in the presence of phorbol esters or anti-~, 
express the high affinity IL-2 receptor, and purified B-CLL cells respond to IL-2 with 
increased DNA synthesis and differentiation (Ernilie et al. 1988). There is also evidence that 
IL-2 is able to prevent apoptosis (Huang et al. 1993a). 
B-lymphocytes from patients with B-CLL also secrete IL-l , but its production, as assessed by 
mRNA and protein analysis, does not correlate with disease progression (Aquilar-Santelines 
et al. 1989 and 1991 ). However, IL-l alone does not induce DNA synthesis in B-CLL B-
lymphocytes, therefore it is unlikely to be an important autocrine growth factor. 
Apoptosis is an important process through which the ontogeny of both B- and T-lymphocytes 
can be regulated. Disruption ofthis process may lead to malignancy. There is evidence that the 
presence ofcertarn cytokines may be responsible for the long life in vivo ofB-lyrnphocytes from 
B-CLL patients. These cytokines include IFN-y and IL-4. IFN-y prolongs the life span ofB-CLL 
cells and is present in sera of B-CLL patients (Buschle et al. 1993). The mechanism by which 
INF-y inhibits apoptosis is unclear but some data suggests inhibition of the loss of bcl-2 protein 
in malignant B-lymphocytes (Buschle et al. 1993). 
The effect of IL-4 on B-lyrnphocytes from patients with B-CLL depends on which eo-
stimulatory signals are used in vitro experiments. IL-4 increases DNA synthesis in B-CLL B-
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lyrnphocytes when they are stimulated with PMA or anti-CD40 monoclonal antibodies 
(Carsson et al. 1989), but inhibits DNA synthesis when the B-lymphocytes are stimulated 
with TNF or IL-2 (Karray et al. 1988). Most importantly, however, it has been shown that IL-
4 inhibits spontaneous apoptosis, thus arresting the malignant B-lymphocytes in Go phase. 
This rescue from apoptosis is associated with an increase in bcl-2 levels (Panayiotidis et al. 
1993 and Dancescu et al. 1992). It has also been demonstrated that IL-8, IL-13 and IFNa. can 
suppress apoptosis of B-CLL cells ( di Celle et al. 1996a,b and Chaouchi et al. 1996). A delay 
in down-regulation of bcl-2 in vitro has been proposed as a common mechanism for the 
suppression of apoptosis by IFNa., IL-4 IL-6 IL-13, TNFSA2 (Tanquye et al. 1997). In 
addition IL-5 increases apoptosis of B-CLL cells (Mainou-Fowler et al. 1994). There is an 
inverse correlation between IL-10 mRNA expression and disease progression in B-CLL, but 
this is not so apparent when serum levels and B-CLL status are compared (Sjoberg et al. 1996 
and Eagle et al. 1996). 
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Figure 1.8: Regulation of apoptosis in B-CLL 
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Many factors that regulate proliferation and apoptosis of B-CLL cells are cytokines. They act on cell in 
autocrine and paracrine fashion and their action involves stimulation or blocking of proliferation and blocking or 
activation of apoptosis. 
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1.6. APOPTOSIS OF MALIGNANT B-L YMPHOCYTES 
1.6.1. Introduction 
B-cell chronic lymphocytic leukaemia (B-CLL) results from a clonal accumulation of 
CD5+ve B-lymphocytes. This expansion of B-lymphocytes is due to increased proliferation 
and extended survival due to decreased cell death (CoUins et al. 1989). 
Cell death can occur by two quite distinct mechanisms, namely necrosis and apoptosis 
(Wyllie et al. 1980 and Duvall et al. 1986). Necrosis occurs when cells are exposed to 
external conditions such as inflammation, ischaemia, hypoxia or toxic injury. It is a 
pathological process and begins with impairment of the cells ability to maintain homeostasis, 
leading to an influx of water and extracellular ions. Intracellular organelles such as 
mitochondria and the entire cell swell and rupture (cell lysis). The cytoplasmic contents, 
including lysosomal enzymes, are released into the extracellular fluid. Therefore in vivo, 
necrotic cell death is often associated with extensive tissue damage resulting in an intense 
inflammatory response (Van Furth et al. 1988). 
The term apoptosis (programmed cell death-PCD) is derived from the Greek word meaning 
'falling off' and was first introduced in 1972 by Kerr (Kerr et al. 1972). Although it was 
described many decades ago, the significance of apoptosis has been largely overlooked until 
recent years. Apoptosis is essential for the development and homeostasis of multicellular 
organisms. It is an active, metabolic, genetically determined and evolutionary selective death 
pathway (Wyllie et al. 1992), in which cell death can be influenced by external and internal 
factors (Hale et al. 1996). The scanning electron microscope has allowed more detailed 
images of apoptosis. An irradiated erythroleukemia model was used to demonstrate the 
importance of the redistribution of the nuclear membrane pores at the start of apoptosis 
(Pietro et al. 1994 and Falcieri et al. 1994). The main ultrastructural features of the apoptotic 
cell are condensation of nuclear chromatin, distinct crescent forming and undergoing of 
nucleolar segregation (Figure 1.9). The cell shrinks, becomes dense and cytoplasmic 
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vacuolisation occurs. The nucleus fragments into membrane-bound segments and the cell 
surface undergoes a budding process, resulting in the formation of apoptotic bodies, which 
are targets for phagocytes (Samaha et al. 1995). This process allowed removal of the 
apoptotic cells without the cytoplasmic contents coming into contact with the neighbouring 
cells. The biochemical features of apoptosis are endogenous endonuclease activation, 
resulting in fragmentation of double stranded DNA. This cleavage of DNA at the 
internucleosomallinker regions results in a ' ladder' of 180-200 base pairs fragments that are 
easily observed after gel electrophoresis. Laddering is considered to be a hallmark of 
apoptosis (Compton, 1992). 
The entire process of apoptosis is very rapid, the morphological changes appearing in 5 to 30 
minutes. It is also so precisely executed that, for example, in the development of nematode 
Caenorhabditis elegans, exactly 131 cells die according to a well-regulated genetic 
programme (Hergartner et al. 1994). To ensure homeostasis as many as 1011 cells die by 
apoptosis in the adult human daily. But apoptosis occurs under physiological and pathological 
conditions. For example it is essential for deleting autoreactive cells during lymphoid 
development (Rothstein, 2000, Nilsson et al. 2000). It is a significant physiological 
mechanism for establishing B-lymphocytes tolerance and shaping B-lymphocyte repertoire. 
B-lymphocytes are most probably eliminated within the germinal centres. Mature B-
lymphocytes also undergo apoptosis by signalling through CD95/APO 1/Fas. CD95 is a 48-
kd transmembrane glycoprotein, which belongs to the tumour necrosis factor/nerve growth 
factor receptor family and it is expressed on a variety of normal human tissue and tumours 
(Trauth et al. 1989). Similarly apoptosis in thymocytes is associated with the elimination of 
self-reactive clones of developing T cells following their interaction with antigens in the 
thymus. Incubation of naive T -lymphocytes with antibodies against T -cell receptor (TCR) or 
anti-CD3 antibodies, leads to their activation, proliferation, and cytokine production. On the 
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other hand, the same stimulation of activated T -lymphocytes, causes their death by apoptosis 
(Brunner et al. 1995). 
Increased proliferation as well as reduced apoptosis may lead to disease (Akbar et al. 1997 
and Graig et al. 1995). 
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Figure 1.9: Morphology of necrotic and apoptotic cells 
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Necrosis accurs when cells are exposed to extreme conditions resulting in damage of the plasma membranes. 
Cells ability to maintain homeostasis leads to an influx of water and extracellular ions. Intracellular organelles, 
most notably mitochondria and entire cell swells and ruptures. 
Apoptotic cells show characteristic morphological and biochemical features. These features include chromatin 
aggregation. nuclear and cytoplasmic condensation and formation of apoptotic bodies that contain mitochondria 
and nuclear material. Adapted from Trauth et al. 1997. 
92 
1.6.2. Regulators of apoptosis 
The whole process of apoptosis can be divided into three groups: induction, execution and 
degradation. The induction phase is characterised by changes in the cellular environment 
leading to the cell activating the mechanism of apoptosis. In the execution phase, processes 
within the cell that result in committal to apoptotic cell death take place (Kroemer et al. 
1997). In the degradation phase, the final disposal of the cell takes place. Our knowledge of 
the components of the regulatory machinery, which include the bcl-2 family members and 
caspases or cysteine proteinases related to IL-l p converting enzyme (ICE), continues to 
develop. Apoptotic regulators such as FasL and TNF, induce apoptosis, a fact that is largely 
confined to the development and regulation of the immune system. 
Triggers Regulators Executors 
DNA damage p 53 Apaf-1 
Cytokines bcl-2 Caspases 
Hypoxia Myc/oncogenes 
Temperature Cytochrome c 
Death receptors 
A number of pathological and physiological triggers can activate apoptosis. Regulators 
include factors which can stimulate or suppress apoptosis and executioners represent a point 
of no return in the life ofthe cell. 
Apoptosis is regulated by a large number of internal and external factors (Staunton et al. 
1998). Some play a role as initiators or inducers of apoptosis; oncogenes and tumour 
suppressor genes (c-Myc, p53, Bax, Bak), tumour necrosis factor (TNF), hyperthermia, 
cytokines, bacterial toxins, viral infections, Fas ligand, glucocorticoids, oxidants, radiation 
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therapy and cytotoxic drugs. Others act as inhibitors of apoptosis: growth factors, CD40 
ligand, interleukins, estrogens and androgens, pharmacological inhibitors and oncogenes and 
tumour suppresser genes (Bcl-2, Bcl-xL, Mcl-1) (Staunton et al. 1998). These gene products 
constantly interact with each other, which suggests that the process of proliferation and cell 
death is closely linked. Generally, there are two central pathways that can lead to apoptosis: i) 
positive induction by ligand binding to the plasma membrane receptor and ii) negative 
induction by loss of suppressor activity. Negative induction of apoptosis involves the 
mitochondria (Figure 1.6). The release of cytochrome c from mitochondria into the cytosol 
serves as a trigger to activate caspases (Green et al. 1998 and Liu et al. 1996). Each leads to 
the activation of cysteine protease, which has homology to the IL-l p converting enzyme 
(ICE) (Thomberry et al. 1998). 
1.6.2.1. Inducers of apoptosis 
Fas ligand, tumour suppressor genes (bax, bak, c-Myc and p53) as well as TNF, 
hyperthermia, cytokines, bacterial toxins and viral infections can act as initiators or inducers 
of apoptosis. 
1.6.2.1.1. Fas/CD95/AP0-1 
The Fas receptor (CD95, Apo-1 , TNFRSF6) belongs to a family of receptors including the 
tumour necrosis factor (TNF) and nerve growth factor (NGF) (Nagata et al. 1995). Fas, is a 
cell surface receptor for a ligand FasL and cross-linking ofFasL (TNFSF6) triggers apoptosis 
on the target cells. FasL trimerises when it binds to its cell surface receptor (Ashkenazi et al. 
1998). The intracellular portion of these receptors contains an 80 amino acid death domain 
(DD) (Figure 1.1 OA). The DD domain binds to MORT1/F ADD, which interacts with caspase-
8, a member of ICE/Ced-3 protease family. After caspase-8 activation, the cascade of 
caspase-mediated disassembly proceeds. It is expressed in abundance in activated mature 
lymphocytes, lymphocytes transformed with human immunodeficiency virus (HIV) or human 
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leukaemia vrrus (HTL V -1) and also on certain tumour cells. The ability of primary B-
lymphocytes to Fas-mediated apoptosis is modulated by additional signals. CD40 engagement 
produces up-regulation of Fas expression and sensitivity to Pas-induced death, whereas 
antigen receptor or IL-4R engagement inhibits Fas induced killing (Rothstain et al. 2000). 
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Figure 1.10: Structure of Fas, TNFSF6 and bcl-2 family 
A) Structure of Fas and TNFSF6 
FAS TNFSF6 
Schematic diagram of the structure of Fas and TNFSF6. The extracellular domain of Fas contains three 
cysteine-rich subdomains (shaded areas). The intracellular domains are shown as bold lines. The arrow 
indicates N-glycosylation sites. The TNFSF6 is a type fl membrane protein. The shaded area is the 
extracellular domain. Adapted from Kabelitz et al. 1997 
B) Structure of some ofthe members ofBcl-2 family 
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All members of Bcl-2 family (except Bad and Bid) contain a hydrophobic C-terminus transmembrane (TM) 
domain, which serves to anchor protein to membranes. Bad lacks this sequence. BHI and BH2 in death 
antagonists (Bel-l , Bcl-xL) allow heterodimerisation with Bax to repress cell death. BHJ in death agonists (Bax, 
Bak) allows heterodimerisation with Bcl-xL and Bcl-2 to promote cell death. BH4 domain is conserved in death 
antagonists (Bcl-xL). It allows interaction with death regulatory proteins such as Raf-1 , Bad and Ced-4. Adapted 
from Adams et al. 1989 
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1.6.2.1.2. Bax, Bak and Bad 
These are members of the pro-apoptotic bcl-2 family. They do not induce apoptosis because 
their activity is maintained in a latent form. After an appropriate signal, Bax undergoes a 
conformational change and moves to the mitochondrial membrane where it induces release of 
the mitochondrial cytochrome c into the cytosol (Wolter et al. 1997). Similarly Bak appears 
to undergo conformational changes and Bad is sequestered in the cytosol when cytokines are 
present (Datta et al. 1997). An activation cascade of pro-apoptotic proteins from bid to bak or 
bax integrates the pathway from surface death receptors to the irreversible efflux of 
cytochrome c (Korsmeyer et al. 2000). 
1.6.2.1.3. C-myc 
c -myc is a proto-oncogene whose dysregulated expression promotes cell proliferation and 
neoplastic transformation. It is localized in the nucleus and has a short half-life. When factors 
which suppress c-myc, such as bcl-2, insulin-like growth factor or platelet-derived growth 
factor are missing, c-myc is able to induce apoptosis (Evan et al. 1992). 
1.6.2.1.4. p53 
P53 is a tumour suppressor that inhibits or reduces transformation by viral and cellular 
oncogenes or other genotoxic stresses like DNA damage and hypoxia (Levine et al. 1997, 
Miyashita et al. 1994 ). P53 is capable of inducing apoptosis in several physiological 
conditions and, above all, following radio- or chemo-induced DNA lesions (Lane, 1992). It 
appears to act as a component of feedback control mechanisms, which regulate entry of the 
cell from the 0 1 phase of the cell cycle into S phase and passage through the S phase to 0 2 
and mitosis. Cells with inactivated p53 might therefore survive abnormally. After exposure to 
stressful stimuli, p53 is activated through post-translational mechanisms. One of the 
important target genes transcriptionally activated by p53 is the cyclin-dependent kinase 
(CDK) inhibitor (Milne et al. 1994). 
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Mutations or deletion of p53 are the most frequent genetic abnormalities found in human 
tumours. P53 is a short-lived protein that is maintained at very low or undetectable levels. 
Many human p53 mutants have been described. As far as apoptosis is concerned, p53 target 
genes such as bax and Fas/ AP01 have been implicated. Translocation of bax to the 
mitochondria and release of cytochrome c trigger activation of caspase 9 and the downstream 
caspase cascade (Somasundaram, 2000). 
1.6.2.2. Inhibitors of apoptosis 
1.6.2.2.1. Bcl-2 
The main anti-apoptotic protein is bcl-2. Bcl-2 is a member of the family of over a dozen 
proteins including suppressors of apoptosis (bcl-2 or Bcl-xL) or promoters of apoptosis (bak 
and bax) (Korsmeyer et al. 2000) (Figure 1.1 OB). These proapoptotic proteins interact 
antagonistically with anti-apoptotic proteins via their BH3 (Bcl-2 homology domain) domain 
that is determined by the ratio of the level of expression of each protein (Han et al. 1996 and 
Zha et al. 1996). BH3-dependent heterodirnerisation between bcl-2 family members appears 
to be the key function of the anti-apoptotic bcl-2 family members (Degterev et al. 2001). 
The bcl-2 gene was first discovered as a proto-oncogene found at the break points oft (14:18) 
chromosomal translocations in low-grade B cell lymphoma (Tsujimoto et al. 1984, Cleary et 
al. 1986). This translocation was found to increase expression of the bcl-2 gene by placing the 
coding region under the control of the immunoglobulin heavy chain enhancer (Tsujirnoto and 
Croce, 1986). The bcl-2 protein is 239 amino acids in length. It is localised in the outer 
mitochondrial membrane and the nuclear envelope, with a portion of the bcl-2 protein in the 
endoplasmic reticulum (Krajewski al. 1993). The level of bcl-2 expression is regulated during 
normal lymphoid development. An example of this is up-regulation of bcl-2 in the earliest 
stages of lymphoid maturation in pro-B-cells and CD4 and CD8-thymocytes and down-
regulation at the later stage in pre-B!IgM lgD- and CD8+CD4+ lymphocytes. This is 
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followed by up-regulation of bcl-2 in mature B- and T-1ymphocytes (Pezzella et al. 1990). 
An additional role for bcl-2 in survival of the high-atfmity B-lymphocytes in the germinal 
centres has also been proposed (Liu et al. 1991 ). 
Over-expression of bcl-2 is capable of antagonising apoptosis triggered by c-myc or p53. 
However, bcl-2 rescues apoptosis without affecting the mitogenic function of c-myc nor 
reversing growth arrest by p53. This suggests that bcl-2 may be a downstream regulator of c-
myc or p53. Bcl-X is a member of the bcl-2 family. Bcl-X transcripts are alternatively spliced 
into two products: bcl-XL, the long form and bcl-Xs, the short form. Bcl-XL acts to inhibit 
apoptosis in a similar fashion to bcl-2, whereas bcl-Xs antagonises its action (Dietrich, 1997). 
Many questions remain concerning the molecular mechanisms by which these membrane 
bound bcl-2 family members exert their control over caspase activation. Recent reports 
demonstrate that the mitochondrial protein cytochrome c can promote caspase activation in a 
cell-free apoptosis system (Liu et al. 1996). It is released into the cytosol following the 
induction of apoptosis by many different stimuli, including CD95, TNF and chemotherapeutic 
DNA-damaging agents (Reed et al. 1997). Cytochrome c is released from mitochondria in 
cells undergoing apoptosis and activation of caspase-3 is prevented by bcl-2 or bci-XL 
expression (Y ang et al. 1997 and Kharbanda et al. 1997). In B-CLL, bcl-2 is over-expressed 
and may prolonged survival of the malignant B-CLL clone (Aviram et al. 2000) and over-
expression ofbcl-2 may correlate with the stage of the disease (Niewiadomska et al. 2000). 
1.6.2.3. Executioners of apoptosis 
1.6.2.3.1. Caspases 
The basic effectors of apoptosis are death proteases, referred to as caspases. Cysteine 
Aspartate Specific Proteases (Caspases) are synthesized as inactive " proenzymes" that are 
processed by proteolitic cleavage to form an active enzyme. Within apoptotic cell, caspases 
trigger a cascade of proteolitic cleavage events and are thought to participate in apoptosis by 
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disabling important cellular processes and breaking down structural components of the cells 
(Nicholson and Thornberry, 1997). 
The caspases are a family of cysteine proteases that play a critical role in the execution phase 
of apoptosis. They are responsible for many biochemical and morphological changes 
associated with apoptosis (Cohen, 1997 and Cryns et al. 1998). Caspases are related to 
mammalian interleukin 1 P-converting enzyme (ICE) and to the nematode apoptotic gene 
product Ced-3 (Salveson et al. 1997). Since their discovery in 1993 at least lO different 
caspases have been identified. It has been proposed that 'initiator' caspases with long pro-
domains, such as caspase-8, either directly or indirectly activate 'effector' caspases such as 
caspases 3, 6, and 7 (Cohen, 1997, Fraser et al. 1996). These effector caspases then cleave 
intracellular substrates, such as poly polymerase (PARP) and lamins, during the execution 
phase of apoptosis. Caspase-8 is though to be an initiator caspase in many forms of apoptosis 
in addition to CD95-induced apoptosis. Procaspase-9 has been also proposed to be an initiator 
caspase. In the presence of dA TP and cytochrome c, its long N-terrninal domain interacts 
with Apaf-1 resulting in the activation ofcaspases -3, -6 and - 7 (Li et al. 1997, Zou et al. 
1997 and Srinivasula et al. 1998). 
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Figure 1.11: Death receptor pathway 
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The death-receptor pathway is triggered by CD95. Binding of CD95 ligand (CD95L) induced receptor 
clustering and formation of a death inducing signalling complex. This complex recruits via the adaptor 
molecule FADD (Fas-associated death domain protein), multiple procaspase-8 molecules, resulting in caspase 
8 activation. This action can be blocked by recruitment of the degenerate caspase homologue c-FLIP (FLICE-
Iike inhibitory protein). The mitochondrial pathway is used in response to extracellular cues and internal 
insults such as DNA damage. Pro and anti-apoptotic Bcl-2 fumi ly members meet at the surfuce of 
mitochondria, where tbey complete to regulate cytochrome c by a mechanism, which is still unknown. If a pro-
apoptotic member wins, an array of molecules is released from the mitochondrial compartment. The main of 
these is cytochrome c, which associates with AP AF- 1 (apoptotic protease-activating fuctor- 1) and then 
procaspase-9 to form the apoptosome. The death-receptor and mitochondrial pathways converge at the level of 
caspase 3 activation. Caspase-3 activation and activity is antagonised by the lAP proteins (inhibitor of 
apoptosis), which themselves are antagonised by the Smac/DIABLO protein (mitochondrial protein, 
Smac=DIABLO) released from mitochondria. Cross talk between death-receptor and mitochondrial pathway is 
provided by Bid, a pro-apoptotic BCL-2 family member. Caspase 8-mediated cleavage of Bid greatly increases 
its pro-apoptotic activity. 
Adapted from Hergartner, 2000. 
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1.6.3. Apoptosis in B-CLL 
Apoptosis is the physiological process in the homeostasis of cells, including normal B-
lymphocytes (Krammer et al. 1994). B-CLL is characterised by a progressive accumulation of 
clonal malignant B-lymphocytes, increased proliferative capacity and diminished cell death. It 
has been suggested that apoptosis is in some way 'defective' or inhibited in cancer (Hoffinan 
et al.l994). Malignant B-lymphocytes when cu ltured in vitro die by apoptosis suggesting the 
influence of humoral factors and/or cellular interactions (Collins et al. 1989). Spontaneous 
apoptosis (SP), which shows inter-patient variation, affects 3% to 65% of cells at 72br. It is 
not found in normal Band T lymphocytes under the same culture conditions. During SP, the 
level of bcl-2 protein decreases, while the expression of c-myc and wild type p53 protein 
increases (Panayiotidis et al. 1995). Cytokines such as, IFNa, IFNy, IL-l , IL-2, IL-4, IL-6, IL-
8 and IL-13 are able to suppress apoptosis of malignant B-lymphocytes. In these situations, 
apoptosis is decreased by the preservation of bcl-2 expression (Tangye et al. 1997, 
Panayoiditis et al. 1993 and Jewell et al. 1995). On the other hand B-lymphocytes can be 
induced to undergo apoptosis by in vitro treatment with IL-5 and IL-10 (Mainou-Fowler et al. 
1994, Osorio et al. 1998). 
Apoptosis of leukaernic cells in vitro is associated with down-regulation of expression of the 
bcl-2 oncogene (Tangye et al. 1996). Oncogenes are mutated form ofproto-oncogenes, whose 
functions are to promote normal growth and division of cells. The term oncogene itself is 
derived from the Greek ward 'oncos' meaning tumor. Elevated levels of bcl-2 protein have 
been observed in B-CLL patients (Schena, 1992 and Hanada et al. 1993) but this is not 
associated with the clinical stage of the disease (Robertson et al. 1996 and McConkey et al. 
1996). Evidence that bcl-2 may play a central role in preventing malignant B-lymphocytes 
from apoptosis come from several stud ies. The induction of anti-AP0-1 mediated apoptosis 
in activated B-CLL cells appears to correlate with reduced expression of bcl-2 rnRNA 
(Mapara et al. 1993). 
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There are conflicting reports about the correlation of bcl-2 and apoptosis in drug induced cell 
death. Some authors found a decrease in bcl-2 protein after treatment with chlorambucil, 
theophiline and nucleoside analogues (Mentz et al. 1996, Peterson et al. 1996), while others 
found no correlation at all (Consoli et al. 1998). 
Mutations in the tumour suppressor gene p53 occur in 20 to 30% of all cases of B-CLL. This 
percentage becomes more apparent with disease progression. Inactivation of the p53 gene can 
occur as the consequence of a mutation or possibly from functional inactivation of the protein 
product by the mdrn2 protein (Bannerji et al. 2000). This protein is upregulated by p53 and 
then binds to p53 to inactivate it as part of an intracellular negative feedback and as a 
consequence an accumulation of the malignant cells takes place. 
Receptor mediated signaling through receptors such as CD6, CD40 (TNFRSF5) and CD23 
are also responsible for the regulation of B-CLL apoptosis. Anti-IgM induced apoptosis is 
counteracted by cross-linking ofthe CD6 receptor. This in turn is related to the increase in the 
bcl-2/bax ratio (Osorio et al. 1997). Another signaling molecule, TNFRSF5, is a 
transmembrane glycoprotein belonging to the TNF family. CD40 ligand (CD40L, TNFSF5) is 
expressed on activated T -lymphocytes. Interaction between CD40 and its ligand leads to 
inhibition of apoptosis of malignant B-lymphocytes (Buske et al. 1997). The mechanism of 
TNFSF5 action is not yet fully understood, but it is possible that stimulation with TNFSF5 
affects cell proliferation rather than being directly involved in the apoptotic process. 
Triggering via CD40 correlates with an increase in the nuclear levels of NFKB I Rei 
complexes (Romano et al. 1998). 
CD23 is a molecule expressed in the majority of B-CLL cells. Cross-linking of the CD23 
antigen also results in an anti-apoptotic effect (Zhao et al. 1998). 
Cross-linking of the Fas receptor can induce B-lymphocyte apoptosis (Nagata et al. 1995). 
Fas (AP0-1 , CD95 or TNFSF6) is a member of the tumour necrosis factor/nerve growth 
factor family. However malignant B-lymphocytes are either Fas negative or have very weak 
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expression of Fas and are resistant to anti-Fas induced apoptosis (Panayiotidis et al. 1995). 
On normal B-lymphocytes, CD95 is expressed in 11 to 30% of cells. Interferon gamma and 
anti TNFSF5 are able to increase Fas expression on normal and malignant B-lymphocytes, 
whilst IL-2, IL-4, IL-l 0 and TNFSF2 have no effect on Fas expression (Cantwell at al. 1995). 
IL-2 and IL-7 were able to increase Fas expression in B-CLL with a parallel increase in bcl-2 
and bel-XL, a decrease in ICE and a stable level ofbax (El-Tounsi et al. 1995). 
Various drugs are able to induce apoptosis of malignant B-lyrnphocytes. Irradiation, 
corticosteroids, fludarabine, chlorambucil, 2-chlorodeoxyadenosine, mitoxantrone, etoposide, 
vincristine and vinblastine all mediate apoptosis (Binet et al. 1995). Furthermore, some data 
suggest that high bcl-2/bax ratios may be predictive of a drug resistant phenotype in B-CLL 
cells and that modulation of these proteins is essential for the induction of cell death (Pepper 
et al. 1999). Theophiline may also induce apoptosis, and this action can be inhibited by IL-4 
(Mentz et al. 1996). There is also some evidence that telomere length, as well as telomerase 
activity, exerts a strong impact on the survival of B-CLL patients (Bechter et al. 1998). All 
the internal and external factors described here may extend the life of B-CLL cells, increase 
their proliferative capacity and diminish cell death (Figure 1.11 ). 
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Figure 1.12: Proliferation and apoptosis in 8 -CLL 
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An altered balance between proliferation and apoptosis can lead to the progressive accumulation of COS 
positive B-CLL cells. Cytokines, proliferatioo/apoptosis-related genes and co-receptor signaling (e.g. 
TNFRSF6, CD6), are important factors in the regulation of the balance. Adapted from Osorio et al. 1998 
105 
1.6.4. Identification of apoptosis 
There are a number of methods for measuring apoptosis. Classical histological features of 
apoptosis are seen by light microscopy using nucleic acid binding dyes such as acridine 
orange or propidium iodine. However, this method is often not objective. The characteristic 
features of the apoptotic cell are reduced size due to cell shrinkage and cytoplasmic 
condensation, plasma membrane undulation (blebbing), condensation of chromatin, beginning 
at the periphery ofthe nucleus followed by nuclear fragmentation (karyorrhexis), dilatation of 
endoplasmic reticulum and finally formation of apoptotic bodies (Arends et al. 1990 and 
Arends and Wyllie 1991). Nuclear swelling and patchy chromatin condensation can 
distinguish necrotic cells. Swelling of the mitochondria, vacuolization of cytoplasm and 
plasma membrane rupture leads to the formation of 'ghost like cells' and finally dissolution 
of DNA (karyo lisis) (Kerr et al. 1972). Changes in the membrane of apoptotic cell and loss of 
transport function across the membrane are used to assay cell viability. Cationic dyes such as 
trypan blue, propidium iodine or 7 arnino-actinomycin-D are able, after a short incubation, to 
distinguish between necrotic and late apoptotic cells. Another dye, H0342 stains apoptotic 
cells strongly and live cells weakly. 
Flow cytometric identification of apoptotic or necrotic cell death is based on the analysis of 
those biochemical and morphological changes that enable us to distinguish between apoptotic 
and necrotic cell (Gorczyca, 1999). Apoptotic cells differ from necrotic cells in their ability 
to deflect light. The intensity of the light scatter in forward direction provides information on 
the cell size and structure while the intensity of the light scattered at the right angles to the 
laser (side scatter) correlates with granularity, refractiveness and the presence of intracellular 
structures that can reflect light. In apoptotic cells, forward light scatter decreases due to cell 
shrinkage while side scatter may increase transiently due to condensed chromatin and 
fragmented apoptotic bodies (Salzman et al. 1990, Ormerod et al. 1995, Cotter, 1998). 
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Other methods are based on detection of apoptosis-associated changes in distribution of 
plasma membrane phospholipids or transport functions of the membrane. Annexin V -FITC 
staining determines the percentage of cells undergoing apoptosis (Kopmann et al. 1994). 
Annexin V relies on the property of cells to lose membrane asymmetry in the early phases of 
apoptosis. In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner leaflet of the plasma membrane to the outer leaflet, thereby 
exposing PS to the external environment. Annexin V is a calcium-dependent, reversible, 
phospholipid-binding anti-coagulant protein with a high affmity for PS. About 50 exposed 
phospholipid monomers bind per Annexin V molecule. Propidium iodide (PI) is used to 
distinguish viable from nonviable cells in conjunction with Annexin V. Viable cells with 
intact membranes exclude PI, whereas the membranes of dead and damaged cells are 
permeable to this agent. Cells undergoing apoptosis stain with Annexin V and cells that stain 
negative for both Annexin V and PI are either at the end stage of apoptosis, undergoing 
necrosis. or are already dead. 
The major advantage of flow cytometry is that it offers a multiparametric analysis of several 
cell attributes, including cell cycle position. It can provide a rapid, simple, quantitative and 
objective assay for the enumeration of cell viabi lity and death. Flow cytometric data correlate 
with classical DNA fragmentation assays (N ico letti et al. 199 1 , Darzynkiewicz et al. 1992 
and Carbonari et al. 1995). 
The most commonly applied flow cytometric methods are based on the detection of 
endonucleotic DNA degradation. The degradation occurs first as multiple nicks are made 
along the DNA between nucleosomes (Linch, 1998). Certain enzymes can add biotin or 
digoxigenin labeled nucleotides to the DNA ends. The method, which is often used to detect 
fragmented DNA, utilizes a reaction catalyzed by exogenous TdT (terminal deoxytidyl 
transferase), often referred as ' end-labeling' or TUNEL (terminal deoxynucleotidyl 
transferase-med iated dUTP nick end-labeling) (Gold et al. 1 994). 
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1.7. ANTISENSE OLIGONUCLEOTIDES 
1.7.1. General introduction 
One way of controlling the expression of cytokines or other molecules that are upregulated in 
particular diseases is by the use of antisense oligonucleotides (ONs). The foiJowing is an 
outline of the way in which ONs function. 
The use of antisense or complementary single-stranded DNA able to inhibit translation of 
corresponding RNA, in cell-free systems has been considered for some time (Paterson et al. 
1977). Subsequently, in 1978 the Rous sarcoma virus was reported to interfere with viral 
production and cell transformation when exposed to oligonucleotides complementary to the 
3 '-reiterated terminal sequences in chick embryo fibroblasts (Zamecnik, 1978). Antisense 
oligodeoxynucleotides (ONs) are short synthetic, chemicaiJy modified stretches of DNA (13-
30 nucleotides in length) that are complementary to a target sequence (DNA or RNA). ONs 
are added extraceUularly to a cell culture system and are expected to enter the ceU and 
selectively hybridise with corresponding RNA or DNA, forming a duplex using Watson-
Crick base pairing rules which blocks transcription, translation or splicing. 
The base cytosine forms hydrogen bonds exclusively with guanosine (C-0) and adenine with 
thymine or uracil (A-T or A-U). Non-homologous or mismatched sequences of other genes 
do not form stable hybrids. There are several possible mechanisms by which antisense 
oligonucleotides disrupt protein synthesis. The most plausible is an active mechanism, which 
allows for binding of RNase H. RNase H is an endonuclease that recognises the RNA-DNA 
duplex and destroys the RNA but leaves the DNA oligonucleotide intact to hybridise with yet 
another mRNA target (MinhuiJ et al. 1986, Dash et al. 1987, Walder, 1988) (Figure 1.13). 
Another possible way of inhibiting protein synthesis is steric blockade of ribosomal subunit 
attachment to mRNA at the 5' cap site or interference with proper mRNA splicing through 
antisense binding to splice donor or splice acceptor sites (Meyers et al. 2000). 
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The cell takes up oligonucleotides via adsorptive endocytosis or pinocytosis or both (Gao et 
al. 1993, Crooke et al, 1995). The existence of oligonucleotide receptors has also been 
postulated (Hanss et al. 1998). A series of experiments was devised to evaluate the use of 
oligonucleotides as hybridisation competitors and future therapeutic agents. However it soon 
become apparent that although the concept of antisense technology is simple, the 
development as a therapeutic agent has been slow and difficult (Stain et al. 1993). Most 
mammalian cells appear to be able to internalise oligonucleotides but this process requires 
long incubation times and high doses of antisense (Crooke et al. 1993). Cell cultures in vitro 
provide the most convenient way to investigate antisense oligonucleotides. 
Figure 1.13: Mechanism of action of antisense oligonucleotides 
Cell 
Nucleus antisense oligonucleotide 
Antisense oligonucleotides (ONs) can bind to the targeted RNA in the nucleus or cytoplasm. Binding in the 
nucleus results in degradation of RNA-ON duplex by RNase H. In the cytoplasm, the bound antisense inhibits 
expression of the mRNA by interfering with protein translation. In effect, the protein of interest fails to be 
synthesised. 
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1.7.2. Oligonucleotide modulation of cytokine expression and their value in 
hematological malignancies 
Naturally occurring antisense RNAs in prokaryotes play a role in regulating expression of 
their corresponding genes (Mizuno et al. 1984, Sirnmons et al. 1988). This phenomenon is 
also present in eukaryotic cells (Izant et al. 1984, Izant et al. 1985). Therefore one can assume 
that ONs may be therapeutic in malignancy. However, the development of a reliable gene 
disruption strategy and its application in living cells has been very difficult, particularly in a 
clinical setting. The number of potential gene targets for baematological disorders is very 
wide and there are many reports of experiments demonstrating antisense effects (Bishop et a l. 
1994, Cotter, 2000). One of the most important is using antisense oligonucleotides to inhibit 
the function of the tumour suppressor gene p53 and the bcl-2 oncogene. In some forms of 
neoplasia, such as acute leukaemia and CML, p53 is mutated, and targeting p53 by 
oligoantisense in vitro results in inhibition of colony growth (Bishop et a l. 1994). Probably 
more important is the suppression of bcl-2 overproduction by antisense ol igonucleotides 
(Cotter, 2000). Overproduction of bcl-2 protein prevents apoptosis so blocking bcl-2 
expression may reverse this. 
Since many cytokines prevent apoptosis of malignant B-CLL B-lymphocytes, it seems 
reasonable to specuJate that reguJation of cytokine production by antisense oligonucleotides 
may be a logical approach to prevention of disease. 
Human IL-2 has been the target of one antisense approach resulting in up to 80% inhibition of 
PBMC proliferation, a decrease in T-cell receptor expression and 0 0/01 arrest of PBMC 
(Kato et al. 1994). Similarly oligonucleotide antisense targeting different regions of murine 
IL-4 mRNA resulted in the inhlbition of IL-4 production in murine B-lymphocytes or 
inhibition of B-celllymphoma clones (Haruna et al. 1993, Louie et al. 1993). Other cytokines 
such as IFN-y, IL-1 -a, IL-6, TNFSF2 and TNFSFl have also been modulated by antisense 
approaches (Abken et al. 1992, Boeve et al. 1994). Many cancer-associated genes are 
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alternatively spliced. Modification of splicing using antisense therapy may be yet another way 
of introducing gene therapy (Mercatante et al. 2000). 
1.8. AIMS OF THE PROJECT 
8-CLL is a clonal expansion of B-lymphocytes characterised by irnrnunophenotypic and 
genetic changes that influence their behaviour. There are also changes in the 8-CLL T-
lyrnphocyte population that may effect the malignant 8-lymphocytes. Cytokines that act as 
intra and inter-cellular messengers are known to have anti-apoptotic affects on malignant 8 -
lymphocytes. However this may be further complicated by the presence of cytokine splice 
variants that act as a self-regulatory system that may also afect malignant 8-Lymphocytes. 
Thus the balance between expression of different cytokines and also between expression of 
cytokine wild type and splice variant(s) may affect cell homeostasis. Using antisense 
oligonucleotides that interfere with transcriptional control of cytokine genes, the influence of 
cytokines on apoptosis of malignant and normal 8-Iymphocytes can be studied. 
Therefore the aims of this project were: 
I . To establish whether malignant 8-lymphocytes express intracellular IL-4, a cytokine not 
normally associated with 8-lymphocytes, to determine surfuce IL-4R expression and to 
compare these results with their normal counterparts. 
2. To measure mRNA transcript expression of the IL-2 y chain receptor family (lL-2, IL-4, 
IL-7, IL-9 and IL-15) in 8 - and T -lymphocytes of 8-CLL patients and compare the results 
with the expression in normal cells. 
3. To modulate cytokines and their spliced mRNA variants and protein expression by 
antisense oligonucleotides and to measure the effect of this modulation on apoptosis of 
malignant as well as normal 8 -lymphocytes. 
4. To measure the effect of cytokine specific antisense oligonucleotides on intracellular 
expression of these cytkines in malignant as well as normal B-lymphocytes. 
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CHAPTER 2: MATERIALS AND METHODS 
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2.1. PATIENTS 
A group 34 of patients with B-CLL, stage A(O), who were untreated or had not received any 
treatment in the last 6 months was studied. Diagnosis was based on a sustained lymphocytosis 
of more than 5.0 x 10 9 I I accompanied by the presence of more than 40% lymphocytosis in 
the bone marrow. AJI patients were of Caucasian origin. For practical reasons (patients dying, 
commencing treatment or refusing to give subsequent samples), different patients were used 
for each part of the project. Some of the patient characteristics, such as the percentage of 
CD5+ve lymphocytes and total lymphocyte count, were obtained from the diagnostic 
laboratory results. Local Research Ethics Committee approval was obtained for this study. 
2.2. CONTROLS 
The controls used in this study were normal healthy Caucasian volunteers from within the 
Derriford Combined Laboratory. The same group was used throughout the study. 
2.3. BASIC CULTURE MEDIUM PREPARATION 
Culture medium was prepared using RPMI 1640 (Gibco Ltd, UK.) supplemented with 100 
JU/ ml penicillin, I 00 Jlg/ml streptomycin (Gibco Ltd, UK), 2 mM glutamine (Sigma 
Chemicals, UK.), 0.2 % sodium bicarbonate and fetal calf serum 10% FCS (Gibco Ltd, UK). 
2.4. PERIPHERAL BLOOD MONONUCLEAR CELL ISOLATION 
For the cytokine protein studies, venous blood was collected in sodium heparin vacutainer 
tubes (Becton Dickinson, UK.), transferred to universal tubes (Philjp Harris Scientific, UK) 
and peripheral blood mononuclear cells (PBMC) isolated by density gradient centrifugation 
using LymphoPrep (Nycomed, UK) at 2000 rpm for 20 min. For the mRNA study, peripheral 
blood was collected in 5% disodium ethylene d iamine tetra-acetic acid (Na2EDTA) and 
PBMCs were iso lated as described above. The layer containing PBMCs was then transferred 
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to fresh universal tubes and washed three times with RPMI 1640 (Gibco Ltd, UK). Following 
centrifugation, the supernatant was removed and the pellet of cells resuspended in basic 
culture medium (1 mJ). The number of cells present in 1 ml of this suspension was determined 
using a Neubauer Haemocytometer (Weber Scientific International, UK). Briefly cells were 
resuspended 1: 1 in trypan blue solution (Sigma, UK) and counted under the microscope. The 
number of cells was calculated according to the following formula: 
Number of lymphocytes in l ml = n x 4 x 2 x 104 
n= number of cells present in 4 small squares of haemocytometer chamber 
2.5. ISOLATION OF L YMPHOCYTES USING DYNABEADS 
Peripheral blood was obtained by venepuncture in 5 % Na2EDTA and PBMCs were obtained 
and washed as described in 2.4. Using Dynabeads M-45-CD 19 (Pan B) and CD2 (Pan T) 
(Dynal, UK), CD 19+ve and CD2+ve cells were positively depleted from the PBMC 
suspension according to the manufacturer's instructions. Attempts were made to count the 
obtained lymphocytes but thjs proved to be difficult due to Dynabeads still attached to the 
cells. The cells were then pe lleted and frozen in liquid nitrogen until required for Western 
Blotting, Northern Blotting and nested RT-PCR. 
2.6. PREPARATION OF RNA 
Pure CD19+ve and CD2+ve cell populations were isolated using Dynabeads M-450 (Dynal, 
UK), according to the manufacturers instructions (section 2.6). Total cellular RNA was 
extracted from CD l9+ve and CD2+ve lymphocytes using RN A ST AT -60 (B iogenesis Ltd, 
UK) according to the manufacturer's instructions. Briefly, cells were homogenised using 1 ml 
of RNA STAT-60 (1 ml per 5-l0x106 cells) by repetitive pipetting. Fo llowing 
homogenjsation, homogenate was stored for 5 mm at room temperature to permit the 
complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform per 1 mJ of RNA-
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ST AT -60 was added to the homogenate and the mixture was shaken vigorously for 15 
seconds and incubated at room temperature for further 2-3 min. Homogenate was centrifuged 
at 12,000 g (max) for 15 min at 4°C. Following centrifugation, the upper aqueous phase was 
removed to a fresh tube and mixed with 0.5 ml of isopropranolol. After 5-10 min of 
incubation at room temperate the mixture was centrifuged at 12,000 g for 10 min at 4°C. The 
RNA precipitate was washed with 75% ethanol. The RNA pellet was dried in a vacuum for 5-
10 rnin and dissolved in RNase free water. RNA was diluted in 50 J..tl of pure water and 
frozen at - 70°C. The purity and concentration of the cellular RNA was confirmed using a 
Cecil 5500 spectrophotometer (Cecil Instruments, UK). 
The concentration of RNA was calculated according to the formula recommended in RNA-
STAT-60 manuals: 
I unit at 260 nm corresponds to 40 J..tg of RNA per ml 
A260 = 1 = 40 J..tg/ml 
Pure RNA has a ratio A260 I A2so of 1.7-2.00 
Concentration of RNA = 40 x A260 x dilution factor = concentration J..tg/ml 
Total yield = concentration x volume of stock in ml 
2. 7. STATISTICAL ANALYSIS 
2.7.1. T-test 
Pairwise evaluation of means was performed with the Students t test. The Students t test is 
used to determine whether two samples are likely to have come from two underlying 
populations, which have the same mean. Mackintosh software was used to evaluate the 
Students t-test. P values less than 0.05 were considered to indicate statistical significance. 
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2.7.2. Spearmans' Rank Correlation Test 
The Spearmans' Rank Correlation Test measures the degree of relatedness between two 
continuous variables. It is used to compare rankings of cases of a variable in two different 
conditions (before and after treatment with antisense oligonucleotides). Mackintosh software 
was used to evaluate the results. P values less than 0.05 were considered to indicate statistical 
significance. 
2.8. FLOW CYTOMETRIC ANALYSIS OF IL-4 AND IL-4 RECEPTOR (IL-4R) 
EXPRESSION 
Flow cytometry is a technique that allows measurements of single cells or particles as they 
flow in a fluid stream one by one through the sensing point (collimated laser beam). In the 
first part of the study flow cytometry was used to measure the percentage of CD 19+ve and 
CD3+ve lymphocytes expressing intracellular IL-4 and surface IL-4R. The PBMCs used in 
this part of the study were unstimulated. The reasons for using unstimulated cells was that 
mitogens addition may artificially interfere with actual state of the malignant cells. 
2.8.1. Measurement of surface IL-4 receptor expression by flow cytometry 
The protocol used below is a modification of the protocol used in the Derriford Combined 
Laboratory. PBMCs, isolated according to the procedure described in section 2.1.4, were 
washed and resuspended in PBS (phosphate buffered saline) (Sigma, UK) at a concentration 
of 1 Ox I 0 6/ml. 100 J.tl of PBMCs suspension was then pipetted into labelled tubes and the 
appropriate antibody added. For single CD 19 or CD3 staining, 10 Jll of mouse anti-human 
lgG 1 fluorochrome conjugated (FITC) antibody (Dako, UK) was used. For determination of 
surface IL-4R expression, cells were incubated with primary mouse anti-human IL-4R IgG l 
antibody (Genzyme, UK) at a concentration of 5 J.tg/ml. After 30 min of incubation at 4°C, the 
cells were washed three times in cold PBS supplemented with 0.2 % bovine serum albumin 
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(BSA) (Gibco Ltd, UK). After washing, 10 J.ll of secondary, sheep anti-mouse R-
Phycoerythrin (PE) conjugated antibody (Sigma, UK) was added. After a further 30 min of 
incubation at 4°C, the cells were washed 3 times and each sample was stained for the presence 
of CD19 or CD3 antigen respectively. 10 J.ll of mouse anti-human CD19 and CD3 (FITC) 
lgG 1 monoclonal antibody (Dako, UK) was added. After 30 min of incubation at 4°C and 
washing with PBS buffer, the cells were resuspended in I m1 of PBS and analysed 
immediately by flow cytometry (Becton Dickinson-F ACScan, UK). 
2.8.2. Measurement of intraceUular IL-4 by flow cytometry 
The protocol used below is a modification of the protocol described in Serotec Catalogue 
( 1996). A washed PBMCs suspension, isolated according to the protocol described in section 
2.1.4, was diluted to a concentration of 1x106/ml in culture medium consisting ofRPMI 1640 
(Gibco Ltd, UK) supplemented with I 0 % FCS (Gibco, Ltd, UK) and 2 mM monensin 
(Sigma, UK). The PBMCs were plated out in a 24 well tissue culture plate and incubated for 6 
hr in a 5 % C02 incubator at 37°C. After 6 hours of incubation, the cells were washed in PBS 
containing 0.2 % BSA (Gibco Ltd, UK) and 0.02 % sodium azide (Sigma, UK) and adjusted 
to a concentration of0.5 x106/ml. 50 J.ll of Fixation medium (Serotec UK) was added. After 
15 min incubation and one wash, 50 J.ll ofPermeabilisation Medium (Cytoperm, Serotec, UK) 
together with the appropriate antibody (negative control-mouse lgG), anti-CD 19 FITC, anti-
CD3 FITC and/or mouse IgG 1 anti-human IL-4 PE (Pharmingen, USA) was added and 
further incubated for 30 min at room temperature. The cells were then washed once in PBS 
buffer and resuspended in 0.25 ml of 0.5 % paraformaldebyde (Sigma, UK) and store at 4°C 
until acquisition on the flow cytometer. 
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2.8.3. Preincubation of PBMCs with anti-IL-4R monoclonal antibody 
PBMCs were isolated from two patients with B-CLL. The cells were resuspended in basic 
culture medium (section 2.3) at a concentration of 1x106/ml. To 3 mJ ofresuspended cells, 10 
J .. d of anti-IL-4R monoclonal antibody was added and the mixture incubated for 1 hr at 37°C. 
After incubation, thePBMCs were washed twice ready to be used in section 2.8.2. 
2.8.4. Analysis of flow cytometric data 
Analysis on the F ACScan (Becton Dickinson, UK) was performed using an argon ion laser. 
Instrument calibration I standardisation was performed using the manufacturer instructions. 
Live gating of the forward (FSC) and side scatter (SS C) channels was used to exclude debris 
and to selective ly acquire lymphocyte events. All values presented are based on the 
percentage of lymphocytes as determined by light scatter. Individual fluorescence populations 
were determined by the use of acquisition and quadrant analysis software (Cellquest, Becton 
Dickinson). Results are shown as the percentage of CD3+ve, CD 19+ve lymphocytes 
expressing intracellular IL-4 and surface IL-4R in PBMC suspensions corrected for non-
specific binding using non-specific controls. Joining dots of the same density derived the 
individual contour plots (Figure 2.1). The number of events acquired for each sample was 
10,000 whenever possible. 
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Figure 2.1: Flow cytometric analysis of different cell populations 
A} 
CD19PE 0 
• CD3 FITC 
B) 
IL-4 PE 0 • IL-4 PE/CD3 FITC 
0 • 
CD3 FITC 
Plot ofCDJ FJTC (f-lymphocytes) versus CD I9 PE (B-Iymphocytes) showing three discrete populations (A). Plot 
ofCDJ FITC versus TL-4 PE CD3+ve lymphocytes stained for IL-4 (B) 
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2.8.5. Measurement of secreted IL-4 protein by ELISA 
CelJs were set up as folJows. Washed PBMCs prepared according to the procedure described 
in section 2.4 were adjusted to a concentration of 1 x 106 /ml in culture medium consisting of 
RPMI 1640 (Gibco Ltd, UK) supplemented with 10% FCS (Gibco Ltd, UK). The PBMCs 
were plated out in a 24 well tissue culture plate and incubated overnight in a 5% C02 
incubator at 37°C. Cells were stimulated with phytohemagglutynin (PHA) (Sigma, UK) at a of 
concentration 1flg/ml or pokeweed mitogen (PWM) at a concentration of 5 f.!g/ml (Sigma, 
UK) and incubated for 48 hours at 37°C. PHA is a specific T celJ mitogen whlle, PWM is able 
to stimulate both B and T-lymphocyte population to release cytokines. Since IL-4 is not easily 
detected in supernatants of unstimulated celJs by ELISA addition of mitogens increase cells 
capacity to produce IL-4. Collected supematant were frozen at - 20 °C. Thawed supematants 
were then assayed in duplicate for the concentration of IL-4 using a commercial ELISA kit 
(Amersham, UK). The ELISA plates were read at 450 run and the samples calculated using a 
Dias Microplate Reader (Dunatech Laboratory, UK) 
2.9. NESTED REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION 
(RT-PCR) mRNA ANALYSIS 
The intracellular staining results have shown an increased percentage of malignant B-
lymphocytes as well as norma] T-Jymphocytes expressing intracellular IL-4. In view ofthis more 
specific tests needed to confirm the presence or absence of specific mRNA transcripts in B and 
T-lymhocytes separated from patients and normal controls. There are many transcript assays able 
to quantitatevely or semi-quantitatevely detect mRNA transcripts (e.g. competetive RT-PCR, real 
time PCR, expression microarrays, RNA protection assay). However in view of the previews 
inconclusive foundings of the IL-4 mRNA transcripts in the malignant B-cell populationand the 
low aboundance of this transcripts a modificationof RT-PCR method was chosen. A nested 
reverse transcriptase polymerase chain reaction (RT-PCR) was used to amplifY mRNA 
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sequences of the cytokines that use the common gamma chain (ye) as part of their individual 
receptor as well as IL-2 32, IL-2 33, IL-4 32, IL-4 33, IL-4R, IL-5 and IL-13. In the first instance 
this assay was used check the presence or absence of individual transcripts. However with the 
purchase of Multi-Imager the semi-quantitive measurements of each individual band were 
obtained. Due to limited amounts of cDNA each experiment was repeated only once. 
The amplification of beta-actin gene was performed as a single RT-PCR reaction. 
2.9.1. Preparation of cDNA 
Total RNA was prepared according to the protocol described in section 2.6 and frozen at -
80°C until further use. First strand complementary DNA (cDNA) was prepared using the 
SUPERSCRIPT™ Preamplification System for the First Strand cDNA Synthesis (GIBCO 
Ltd, UK) according to the manufacturer's specifications. Briefly, 1J..1.l of oligo dT12-18 (0.5 
J..lg/ml) was added to RNA at a final concentration of2 J..lg/rnl. DCPE water was then added to 
achieve a final volume of 12 111. The mixture was first incubated for 10 min at 70°C and then 
on ice for 1 min. 7 J..ll of the reaction mixture (2 J..ll of 10 x buffer, 2 J..ll of 25 mM MgCh, 1 Jll 
of 1 OnM dNTPs and 2 J..ll of 0.1 M DTT) was added to the RNA mixture and incubated for 5 
min at 42°C. After incubation, 1 Jll (200 U) of Superscript IJ RT was added to each tube and 
incubated at 42°C for SO min. The reaction was terminated at 70°C for 1 S min. 1 111 of RNase 
H was added to each tube and the mixture incubated for 20 min at 37°C. 
2.9.2. Nested RT-PCR protocol 
The PCR mixture at a final concentration of 25 Jll, contained 2 J..ll of cDNA, 2.5 111 of 1 Ox 
buffer (Tris-HCL-10 mM, KCL-50 mM, MgCL2- l.S mM) (HT Biotechnologies, UK), 2 J..ll of 
dNTPs mixture (0.125 mM each) (Bioscience, UK), 1 111 of each primer (lOOng/ul=lO pmol) 
(MWG-Biotech, Germany), 0.5 Ill of super Taq (0.125 U) (HT Biotechnology, UK) and 
121 
fmally water. The primers used in the ftrst and second round of amplification are listed in 
table 2.2. The PCR mixture conditions are described in Table 2.2. For the second round of 
amplification, l J.!l of fust round product was used together with other elements of the mixture. 
After the second round of amplification, the PCR products were subjected to electrophoresis 
on a 1.4 % UltraPure agarose gel (Gibco, UK). Ethidium bromide (2,7-diamino-10-ethyl-
9phenyl-pheanthridinium) (Sigma, UK) staining was used to detect individual bands. A 
molecular weight marker lOO to 2642 bp (Boehringer Marmbeim, UK) was used with each 
gel. The gel was run in O.Sx TBE buffer at 200 V for 30 min to 1 hour. The gel was visualised 
using a UVP computer software package (UVP International, UK) and UVP UV 
transiluminator (UVP International, UK). 
The following stock solutions were used: 
Trislborate electrophoresis buffer ([BE) 
5 X concentrated solution = 54 g Tris base+ 27.5 g boric acid+ 20 ml of0.5M EDTA added 
to l L of water (pH 8.0) 
Working solution = 0.5 x 
Ethidium bromide 
I 0 mg/mr1 in H20 
Xylene cyano/ loading buffer 
0.25% v/v Xylene cyano~ 10% v/v Glycero l in lO x TBE 
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Table 2.1: Primers used in nested RT-PCR reaction · 
Cytokine Sense primer (5'-3') Anti-sense primer (5'-3') 
P-actin Exon 5'-GTG GGG CGC CCC Exon 5'-CGC GCT CGG TGA 
AGG CAC C-3 ' GGA TCT CT-3 ' 
IL-2 outer primer Exon 1-5 -CCT CAA CTC CTG Exon 4-5 -GAG CCC CTA GGG 
CCACAA TG-3 CAC AAA AAG AAT C-3 ' 
I L-2 inner primer Exon 1 :-5 -CAC T AA GTC TTG Exon 4-5 -GTG TTG AGA TGA 
CAC TTG TCA C-3 ' TGC TIT GAC-3·. 
IL-2 o2 inner primer Exon 1: 5 -CAC T AA GTC TTG Exon 3: 5 -CTG ATI AAG TCC 
CAC TIG TCA C-3 CTG GGT CTT AAG-3 
IL-4 outer primer Exon 1: 5' -CTC ACC TCC CAA Exon 4: 5'-GAT CGT CTI TAG 
CTG CTT CCC CC-3' CCT TIC CAA G-3 ' 
IL-4 inner primer Exon 1: 5' -GGC AAC TIT GTC Exon 4: 5' -GTT GGC TTC CTT 
CAC GGA CAC AAG-3' CAC AGG AGA GG-3 ' 
IL-482 outer primer Exon 1: 5'-CAG CAT TGC ATC Exon 3:5 ' -GGT TCC TGT CGA 
GTI AGC TIC TCC TG GCC GTT TCA GTT AT-3 ' 
IL-4 o2 inner primer Exon 1: 5'-GGC AAC TIT GTC Exon 3:5'-GCA GCC CTG CAG 
CAG GGA CAC AAG-3 ' AAG GTT TCC TT-3 ' 
IL-7 outer primer Exon 1: 5'-GCC ACG CCG TAG Exon 6:5' -CTT GGA GGA TGC 
TOT GTG CCG C-3' AGC T AA AGT TC-3 ' 
I L-7 inner primer Exon 1: 5 -CAC AGA CTC GGC Exon 6: 5 -CAG TGT TCT TT A 
AAC TCC GCG GAA G-3 ' ' GTG CCC ATC-3 
IL-9 outer primer Exon 1-5 '-GGT CCT TAC CTC Exon 4-5'-CTT GCC TCT CAT 
TGC CCT GCT CC-3' CCC TCT CAT C-3 ' 
IL-9 inner primer Exon 1-5'-CTT CCT CAT CAA Exon 4-5'-GGT TGC ATG GCT 
CAA GAT GC-3 ' GTT CAC AG-3 ' 
IL- 15 outer primer Exon 1-5 -GGA TGG ATG GCT Exon 6-5 -GAG TIC ATC TGA 
' GCT GGA AAC-3 TCC AAG GTC-3 
IL- 15 inner primer Exon 1-5 -GTG GCT TTG AGT Exon 6-5 -GTC T AA GCA GCA 
AAT GAG AAT T-3 GAG TGA TG-3 
ye outer primer Exon 1-5'-CAT CAT TAC CAT Exon 8-5 ' -CTG TAG TCT GGC 
TCA CAT CCC TC-3' TGC AGA CTC TC-3 ' 
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. . Exon 1-5'-CTG CTG GGA GTG Exon 8-3' -CCC TTA GAC ACA ye mner pnmer 
GGG CTG AAC AC-3' CCACTCCAGG 
IL-5 outer primer Exon 1: 5 ' -GAG GAT GCT TCT Exon 4-5' -CTA ITA TCC ACT 
GCA TIT GAG-3 ' COG TGTTC-3 ' 
IL-5 inner primer Exon 1 : 5 '-CCT TGG CAC TGC Exon 4:5'-CTT GCA GOT AGT 
TIT CTA CTC-3' CTA GGA ATT GG-3 ' 
IL- 13 outer primer Exon l: 5'-GGC GCT TIT GTT Exon 4:5' -GAA CCG TCC CTC 
GAC CAC GOT C-3' GCG AAA AAG-3' 
IL-13 inner primer Exon 1: 5'-CAT TGA GGA GCT Exon 4:5'-GCC ACC TCG ATT 
GOT CAA CAT C-3' TTG GTG TCT CG-3 ' 
IL-4R inner primer Exon l: 5' -GCG AAA TOT CCT Exon: 5 '-CCA GTC CAA AGO 
CCA GCA TG-3 ' TGA ACAAGG GG-3 ' 
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Table 2.2: Condition for the first and second round of nested RT -PCR amplification 
Cytokine Nr. of Denaturation Annealing Extension Band size 
cycles (temp/time) (temp) (temp) (base pair) 
Beta actin 30 94°C-2 min 63°C 72°C 487 bp 
Gammac 1st 35 94°C-2 rnin 59°C 72°C 961 bp 
Gammac 2nd 35 94°C-2 min 63°C 72°C 889 bp 
IL-2 1st 35 94°C-2 rnin 59°C 72°C 644 bp 
IL-2 2nd 35 94°C-2 min 55°C 72°C 420 bp 
IL-2delta2 I st 35 94°C-2 min 57°C 72°C 259bp 
IL-2delta2 211<1 35 94°C-2 min 60°C 72°C 162 bp 
IL-4 delta2 151 35 94°C-2 min 62°C 72°C 443 bp 
IL-4 delta2 200 35 94°C-2 mm 62°C 72°C 11 5 bp 
IL-4R 1st 35 94°C-2 mm 62°C 72°C 1515 bp 
IL-4R 2nd 35 94°C-2 min 62°C 72°C 308 bp 
IL-7 1st 35 94°C-2 min 61°C 72°C 798 bp 
IL-7 211<1 35 94°C-2 min 61°C 72°C 659 bp 
IL-9 1st 35 94°C-2 min 62°C 72°e 411 bp 
IL-9 211<1 35 94°C-2 min 55°e 72°e 246 bp 
IL- 15 1st 35 94°e-2 min 57°C 72°C 708 bp 
IL-15 211<1 35 94°e-2 mill 54°e 72°e 558 bp 
IL-5 1st 35 94 e 0-2 mill 54 e 0 72 eo 391 bp 
IL-5 2nd 36 94 C0 -2 min 57 eo 72 eo 260 bp 
IL-13 1 SI 35 94 e 0-2 rnin 60 e 0 72e0 385 bp 
IL- 13 2nd 36 94 C0-2min 60 C0 72 C0 234bp 
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2.9.3. Data analysis 
The density of bands was measured using Fluor-S™ Multi-Irnager (BioRad Laboratories, UK) 
by drowing individual and the same size quadrants around each band. The data analysed using 
the Student t-test and Spearmans Rank Correlation test described in section 2.8. 
2.10. ANTISENSE STUDY 
2.10.1. Introduction 
The techniques described above were used for detecting protein and mRNA of cytokines that 
may play a role in the pathogenesis of B-CLL. Antisense oligonucleotides (ONs) were used to 
try to modify the transcription and protein expression ofiL-2 and IL-4 cytokines. 
However, since oligonucleotide technology is relatively new, several general considerations 
have to be applied in order to obtain optimal results. The first is the choice of cell type. Cells 
that are known to express the gene of interest and preferably at a high level are the best choice. 
The state of the cells as well as the type of cell lines is also important. 
The others are modification, length and sequence selection as well as purity and the delivery 
system Several chemical modifications have been proposed. In phosphorothioate 
oligodeoxynucleotides (S-ODN), one of the non-bridging oxygen atoms in the nucleotide 
backbone is replaced with sulphur. This increases the protection from both endonucleases and 
exonucleases and supports RNase H activity (Camp bell et al. 1990 and Aghtar et al. 1991 ). S-
OON have a half-life greater than 18 hr in pure fetal calf serum and more than a week in cell 
culture medium containing 10% FCS (Shaw et al. 1991 ). Other modifications give rise to 2 '-
0 -methyl oligonucleotides. In this modification there is an addition of a methoxy group to the 
C2' position of the sugar. This modification enhances nucleases resistance but does not 
support RNase H activity. In order to secure RNase H activity this modification must be 
incorporated into a gapped or chimeric structure (McKay et al. 1999). However they have 
lower water solubility but are highly resistant to nuclease degradation (Tidd et al. 1989). To 
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further increase nuclease resistance, to improve the affmity to the target RNA and to facilitate 
cellular uptake, new backbone modifications have been designed (Figure 1.14). They include 
hydroxymethyl phosphonates, carbonates or arninoalkyl derivatives (Agraval et al. 1995). 
Chimeric oligos have also been created. Oligos with phosphorothioate core and 
methylphosphonate caps at both ends have favourable characteristics of in vivo stability and 
distribution (Agraval et al. 2000). 
In the process of selecting the best oligonucleotides, the length of the antisense molecule is 
very important. It has been calculated that the minimum length of an oligonucleotide has to 
be between 15-20 bases (Branch et al. 1998). It has been shown that antisense longer than 
30 bases can trigger a genetic cascade of cellular antiviral response (Manche et al. 1992) 
Another important consideration is sequence selection. One successful strategy has been to 
adopt a 'gene-walk' approach. Another approach, which helps in the selection of the best 
oligonucleotides, is to use DNA chip technology. In this case the antisense sequence is 
bonded to a silicone chip. The target RNA is labelled with radioactive nucleotide and 
hybridised to the chip. The 'hot spots' created by areas of strongest radioactive signals 
correlate with accessible sites (Milner et al. 1997 and Kuss and Cotter, 1999). One of the 
most popular sites is the region surrounding the start codon (AUG), followed by mismatch 
sites. Targeting splicing sites in order to inhibit the mRNA processing mechanism, as 
opposed to the message (Sierakowska et al. 1996), is also plausible. Four contiguous G 
residues are known to exhibit non-specific anti-proliferative action independent of the overall 
sequence of the oligos (Yamamoto et al. 1994). Palindromes such as GACGTC, AGCGCT 
and AACGTT are known to induce interferon production (Yamamoto et al. 1994), whereas 
GT rich oligos inhibit action of IFN-y (Yaswen et al. 1993). Finally, the use of certain CpG 
motifs will result in B lymphocyte and natural killer cell stimulat ion with the release of 
cytokines such as tumour necrosis factor and interferon (Krieg et al. 1995). 
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Purification by reverse phase HPLC is often the best choice, although not all toxic by-
products are removed. 
Transfection agents such as liposomes, peptides and poly-cations greatly facilitate 
oligonucleotide activity (Bennet et al. 1992, Bongartz et al. 1995, Kukowaska-Latallo et al. 
1996, Boussif et al. 1995). One of the most effective delivery systems is the use of cationic 
lipids. They can enhance cellular uptake by 1000-fold (Bennett et al. 1992) at the same time 
promoting nuclear accumulation. If a delivery system is not used, isolated spots are visible 
only in the cytoplasm (Shoji et al. 1991 ). 
2.10.2. Testing for antisense entering tbe cells 
IL-2a rodarnine-red conjugated antisense ON was tested for its ability to enter PBMCs by a 
process of endocytosis. B-CLL and normal control PBMCs prepared according to the protocol 
described in section 2.4, were washed and resuspended at a concentration of lx105/ml in 
culture medium described in section 2.3 and plated into a 96 well plate. Rodarnine-red 
conjugated IL-2a antisense ON was added at concentrations of 0.5 J.!M, 1 Jlffi, 1, 75 J.!M, 2.5 
J.!M, 5 J.!M, and l 0 J.!M. The lymphocytes were then viewed under an UV microscope after 30 
m in, 1, 2, 3 and 4 hours. No carrier was used. 
2.10.3. MTT cytotoxicity assay 
The MTT cytotoxicity assay is based on the capacity of active mitochondrial dehydrogenase 
in living cells to convert 3-[ 4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; 
thiazolyl blue (MTT) by the cleavage of the tetrazoliurn ring, into a water-insoluble dark blue 
formazane product. The MTT assay has been developed as an alternative system to 
conventional 3H-thymidine uptake for measurements of cell proliferation. In this study the 
TACS™ MTT Assay Kit (R&D) was used to measure cell proliferation and viability of B-
CLL cells and normal controls PBMCs after incubation with various antisense ONs. 
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Sequences of all the antisense oligonucleotides used are listed in Table 2.3. Figure 2.1 a and b 
describes the location of appropriate antisense oligonucleotides. The number of antisense ONs 
were specially designed to interfere with the transcription of wild type and spliced variants of 
IL-2 and IL-4. 
Figure 2.2: Individual antisense oligodeoxynucleotide (ONs) positions 
a) 
Exon 1 Exon 2 Exon 3 Exon 4 
• • • • 
IL-2a/IL-4a IL2b!IL-4b 
Exon 1 Exon 3 Exon 4 
• • 
IL2c/IL-4c 
Exon 1 Exon 2 Exon 4 
• • 
IL-2d/l L-4d 
IL-2a. IL-4a. IL-2b, IL-4b, IL-2c, and IL-4c antisense ONs were designed at the junction of appropriate exons. 
lL-2d and IL-4d antisense ONs were situated within exon one. 
b) 
Antisense Blocking effect 
IL-2a or IL-4a IL-2 or IL-4 wild type and 83 
IL-2b or IL-4b IL-283 or IL-4o3 
IL-2c or IL-4c IL-282 or IL-482 
IL-2d or IL-4d IL-2 or IL-4 wild type and 82 and 83 spliced 
variants 
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Table 2.3: Sequences of the antisense oligonucleotides 
Name Oligonucleotide antisense 
Control antisense (1) 5 - AGT AGT TIT GGA AA-3 
Control antisense (2) 5'-TTT TTA AAA AAA ATT T-3' 
IL-2a 5 -CTT GTA ATA TTAATT-3 
IL-2b 5 -TCA GAT CCC TIT AGT-3 
IL-2c 5 -TIC TOT GGA TTA ATT-3 
IL-2d 5 -AGT GCA AGA CTT AG-3 
IL-4a 5 -GCA CAG AGC TTC TAC T-3 
IL-4b 5 -CAG GAA TIC AAG CCC-3 
IL-4c 5 -OTT GTG TCT TCT GCT-3 
IL-4d 5 -AAA GOT TIT GAT GA-3 
2.10.3.1. Protocol 
PBMCs from patients with B-CLL were separated according to the protocol described m 
section 2.4. Following separation, PBMCs were washed in 5 ml of sterile PBS (Gibco, UK) 
centrifuged at 1200 rpm for 5 min, resuspended in culture medium (section 2.3) and serially 
diluted from 5 x l 06 to 5 x l 03 cells/ml. This was undertaken to determine the appropriate 8-
CLL cell number for the use in the MTT assay. PBMCs suspention was plated out at 100 fll 
per well. Three control wells of culture medium were included. The cells were then incubated 
for 48 hours at 37°C in a C02 incubator. 
The MTT assay was performed according to the manufacturer's protocol. Briefly, 10 fll of 
MTT reagent (TACS™ MTT Assay Kit, R&D, UK) were added to each well and the plate 
incubated for 3 hours at 37 °C. When the cells were viewed using an inverted microscope, the 
appearances of punctuate intracellular precipitate was visible. 
130 
When a purple precipitate was visible, 100 ~1 of Detergent Regent was added to all the cells. 
The plate was left in the dark at 18-24°C for at least 2 hours. The absorbency was measured at 
570 run with a reference wavelength of 650 run and the results calculated using a Dias 
microplate reader Dynatech Laboratory, UK). 
2.10.4. Annexin V staining 
Annexin V -FITC staining was used to determine further the percentage of cells undergoing 
apoptosis after addition of various antisense ONs. Annexin V relies on the property of cells to 
Jose membrane asymmetry in the early phases of apoptosis. 
2.10.4.1. Protocol 
PBMCs isolated according to the protocol described in section 2.4 were resuspended to a 
concentration of 0.5x106 and put into in a 24 well plate. Different antisense ONs (Table 2.4) 
were added at a final concentration of 6 ~M (3x2 ~M). The cells were incubated for 48 hours 
at 3 fc in a C02 incubator, collected into separate tubes, centrifuged at approximately 1200 
rpm for lO min. and washed. Annexin V staining was performed according to the 
manufacturers protocol. Briefly, the cells were washed in 1 x cold PBS buffer containing 
calcium (Gibco, UK), and then gently resuspended in Annexin V Incubation Reagent (R&D 
System, UK) (buffer contained 10 ~~ of 1 Ox b Binding buffer, l 0 ~I Propidium iodide, 0.5 ~I 
of Annexin V FITC and 79 ~I of H20) together with 10 ~I of appropriate monoclonal (Table 
2.4). The mixture was incubated in the dark for 15 min at room temperature. After incubation, 
the cells were washed once in 300 ~1 of Binding buffer (R&D System, UK) and resuspended 
in 400~1 of 1 x Binding Buffer (R&D System, UK) ready fo r flow cytometric analysis. 
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Table 2.4: Tube labelling 
Nr Content Antibody Amount 
1 negative control Mouse lgGt FITC, mouse IgGt PE (Becton 10 ~1 each 
Dickinson, UK) 
2 leucogate Anti human CD45/CD 14 (Becton Dickinson, UK) lO ~I 
3 single staining Mouse anti human CD19 PE (Becton Dickinson, 5 ~1 
UK) 
4 single staining Mouse anti human CD3 PE (Becton Dickinson, 5 ~I 
UK) 
5 single staining Annexin V FITC 0.5 ~I 
6 single staining Propidium iodide 10 ~I 
7 double staining Annexin V FITC 0.5 ~1 
plus mouse anti-human CD t 9 PE 5 ~1 
8 double staining Annexin V FITC 0.5 ~1 
plus mouse anti-human CD3 PE 5 ~~ 
2.10.4.2. Flow cytometric analysis of Annexin V stainning. 
Cells were studied in an Epics Elite flocytometer (Coulter, UK). Alignment ofthe instrument 
was performed daily according to the manufacturer's protocol. Annexin V conjugated to 
FITC, and PI, were used to analyse multiple antigenic determinants within wanted cell 
population. This was accomplished with a single excitation wavelength (488nm), using a l5m 
Watt argon ion laser. FITC emission was measured as a green signal (530nm-peak 
fluorescence) by the FLI detector and R-PE was measured as an orange signal (575nm-peak 
fluorescence) by the FL2 detector. FLI is a green fluorescence signal received by the 
photomultiplier tube (PMT) and FL2 is an orange-red fluorescence signal received by the 
PMT. An electronic calculation to remove signal overlap was also performed through 
compensation. In this case the fluorescence measurements of the cell sample stained with one 
fluorochrome was electronically forced to be identical to that of the unstained cells. In each 
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individual experiment, PBMCs were also stained with CD45 FITC/CD14 PE conjugated 
antibody to allow cells to be identified as lymphocytes only. 
Results are shown as the percentage of CD3+ve, CD 19+ve lymphocytes double stained with 
Annexin V FITC or Propidium iodine. Joining dots of the same density derived the individual 
contour plots (Figure 2.1 ). The number of events acquired for each sample was I 0,000 
whenever possible. 
2.11. FLOW CYTOMETRIC ANALYSIS OF INTRACELLULAR IL--2 AND IL-4 
AFTER INCUBATION WITH ANTISENSE ONs 
2.11.1. Cell incubation 
PBMCs from patients with B-CLL and from normal controls were prepared according to the 
protocol described in section 2.4. Cells were resuspended in appropriate culture medium 
(section 2.3), seeded out in 24-culture plate at a concentration of 0.5xi 06 and incubated at 
3i>C for 6 hours. The cells were stimulated with PMA at a final concentration of 5ng/ml. 
Ionomycin was added at a concentration of 0.5 1-lg/ml. Antisense ONs at a total concentration 
of 6 1-1M (3x2 1-1M) were added to the appropriate wells together with Golgi Plug ™ 
(Pharmingen, UK), which contains Brefeldin A (Pharmingen, UK), a fungal metabolite and a 
protein transport inhibitor which interferes with vesicular transport from the rough 
endoplasmic reticulum to the Golgi complex. Addition of protein transport inhibitor is 
necessary since it prevents cytokines been used by the cell or being released into supernatants. 
For every I ml of cell culture lf .. d of Golgi Plug mixture was added. 
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2.11.2. Flow cytometric analysis of intracellular IL-2 and IL-4 after incubation with 
antisense ONs 
After 6 hours incubation, the PBMCs incubated as described in section 2. 14.1, were washed in 
Dulbecco's PBS without Mg2+ or Ca2+ (Gibco BRL, UK), l% heat inactivated FCS and 0.09% 
sodium azide (Staining Buffer) and resuspended in 50 J.ll of the above buffer. About 5J.ll of 
CD45FITC /CD14PE, CD19 or CD3 conjugated monoclonal antibody (Becton Dickinson, 
UK) was added. The PBMCs were incubated for 30 min at 4°C. After incubation, the cells 
were washed twice in staining buffer ( 1 ml/wash per tube) and pelleted by centrifugation (250 
x g). The cells were then resuspended in 250 J.ll per tube of CytofJ.X!Cytoperm solution 
(Pharmingen, UK) for 20 min at 4°C, washed twice in 1 x Perm/Wash solution (Pharmingen, 
UK) (1 m1 per tube) and pelleted. Fixed and permeabilised cells were then resuspended in 50 
J.ll of Perm/Wash solution containing IL-2 or IL-4 specific PE conjugated antibody (Beckton 
Dickinson, UK). The cells were then incubated at 4°C for 30 min in the dark. After 
incubation, the cells were washed twice in 1 x Perm/Wash (1 ml per tube) and resuspended in 
Staining Buffer prior to flow cytometry (described in section 2.12.3 .2). 
2.11.3 . . Flow cytometric analysis of intracellular IL-2 and IL-4 after incubation with 
antisense ONs and Lipofectin 
Separated PBMCs (section 2.4) were washed with serum free growth medium without 
antibacterial agents (section 2.3). Cells were seeded in 6 well culture plate at a concentration 
of2-3 x 106 per well in 0.8 mJ serum free growth culture medium (OPTI-MEM Gibco, UK). 
This experiment was performed according to the manufacturer' s protocol. Briefly, 100 J.ll of 
lJ.lM antisense ONs solution in OPTI-MEM (no serum here) was prepared. Different 
concentration ( 1J.l~ 2 1-l~ 5 J.ll, 1 0 J.ll, 15 J.ll and 25 J.ll) of of Lipofectin (Gibco BRL, UK) were 
added to 100 J.ll ofOPTI-MEM reduced serum medium and allowed to stand for 30-45 min. 
134 
The two solutions were mixed together gently and incubated at room temperature for I O-I5 
min. 200 J.Ll of Lipofectin/oligonucleotide solution were added and the cell suspension was 
incubated for 5-24 hr at 37°C in a C02 incubator. Then 4 mls of culture medium were added 
and the cells incubated for 48 hours at 3'f>C in 5 % C02 incubator. At the end of the incubation 
period, the cells were colLected by centrifugation at I200 rpm for I 0 nun, resuspended and 
analysed immediately by flow cytometry. Flow cytometric analysis of the cell samples was as 
described in section 2.13 .3 .2. 
2.1 1.4. lL-2 and IL-4 protein measurements by ELl SA after incubation with antiscnse 
ONs 
The washed PBMCs suspension (described in section 2.4) was adjusted to a concentration of 
Ixl06/ml cells in culture medium consisting of RPMJ 1640 supplemented with 5% FCS. 
Various antisense ONs were added at a concentration of 6 J.LM (total concentration) (first dose 
I hour before PHA stimulation, second at stimulation time and third after 24 hours of 
incubation). The PBMC suspension was plated out in a 24 well tissue culture plate. Some 
samples were stimulated with PHA at a concentration of I J.Lg/ml. The cells were incubated for 
24 hours at 37°C in a 5% C02 incubator. The cells were then harvested and the supernatants 
stored at - 20°C until required. The supernatants were thawed and assayed in duplicate using a 
commercial ELISA kit (R&D Systems) for the concentration of IL-2 and IL-4 protein. The 
ELISA plates were read at 450nm and 490nm respectively and the results calculated using 
Dias Microplate Reader (Dynatech Laboratory, UK) 
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CHAPTER 3: RESULTS OF FLOW CYTOMETRIC ANALYSIS OF IL-4 AND IL-4 
RECEPTOR (IL-4R) EXPRESSION IN 8-CLL AND NORMAL CONTROL CELLS 
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3.1. Introduction 
Flow cytometry, using fluorescent probes that bind to specific cell-associated antigens, 
enables the measurement of different phenotypic, biochemical and molecular characteristics 
of individual cells (Jason et al. I 997, Prussin et al. 1995). In this study, flow cytometry was 
used to enumerate percentages of CD I 9+ve and CD3+ve lymphocytes expressing intracellular 
IL-4 and its surface receptor (IL-4R). IL-4 displays anti-apoptotic activity on malignant B-
lymphocytes in B-CLL. Thus the intracellular presence of IL-4 as well as the IL-4R in B and 
T-lymphocytes of B-CLL patients and normal healthy controls was investigated and the 
results were analysed using the Student t-test. 
3.1.1. Patients and controls 
Patient characteristics, including phenotyping, were obtained by the method described in 
section 2.1 , and are listed in Table 3 .1. Some of the patient characteristics, such as the 
percentage of CDS+ve lymphocytes and the total lymphocyte count were obtained from the 
Derriford Combined Laboraotory. 
The controls used in this study consisted of normal healthy Caucasoid volunteers from within 
the Derriford Combined Laboratory. The same controls were used throughout the study (Table 
3.2). 
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Table 3.1: Clinical and immunophenotypic features of the B-CLL patients used in the 
IL-4 intracellular study 
Patients Gender Age 0/o 0/o Absolute Stage 
Nr. (Years) CD3+ve CD19+ve lymphocyte (Binet/Rai 
cells cells count (xl0911) ) 
l F 55 14.0 70.1 18.6 A(O) 
2 F 45 2.5 92.6 66.2 A(O) 
3 M 80 7.5 60.9 38.7 A(O) 
4 F 85 11.3 49.4 19.2 A(O) 
5 M 60 9.5 88.3 40.2 A(O) 
6 M 64 10.5 27.3 8.5 A(O) 
7 M 67 21.8 45.5 13.2 A(O) 
8 M 66 11.6 72.2 90.0 A(O) 
9 M 69 5.3 53.6 52.1 A(O) 
10 M 77 9.3 75.0 163.3 A(O) 
Mean value 10.1 63.5 
SD+/-5.2 SD+/-20.1 
The table shows flow cytometric analysis of the percentage of CD 19+ve and CD3+ve lymphocytes present in the 
PBMC population of patients with 8-CLL. PBMCs were stained with anti-CD 19 FITC and anti-CD3 PE. The 
absolute lymphocyte count was obtained from the diagnostic laboratory. The staging system used at the time of 
the diagnosis is that described by Binet and Rai. 
F=Female, M=Male, %=Percentage, SD=Standard deviation 
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Table 3.2: lmmunophenotypic features of normal healthy controls 
Controls Age (Years) Gender % CD3 +ve cells % CD19 +ve cells 
Nr. 
1 42 F 61.5 4.9 
2 45 F 41.8 4.2 
3 35 F 34.8 3.6 
4 55 M 38.5 8.9 
5 61 F 54.8 10.1 
6 51 M 31.1 1.4 
7 50 F 55.4 6.8 
8 48 M 52.5 8.2 
9 55 F 62.1 12.0 
10 60 M 58.5 6.0 
Mean value 49.0 6.6 
SD+/-11.5 SD+/-3.2 
The table shows flow cytometric analysis ofthe percentage ofCDI9+ve and CD3+ve lymphocytes in the PBMC 
population of normal controls. PBMCs were stained with anti-CD 19 FITC and anti-CD3 PE conjugated 
monoclonal antibodies. 
F=Female, M=Male, %=Percentage, SD=Standard deviation 
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3.1.2. Flow cytometric analysis of the percentage of CD19+ve and CD3+ve lymphocytes 
in B-CLL patients and normal controls 
B-CLL is characterised by an increased percentage of CD 19+ lymphocytes. Flow cytometry 
was used to measure the percentage of cells expressing surface CD19 and CD3 antigens in 
patients with B-CLL and in normal controls. Separated PBMCs (section 2.4) were stained 
with anti-CD 19 FITC and anti-CD3 FITC conjugated monoclonal antibodies. Each 
experiment was performed only once. The percentage of CD19+ve cells was significantly 
higher in B-CLL patients than normal controls (mean value: 63.5%, SD+/-20.1 [range: 27.3-
92.5] and 6.6%, SD+/-3 .2 [range: 1.4-11.9] respectively, p=0.001). Conversely the percentage 
of CD3+ve cells was significantly higher in normal controls than in patient samples (mean 
value: 49.0%, SD+/-11.5 [range: 31. 1-62.1] and 10.1%, SD+/-5.2 [range: 2.4-21.8] 
respectively, p=O.OOI) (Table 3. 1 and 3.2, Figure 3.1). Normal control PBMCs had a 
percentage ofCD19+ve and CD3+ve lymphocytes at a ratio of1:7.4. B-CLL patient PBMCs 
had a percentage of CD 19+ve and CD3+ve lymphocytes at an inverted ratio of 6: 1. The result 
shows diversity in the percentage of the CD3+ lymphocytes in patients. Patient 2 has 2.5% 
CD3+ lymphocytes while patients 7 has 21.8% CD3+ lymphocytes. The same percentage in 
normal controls remained relatively stable (Table 3.2). Using Spearmans' Correlation Test no 
significant correlation between the percentage of CD l9+ve and CD3+ve lymphocytes was 
found in patients and controls (r=-0.43, p=ns and r=0.06, p=ns respectively). 
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Figure 3.1: Percentage of CD19+ve and CD3+ve lymphocytes in PBMCs of B-CLL 
patients and normal controls 
p=O.OOOl p=O.OOOI 
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The graph shows the mean values as well asp-values of the percentage ofCDI9+ve and CD3+ve lymphocytes in 
patients with B-CLL and normal controls. A Student Hest was performed The percentage of CD 19+ve 
lymphocytes was significantly higher in patients with B-CLL than in controls (mean value: 63.5%, [range: 27.3-
92.6] and 6.6%, [range: 1.4-11.9] respectively, p=0.001). Conversely, the percentage of CD3+ve cells was 
significantly higher in normal controls than in patients with B-CLL (mean value: 49.0%, [range: 31.1-62. 1] and 
I 0.1% [range: 2.5-21.8] respectively, p=O.OO I). 
%=Percentage 
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3.1.3. Measurement of intracellular IL-4 expression in CD19+ve and CD3+ve 
lymphocytes in B-CLL patients and normal controls 
In order to study the intracellular expression of IL-4, PBMCs from ten patients with B-CLL 
and from ten normal healthy controls were double-stained with anti-CD3 FITC or anti-CD 19 
FITC and IL-4 PE-conjugated monoclonal antibodies, and analysed by flow cytometry. Figure 
3.2 is a representation of the flow cytometric results obtained using a Becton Dickinson flow 
cytometer. Each individual experiment was performed only once. The results represent mean 
values and the percentage of double stained CD19+/IL-4+ or CD3+/IL-4+ lymphocytes 
(Figure 3 .3, Appendix 1 ). It shows a significantly higher proportion of CD 19+ve lymphocytes 
expressing intracelJular IL-4 in patients with B-CLL than in controls (means: 22.4%, SD+/-
13.1 [range: 6.4-53.8] and 7.2%, SD+/-3.1 [range: 1.5-11.9] respectively, p=0.03). The 
proportion of CD3+ve celJs containing IL-4 was also significantly higher in patients with B-
CLL compared to controls (means: 9.6%, SD+/-8.5 [range: 2.2-26.1] and 2.2 %, SD+/-1.3 
[range: 0.41-4.2] respectively, p=0.01) (Figure 3.3). 
In addition, PBMCs obtained from two patients with B-CLL were pre-incubated with anti-IL-
4R antibody and the percentage of CD19+ve and CD3+ve lyrnphocytes expressing 
intracellular TL-4 was measured. As show in Table 3.3, pre-incubation of PBMCs with anti-
IL-4R antibody did not change the percentage of cells expressing intracellular IL-4. 
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Figure 3.2: Flow cytometric analysis of patient PBMCs stained with anti-
CD19 and anti-D..--4 monoclonal antibody 
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PBMC from patients with B-CLL was stained with anti-CDI9 FITC and anti-rL-4 PE monoclonal 
antibodies. Figure-A shows negative control. Figure-B shows the results after intracellular staining 
with anti-IIA PE antibodies. Figure-C shows staining with anti-CD19 FITC antibody but the gate 
was set on quadrants 2 and 4 only. Figure-D is a representation of the cells stained with surface 
anti-CD 19 FITC and intracelluJar anti-IL-4 PE conjugated antibodies. Double stained cells appear 
in quadrant 2. Number of events in each case was I 0000. 
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Figure 3.3: Percentage of CD19+ve and CD3+ve lymphocytes expressing intraceUular 
IL-4 in patients with B-CLL and normal controls 
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The graph shows the mean values and the p values of the data presented in Appendix I. The percentage of 
CD 19+ve lymphocytes expressing intracellular IL-4 was significantly higher in B-CLL patients than in controls 
(mean value: 22.4% [range: 6.4-53.8) and 7.2% [range: 1.5- 11 .9] respectively, p=0.03). The percentage of 
CD3+ve lymphocytes expressing intracellular LL-4 was also significantly higher in patients than in controls mean 
value: 9.6%. [Range: 2.2-26.1) and 2.2% [range: 0.4-4.2) respectively, p=O.OI). 
%=Percentage, IL=Interleukin 
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Table 3.3. The percentage ofCD19+ve and CD3+ve lymphocytes expressing intracellular 
IL-4 after pre-incubation with anti-IL-4R monoclonal antibody 
Patient %CD19+/IL-4+ %CD19+/IL-4+ %CD3+~-4+ %CD3+/IL-4+ 
Nr 
(Pre-incubated) (Pre-incubated) 
5 53.8 50.0 4.7 6.5 
6 21.7 22.5 2.5 3.5 
PBMCs from two patients with B-CLL were pre-incubated with anti-IL-4R monoclonal antibody and the 
percentage of CD 19+ve and CD3+ve lymphocytes expressing intracellular IL-4 measured by flow cytometry. ln 
each experiment I 0,000 CD 19+ or CD3+ lymphocytes were collected. 
fL=Tnterleukin, o/o=Percentage 
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3.1.4. Measurement of surface IL-4R expression in CD19+ve and CD3+ve lymphocytes 
in B-CLL patients and normal controls 
The function of cytokines is dependent on appropriate receptors expressed on target cells. The 
aim of this part of the project was to establish whether unstimulated CD 19+ve and CD3+ve 
lyrnphocytes from patients with B-CLL and from normal controls were able to express surface 
IL-4R Unstimulated PBMCs were immediately stained with anti-CD19 FITC and anti-JL-4R 
PE or anti-CD3 FITC and anti-IL-4R PE conjugated monoclonal antibodies and analysed by 
flow cytometry. In each individual experiment, whenever possible, 10,000 of CD19+ve or 
CD3+ve cells were collected as shown in Figure 3.4. The results were calculated using the 
Student t-test. 
There was a marked difference in the range of CD 19+ve lyrnphocytes expressing surface IL-
4R between individual patients (range 11 .22-97.13). This difference was not so marked within 
the normal control population (range: 41.55-88.37). 
The proportion of CD19+ve lymphocytes expressing IL-4R was not significantly different 
between B-CLL cells and normal healthy controls (mean value: 57.7%, SD+/-31.0 [range: 
11.2-97.1] and 68.7%, SD+/-14.3 [range: 41.6-88.4] respectively, p=ns). The proportion of 
CD3+ve lymphocytes expressing IL-4R in B-CLL patients was significantly higher in patients 
than in controls (means: 4.1 %, SD+/-2.3 [range: 0.6-7.8] and 1.7%, SD+/-1.1 [range: 0.6-3.7] 
respectively, p=O.OOI), (Figure 3.5, Appendix 2). 
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Figure 3.4: Flow cytometric analysis of patients PBMCs stained with anti-
CD19 and anti-IL-4R antibody 
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PBMCs from patients with B-CLL were stained with anti-CD 19 FITC and anti- IL-4 receptor PE (IL-4R) 
monoclonal antibodies. Figure A show negative control. Figure B shows the results after staining with 
anti-CD 19 FITC conjugated antibody. Figure C shows staining with anti-CD 19 FITC antibody but the 
gate set on quadrants 2 and 4 only. FigureD shows the cells stained with anti-CDI9 FITC and anti-LL-4R 
PE antibody. Double stained cells appear in quadrant 2. Number of events in each case was I 0000. 
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Figure 3.5: Percentage of CD19+ve and CD3+ve cells expressing surface IL-4R 
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The graph shows the data from Appendix 2. PBMCs separated from ten patients with and ten nonnal controls 
were stained with anti-CDI9 FITC and anti-IL-4R PE or anti-CD3 FITC and anti-IL-4R PE conjugated 
monoclonal antibodies and analysed by flow cytometry. The figure shows the mean values of the percentage of 
CD3+ve and CDI9+ve lymphocytes expressing surfuce IL-4R. The percentage of the CDI9+ve lymphocytes 
expressing 1L-4R was higher in normal controls but did not reach statistical significance (mean value: 57.7% 
[range: 11.2-97.1} and 68.7% [range: 41.6-88.4] respectively, p=ns. The percentage of CD3+ve lymphocytes 
expressing surfuce lL-4 R was sign ificantly higher in patients than in controls (mean value: 4 .1% [range: 0.6-7.8] 
and 1.?0/o [range: 0.6-3.7] respectively, p=O.OOI). 
%=Percentage, ns=Not significant, IL-Interleukin 
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3.1.5. Quantification of IL-4 protein secretion by ELISA 
The previous experiments (section 3.1 .3) showed that patients with B-CLL have a 
significantly higher percentage of CD l9+ve lymphocytes expressing intracellular IL-4 
protein. In order to evaluate the correlation between the expression of intracellular IL-4 in B-
and T-lymphocytes and the level of IL-4 protein, phytohaemagglutinin (PHA) (T cell 
mitogen) and pokeweed mitogen (PWM) (B and T -lymphocyte mitogen) -stimulated and 
unstimulated cell cultures were set up, using PBMCs separated from seven B-CLL patients 
and from seven normal health controls. Due to high cost of ELISA immunoassay this 
experiment was performed only once using one ELISA plate. PBMCs were harvested after 48 
hours incubation and cell free supernatant analysed by a commercial ELISA kit. Table 3.4 
shows the level ofiL-4 protein secretion. The unstimulated PBMCs from patients and controls 
did not secrete detectable IL-4 protein. Supernatants from six control samples had an 
increased amount of IL-4 protein following stimulation with PHA mean value: 2.53 pg/ml 
(range: 0-5.74pglml) or PWM mean value; 1.69 pg/ml (range: 0-4.78pg/ml). The cell culture 
supernatants from only two of the seven B-CLL patients had measurable amounts of IL-4 
protein after PHA stimulation; mean value: 2.04 pg/ml (range: 0-13.27pglml) and none after 
PWM stimulation. The overall level of PHA and PWM stimulated IL-4 protein secretion in 
patients with B-CLL was low. 
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Table 3.4: IL-4 protein secretion in patients with B-CLL and in normal controls 
Patient IL-4 lL-4 IL-4 Number IL-4 IL-4 IL-4 
number spont. secretion secretion of spont. secretion Secretion 
secretion PHA PWM controls secretion PHA stim. PWM 
(pglml) stim. stim. (pg/ml) (pglml) stim. 
(pglml) (pg/ml) (pg/ml) 
1 nd 13.27 nd 1 nd 0.31 0.23 
2 nd nd nd 2 nd 5.51 3.27 
3 nd nd nd 3 nd 1.02 1.02 
4 nd nd nd 4 nd 5.12 0.1 5 
5 nd 1.02 nd 5 nd 0.00 2.37 
6 nd nd nd 6 nd 5.74 4.78 
7 nd nd nd 7 nd nd nd 
Mean 
value 0 2.04 0 0 2.53 1.69 
PBMCs isolated from patients with B-CLL and from nonnal controls were stimulated with either PHA or PWM 
and, following 48 hours incubation, IL-4 protein was measured in cell free supematants by a commercial ELJSA 
kit. In unstirnulated PBMC from patients and controls no detectable amount oflL-4 was observed. Spont. 
secretion=Spontaneous secretion, PHA= Phytohemagglutinin, PWM =Pokeweed mitogen, nd = Not detectable 
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3.1.6. Measurement of intracellular IL-4 expression in CD19+ve B-lymphocytes in 
PBMCs after depletion ofT-Iymphocytes and monocytes 
The effect ofT-lymphocytes and monocytes populations on the intracellular expression ofiL-
4 in CD19+ve B-lymphocytes from patients with B-CLL was investigated in this part of the 
study. The T-lymphocyte population was depleted from PBMC preparations from five 
patients with B-CLL, using CD2+ve Dynabeads. Monocytes were depleted by repeated 
adherence to plastic. Because Dynabeads were still attached to the lymphocytes at the time of 
analysis, no attempt was made to establish the purity of the CD l9+ve lymphocyte population. 
As shown below (Table 3.5), the presence of the T-lymphocyte and monocyte populations 
influenced the percentage of CD l9+ve lymphocytes expressing intracellular IL-4. The 
expression of intracellular IL-4 was highest in 8-lymphocytes incubated on their own 
compared to B-lymphocytes incubated with monocytes and T-lymphocytes together, although 
this did not attain significance (mean value: 32.1 % , SD+/-27.6 [range: 4.2-76.7] and 24.6%, 
SD+/-27.9 [range: 5.4-70.8] respectively, p=ns). No statistically significant difference was 
observed between the percentage of CD l9+ve lymphocytes expressing intracellular IL-4 
when 8- and T-lymphocytes where incubated together versus undepleted P8MCs (mean 
value: 25.5%, SD+/-19.7 [range: 8.7-53.9] and 24.6%, SD+/-27.9 [5.4-70.8] respectively, 
p=ns), (Table 3.5). 
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Table 3.5: Flow cytometric analysis of CD19+ve lymphocytes expressing intracellular 
0..-4 after depletion ofT -lymphocytes and monocytes 
Patients PBMCs PBMCs minus PBMCs minus 
number (I) monocytes monocytes and T 
(ll) lymphocytes 
(Ill) 
%CD19+/IL-4+ %CD 19+/IL-4+ %CD 19+/IL-4+ 
3 31.8 35.9 35.3 
5 70.8 54.0 76.7 
8 5.4 8.7 15.8 
9 10.8 20.8 28.5 
10 4.5 7.3 4.2 
Mean value 24.6 25.3 32.1 
SO+/- 27.9 19.7 27.6 
Variable: I In Variable: I I m 
p=ns p=ns 
The table shows flow cytometric analysis of the percentage of CD 19+FITC/lL-4+ in PBMCs from five patients 
with B-CLL before and after the depletion of T-lymphocytes and monocytes or monocytes only. Student t-test 
was used to evaluate the statistical significance between percentage of CDI9+/lL-4+ lymphocytes in PBMCs 
population (I) and PBMCs population depleted of monocytes (IT) or monocytes and T-lymphocytes respectively 
(Ill). No significant difference was observed in both cases. 
SD =Standard deviation, ns=Not significant, %=Percentage, IL-Interleukin 
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3.5. Summary 
• PBMCs from patients with B-CLL had a higher percentage of CD 19+ve B-lymphocytes 
than normal healthy controls. This is not surprising since one of the features of B-CLL is 
an increased lymphocyte count with the majority ofB-lymphocytes being of clonal origin. 
• PBMCs from patients with B-CLL contained a significantly greater percentage of 
CD 19+ve as well as CD3+ve lymphocytes expressing intracellular IL-4 compared to 
normal healthy controls. 
• In addition., pre-incubation of PBMCs with anti-IL-4R antibody did not change the 
percentage of cells expressing intracellular IL-4. 
• Only patients' CD3+ve lymphocytes had a significantly higher percentage of CD3+ve 
lymphocytes expressing surface IL-4R compared to normal controls. 
• Supernatants from unstimulated PBMCs from patients with B-CLL had no detectable IL-4 
protein. However, when the cells from the patients were stimulated with either PHA or 
PWM alone, two patients had detectable IL-4 protein after PHA stimulation but none after 
PWM stimulation. In contrast, normal controls had detectable IL-4 protein after 
stimulation with PHA and PWM. 
• Depletion ofT lymphocytes and monocytes from patient PBMC increased the percentage 
of CD l9+ve lymphocytes expressing intracellular IL-4 protein. These results show a trend 
towards T -lymphocytes having some influence on the B-lymphocytes expression of 
intracellular IL-4. 
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CHAPTER 4: RESULTS OF MEASUREMENT OF CYTOKINE mRNA 
EXPRESSION BY NESTED RT -PCR 
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4.1. Introduction 
It was previously established that PBMCs from patients with B-CLL bad a greater percentage 
of CD19+ve and CD3+ve lymphocytes expressing intracellular IL-4. However it was not 
possible to demonstrate increased secretion of IL-4 protein (by ELISA) or the presence of 
mRNA (by Northern blotting) in CD19+ve lymphocytes isolated from patients with B-CLL 
(data not shown). In view of this it was decided to study the expression of mRNA using a 
more sensitive technique such as nested RT-PCR. In addition to IL-4, several other cytokines 
or receptors such as lL-2, IL-4, IL-7, IL-9, IL-15, IL-4Ra, ye, IL-5 and IL-13 mRNA were 
also analysed. 
High quality RNA was isolated from the population ofCD19+ve and C02+ve lymphocytes as 
described in section 2.5. This RNA was run on 1% agarose gel and the presence of the 
characteristic 18S and 28S bands identified (Figure 4.1 A). The ratio between the density of 
the 28S and 18S RNA bands should be 2:1. If the 18S RNA band is more intense than 28S, 
this is an indication of RNA degradation. The optical density (OD) of each individual RNA 
sample was measured and the presence of RNA quantified (Figure 4.1 B). 
However before the RT-PCR studies were performed, the PCR conditions were optimised. 
The magnesium concentration (Mg++ ), annealing temperature, cycle length and the number of 
cycles were checked. Proper evaluation of magnesium concentration is important since this 
affects several aspects of PCR including DNA polymerase activity which can affect primer 
annealing which in turn can affect specificity (Figure 4.1 C). Figure 4.2 shows the presence of 
the B-actin mRNA "housekeeping gene" in all samples used in this study. Some of the 
samples had to be repeated to confirm the presence of P-actin gene. Due to limited quantity of 
cDNA obtained from each patient and the difficulties in obtaining further samples from the 
same patients each experiment was performed only once. All the samples were run 
simultaneously on one gel. Using densitometry, the density of each band was measured by 
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drawing a rectangular shape. However due to a different intensity of the bands and their 
different size some human effort may have occurred. 
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Figure 4.1: Optimisation ofRT-PCR reaction 
A) TotaJ RNA was separation using RNA-zol or RNA-STAT 60 
~ ... 
1·1·1·-·, ··I .,.... ,' · ~ .· i ' ..... :" '' , I [ . . 
2 3 4 5 6 7 8 
~ 28S 
~ 18S 
RNA in lane I, 2 and 3 was purified using RNA-STAT 60. RNA in lane 4,5,6,7 and 8 was 
prepared using RNA-zol 
B) RNA optical densitometry 
Optical density of each of the RNA preparations was measured using Cecil 5000 series 
spectrophotometer. Pure RNA bas an A260/A280 ratio of 1.9-2.1. 
l absorbance unit at 260nm corresponds to 40 f.lg of RNA per J rnJ 
C) Optimisation of magnesium concentration 
H20 1.5mM 2.5mM 4rnM 5mM 6mM MW 
PCR reaction was performed using cDNA from B-CLL patient. IL-4 specific primers 
were used. Different concentration of magnesium did not influence the quality of the 
PCR product. 
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Figure 4.2: Beta-actin (f3-actin) RT-PCR results after first round of amplification 
Patients 8-lymphocytes Patients T-lymphocytes 
2 3 4 5 6 7 8 9 10 I 2 3 4 5 6 7 8 9 
Controls 8-lymphocytes Controls T-lymphocytes 
2 3 4 5 6 7 8 9 10 I 2 3 4 5 6 7 8 9 MW 
Spat B cont 
2 4 7 10 
11 
Tcont T cont B pat T pat 
(-) 2 3 6 10 11 
----
487 bp 
487 bp 
487 bp 
A nested RT-PCR technjque was used to identify ~-actin products in 8- and T-lymphocyte 
samples of patients with 8-CLL and normal controls. ~-actin primers were used to check the 
quality of the cDNA samples prepared for further experiments. Some of the samples were 
repeated twice. 
MW=molecular weight marker, (-)=negative control, B pat= patients 8 cells, B cont= controls 
B cells, T pat= patients T cells, T cont= controls T cells 
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1.2. Patients and controls 
Details concerning normal healthy controls are listed in table 3.2 and clinical and 
immunophenotypic features ofthe patients are listed in table 4.1. However, in patients 12 and 
19 data concerning the percentage of CD5+ve lymphocytes were not available from their 
hospital records. 
Table 4.1: Clinical and immunophenotypic features ofB-CLL patients 
Patient Gender Age (Years) %CD5 Absolute Stage 
number lympbocytes lympbocyte (Binet/Rai) 
count 
_{_x109/l) 
11 M 77 32 92.0 A(O) 
12 M 76 25 53.5 A(O) 
13 M 64 84 53.3 A(O) 
14 M 64 96 16.8 A(O) 
15 F 60 79 46.7 A(O) 
16 F 70 50 25.0 A(O) 
17 F 70 15 75.0 A(O) 
18 F 79 84 86.0 A(O) 
19 M 65 37 48.8 A(O) 
20 F 61 15 15.0 A(O) 
21 F 64 63 18.4 A(O) 
The percentage of CD5+ve lymphocytes and the absolute lymphocyte count were obtained from the diagnostic 
laboratory. The staging system used at the time of the diagnosis is that described by Binet and Rai . 
F=Female, M=Male, o/o=Percentage, na=Not available 
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4.3. Analysis of JL..4 receptor (llr4R) a. chain mRNA expression by nested RT -PCR 
The expression ofiL-4R a. chain mRNA in purified populations ofB and T-lymphocytes from 
patients with B-CLL and from normal controls were analysed (Figure 4.3). The IL-4R a. chain 
RT-PCR product was present in B and T-lymphocytes in patient and control samples. 
Statistical significance was measured using the Student t-test. There was no significant 
difference between the density of patient and control B-lymphocyte IL-4Ra. chain RT-PCR 
products (mean value: 40.5 [range: 32.5-46.6] and 36.5 [range: 20.1 -42.7) respectively, p=ns). 
In contrast there was a strong statisticaUy significant difference between the density of patient 
and normal T-lymphocyte IL-4Ra. chain RT-PCR products (mean value: 45.0 [range: 40.3-
49.4] and 45.0 [range: 42.6-47.9] respectively, p=ns). In addition the rat io between patient B 
and T-lymphocyte mean density values ofiL-4R a. chain RT-PCR products was 1: 1.05 while 
the ratio in normal healthy controls was I: 1.2 (Figure 4.4, Appendix 3). 
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Figure 4.3: IL-4R alpha (IL-4Ra) chain RT-PCR products after a second 
round of amplification 
Paltenls B cells 
234 5678 
~a;a~aa• ~-~ IL-4R 308 bp 
. ~ ... .. ..... 
Pauems T cells 
2345678(-) 
L-4R 308 bp ......... 
ll-4R 
IL 4A 
Controls B cells 
1 2 3 4 5 6 7 8 9 10 MW 
... • ~..- .. ~111'-1 
-·········-
.. 
Conlrols T cells 
?3456789 
·-········ 
308 bp 
308 bp 
A nested RT-PCR technique was used to identifY IL-4R mRNA transcripts in B- and T-
lymphocytes in patients with B-CLL and in normal controls. The figure shows transcripts after a 
second round of amplification. A I 00 bp molecular weight marker was used. 
MW=molecular weight marker 
(-)=negative control 
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Figure 4.4: Mean density values of IL-4R a. chain nested RT -PCR products 
Mean 
density 
values 
~~----------------~----------------------~ 
45+-----~--~~----------~~-r------------~ 
«> 
35 
:1) 
25 
aJ 
15 
10 
5 
0 
B-patieots B-controls T -patients T -controls 
Figure 5.4 shows mean values of the densitometry results of the TL-4R a chain RT-PCR product shown in 
Appendix 3. The Students t test was used to measure statistical significance. No significant difference was found 
between the density of patient and control B-lymphocyte IL-4R a chain RT-PCR products (mean value: 40.5 
[range: 32.5-46.6] and 36.5 [range: 20.1 -42.7] respectively, p=ns). In contrast, there was a significant difference 
between the density of patient and normal control T -lymphocyte rL-4R a chain RT-PCR products (mean value: 
45.0[range 15.9-23.8] and 45.0 [range: 42.6-47.9] respectively, p=ns). Tn addition, the ratio between patient B 
and T-lymphocyte mean density values of IL-4R a chain RT-PCR products was I :05 and the same ratio in 
normal healthy controls was I: 1.2. 
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4.4. Analysis of common gamma (ye) chain mRNA expression by nested RT-PCR 
The presence of ye transcripts in B-CLL and control B- and T -lyrnphocytes was measured 
using primers spanning the entire region of the ye chain (Figure 4.5, Appendix 4). There was 
no significant difference between the density of patient and control B-lymphocyte ye RT-PCR 
products (mean value: 2039.2, SD+/644.0 [range: 830.9-2619.5] and 2025.4, SD+/-466.2 
[range: 1381.0-2604.3] respectively, p=ns). There was no statistical ly significant difference 
between the density of patient and normal T-lymphocyte ye RT-PCR products (mean value: 
2094.9, SD+/-348.1 [range: 1353.2-2528.2] and 1893.2, SD+/-699.7 [range: 610.0-2793.6] 
respectively, p=ns). The ratio between patient Band T-lymphocyte mean densities of ye chain 
RT -PCR products was 1: 1 and in normal healthy controls was I: 0.9 (Figure 4.6). 
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Figure 4.5: Common gamma chain (ye) RT -PCR products after a second 
round of amplification 
(-) I 2 3 4 5 6 7 8 9 10 11 MW 
889 bp 
2 3 4 5 6 7 8 9 10 MW 
889 bp 
MW 1 2 3 4 5 6 7 8 9 10 ll 
889 bp 
MWI 2 3 4 567 89 lO 
889 bp 
Patients 
B-lymphocytes 
Controls 
B-lymphocytes 
Patients 
T-lymphocytes 
Controls 
T -lymphocytes 
A nested RT-PCR technique was used to identify common gamma (ye) chain products in B-and 
T-lymphocytes in patients with B-CLL and in normal controls. The figure shows RT-PCR 
products after a second round of amplification. A IOObp molecular weight ladder was used. 
MW-molecular weight marker 
(-)- negative control 
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Figure 4.6: Mean density values of common gamma (ye) chain nested RT -PCR products 
Mean 
density 
values 
B-patients B-controls T -patients T -controls 
The figure shows mean density values of the ye RT-PCR products presented in Appendix 4. The 
Students t test was used to measure statistical significance. No significant difference was demonstrated between 
the density of patient and control B-lymphocyte ye RT-PCR products (mean value: 2039.2 [range: 830.9-2619.5] 
and 2025.4 [range: 1381.0-2604.3] respectively, p=ns). Simjlarly, there was no significant difference between the 
density of patient and normal T-lymphocyte ye RT-PCR products (mean value: 2094.9 [range: 1353.2-2528.2] 
and 1893.2 [range: 610.0-2793.6] respectively, p=0.406). ln addition the ratio between patient B and T-
lymphocyte mean density values of ye RT-PCR products was I: I and in normal healthy controls I: 0.9. 
SD=Standard deviation, ns=Not significant 
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4.5. mRNA analysis of cytokines belonging to the common gamma chain (ye) receptor family 
by nested RT-PCR 
Using primers specially designed to cover the entire region ofthe IL-2, IL-4, IL-7, IL-9, and IL-
15 genes, the presence of individual mRNA RT-PCR products in B- and T-Lymphocytes from 
patients and controls was investigated. These cytokines share a common subunit known as the 
common gamma chain (ye) receptor. Statistical significance was measured using the Students t 
test. 
The IL-2 RT-PCR product density was higher m patient than in control B-lymphocyte 
samples (mean value: 521.0, SD+/-747.0 [range: 10.1-1802.3] and 22.9, SD+/-18.7 [range: 0-
66.4] respectively, p=0.04) (Figure 4.7). There was a difference between IL-2 RT-PCR 
product density in patient and control T -lymphocyte samples but this did not reach statistical 
significance (mean value: 1220.0, SD+/-894.5 [range: 0-2272.9] and 1717.0, SD+/-524.3 
[range: 252.8-2027.1] respectively, p=ns). In addition, the ratio between patient T and B-
lymphocyte mean density values ofthe IL-2 RT-PCR products was 1: 2.3. More importantly, 
the same ratio in normal healthy controls was much higher at 1: 75 (Appendix 5, Figure 4.8). 
There was no significant difference in the density of the IL-4 RT-PCR product comparing 
patient and control B-lymphocytes (mean value: 127.2, SD+/-1 33.9 [range: 7.7-416.7] and 
51.3, SD+/-72.6 [range: 0-221.0] respectively, p=ns) or patient and normal T -lymphocytes 
(mean value: 252.1, SD+/-249.6 [range: 3.8-673.8] and 337.7, SD+/-284.5 [range: 0-743.6] 
respectively, p=ns). The ratio between patient T- and B-lymphocyte mean density values of 
the IL-4 RT-PCR products was 1: 1.9. The same ratio in normal healthy controls was much 
higher at 1: 6.6 (Appendix 6, Figure 4.9, 4.1 0). 
There was a significant difference between the IL-7 density of patient and control B-
lymphocyte IL-7 RT-PCR products (mean value: 1600.0, SD+/-772.8 [range: 465.1-2693.0] 
and 1239.9, SD+/-925.5 [range: 0-2610.8] respectively, p=0.03). There was a significant 
difference between the density of patient and normal T -lymphocytes IL-7 RT -PCR products 
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(mean value: 2480.5, SD+/-868.9 [range: 800.2-3229.5] and 1484.6, SD+/-1202.6 [range: 
20.1-3349. 7] respectively, p=0.04). The ratio between patient B and T -lymphocyte mean 
density values ofiL-7 RT -PCR products was 1: 1.6 and the ratio in healthy controls was 1: 1.2 
(Appendix 7, Figure 4.11, 4.12). IL-9 RT-PCR products were not detected. 
No significant difference between the IL-15 RT-PCR product density of patient Band control 
B-lymphocyte IL-15 RT-PCR products was demonstrated (mean value: 1861.7, SD+/-201.1 
[range: 1545.8-2293.6] and 1777.2, SD+/-95.4 [range: 1626.4-1905.1] respectively, p=ns). 
However, a significant difference between the density of patient and normal T-lymphocytes 
IL-15 RT-PCR products was found (mean value: 1432.4, SD+/-433.9 [range: 459.1-1974.9] 
and 2279.6, SD+/-251.9 [range: 1698.4-2529.8] respectively, p=0.001). The ratio between 
patient Band T-lymphocytes mean density values ofiL-15 RT-PCR products was 1: 0.8 and 
in normal healthy controls was l : 1.3 (Appendix 8, Figure 4.13, 4.14). Figure 4.9 shows the 
mean density values of all cytokines belonging to the ye receptor family plus IL-4R and ye 
RT-PCR products. 
In addition, IL-7 RT-PCR products were composed of many additional unidentified bands 
most probably representing IL-7 splice variants. However, I was unable to provide evidence 
about their identities (due to inconclusive sequencing). In addition, an additional band was 
present when the IL-15 RT -PCR product was run on a gel. The additional band had a higher 
molecular weight than IL-15 and was not sequenced. Automated sequencing (MWG, 
Germany) was used to identify the RT -PCR products (Appendices (22-28). 
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Figure 4.7: ll--2 wild type RT-PCR products after a second round of 
amplification 
420bp 
420bp 
420bp 
420bp 
2 3 4 5 6 7 8 9 10 11 MW 
(-) l 2 3 4 5 6 7 8 9 10 MW 
2 3 4 5 6 7 8 9 10 11 
2 3 4 5 6 7 8 9 I 0 MW 
Patients 
B cells 
Controls 
B cells 
Patients 
Tcells 
Controls 
T cells 
A nested RT-PCT technique was used to identify IL-2 wi ld type (primers spanning exon I to 4) 
m RNA in Band T cells of patients with B-CLL and normal controls. A I 00 bp molecular weight 
marker was used. 
MW=molecular weight ladder 
(-)=negative control 
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Figure 4.8: Mean density values of IL-2 nested RT-PCR products 
p=0.04 
3000 
2500 
Mean 2000 
density 
values 1500 
1000 
500 
0 
B-patients B-controls T-patients T-controls 
Figure 5.8 shows mean density values of the densitometry results of the rL-2 RT-PCR products presented in 
Appendix 5. The Students t test was used to measure statistical significance. There was a significant difference 
between the density of patient and control B-lymphocyte rL-2 RT-PCR products (mean value: 521.1 [range: 0-
1860.5] and 22.9 [range: 0-66.4] respectively, p=0.04). There was no significant difference between the density 
of patient and nonnal T-lymphocyte IL-2 RT-PCR products (mean value: 1220.0 [range: 0-2272.9] and 1717.0 
[range: 252.8-2027. 1] respectively, p=ns). The ratio between mean density value of patient Band T-lymphocyt 
IL-2 RT-PCR products was I : 2 .3. The same ratio in nonnal healthy controls was much higher at I: 75. 
SD=Standard deviation, ns=Not significant 
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Figure 4.9: IL-4 wild type RT -PCR products after the second round or ampUfia.tion 
1 2 3 4 5 6 
329bp 
1 2 3 4 5 
329bp 
(-) 1 2 3 4 5 
329bp 
329bp 
7 8 9 
6 7 8 
6 7 8 9 
10 11 MW 
9 10 MW 
10 11 MW 
Patients 
B-lymphocytes 
Controls 
B-lymphocytes 
Patients 
T -lympbocytes 
Controls 
T-lympbocytes 
A nested RT-PCR technique was used to identify IL-4 wild type (primers spanning exon 1 to 4) 
PCR products in B and T -lymphocytes in patients with B-CIL and in normal controls. The figure 
shows IL-4 PCR product after a second round of amplification. A lOObp molecular weight ladder 
was used 
MW=molecular weight rruuker, (-)== negative control 
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Figure 4.10: Mean density values ofllr4 nested RT-PCR products 
Mean 
density 
values 
nD .---~------~----------------------------. 
800+--------------------------+--------------~ 
50+--------------------T----+-------------~ 
«0+--------------------+----+-------------~ 
D +--------------------+--1 
200 +-----+--------
100 
0 
B-patients B-controls T-patients T -(;Ontrols 
Figure 4. 10 shows mean density values of the densitometry results of the IL-4 RT-PCR products presented in 
Appendix 6. The Students t test was used to measure statistical significance. There was no significant difference 
between the density of patient and control B-lymphocyte LL-4 RT-PCR products (mean value: 127.2 [range: 7.7-
416. 7) and 51.3 [range: 0-221.0) respectively, p=ns). There was no significant difference between the density of 
patient and normal T-lymphocyte IL-4 RT-PCR products (mean value: 252. 1 [range: 3.8-673.8) and 337.7 
[range: 0-743.6) respectively, p=ns). The ratio between mean density value of patient Band T-lymphocyte IL-4 
RT-PCR products was ratio: I: 2. More importantly, the same ratio in the normal healthy controls was much 
higher at I: 6.6. 
SD=Standard deviation, ns=Not significant 
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Figure 4.11: ll..-7 wild type RT -PCR products after a second round of 
amplification 
MWI 2 3 4 5 6 7 8 9 10 11 (-) 
659bp Patienls 
B-lymphocytes 
2 3 4 5 6 7 8 9 10 MW 
659bp 
Controls 
B-lymphocytes 
2 3 4 5 6 7 8 9 10 11 MW 
659bp Patients T -lymphocytes 
2 3 4 5 6 7 8 9 10 MW 
Controls 
659bp T-lymphocytes 
A nested RT-PCR technique was used to identify IL-7 products in B- and T-lymphocytes in patients 
with B-CLL and in normal controls. The figure represents RT-PCR products after a second round of 
amplification. A lOO bp molecular weight marker was used. 
MW=molecular weight marker 
(-)=negative control 
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Figure 4.12: Mean density values of IL-7 nested RT -PCR products 
Mean 
density 
values 
p=0.03 p=0.04 
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Figure 4.13 shows mean density values of the densitometry results of the IL-4 RT-PCR products presented in 
Appendix 7. The Students t test was used to measure statistical significance. There was a significant difference 
between the density of patient and control B-lymphocyte IL-7 RT-PCR products (mean value: 1600.0 [range: 
465.1-2693.0] and 1239.9 [range: 0-2610.8] respectively, p=0.03). There was a significant difference between the 
density of patient and normal T-lymphocyte JL-7 RT-PCR products (mean value: 2480.5 [range: 800.2-3229.5] 
and 1484.6 [range: 20.1-3349.7] respectively, p=0.04). The ratio between patient Band T-lymphocyte IL-7 RT-
PCR products was 1: 1.6 and in normal healthy controls was I: 1.2. 
SD=Standard deviation, ns=Not significant 
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Figure 4.13: IL-5 wild type RT -PCR products after a second round of 
amplification 
2 3 4 5 6 7 8 9 10 11 MW 
260bp 
Patients 
B-lymphocytes 
2 3 4 5 6 7 8 9 10 MW 
260bp Controls 
B-lymphocytes 
1 2 3 4 5 6 7 8 9 10 ll MW 
260bp 
Patients 
T -lymphocytes 
(-) I 2 3 4 5 6 7 8 9 10 MW 
260bp 
Controls 
T -lymphocytes 
A nested RT-PCR technique was used to identify IL-5 products in B- and T-lymphocytes of 
patients with B-CLL and normal controls. The figure represents RT-PCR products after a second 
round of ampl ification. A I 00 bp molecular weight ladder was used. 
M=-molecular weight marker 
(-)=negative control 
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Figure 4.14: Mean density values ofiL-15 nested RT-PCR products 
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Figure 4.14 shows mean density results ofthe densitometry results of the IL-15 RT-PCR products presented in 
Appendix 8. The Students t-test was used to measure statistical significance. There was no significant difference 
between the density of patient and control 8-lymphocyte IL-15 RT-PCR products (mean value: 1861.7 [range: 
1545.8-2293.6] and 1777.2 [range: 1626.4-1905.1] respectively, p=ns). There was a significant difference 
between the density of patient and normal T-lymphocyte IL-15 RT-PCR products (mean value: 1432.4 [range: 
459.1-1974.9] and 2279.6 [range: 1698.4-2529.8] respectively, p=O.OOI). The ratio between mean density va lues 
of patient 8 and T -lymphocyte LL- 15 RT -PCR products was I: 0.8 and in normal healthy controls I: 1.3. 
SD=Standard deviation , ns=Not significant 
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4.6. Correlation between gamma chain related cytokine RT-PCR product densities 
Since it is known that IL-2, IL-4, IL-7 and IL-15 use the ye chain as part of their 
individual receptor complexes, inter-cytokine regulation may occur. In order to determine 
whether a correlation existed between the OD of RT-PCR products of the above 
cytokines, the data was analysed using Spearman's Rank Correlation. In B-CLL B-
lymphocyte samples, a strong positive correlation was found (0.74, p=0.008) between the 
densities of the IL-2 and IL-4 RT-PCR products. In B-CLL T-lymphocyte samples, a 
positive correlation was found between IL-2 and IL-4 RT -PCR products and between JL-
4 and lL-7 RT-PCR products (r=0.62, p=0.03 and r=0.06, p=0.05 respectively). Finally in 
control T -lymphocytes samples, a strong negative correlation was found between IL-2 
and IL-4 RT-PCR products (r=-0.72, p=O.Ol) (Figures 4.15-4.17). 
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Figure 4.15: Correlation between IL-2 and IL-4 RT-PCR product density in patient B-
and T -lymphocytes 
A) B-lymphocytes 
D 2011 
E 
N 1581 
s 1000 
I 500 
T • Ilr2 y 
- 500 
• Ilr4 
- 1000 
Patients 
Speannan's Correlation was used to measure the correlation between IL-2 and fL-4 RT-PCR product density in 
patient B-lymphocytes. A strong positive correlation was found (0.74, p=0.008). 
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Spearrnan's Rank Correlation was used to measure the correlation between IL-2 and IL-4 mRNA transcript 
density in patient T-lymphocytes. A positive correlation was found (r=0.62, p=O.OJ). 
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Figure 4.16: Correlation between IL-2 and IL-4 RT-PCR product density in control T-
lymphocytes 
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Speannan's Rank Correlation was used to measure the correlation between lL-2 and IL-4 RT-PCR product 
density in control T-lymphocytes. A negative correlation was found (r= -0.72, p=O.O I). 
Figure 4.17: Correlation between TL-4 and IL-7 RT-PCR product density in patient T-
lymphocytes 
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Spearrnan's Rank Correlation was used to measure the correlation between IL-7 and IL-4 RT-PCR product 
density in patient T-lymphocytes. A positive correlation was found (r=0.06, p=0.05). 
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4.7. mRNA analysis of IL-2 wild type, D...-2 52, D...-4 wild type and IL-4o2 RT-PCR 
products 
For the detection of IL-2 RT-PCR products, the following primers were used: for the first 
round of amplification primers spanning exons 1 to 4; for the second round of amplification 
primers spanning exons 1 to 3. For the detection of IL-4 RT-PCR products, both sets of 
primers spanned exons I to 3. 
There was a significant difference between the IL-2 wild type RT-PCR product density of 
patient and control B-lymphocytes (mean value: 172.4, SD+/-73.2 [range: 21.4-249.6] and 
53.0, SD+/-35.3 [range: 0-109.6] respectively, p=O.OOl). There was no significant difference 
between the density of patient and normal T-lymphocytes IL-2 wild type RT-PCR products 
(mean value: 175.3, SD+/-79.0 [range: 48.3-274.4] and 195.7, SD+/-67.9 [range: 30.3-268.1] 
respectively). In addition, the ratio between patient B and T -lymphocyte mean density values 
ofiL-2 wild type RT-PCR products was 1: 1 and in normal healthy controls l: 3.7 (Appendix 
9, Figure 4.18 and 4.19). 
There was a significant difference between the IL-2 splice variant IL-2 delta 2 (IL-2 82) RT-
PCR product density of patient and control B-lymphocytes (mean value: 13.1, SD+/-16.7 
[range: 0-56.6] and 0.53, SD+/-1 .6 [range: 0-5.3] respectively, p=0.03). There was no 
significant difference between the density of patient and normal T-lymphocyte IL-2 82 RT-
PCR products (mean value: 38.8, SD+/-41.1 [range: 0-138.2] and 80.6, SD+/-61.7 [range: 0-
172.4] respectively). The ratio between patient B and T -lymphocyte mean density values of 
IL-2 82 RT-PCR products was 1: 2 and in normal healthy controls 1: 152 (Appendix 9, Figure 
4.18, Table 4.19). 
There was a significant difference between the IL-4 wild type RT-PCR product density of 
patient and control B-lymphocytes (mean value: 27.0, SD+/-4.1 [range: 18.7-29.9] and 21.2, 
SD+/-1.9 [range: 19.0-22.9] respectively, p=0.03). There was no significant difference 
between the density of patient and normal T-lymphocyte IL-4 wild type RT-PCR products 
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(mean value: 24.8, SD+/-10.9 (range: 13.3-35.3] and 21.2, SD+/-9.6 [range: 11.4-34.4] 
respectively, p=ns). The ratio between patient Band T-lymphocyte mean density values oflL-
4 wild type RT-PCR products was 1: 0.9 and in normal healthy controls 1:1 (Appendix 10, 
Figure 4.20 and 4.21). 
No significant difference between the IL-4 splice variant IL-4 delta 2 (IL-4 82) RT-PCR 
product density of patient and control B-lymphocytes was demonstrated (mean value: 11.4, 
SD+/-1.9 [range: 9.0-14.1] and 11.8, SD+/-2.0 [range: 9.5-14.0] respectively, p=ns). There 
was a significant difference between the density of patient and normal T -lymphocyte IL-4 82 
RT-PCR products (mean value: 2.1, SD+/-0.7 [range: 1.0-3.1] and 15.8, SD+/-7.6 [range: 7.1-
24.3] respectively, p=O.OO 1 ). The ratio between patient B and T -lymphocyte mean density 
values of IL-4 82 RT-PCR products was 1: 7.6 and in normal healthy controls 1: 1.3 
(Appendix 10, Figure 4.20, Table 4.21 ). 
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Figure 4.18: IL-2 wild type and IL-2 delta 2 (IL-2B2) RT-PCR products after a 
second round of amplification 
A nested RT-PCR technique was used to identify IL-2 wild type and IL-282 splice variant products 
in B- and T-lymphocytes of patients with B-CLL and nonnal healthy controls. The figure shows 
RT-PCR products after a second round of amplification. A I OObp molecular weight ladder was 
used. 
MW-molecular weight 
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Figure 4.19: Mean density values ofllr-2 wild type and llr2o2 nested RT-PCR products 
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Figure 4.19 shows the densitometry results of the fL-2 and IL-2 o2 RT -PCR products presented in Appendix 9. 
The Students t test was used to measure statistical significance. A significant difference between IL-2 wild type 
RT-PCR product density of patient and control B-lymphocytes was found (mean value: 172.4 [range: 21.4-
249.6] and 53.0 [range: 0-1 09.6] respectively, p=O.OO I). No significant difference between the density of patient 
and normal T-lymphocyte LL-2 wild type RT-PCR products was found (mean value: 175.3 (range: 48.3-274.4] 
and 195.7 [range: 30.3-268.1] respectively, p=ns). In addition, the ratio between patient Band T-lymphocyte 
mean density values of IL-2 wild type RT-PCR products was I: I and in normal healthy controls I: 3.7. 
There was a significant difference between the LL-2 splice variant IL-2 02 RT-PCR product density of patient and 
control B-lymphocytes (mean value: 13.1 [range: 0-56.6] and 0.53 [range: 0-5.3] respectively, p=0.03). There 
was no significant difference between the density of patient and normal T-lymphocyte IL-2 o2 RT-PCR products 
(mean value: 38.8 [range: 0-138.2] and 80.6 [range: 0-172.4] respectively, p--ns). In addition, the ratio between 
the mean density values of patient B-lymphocyte LL-2 02 RT-PCR products was I: 2 and in normal healthy 
controls I: 152. 
SD=Standard deviation, ns=Not significant 
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Figure 4.20: IL-4 wild type and IL-4 delta 2 (IL-4 82) RT -PCR 
products after a second round of amplification 
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A nested RT-PCR technique was used to identify fL-4 and LL-4 o2 products in B-and T-
lymphocytes in patients with B-CLL and in nonnaJ controls. The figure shows RT-PCR products 
after a second round of amplification. A 100 bp molecular weight marker was used. 
MW=molecular weight marker 
(-)=negative control 
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Figure 4.21: Mean density values ofll..-4 wild type and ll..-4o2 nested RT-PCR products 
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Figure 4.2 1 shows mean values ofthe densitometry results of the fL-4 and IL-4 o2 RT-PCR products presented in 
Appendix 10. The Students t test was used to measure statistical significance. There was a significant difference 
between the rL-4 wild type RT-PCR product density of patient and control B-lymphocytes (mean value: 27.0 
[range: 18.7-29.9] and 21.2 [range: 19.0-22.9] respectively, p=0.03). No significant difference was found 
between the density of patient and normal T-lymphocyte IL-4 wild type RT-PCR products (mean value: 24.8 
[range: 13.3-35.3] and 21.2 [range: 11.4-34.4] respectively, p=ns). The ratio between patient Band T-lymphocyte 
mean density values of JL-4 wild type RT-PCR products was I: 0.9 and in nonnal healthy controls 1: I. 
No significant difference between IL-4 splice variant IL-4 o2 RT-PCR product density of patient and control B-
lymphocytes was found (mean value: 11.4 [range: 9.0-14.1] and 11.8 [range: 9.5-14.0] respectively, p=ns). 
However, a significant difference between the density of patient and normal T-lymphocyte rL-4 o2 RT-PCR 
products was demoostrated (mean value: 2.1 (range: 1.0-3.1] and 15.8 [range: 7.1-24.3] respectively, p=O.OOI). 
The ratio between patient Band T-lymphocyte mean density values of rL-4 o2 RT-PCR products was I: 7.6 and 
in normal healthy controls I: 1.3. 
SD=Standard deviation, ns=Not significant 
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4.8. Correlation between IL-2 wild type and IL-2 B2 RT -PCR product densities 
Using Spearman's Correlation, a significant positive correlation was found between IL-2 wild 
type bands and IL-2 B2 splice variant bands in patient and control T-lymphocyte samples 
(r=0.76, p=0.006 and r=0.75, p=O.Ol respectively). No significant correlation between IL-2 
wild type bands and IL-2 B2 splice variant bands in patient and control B-lymphocyte samples 
was found (Figure 4.22 A and B) 
4.9. Correlation between IL-4 wild type and IL-4 B2 RT -PCR product densities 
Using Spearman's Rank Correlation, a significant positive correlation between IL-4 wild type 
bands and IL-4 B2 spliced variant bands in patient 8-lymphocyte samples was found (r=0.87, 
p=0.005) (Figure 4.23). No significant correlation was found between IL-4 wild type bands 
and IL-4 82 splice variant bands in patient and in control T -lymphocyte samples as well as in 
control B-lymphocyte samples. 
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Figure 4.22: IL-2 wild type versus IL-2 52 RT-PCR product density in patient and 
control T -lymphocytes 
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Speannan's Rank Correlation was used to measure the correlation between IL-2 and IL-o2 RT-PCR product 
density in patient 8-lymphocytes. A significant correlation was fmmd (r=0.76, p=0.006). 
B) Control T-lymphocytes 
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Speannan' s Rank Correlation was used to identify the correlation between I.L-2 and IL-20 RT-PCR product 
density in patient 8-lymphocytes. A significant correlation was found (r=0.75, p=O.OI ). 
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Figure 4.23: IL-4 wild versus a-4 32 RT-PCR product density in patient B-lymphocytes 
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Spearman's Rank Correlation was used to measure the correlation between lL-4 and IL-4 ~2 RT-PCR product 
density in patient B-lymphocytes. A significant positive correlation was found (r=0.87, p=0.005). 
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4.10. mRNA analysis ofiL-5 and IL-13 RT-PCR products 
A nested RT-PCR technique was also used to identifY IL-5 and IL-13 RT-PCR products in B 
and T -lymphocytes of patients with B-CLL and in normal controls. The reason for 
investigating IL-5 is that IL-5 is thought to have a strong apoptotic effect on malignant B-CLL 
cells. IL-13 on the other hand presents many similarities to IL-4. The IL-4R a. chain is a 
common component ofiL-4R and the IL-13 R. IL-13 is anti-apoptotic cytokine for malignant 
B-CLL cells. Throughout the study, the same cDNA samples were used and the primers used 
for detecting IL-5 and IL-13 were designed to cover the entire mRNA size. No significant 
difference between the density of patient and control B-lymphocytes IL-5 RT-PCR products 
was found (mean value: 788.0, SD+/-373.8 [range: 16.7-1173] and 486.2, SD+/-353.9 [range: 
0-666.3] respectively, p=ns). There was no significant difference between the density of 
patient and normal T-lymphocyte IL-5 RT-PCR products (mean value: 704.4, SD+/-374.8 
[range: 0-1076.7] and 537.8, SD+/-465.0 [range: 0-974.5] respectively, p=ns). In addition, the 
ratio between patient Band T-lymphocyte mean density values ofiL-5 RT-PCR products was 
1: 0.9. The same ratio in normal healthy controls was I: 1.1 (Appendix 11 , Figure 4.24 and 
4.25). 
There was no significant difference between the density of patient and control B-lymphocyte 
IL-13 RT-PCR products (mean value: 328.2, SD+/-130.6 [range: 39.4-536.2] and 349.5, 
SD+/-166.0 [range: 34.8-541.3] respectively, p=ns). There was no significant difference 
between the density of patient and normal T-lymphocyte IL-13 RT-PCR products (mean 
value: 308.4, SD+/-145.8 [range: 48.5-455. 7] and 349.0, SD+/-158.6 [range: 0-510.8] 
respectively, p=ns). In addition, the ratio between patient B and T -lymphocyte mean density 
values ofiL-13 RT-PCR products was 1: 0.9. The same ratio in normal healthy controls was 
1: 1 (Appendix 12, Figure 4.26 and 4.27). Automated sequencing (MWG, Germany) was used 
to identify the RT-PCR products (Appendices (29-30). 
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Figure 4.22: ll..--5 RT -PCR products after a second round of amplification 
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A nested RT-PCR technique was used to identify IL-5 products in 8 - and T-lymphocytes of 
patients with 8-CLL and normal controls. The figure represents RT-PCR products after a second 
round of amplification. A I 00 bp molecular weight ladder was used. 
M=-molecular weight marker 
(-)=negative control 
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Figure 4.25: Mean density values of IL-5 nested RT -PCR products 
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Figure 4.25 shows the densitometry results of the IL-5 RT-PCR products presented in Appendix 11. The Students 
t test was used to measure statistical significance. There was no significant difference between the density of 
patient and control B- lymphocyte IL-5 RT-PCR products (mean value: 788.0 [range: 16.7-1173] and 486.2 
[range: 0-666.3] respectively, p=ns). There was no significant difference between the density of patient and 
control T-lymphocyte IL-5 RT-PCR products (mean value: 704.4 [range: 0-1076.7) and 537.8 [range: 0-974.5] 
respectively, p=ns). The ratio between patient B and T-lymphocyte mean density values of IL-5 RT-PCR 
products was I: 0.9. The same ratio in normal healthy controls was I: 1.1. 
SD=Standard deviation, ns=Not significant 
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Figure 4.24: IL-13 nested RT-PCR products after a second round of 
amplification 
MW (-) l 2 3 4 5 6 7 8 9 10 11 
234 bp ~ ro:r--~;:-:""J---
- - -
2 3 4 5 6 7 8 9 10 
234bp ___. 
- - .-- --1- - -
-
MW I 2 3 4 5 6 7 8 9 10 11 
234bp ___. 
-- ---- ---
. ,. 
I 
I 2 3 4 5 6 7 8 9 10 MW 
234bp -~----- --..... . 
Patients 
8-lymphocytes 
Controls 
8-lymphocytes 
Patients 
T-lymphocytes 
Controls 
T-lymphocytes 
A nested RT-PCT technique was used to identity IL-13 products in 8- and T-lymphocytes in 
patients with 8-CLL and in normal controls. The figure represents RT-PCR products after a second 
round of amplification. A I 00 bp molecular weight marker was used. 
MW=molecular weight marker 
(-)=negative control 
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Figure 4.27: Mean density values ofiL-13 nested RT-PCR products 
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Figure 4.27 shows the densitometry results of the I L-13 RT -PCR products presented in Appendix 12. The 
Students t test was used to measure statistical significance. There was no significant difference between the 
density of patient and control 8-lymphocyte LL-13 RT-PCR products (mean value: 328.2 [range: 39.4-536.2] and 
349.5 [range: 34.8-541.3) respectively, p=ns). There was no significant difference between the density of patient 
and control T-lymphocyte IL- 13 RT-PCR products (mean value: 308.4 [range: 48.5-455.7) and 349.0 [range: 0-
51 0.8) respectively, p=ns). The ratio between patient 8 and T-lymphocyte mean density values of IL-13 RT-PCR 
products was I: 0.9. The same ratio in normal healthy controls was ratio: I : I. 
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4.10. Correlation between IL-4 and IL-13 RT-PCR product densities 
Since it is known that IL-4 and 13 use the IL-4Ra chain as part of their individual receptors, 
inter-regulation of protein expression may occur. In order to determine whether a correlation 
existed between the densities of RT-PCR products of the above cytokines, the data was 
analysed using the Spearman's Rank Correlation test. 
No significant relationship was found between JL-4 and IL-13 RT-PCR product density in 
patient B-lymphocytes although there is a strong tendency for IL-13 RT -PCR products to be 
up-regulated at the same time as IL-4 RT-PCR products. Similarly no significant relationship 
was found between IL-4 and IL-13 RT-PCR products in control B-lymphocytes. 
The correlation between IL-4 and IL-13 RT -PCR product density was not significant in patient 
and control T-lymphocytes. 
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4.12. Summary- nested RT-PCR 
In this part of the project, RT -PCR products of cytokines belonging to the IL-2 receptor ye 
chain family as well as ye chain and IL-4R a. chain RT -PCR products were investigated in 
purified unstimulated B- and T -lymphocytes of patients with B-CLL and in normal controls 
(Table 5.2). In addition, IL-2 and IL-4 spliced variant (IL-2 82 and IL-4 82 respectively) RT-
PCR products were also investigated. All tests were carried out on the same cDNA 
preparation. A nested RT-PCR technique was applied to all the samples. 
• The most striking results were significantly higher IL-2 and IL-4 wild type RT -PCR 
product densities in malignant B-lymphocytes compared to control B-lymphocytes 
samples. 
• IL-2 82 and IL-4 82 RT-PCR products were detected. Patient B-lymphocytes had 
significant ly higher IL-2 82 product densities than control B-lympbocytes. Control T-
lyrnpbocytes had significantly higher IL-4 82 RT-PCR product densities compared to 
patient T lyrnphocytes. 
• IL-7 transcript densities were significantly higher in both B- and T -lymphocytes from 
patients with 8-CLL compared to controls. 
• IL-15 RT -PCR products were also identified in all tested samples although B-and T-
lymphocytes are not considered to be IL-15 producers. In addition, control T-lymphocyte 
samples had significantly higher IL-15 RT -PCR product densities when compared to 
patients T -lymphocytes. 
• No differences were found for ye RT-PCR products in patient and control T lymphocytes 
and in patient and control B-lymphocytes. 
• A significant positive correlation was found between JL-2 and IL-4 RT-PCR product mean 
density values in patient B- and T-lymphocytes and control T -lympbocytes 
• In addition, IL-5 and IL-13 RT-PCR products were also detected. However there was no 
significant difference between the corresponding samples. 
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• Automated sequencing (MWG, Germany) identified the RT-PCR products. 
Table 4.2: Summary of the abundance of cytokines in 8-CLL and normallymphocytes 
Characteristics 8-CLL Normal 8-CLL Normal 
8 lymphocyte 8-lymphocyte T -lymphocyte T -lymphocyte 
t-test used to compared B-CLL B cell/normal B-cell and B-CLL T -cell/normal T -ceU values 
Intracellular IL-4 ++++ * ++ ++ * + 
Surface IL-4R a. ++++ ++++ ++ * + 
IL-4 protein(WB) + Not done ++++ ++++ 
IL-4Ra. mRNA ++++ ++++ ++++ ++++ 
ye mRNA ++++ ++++ ++++ ++++ 
IL-2 mRNA +++ * + ++++ ++++ 
IL-4 mRNA +++ * + ++++ ++++ 
IL-7 mRNA +++ * ++ ++++ * +++ 
IL-1 5 mRNA +++ +++ ++ ++++ 
lL-2 82 mRNA ++ * + +++ ++++ 
IL-4 82 mRNA ++ ++ + ++++ 
IL- 13 mRNA ++++ ++++ ++++ ++++ 
Spearmans' correlation test performed within each lymphocyte subset 
IL-2 mR.NA/ ns ns Positive Positive 
IL-2 82 mRNA correlation correlation 
IL-4 mRNA/ Positive ns ns ns 
IL-4 82 mRNA correlation 
IL-2 mRNA Positive Positive ns Negative 
/IL-4 mRNA correlation correlation correlation 
IL-4 mRNA ns ns Positive ns 
/IL-7 mRNA correlation 
IL-4 mRNA ns ns ns ns 
/lL- 13 mR.NA 
This table indicates the abundance of RT-PCR cytokine products and the percentage of cells express ing IL-4 or 
ITAR. ++++= the most aboundant, += the least aboundant, Ns=Not significant, WB= Western blotting, 
*=s ignificant 
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* 
CHAPTER 5: RESULTS OF ANTISENSE STUDY 
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5.1. Introduction 
In this part of the study, the influence of antisense oligonucleotides (ONs) on the proliferation 
and apoptosis of B-CLL and normal healthy control cells was tested. Previous studies have 
shown that IL-2 and IL-4 have an anti-apoptotic effect on malignant B-lymphocytes (Mainou-
Fowler, 1996). This study also provided evidence for increased intracellular expression of IL-
4 in malignant B-lymphocytes as well as increased mRNA expression of IL-2 and IL-4 
cytokines in these cells. In view of this, MTT {3-( 4,5.dimethylthiazol-2-yl)-2,5-
diphenylterrazolium bromide)} and antisense staining techniques were used to measure the 
effect of the addition of antisense ONs to B-CLL and normal cell cultures. 
The antisense oligonucleotides were designed as follows: 
Exon 1 Exon 2 Exon 3 Exon 4 Exon 1 Exon 3 Exon 4 Exon 1 
lL-2a/LL-4a IL-2b/IL-4b IL-2c/IL-4c IL-2d!IL-4d 
Antisense Blocking effect 
IL-2a or IL-4a IL-2 or IL-4 wild type and o3 
IL-2b or IL-4b IL-283 or IL-483 
IL-2c or IL-4c IL-282 or IL-4o2 
IL-2d or IL-4d IL-2 or IL-4 wild type and 82 and 83 spliced 
variants 
Control antisense ON was designed as a reverse reading ofiL-4d ON. 
5.2. Patients and controls 
Details concerning normal healthy controls are listed in table 3.2 and clinical and 
irnmunophenotypic features of the patients are listed in table 5.1. 
197 
Table 5.1: Clinical and immunophenotypic features of patients used in the antisense 
study 
Patient Gender Age % %CD19 Absolute Stage 
number (Years) CDS+ve +ve lymphocyte (Binet!Rai) 
count 
(x 10911) 
22 M 62 95.0 86.0 12.7 A(O) 
23 M 68 68.5 75.9 41.1 A(O) 
24 M 86 80.3 91.2 62.5 A(O) 
25 M 72 99.0 96.0 71.6 A(O) 
26 M 82 69.0 79.0 12.7 A(O) 
27 M 75 87.5 73.1 38.4 A(O) 
28 F 72 50.0 69.9 14.8 A(O) 
29 F 80 84.0 29.5 89.6 A(O) 
30 M 79 82.0 84.0 84.3 A(O) 
31 F 62 43.6 69.8 58.2 A(O) 
32 F 78 69.5 89.6 20.4 A(O) 
33 M 65 48 .. 0 40.7 43.2 A(O) 
34 F 82 66.0 56.0 15.9 A(O) 
The percentage of CD5+ve and CD 19+ve lymphocytes and the absolute lymphocyte count were obtained from 
the diagnostic laboratory. The staging system used at the time of the diagnosis is that described by Binet and Rai. 
The li st represents details of all the patients used in the anti sense study. 
F=Female, M=Male, %=Percentage 
198 
5.3. Testing for antisense oligonucleotide (ON) penetrance into PBMCs 
Rodamine-red antisense IL-2a ON was tested for its ability to enter lymphocytes. For this 
purpose, PBMCs from patients with B-CLL resuspended to a concentration of lxl05 and 
plated into a 96 well plate and rodamine-red conjugated antisense IL-2a ON was added at the 
following concentrations: I 0 ~M, 5 ~M, 2.5 ~M, 1.75~M, 1 ~M, 0.5 ~M. No carrier was 
used. 
The cells were viewed under UV microscope after 30 min, I hour, 2 hours, 3 hours and 4 
hours. After 2.5 hours of incubation, a discrete, punctuate staining was visible in the 
cytoplasm of the cells. The staining did not increase with time. 
The experiment was repeated using PBMCs separated from patients with B-CLL and from 
normal healthy controls. Similarly after 2.5 hours of incubation, a distinctive punctuate 
staining was visible in the cytoplasm of the cells. Unfortunately, our laboratory does not have 
the facility to photograph stained cells. 
5.4. MTT assay 
The TACS™ MTT Assay kit was used to measure cell proliferation and viability of B-CLL 
cells and normal control PBMCs after incubation with various antisense ONs. 
The MTT assay has been developed as an alternative system to conventional 3H-thymidine 
uptake for measuring cell proliferation. 
5.4.1. Optimisation of cell concentration 
Different concentrations of PBMCs separated from B-CLL patients and normal controls were 
used to establish the optimal concentration of cells to be used in the MTT assay. Double 
diluted PBMCs (from 3.8x106 to 7xl03) were used. All experiments were performed in 
triplicate. Results are given as the mean optical density (OD) value of each experiment. The 
optimal concentration of PBMCs for use in the MTT assay was calculated on the basis of OD 
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distribution. The OD decreased between the cell concentrations 3.8x106 and 2.5x 105. At 
lower cell concentrations (between 1.25xl05 to 7xl03) very similar readings were obtained. 
Thus, the concentration of PBMCs at 2.5x105 was chosen as the optimal concentration to be 
used in further MIT studies (Figure 5.1 A and 5.1 B). 
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Figure 5.1: Optimisation of the concentration ofPBMCs separated from patients with 8-
CLL and from normal controls for use in the MTT assay 
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The graph shows OD results of the MIT assay. PHA-stimulated PBMCs from one nonnal control and from one 
patient with B-CLL were double diluted from 3.8x t06/ml to 7xl03/mJ and incubated for 24 hours in a 96 well 
plate. Optical density measurements show that 2.5x I 05/ml is the optimal concentration of PHA-stimulated cells to 
be used for further studies. 
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5.4.2. Optimisation of antisense ONs concentrations for the MTI assay 
The effect of different concentrations of antisense oligonucleotides (ONs) on the viability and 
proliferation of PBMCs from patients 22 and 23 with B-CLL and two normal controls was 
examined. IL-2a, IL-2b, IL-2c IL-2d as well as IL-4a, IL-4b, IL-4c, IL-4d and control 
antisense were used in this study. The control antisense ON was designed as a reverse reading 
offL-4d antisense ON. The following concentrations of antisense ol.igonucleotides were used: 
1 OJ.!M, 5).lM, 2.5J.!M, 1.25J.!M, 0.625J.!M. All experiments were performed in triplicate. The 
ONs were added to the cells twice (one hour before the addition ofPHA and 1 hour after). The 
results are given as the mean OD value of each experiment performed in triplicate. 
MTT assay mean OD values were lowest when antisense ONs IL-2a, IL-2b, IL-2c were added 
at a concentration of 1.25J.!M. The strongest suppression of proliferation in normal PHA-
stimulated cells after the addition of IL-2d occurred at a concentration of 5J.!M. PTO-modified 
ON at a concentration of 1.25 J..lM were therefore considered the strongest suppressors of 
proliferation of normal PHA-stimulated PBMCs (Figure 6.2 A, B, C, D and E). Similarly IL-
4a, JL-4b, IL-4c, JL-4d ONs at a concentration of 1.25 J..lM were the strongest suppressors of 
cell viability of normal PHA-stimulated PBMCs (Figure 5.3 A, B, C, D and E). 
PTO-modified IL-2a, IL-2b, IL-2c, IL-2d ONs at a concentration of 1.25 J..lM were the 
strongest suppressors ofprol.iferation ofPHA-stimulated B-CLL PBMCs (Figure 5.4 A, B, C, 
D and E). Finally, PTO-modified IL-4a and IL-4b at a concentration of 1.25 J..lM were the 
strongest suppressors ofproliferation ofPHA-stimulated B-CLL PBMCs (Figure 5.5 A, B, C, 
D and E). The optimal concentration of antisense ON chosen for further studies was 1.25J..lM. 
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Figure 5.2: Optimisation of PTO-modified IL-2 antisense ONs concentrations for the 
MTT assay, using PHA-stimulated PBMCs from normal controls 
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This figure represents MTI assay mean optical density (OD) values of each experiment performed in triplicate. 
PBMCs from two normal controls were incubated with various PTO-modified LL-2 antisense oligonucleotides 
added at different concentrations to the cell culture (Range: 10 ~-0.625 ~M). PBMCs were stimulated with 
PHA at a concentration of I ~g/ml and incubated in 96 well plates for 24 hours at 37°C. ONs were added at the 
beginning of the incubation, I hour before PI-lA-stimulation and I hour after PI-lA addition. LL-2a, lL-2b, TL-2c 
ONs at a concentration of 1.25 ~M were the strongest suppressors of proliferation of normal PHA-stimulated 
PBMCs (Figure A-C. The strongest suppression of proliferation was after addition of LL-2d antisense ON at a 
concentration of 5~M. The optimal concentration of antisense ONs chosen for further studies was l.25~M. 
Arrows indicate the lowest OD values after addition of antisense ON. OD-Optical density 
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Figure 5.3: Optimisation of PTO-modified IL-4 antisense ON concentrations for tbe 
MTT assay, using PHA-stimulated PBMCs from normal controls 
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This figure represents MTT assay mean optical density (OD) va lues. All experiments were performed in 
triplicate. PBMCs from two normal controls were incubated with various PTO-modified IL-4 antisense 
oligonucleotides added at different concentrations to the culture (Range: IOJ.lM-0.625J.lM). Cells were stimulated 
with PHA. ONs were added at the start of the incubation and I hour after PHA addition. IL-4a ON at a 
concentration of 1.25 J.lM was the strongest suppressor of proliferation of normal PHA-stimulated PBMCs 
(Figure A). IL-4b and IL-4c ONs at a concentration of 0.625 J.lM were the strongest suppressors of proliferation 
of normal PHA-stimulated PBMCs (Figures B and C). The strongest suppression of proliferation was after 
addition of JL-4d anti sense ON at a concentration of I OJ.!M. Arrows indicate the lowest OD values after addition 
of antisense ON. OD=OpticaJ density 
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Figure 5.4: Optimisation of PTO-modified IL-2 antisense ON concentrations for the 
MTI assay, using PHA-stimulated PBMCs from patients with B-CLL 
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This figure represents M1T assay mean optical density (OD) values. All experiments were performed in 
triplicate. PBMCs from two patients with B-CLL were incubated with various PTO-modified IL-4 antisense ONs 
added at different concentrations to the culture (Range: IOJ.lM-0.625 J.lM). Cells were stimulated with PHA, 
which was added one hour after the start on the incubation. Antisense ONs were added at the start of the 
incubation and I hour after the add ition of PHA. 
IL-2b and lL-2c antisense ONs at a concentration of 1.25 J.1M were the strongest suppressors of proliferation of 
PHA-stimulated PBMCs from B-CLL patients (Figure Band C). £L-2a antisense ON at a concentration of0.625 
1-1M was the strongest suppressor of proliferation of PHA-stimulated PBMCs (Figures A) and lL-2d at the 
concentration of 5J.1M was the strongest suppressor of proliferation (Figure D). Arrows indicate the lowest OD 
values after addition of antisense ON. 
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Figure 5.5: Optimisation of PTO-modified IL-4 antisense ON concentrations for the 
MTI assay, using PRA-stimuJated PBMCs from patients with B-CLL 
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This figure represents MTI assay mean optical density (OD) values. P8MCs from two patients with 8-CLL were 
incubated with various PTO-moditied IL-4 antisense ONs at different concentrations (Range: 10 ~M-0.625 ~M). 
PHA was added one hour after the start of the incubation. IL-4 antisense ONs were added at the start of the 
incubation time and an hour after PHA stimulation. 
IL-4a, IL-4b and IL-4c ONs at a concentration of 1.25 ~M were the strongest suppressors of proliferation of 
PHA-stimulated PBMCs from 8-CLL patients (Figures A, 8 and C). IL-4d ON at a concentration of 5 ~M was 
the strongest suppressor of proliferation of PHA-stimulated P8MCs (Figure D). Arrows indicate the lowest OD 
values after addition of antisense ON. Arrows indicate the lowest OD values after addition of antisense ON. 
OD=Optical density 
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5.4.3. Effect of PTO-modified IL-2 and IL-4 antisensc ONs on the viability of PBMCs 
from patients with B-CLL 
In this experiment, PBMCs from patient Patient 22, Table 6.1) with B-CLL were isolated by 
density gradient centrifugation. All antisense ONs were added three times at a concentration of 
1.25~-tM. The frrst dose of antisense ONs was added at the start of the incubation time, the 
second dose one hour after the addition of PHA and the third dose was added 24 hours later, 
just prior to the cells being used for the MTT assay. 
Spectrophotometrical analysis revealed that the viability of PBMCs decreased after incubation 
for 48 hours with IL-2a, IL-2b, and IL-2c as well as in negative controls and increased at 72 
hours of(Figure 5.6 A, B, C, D and E). 
OD readings after 24 hours of incubation were higher in PHA-sti.mulated cells compared to 
unstimulated PBMCs. OD readings after 48, 72 and 96 hours of incubation did not differ very 
much between PHA-stimulated and unstirnulated PBMCs incubated with IL-2 antisense ONs. 
In conclusion, addition of IL-2 antisense ONs to unstirnulated and PHA-stirnulated PBMCs 
from B-CLL patients partially decreased the proliferation of the cells when compared to 
negative controls as shown by a decrease in OD readings (Figure 5.6 A, B, C, D and E). 
Similarly, incubation of unstimulated and PHA-stimulated PBMCs from B-CLL patient with 
IL-4a, IL-4b, IL-4c and JL-4d antisense ONs dramatically decreased the OD after incubation 
for 48 hours and increased the OD at 72 hours of incubation (Figure 5.7 A, B, C, D and E). In 
addition, OD readings after 24 and 48 hours of incubation were higher in PHA-stirnulated 
cells compared to unstirnulated cells. At 72 hours of incubation, OD readings of the non-
stimulated cells incubated with IL-4 antisense ONs were slightly higher than those of PHA-
stirnulated cells. 
In summary, addit ion ofPTO-modified IL-4a, IL-4b, IL-4c and IL-4d PTO-modified antisense 
ONs decreased proliferative responses in PBMCs from B-CLL patients compared to negative 
controls (Figure 5.7). 
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Figure 5.11: Flow cytometric analysis of the effect of different incubation times with PTO-
modified IL-2 antisense ONs on apoptosis ofCD19+ve lymphocytes from B-CLL patients 
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D) Percentage ofCD19+/A+ and PI+/A+ cells after incubation with IL-2d ON 
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The figure shows the effect of different incubation times on the percentage of CD 19+/ A+ and PI+/ A+ cells after 
addition of IL-2 antisense ONs. PBMCs were isolated by density gradient centrifugation from patients with B-
CLL. The graph shows the percentage of double stained CDI9+/A+ B-CLL lymphocytes incubated with LL-2 
and IL-4 anti sense ONs for 0, 24, 48, and 72 hours. The percentage of double positive CD 19 PE/ Annex in V 
FITC increased with the incubation time and was highest after 48 hours. The percentage of PI+/ A+ positive cells 
in the negative control a lso increased with time. However, after addition of LL-4a, b and c, the percentage of 
PI+/ A+ cells decreased after 72 hours of incubation. 
%=Percentage, A=Annexin V, ON=Oligonucleotide, Pl=Propidium iodide 
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Figure 5.12: Flow cytometric analysis of the effect of different incubation times with 
PTO-modified IL-4 antisense ONs on apoptosis of CD19+ve lymphocytes from a B-CLL 
patient 
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The figure shows the effect of different incubation times on the percentage of CD19 PE/ Annexin V FITC 
(CD 19+/ A+) and Propidium Iodine/ Annex in V FITC (PI+/ A+) cells after addition of IL-4 antisense ONs. 
PBMCs were isolated by density gradient centrifugation from one patient with B-CLL This graph shows the 
percentage of double stained CD 19+/ A+ lymphocytes incubated with TL-4 antisense oligonucleotides for 0, 24, 
48, and 72 hours. The percentage of double positive CD 19+/ A+ lymphocytes increased with incubation time after 
incubation with IL-4c and TL-4d ONs (Figures C and D) The highest percentage of the CDI9+/A+ lymphocytes 
was seen after 48 hours of incubation with the addition ofJL-4a and b antisense ONs (Figures A and B). Thus, 48 
hours was chosen to be the optimal incubation time to be used for further studies. 
%=Percentage, A=Annexin V, ON=Oligonucleotide, PI=Propidium iodide, Neg. control=Negative control 
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5.6.2. Effect ofthc addition ofPTO-modificd antiscnsc ONs on apoptosis ofB-CLL cells 
After determining the optimal concentrations of antisense oligonucleotides and optimal 
incubation times, the following series of experiments was performed. PBMCs isolated from 
five patients with B-CLL and from five normal controls were used. Cells were stained with 
anti-CD 19 PE, double stained with anti-CD 19 PE/ Annex in V FITC (CD 19+/ A+) and double 
stained with Propidium Jodide/Annexin V FITC (PI+/A+) (Appendix 13 and 14). Staining 
with Annexin V is an indicator of cells undergoing early apoptosis. Staining with Annexin V 
and PI shows the percentage of the cells in the late apoptotic stage and staining with PI shows 
the percentage of dead cells (Figure 5.13). 
The percentage of CD 19+ve lymphocytes undergoing apoptosis was significantly higher when 
the PBMCs from B-CLL patients were incubated with the following antisense ONs: IL-4b 
(p=0.03), 2b (p=0.04), 2c (p=0.02) and 2d (p=0.002) (Table 5.2, Figure 5.14 and 5.15). 
No significant difference was present between the percentage of double positive PI+/ A+ cells 
from B-CLL patients incubated with IL-2 and IL-4 antisense ON and the negative control 
(Figure 5.16). However, it is clear that addition of different antisense ONs and control 
antisense increased the percentage ofPI+/A+ cells. 
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Figure 5.13: Flow cytometric analysis ofB-CLL cells stained with Annexin V 
FITC and anti-CD19 PE or Propidium iodide (PI) 
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P8MCs from patients with 8-CLL were stained with PI and Annex in V (A) FITC or anti-CD 19 PE 
conjugated monoclonal antibody and Annexin V FITC. Figure 8 and C shows flow cytometric analysis 
oflymphocytes from patients with 8-CLL after incubation with IL-2a antisense oligonucleotide. 
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Table 5.2: Statistical analysis of the data presented in Appendix 13 and 14 
T test 
Variable: Variable: 
CD19+/A+ neg. cont. versus CD19+/A+ PI+/ A+ neg. cont. versus PI+/ A+ plus ON 
plus ON 
Mean: 45.7 57.5 IL-4a Mean: 29.3 31.9 IL-4a 
SO+/- 11.5 13.6 SD+/- 13.2 15.3 
p=ns p=ns 
Mean: 45.7 55.8 IL-4b Mean: 29.3 36.5 IL-4b 
SO+/- 11.6 7.2 SO+/- 13.2 8.7 
p=0.032 p=ns 
Mean: 45.7 56.1 IL-4c Mean: 29.3 39.6 IL-4c 
SO+/- 11.6 13.0 SO+/- 13.2 8.5 
p=ns p-llS 
Mean:: 45.7 52.4 IL-4d Mean: 29.3 36.2 IL-4d 
SO+/- 11.6 4.4 SD+/- 13.2 11.7 
p=ns p=ns 
Mean:: 45.7 68.3 IL-2a Mean: 29.3 40.6 IL-2a 
SO+/- 11.7 14.1 SO+/- 13.2 10.2 
p=ns p=ns 
Mean: : 45.7 61.9 IL-2b Mean: 29.3 41.9 IL-2b 
SO+/- 11.7 10.9 SD+/- 13.2 
p= 0.036 p=ns 
Mean:: 45.7 61.2 IL-2c Mean: 29.3 39.8 IL-2c 
SD+/- 11.6 10.5 SD+/- 13.2 10.5 
p=0.021 p=ns 
Mean:: 45.7 56.8 IL-2d Mean: 29.3 31.8 IL-2d 
SO+/- 11.6 12.0 SD+/- 13.2 12.5 
p=0.002 p=ns 
Mean:: 45.6 60.0 Cont. Mean: 29.3 42.2 Cont. 
SD+/- 11.6 SD+/- 13.2 7.7 
p=ns p=ns 
This table shows statistical analysis of the data presented in Appendix 13 and 14. The Student t test was used. 
Values equal or lower than p=0.05 were considered statistically significant. The percentage of CDI9+/A+ 
lymphocytes was significantly higher when PBMCs from B-CLL patients were incubated with the following 
PTO-modified antisense ONs: IL-4b (p=0.04), 2b (p=0.04), 2c (p=0.02) and 2d (p=0.002). 
No significant difference was present between the percentage of double positive Pf+/A+ cells from B-CLL 
patients incubated with different ?TO-modified IL-2 and IL-4 antisense ONs and the negative control. 
ns= Not-significant, SD=Standard deviation 
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Figure 5.14: Flow cytometric analysis of the effect ofPTO-modified IL-2 antisense ONs 
on unstimulated CD19+ve lymphocytes from patients with B-CLL 
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This graph shows the results from Appendix 13. PBMCs from five patients with B-CLL were double stained with 
anti-CD 19 PE antibody and Annex in V FITC. Cells were incubated for 48 hours with PTO-modified ONs at a 
total concentration of 7.5 ~ (3 x 2.5 ~-tM). Stained cells were analysed by flow cytometry and the results are 
shown as the mean percentage of positive cells. The percentage of CDI9+/A+ lymphocytes was significantly 
higher when PBMCs from B-CLL patients were incubated with the following antisense ONs: 2b (p=0.04), 2c 
(p=0.02) and 2d (p=0.002) compared to negative controls. This graph shows that addition of control antisense 
also increased the percentage of CD 19+/ A+ lymphocytes. 
A = Annexin V, neg. cont. =Negative control, cont. ant. =Control antisense 
224 
Figure 5.15: Flow cytometric analysis of the effect of PTO-modified IL-4 antisense ONs 
on unstimulated CD19+ve lymphocytes from patients with B-CLL 
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This graph shows the results from Appendix 14. PBMCs from five patients with B-CLL were double stained with 
anti-CD19 PE antibody and Annexin V FITC. Cells were incubated for 48 hours with PTO-modified ONs at a 
total concentration of7.5~ (3 x 2.5 J.1M}. Stained cells were analysed by flow cytometry and the results shown 
as the mean percentage of positive cells. The percentage of CD 19+/ A+ lymphocytes was higher significantly 
higher when PBMCs from B-CLL patients were incubated with fL-4b antisense ONs (p=Q.03) compared to 
negative controls. The percentage of CD 19+/ A+ lymphocytes was also higher after incubation with IL-4a, c and 
d as well as control antisense ONs. 
A = Annexin V, neg. cont. =Negative control, cont. ant. =Control antisense. 
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Figure 5.16: Flow cytometric analysis of the effect ofPTO-modified IL-2 and IL-4 
antisense ONs on unstimulated PBMC from patients with 8-CLL 
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This graph shows the data from Appendix 13 and 14. PBMCs from B-CLL patients were double stained with PI 
and Annexin V FITC. Cells were incubated for 48 hours with PTO-modified ONs at a total concentration of 
7.5j.!M (3 x 2.5 j.!M). Stained cells were analysed by flow cytometry and the results presented as the mean 
percentage of positive cells. The cells double stained for PI and Annexin V FITC (PI+/A+) represent the 
percentage of cells in the late apoptotic stage. No significant difference was found between the percentage of 
double positive PI+/A+ cells from patients with B-CLL incubated with different PTO-modified IL-2 and rL-4 
antisense ONs and the negative control. However, it is clear that addition of different antisense ONs and control 
antisense increased the percentage of PI+/ A+ cells. 
Pl=Propidium iodide, A=Annexin V, cont. ant.= Control antisense, neg. cont.= Negative control 
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5.6.3. Effect of the addition of PTO-modified antisense ONs on apoptosis of normal 
control cells 
PBMCs isolated from five normal control samples were stained with anti-CD t 9 PE, double 
stained with anti-CD 19 PE and Annex in V FITC and double stained with Annexin V FITC 
and Propidium iodine (PI) (Appendix 15 and t 6). 
No significant difference was found between the percentage of double stained CD 19 
+/Annexin V+ (CD19+/A+) positive lymphocytes incubated with antisense ONs and the 
negative control. Only incubation of the cells with PTO-modified IL-2d antisense ONs 
significantly increased the percentage ofPI+/Annexin V (PI+/A+) positive cells compared to a 
negative control (p=O.Ol3) (Table 5.3, Figure 5.17, 5.18 and 5.19). 
Normal PBMCs were double stained for CD3 PE and Annexin V FITC (Appendix 16, Table 
6.4). No significant difference was present between the percentage of double stained 
CD3+/ A+ lymphocytes incubated with various PTO-modified IL-2 and TL-4 antisense ONs 
and the negative control (Figure 5.20 A and B). 
When PBMCs from patients with B-CLL were stimulated with PHA and incubated with PTO-
modified IL-2 and IL-4 antisense ONs the results showed that, contrary to previous 
experiments, addition ofONs did not increase the percentage ofCDl9+/A+ cells compared to 
the negative control (Figure 5.21 A and B). 
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Table 5.3: Statistical analysis of data from Appendix 15 and 16 
T test 
Variable: Variable: 
CD19+/A+ neg. cont. versus CD19+/A+ PI+/ A +neg. cont. vesus PI+/ A+ 
plus antisense ON Plus antisense ON 
Mean: 2.5 1.8 IL-4a Mean: 4.8 4.1 ll.--4a 
SD+/- 1.5 1.4 SD+/- 3.0 2.7 
p=ns p=ns 
Mean: 2.5 1.8 IL-4b Mean: 4.8 4.6 IL-4b 
SD+/- 1.5 1.4 SD+/- 3.0 2.6 
p=ns p=ns 
Mean: 2.5 1.6 IL-4c Mean: 4.8 4.7 ll.--4c 
SD+/- 1.5 1.0 SD+/- 3.0 2.2 
p=ns p=ns 
Mean : 2.5 2.2 IL-4d Mean: 4.8 6.9 IL-4d 
SD+/- 1.5 1.3 SD+/- 3.0 4.2 
p=ns p=ns 
Mean: 2.5 1.7 IL-2a Mean: 4.8 4.0 IL-2a 
SD+/- 1.5 1.3 SD+/- 3.0 2.1 
p=ns p=ns 
Mean: 2.5 2.5 IL-2b Mean: 4.8 5.0 IL-2d 
SD+/- 1.5 2.3 SO+/- 3.0 3.9 
p=ns p=ns 
Mean: 2.5 2.2 ll.--2c Mean: 4.8 7.5 IL-2c 
SO+/- 1.5 1.5 SO+/- 3.0 5.0 
p=ns p=ns 
Mean: 2.5 1.8 IL-2d Mean: 4.8 6.1 IL-2d 
SO+/- 1.5 1.3 SD+/- 3.0 2.5 
p=ns p=O.Ol 
Mean: 2.5 2.2 Cont. Mean: 4.8 5.0 Cont. 
SD+/- 1.5 1.5 SD+/- 3.0 3.1 
p= DS p=ns 
The Student t test was used to measure the statistical significance of the data presented in Appendix 15 and 16. 
Values equal or lower than p=0.05 were considered statistically significant. 
No significant difference was found between the percentage of double stained CDI9 PE/Annexin V FlTC 
(CDI9+/A+) lymphocytes incubated with PTO-modified antisense ONs and the negative control. Only 
incubation of the cells with PTO-modified 1L-2d antisense ON significantly increased the percentage of 
Propidium iodine/Annexin V FITC (PI+/ A+) positive cells compared to the negative control (p=O.Ol). 
Ns=not-significant, A=Annexin, Pl=Propidium iodine 
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Figure 5.17: Flow cytometric analysis of the effect of PTO-modified IL-2 antisense ONs 
on nstimulated CD19+ve lymphocytes from normal controls 
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This graph shows the result from Table 5.3. PBMCs from five normal controls were used. PBMCs were 
incubated for 48 hours with IL-2 PTO-moditied ONs at a total concentration of7.5 ~-tM (3 x 2.5 ~-tM). Collected 
PBMCs were double stained with anti-CD19 PE antibody and Annexin V FITC (CDI9+/A+} and were analysed 
by flow cytometry. The results are shown as the mean percentage of positive cells. No significant difference was 
present between the percentage of double stained CD19+/A+ positive lymphocytes incubated with [L-2 PTO-
modified antisense ONs and the negative control. In fuct the percentage ofCD I9+/A+ lymphocytes was lower 
after addition ofi L-2a, c, d and control antisense ONs. 
A = Annexin V, neg. cont. =Negative control, cont. anat. =Control antisense 
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Figure 5.18: Flow cytometric analysis of the effect of PTO-modified IL-4 antisense ONs 
on unstimulated CD19+ve lymphocytes separated from normal controls 
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This graph shows the result from Table 5.3. PBMCs from five patients with B-CLL were used. PBMCs were 
diluted in 5% FCS culture medium to a concentration of0.5xl05/ml. Cells were incubated for 48 hours with lL-4 
PTO-modified ONs at a total concentration of7.5 11M (3 x 2.5 11M). Collected PBMCs were double stained with 
anti-CDI9 PE monoclonal antibody and Annexin V FITC (CD19+/A+) and were analysed by flow cytometry. 
The results are shown as the mean percentage of positive cells. No significant djfference was present between the 
percentage of double stained CDI9+/+A positive cells incubated with IL-2 PTO-modified antisense ONs and the 
negative control. Overall, the percentage of CD 19+/ A+ lymphocytes was lower after the addition of antisense 
ON compared to a negative control. 
A = Annexin V, neg. cont. =Negative control, cont. ant.= Control antisense 
230 
Figure 5.19: Flow cytometric analysis of the effect of PTO-modified IL-4 antisense ONs 
on unstimulated PBMCs from normal controls 
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This graph shows the results from Table 5.3. PBMCs from five patients with 8-CLL were used. PBMCs were 
diluted in 5% FCS culture medium to a concentration of0.5xl05/ml. Cells were incubated for 48 hours with TL-4 
PTO-modified ONs at a total concentration of7.5!1M (3 x 2.5 11M). Collected PBMCs were double stained with 
anti-CD19 PE monoclonal antibody and Annexin V FITC (CDI9+/A+) and were analysed by flow cytometry. 
The results are shown as the mean percentage of positive cells. No significant difference was present between the 
percentage of double stained PI+/ A+ cells incubated with lL-2 PTO-modjfied antisense ONs and the negative 
control. Overall, the percentage of PI+/ A+ was higher after addition of [L-2b, c, d, and fL-4d antisense ONs 
compared to negative control. 
A = Annexin V, neg. cont. =Negative control, cont. ant. = Control antisense 
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Table 5.4: Statistical analysis of the data from Appendix 17 
T test 
Antisense Variable: Antisense Variable: 
CD19+/A+ neg. cont. vs CD19+/A+ neg. cont. vs 
CD19+/A +plus ON CD19+/A+ plus ON 
IL-2a Mean: 5.6 4.8 IL-4a Mean: 5.6 4.4 
SD+/- 4.4 3.3 SD+/- 4.4 2.5 
p=ns p=ns 
IL-2b Mean: 5.6 5.6 IL-4b Mean: 5.6 5.6 
SD+/- 4.4 3.2 SD+/- 4.4 4.4 
p=ns p=ns 
IL-2c Mean: 5.6 5.8 IL-4c Mean: 5.6 4.7 
SD+/- 4.4 3.4 SD+/- 4.4 3.4 
p=ns p=ns 
IL-2d Mean: 5.6 6.1 IL-4d Mean: 5.6 5.9 
SD+/- 4.4 3.3 SD+/- 4.4 3.9 
p=ns p=ns 
Control antisense Mean: 5.6 7.1 
SD+/- 4.4 4.8 
p=ns 
PBMCs from five nonnal healthy controls were double stained with CD3 PE monoclonal antibody and Annexin 
V FITC (CD3+/A+). The Student t test was used. Values equal or lower than p=0.05 were considered statistically 
sign ificant. No significant difference was present between the percentage of double stained CD3+/A+ positive 
lymphocytes incubated with PTO-modified IL-2a, b, c, d and IL-4a, b, c, d antisense ONs and the negative 
control. 
ns= not signi ficant, A=antisense, SD=standard deviation, ON=oligonucleotide 
232 
Figure 5.20: Flow cytometric analysis of the effect of PTO-modified IL-2 and IL-4 
antisense ONs on unstimulated normal CD3+ve lymphocytes 
A) Percentage ofCD3+/A+ lymphocytes in PBMCs from normal control after incubation with 
PTO-modified IL-2a, b, c, and d and control antisense ONs 
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B) Percentage of CD3+/ A+ lymphocytes in PBMCs from normal control after incubation with 
different PTO-modified IL-4a, b, c, and d and control antisense ONs 
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This graph shows data from Table 5.4. Normal PBMCs were incubated for 48 hours with PTO-modified 1L-2a, 
b, c, d and IL-4a, b, c d and control antisense ONs at a total concentration of 3 x 2.5 f.LM The cells were then 
double stained with anti-CD3 PE monoclonal antibody and Annexin V FlTC (CD3+/A+). The stained cells were 
immediately analysed by flow cytometry and the results presented as the mean percentage of positive cells. The 
Student t test was used. Values equal or lower than p=0.05 were considered statistically significant No 
significant difference was present between the percentage of double stained CD3+/ A+ positive lymphocytes 
incubated with various lL-2 and lL-4 antisense ONs compared to the negative controL 
A= Annexin V, cont. ant. = Control antisense, neg. cont.= Negative control 
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Figure 5.21: Flow cytometric analysis of the effect ofPTO-modified IL-2 and IL-4 
antisense ONs on PHA-stimulated CD19+ve lymphocytes from patients with B-CLL 
A) Percentage of CD 19+/ A+ lymphocytes in PBMCs from patients with B-CLL after 
incubation with IL-2 and IL-4 antisense ONs 
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B) Percentage ofPI+/A+ lymphocytes in PBMCs from patients with B-CLL after incubation 
with IL-2 and IL-4 antisense ONs 
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PHA-stimulated P8MCs from two patients with 8 -CLL were were double stained with anti-CD19 PE and 
Annexin V FITC (CDI9+/A+) or Annex.in V FITC and Propidium iodine (PI+/ A+). The cell s were incubated for 
48 hours with various PTO-modified IL-2 and lL-4 ONs at a total concentration of 3 x 2.5 J.!M. Stained cells 
were analysed by flow cytometry and the results are presented as the mean percentage of positive cells. The 
CD 19+ve lymphocytes stained with Annex in V FITC represent the percentage of CD 19+ve 8-lymphocytes cells 
undergoing apoptosis. The graph shows that the percentage ofPHA-stimulated CD19+/A+ and PI+/ A+ cells from 
patients with 8-CLL decreases after addition of IL-2a, b, c, d and IL-4a, b, c, d antisense ONs compared to a 
negative control. 
PI=Propidium iodine, A=Annexin V, cont. ant.= Control antisense, neg. cont.= Negative control 
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5.6.4. Comparison between PTO- modified and unmodified IL-2d antisense ONs 
Previous experiments have shown that the addition of PTO-modified IL-2 and IL-4 antisense 
ON s to B-CLL cell cultures increased the percentage of CD 19+/ Annexin V+ and PI+/ Annexin 
V+ positive cells when compared to a negative control. In this experiment, unmodified 
antisense ONs as well as Phosphorothioate (PTO)-modified antisense ONs were used. A 
different antisense control (Table 2.3, antisense 2) was also used in this experiment. 
The addition of PTO-modified IL-2d antisense ON to the PBMC cell culture from three 
patients with B-CLL increased the percentage of CD19+/A+ positive lymphocytes (12.3%) 
when compared to incubation with unmodified antisense ONs (6.2%) and a negative control 
(8.6%). Control antisense also increased the percentage of CD 19+/ A+ positive Iymphocytes 
but not as much as PTO-modified antisense ON (9.6%) (Appendix 18, Figure 5.22). 
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Figure 5.22: Flow cytometric analysis ofB-CLL ceUs after the addition of control, IL-2d 
PTO-modified and unmodified IL-2d antisense ONs 
A) Percentage of CD 19+/ A+ lymphocytes after incubation with PTO-modified and 
unmodified ONs 
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PBMCs from three patients with B-CLL were incubated with unmodified IL-2d and IL-2 PTO-modjfied 
anti sense ONs as well as control anti sense ON fur 48 hours. Cells were stained with CD 19 PE monoclonal 
antibody and Annexin V FITC (CDI9+/A+) or PI and Annexin V FITC PI+/A+). This graph shows that only 
PTO-modified IL-2d and PTO-modi fied control antisense ONs increased the percentage of double positive 
CD 19+/ A+ lymphocytes compared to a negative control. The percentage of PI+/ A+ lymphocytes that are thought 
to be in a late state of apoptosis was overall very small and increased slightly after incubation with antisense 
ONs. 
Neg. cont.= negative control, cont. ant. =Control antisense, A=Antisense, Pl=Propidium iodine, PTO= 
Phosphorothioate modified 
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5.6.5. Measurements of apoptotic cell death after incubation with PTO-modified 
antisense ON plus Lipofectin 
In order to enhance cellular uptake and to promote nuclear accumulation of PTO-modified IL-
2d antisense ONs, cationic lipids were used as a delivery system. Lipofectin, whjch has been 
described as one of the most efficient carriers was used. This preliminary experiment was 
carried out only once. PBMCs from one patient with B-CLL were incubated with IL-2d 
antisense ON and was supplemented with Lipofectin at various concentrations (Range: 2-
25~1). 
As shown in the Figure 5.23, the addition of Lipofectin to the PBMCs incubated with IL-2d 
antisense ON decreased the percentage of double positive CD19+/A+ lymphocytes in a dose 
dependent manner (30.8%, 25.1 %, 28.2%, 25.8% and 23 .0%). Addition of a higher 
concentration of Lipofectin decreased the percentage of CD 19+ve B-CLL cells compared to 
lower concentrations of Lipofectin and to a negative control. As mentioned before, this 
experiment was performed only once using a much lower concentration of antisense (O.lJ.!M) 
than in all previous experiments (3 x 2.5~M). 
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Figure 5.23: Flow cytometric analysis of unstimulated B-CLL cells after incubation with 
PTO-modified IL-2d antisense ON plus Lipofectin 
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PBMCs isolated from one patient with B-CLL cells were incubated with PTO-modified lL-2d antisense ON for 
48 hours. To increase delivery of the antisense ON, Lipofectin was used at various concentrations (range: 2-
25J.ll). Cells were stained anti-CDI9 PE and Annexin V FlTC (CD\9+/A+). Antisense ON was added at a 
concentration ofO. I J..LM together with different concentration ofLipofectin. 
Addition of Lipofectin as a cationic carrier to the PBMCs decreased the percentage of double positive CD 19+/ A+ 
lymphocytes in a dose dependent manner. In other words, addition of the higher concentration of Lipofectin 
decreased the percentage of CD 19+ve 8-CLL cells compared to lower concentrations of Lipofectin and to a 
negative control. 
A=Antisense, PTO = Phosphorothioate modified 
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5.7. Summary-Anncxin V staining 
Flow cytometric analysis was used to determine the percentage of CD19+ve and CD3+ve 
lymphocytes from patients with B-CLL and from normal healthy controls undergoing 
apoptosis after incubation with different PTO-modified IL-2 and IL-4 antisense ONs. 
• Flow cytometric measurements ofthe percentage ofCD19+/A+ as well as PI+/A+ positive 
lymphocytes bad shown that the addition of various PTO-modified IL-2a, b, c, d and IL-
4a, b, c, d antisense ONs to unstimulated PBMCs increased the percentage of CD 19+/ A+ 
and PI+/A+ cells when compare to a negative control. CD19+ve lymphocytes stained with 
Annexin V are considered to be in an apoptotic state. Therefore IL-2 and IL-4 ONs might 
be considered pro-apoptotic. This effect was most prominent in B-CLL cells, reaching 
statistical significance after the addition of PTO-modified IL-2b, IL-2c and IL-2d 
antisense ONs. 
• PTO-modified control antisense ONs also increased the percentage of CD19+/A+ 
lymphocytes in unstimulated PBMCs from patients with B-CLL compared to a negative 
control. Therefore PTO-modified ONs are cytotoxic. 
• The addition of PTO-modified IL-2 and IL-4 antisense ONs had no significant effect on 
unstirnulated normal healthy control CD3+ve lymphocytes. Although a small percentage 
of CD3+/ A+ positive cells were often present, in some cases the percentage of double 
positive cells actually decreased. 
• Only PTO-rnodified antisense ON was able to increase the percentage of CD19+/A+ 
lymphocytes compared to unmodified antisense ON. Therefore, unmodified ONs are not 
biollogically effective. 
• In PHA-stimulated PBMCs fi·om patients with B-CLL, the percentage of CD 19+/ A+, 
lymphocytes after incubation with IL-2 and IL-4 antisense ONs decreased compared to a 
negative control. 
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• Addition of Lipofectin as a cationic carrier to PBMCs from B-CLL patients decreased the 
percentage ofCDI9+/A+ lymphocytes compared to a negative control. 
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5.8. Measurement of intracellular IL-2 and IL-4 in unstimulated and PMA-stimulated B-
CLL cells after incubation with various PTO-modified antisense ONs 
The effect of PTO-modified IL-4c antisense ON on intracellular expression of IL-2 and IL-4 
was studied in PBMCs from four patients with B-CLL (patients 23-28, table 5.1). 
The optimal incubation time was chosen using normal unstimulated and PMA-stimulated 
PBMCs. Flow cytometric analysis of intracellular stainning was performed after 2, 4 and 6 
hours of incubation with IL-4c antisense ON. The percentage of unstimulated normal 
CD 19+ve cells expressing intracellular IL-2 and IL-4 was higher after incubation with IL-4c 
antisense ON for 2 hours (1.5% and 14.0% respectively) when compared to a negative control 
(0.3% and 6.8% respectively). After 4 and 6 hours of incubation, the percentage of CD19+ve 
lymphocytes expressing intracellular IL-2 and IL-4 was much lower and not very different 
from a negative control (Appendix 19, Figure 5.24 A). 
The percentage of unstimulated CD3+ve lymphocytes expressing intracellular IL-2 was low. 
After incubation with antisense ON for 2 hours, the percentage of CD3+/IL-2+ positive 
lymphocytes decreased from 2.6% to 1.1 %. After incubation with PTO-modified antisense 
ON for 6 hours, the percentage of CD3+/IL-2+ positive lymphocytes decreased from 1. 7% to 
1.0% (Figure 6.24). The percentage of PMA-stimuJated CD 19+/IL-2+ cells decreased after 2 
hours of incubation with IL-4c antisense ON compared to a negative control (from 4.7% to 
0.7%) (Appendix 19, Figure 5.24 A). 
After incubation with PTO-modified antisense ON for 2 hours, the percentage of CD3+/IL-4+ 
positive lymphocytes decreased from 26.1% to 19.6%, after 4 hours from 23.3% to 12.7 % 
and after 6 hours from 27.6% to 9.4% (Appendix 19, Figure 5.24). 
Incubation of PMA-stimulated PBMCs from normal controls with 1L-4c antisense had a 
varied effect on the percentage of CD3+ve and CD 19+ve lymphocytes expressing intracellular 
IL-2 and IL-4. The percentage of CD19+/IL-2+ lymphocytes decreased after 2 hours of 
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incubation with IL-4c antisense ON compared to a negative control (from 4.7% to 0.7%) 
(Appendix 19, Figure 5.25). 
PBMCs from four patients with B-CLL were incubated with IL-4c antisense ON for 6 hours. 
The percentage of unstimulated patients CD 19+ve and CD3+ve lymphocytes expressing 
intracellular IL-2 and IL-4 decreased after addition of IL-4c antisense ON compared to a 
negative control [(CD19+/IL-2+ from 4.6%, SD+/-5.5 to 1.6%, SD+/-1.1), (CD19+/IL-4+ 
from 1 0.3%, SD+/-12.3 to 3.3%, SD+/-2.8), (CD3+/IL-2+ from 1.4%, SD+/-1.3 to 1.1 %, 
SD+/-1.8), (CD3+/IL-4+ from 3%, SD+/-3.3 to 1.1 %, SD+/-1.0)] (Appendix 20, Table 5.5, 
Figure 5.268). 
In contrast, the percentage of PMA-stimulated CD 19+ve lymphocytes expressing intracellular 
IL-2 and the percentage ofCD3+ve cells expressing intracellular IL-2 and IL-4 increased after 
addition of IL-4c antisense ON when compared to a negative control [(CD19+/IL-2+ from 
6.5%, SD+/-2.4 to 9.0%, SD+/-2. 7), (CD3+/IL-2+ from 2.1 %, SD+/-2.6 to 4.6%, SD+/-4.5), 
(CD3+/IL-4+ from 1.8%, SD+/-2.4 to 6.7%, SD+/-8.8)] (Appendix 20, Table 5.5, Figure 
5.268). None ofthese differences was significant. 
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Figure 5.24: Flow cytometric analysis of unstimulated CD19+ve and CD3+ve normal 
cells stained for intraceUular IL-2 and IL-4 
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This graph shows the data from Appendix 19. Unstimulated PBMCs from one nonnal healthy control were 
incubated for 2, 4, and 6 hours with PTO-modified IL-4c antisense ON at the concentration of 2.5J.!M. The 
percentage of CD 19+ve cells expressing intracellular IL-2 and Il.A was higher after incubation with anti sense 
ON for 2 hours ( 1.5% and 14.0% respectively) when compared to a negative control (0.3% and 6.8% 
respectively). The percentage of CD3+ve cells expressing intracellular IL-2 and IL-4 was lower after incubation 
with PTO-modified antisense ON for 2 , 4 and.6 hours when compared to a negative control. 
Neg. cont.= Negative control, hr=Hours 
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Figure 5.25: Flow cytometric analysis of PMA-stimulated CD19+ve and CD3+ve normal 
cells stained for intraceUular IL-2 and IL-4 
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PMA-stimulated PBMCs from one normal healthy control were incubated for 2, 4, and 6 hours with ?TO-
modified IL-4c antisense ON at a concentration of2.5J,.LM. This graph shows that incubation of PMA-stimulated 
PBMCs with lL-4c antisense had a varied effect on the percentage of CD3 and CD 19+ve cells expressing 
intracellular IL-2 and IL-4. 
Neg. cont.= Negative control, hr=Hours 
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Table 5.5: Significance of the addition of antisense ONs to stimulated and unstimulated 
PBMCs from patients with B-CLL on intracellular IL-2 and IL-4 protein expression 
T test 
%CD 19+1IL-4+neg. %CD19+/IL-2+neg. %CD3+/1L-4+neg. %CD3+/IL-2 +neg. 
control control control control 
/%CD19+/IL-4+ /%CD19+/IL-2+ /%CD3+/IL-4 + /%CD3+/IL-2+ 
+IL-4c antisense ON + IL-4c antisense ON + IL-4c antisense ON + ll...-4c antisense ON 
Unstimulated ceUs 
Mean: 10.3 3.3 Mean: 4.6 1.6 Mean: 3.0 1.1 Mean: 1.4 1.1 
SO+/- 12.3 2.8 SO+/- 5.5 1.1 SO+/- 3.3 1.0 SO+/- 1.3 1.8 
p= ns p=ns p= ns p= ns 
Stimulated cells 
Mean: 6.6 5.9 Mean: 6.5 9.0 Mean: 1.8 6.7 Mean: 2.1 4.6 
SO+/- 2.8 2.5 SO+/- 2.4 2.7 SO+/- 2.4 8.8 SO+/- 2.6 4.5 
p=ns p=ns p=ns p= ns 
This table shows the statistical significance of the data presented in Appendix 20. PBMCs from four patients with 
B-CLL were double stained with either of the following; CD3 PE, CD I9 PE and IL-2 FITC or IL-4 FITC 
monoclonal antibodies. The Students t-test was used to analyse the results. Values equal or lover than p=0.05 
were considered statistically sign ificant. No statistically significant difference was present in the percentage of 
CD I9+ve and CD3+ve lymphocytes expressing intracellular IL-2 and JL-4 after incubation witJ1 PTO-modified 
IL-4c antisense ONs compared to a negative control. 
Neg.=negative control, cont.=Control, ant.=Antisense, SD=Standard deviation, ns=Not significant, 
ON=ol igonucleotide 
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Figure 5.26: Flow cytometric analysis of unstimulated and PMA-stimulated CD19+ve 
and CD3+ve B-CLL cells expressing intraceUular IL-2 and IL-4 
A) Intracellular staining of unstimulated CD 19+ve and CD3+ve lymphocytes 
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Neg. +IL-4c 
CD 19+/IL-4+ 
Neg. +HAc 
CD3+11Ir2+ 
Neg. +IL-4c 
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B) Intracellular staining of PMA-stimulated CD 19+ve and CD3+ve lyrnphocytes 
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'This graph shows the data presented in Appendix 20 A and B. The percentage of unstirnulated patient CD19+ve 
and CD3+ve lymphocytes expressing intracelluJar IL-2 and IL-4 decreased after the addition of IL-4c anti sense 
ON when compared to negative control (Figure A). 
In contrast, the percentage of PMA-stimuJated CD 19+ve lymphocytes expressing intracellular IL-2 and the 
percentage ofCD3+ve cells expressing intracellular IL-2 and IL-4 increased after the addition of IL-4c antisense 
ON when compared to a negative control (Figure B). 
Neg. cont.= Negative control, hr=Hours 
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5.8.1. Summary -intracellular staining 
The percentage of unstimulated CD 19+ve and CD3+ve normal cells expressing intracellular 
IL-4 and IL-2 decreased after 4-6 hours incubation with PTO-modified IL-4c ON, compared 
to a negative control. The percentage of PMA-stirnulated CD 19+ve normal cells expressing 
intracellular IL-4 and IL-2 decreased after incubation with IL-4c ON for 4 and 6 hours, 
compared to a negative control. However the percentage of CD3+ve cells expressing 
intracellular IL-4 and IL-2 increased after incubation for 4 and 6 hours with antisense ON. 
• Measurement of intracellular IL-2 and IL-4 expression in normal and CD 19+ve and 
CD3+ve B-CLL cells has shown that the addition of PTO-modified IL-4c antisense 
decreased the percentage ofunstirnulated CDI9+ve and CD3+ve normal and B-CLL cells 
expressing intracellular IL-4 and IL-2. The addition of IL-4c to PMA stimulated B-CLL 
cells increased the percentage of CD 19+ve and CD3+ve cells expressing intracellular IL-2 
and IL-4. 
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5.9. Measurements of IL-2 and IL-4 protein secretion by ELISA after incubation with 
PTO-modified antisense ONs 
The capacity of five five unstimulated and PHA-stimulated BPMCs from patients with B-CLL 
(patients 29-34, Table 5.1) to secrete IL-2 and IL-4 protein was further evaluated. Protein 
levels were measured in cell-culture supernatant following 48 hours incubation with PTO-
modified antisense ONs. Antisense ONs were added at a concentration of3 x 2.5J..1M. 
The addition of PTO-modified IL-2 antisense ONs reduced IL-2 protein level in PHA-
stimulated cells compared to negative controls (Table 5.12). The addition of PTO-modified 
IL-4 antisense ON slightly increased the level of IL-4 protein in the supernatant when 
compared to a negative control (Appendix 21, Table 5.6 and Figure 5.27) 
No measurable amounts of IL-2 were detected in the supernatants of unstimulated PBMCs 
from patients with B-CLL incubated with PTO-modified IL-2 antisense ONs. The level of 
detectable IL-4 protein was very small and increased after incubation with PTO-modified 
control antisense, IL-4b and IL-4c antisense ONs (Table 5.7). 
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Table 5.6: Statistical analysis (t-test) of IL-2 and 0....-4 protein secretion of PHA 
stimulated PBMCs isolated from patients with B-CLL and incubated with IL-2 and IL-4 
antisense ONs 
T test 
D....-2 ELISA readings (pg) D....-4 ELISA readings (pg) 
Variable: Variable: 
Neg. cont. I cells+ antisense ON Neg. cont. I cells + antisense ON 
Mean: 62.09 9.25 Cont. Mean: 3.26 3.21 Cont. 
SD+/- 75.8 12.5 antiscnse SD+/- 3.8 6.0 antisense 
p=ns p=ns 
Mean: 62.09 30.24 IL-2a Mean: 3.26 5.20 IL-4a 
SD+/- 75.8 26.1 ON+ SD+/- 3.8 5.8 ON+ 
p=ns p=ns 
Mean: 62.09 11 .32 IL-2b Mean: 3.26 3.98 D....-4b 
SO+/- 75.8 10.9 ON+ SO+/- 3.8 4.2 ON+ 
p=ns p=ns 
Mean: 62.09 17.47 D....-2c Mean: 3.26 3.62 IL-4c 
SO+/- 75.8 20.6 ON+ SO+/- 3.8 4.3 ON+ 
p=ns p=ns 
Mean: 62.09 24.08 IL-2d Mean: 3.26 5.69 IL-4d 
SO+/- 75.7 19.6 ON+ SO+/- 3.8 5.9 ON+ 
p=ns p= ns 
PHA-stimulated PBMCs from only four patients with B-CLL were incubated with various PTO-modified IL-2 
and lL-4 antisense ONs for 48 hours. Collected supernatants were tested for the concentration of IL-2 and IL-4 
protein by ELISA. The Students t-test was performed. Values equal or lover than p=O.OS were considered 
statistically significant. Addition of different JL-2 and IL-4 antisense oligonucleotides reduced the IL-2 protein 
secretion but the results were not statistically significant. 
ns= not significant, Cont. = control antisense 
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Figure 5.27: Measurement of llr2 and IL-4 protein secretion by ELISA 
LL-2 ELISA results IL-4 ELISA results 
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This graph shows data from Table 5.6. Levels of IL-2 and TL-4 protein were measured in supematant of PBMCs 
from B-CLL patients. Cells were stimulated for 48 hours with PHA added at a concentration of I f..Lg/ml. The 
addition of PTO-modified TL-2a, fL-2b, IL-2c and fL-2d antisense ONs reduced IL-2 protein level in PHA-
stimulated PBMCs when compared to negative controls. The addition of PTO-modified IL-4a, LL-4b, IL-4c and 
LL-4d antisense ON slightly increased the level of IL-4 protein in the supematant when compared to a negative 
control. 
Pg=picogram, IL= interleukin, Cont. ant.= Control antisense, neg. cont. = Negative control 
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Table 5.7: Analysis ofiL-2 secretion by unstimulated normal cells incubated for 48 
hours with IL-2 and IL-4 antisense ONs 
IL-2 ELISA readings (in pg): No IL-2 ELISA reading was recorded with unstimulated normal 
cells 
Concentration ofiL-4 (in pg) 
Control Negative Control IL-4a IL-4b IL-4c IL-4d 
control antisense 
I 0.064 0.281 0 0.292 0.028 0.015 
2 0 0.040 0.040 0.132 0.143 0 
3 0.040 0.087 0.028 0 0.110 0.064 
4 0.121 0.121 0.040 0.040 0.076 0.028 
Mean 0.056 0.132 0.027 0.206 0.089 0.026 
Unstimulated PBMCs from normal healthy controls were incubated for 48 hours with various PTO-modified IL-2 
and LL-4 antisense ONs. 
No measurable amounts of IL-2 were demonstrated in unstimulated supematants incubated with different PTO-
modified IL-2 antisense ONs. The level of detectable lL-4 protein was very small and increased after incubation 
with PTO-modified control antisense, IL-4b and IL-4c antisense ONs. 
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5.10.1. Summary-ELISA 
• Addition of IL-2 antisense ONs reduced the level of IL-2 protein by PHA-stimulated B-
CLL cells. However in unstimulated cells, IL-2 protein was not detectable by ELISA. 
• The addition of PTO-modified TL-4 antisense ONs to PHA stimulated B-CLL cells 
increased the level ofiL-4 protein in supernatants compared to negative controls. However 
in unstimulated cells, IL-2 protein secretion was undetectable in all tested samples. 
• The addition of PTO-modified IL-4 antisense minimally increased the secretion of IL-4 
protein. 
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CHAPTER 6: DISCUSSION 
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6.1. FLOW CYTOMETRIC ANALYSIS OF IL-4 AND IL-4R 
6.1.1. Intracellular expression of IL-4 in B-CLL and normal B-lymphocytes 
Previous studies have shown that ILA has an anti-apoptotic effect on the malignant B-
lymphocytes in B-CLL (Mainou-Fowler et al. 1995 and 1996). In view of this, the 
intracellular expression of IL-4 in B-CLL and normal cells was studied by flow cytometry. 
The results demonstrated an increased expression of intracellular IL-4 in B and T lymphocytes 
from patients with B-CLL patients compared to normal controls. 
Many cytokines have been shown to be involved in the induction or regulation of B-CLL 
proliferation (Nerl et al. 1988, Touw et al. 1987 and Cordingley et al. 1988). Exactly which 
cytokines or cell-cell contacts are important to the survival of B-CLL cells in vivo, and 
whether the cytokines are produced by the tumour cells themselves or by accessory cells has 
proven to be a difficult question to answer. IL-4 was shown to prevent B-CLL cell clones from 
entering spontaneous apoptosis by up-regulating bcl-2 expression (Dancescu et al. 1992). 
Production of IL-4 appears to be mainly but not exclusively, found in T cells, designated Th2 
cells (Mosmann 1997). It has also been shown that B-lymphocytes from normal mice are able 
to produce cytokines previously considered as T -lymphocyte cytokines, depending on the 
cytokine envirorunent in which the cells were stimulated during their primary encounter with 
antigen and T -lymphocytes (Harris et al. 2000). These B-lymphocytes have been divided into 
two populations called Be 1 and Be2 and produce polarised cytokine profiles (Harris et al. 
2000). Bel cells mainly produce cytokines such as IL-2, INF-y, while Be2 cells produce IL-4, 
IL-6 and IL-l 0. 
There are contradictory reports about the production of IL-4 by B-CLL B-lymphocytes. In 
some studies, spontaneous expression of IL-4 mRNA or the presence of IL-4 protein in 
germinal centre and normal mantle zone B-lymphocytes or by B-CLL B-lymphocytes cannot 
be detected (Schena et al. 1992). Others have clearly demonstrated that malignant B-CLL B-
lymphocytes are able to express IL-4 mRNA (Mertz et al. 1990 and di Celle et a l. 1994). In 
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addition, IL-4 and IL-l 0 were found to be produced by neoplastic B-cell lines that were 
considered a murine homologue of human B-CLL since they express the COS surface marker 
(O'Garra et al. 1990). Plate et al. ( 1993), have shown that the majority of individuals studied 
constitutively express IL-4 m-RNA, but this is most probably unrelated to leukaemic 
transformation as it was expressed as frequently in normal as in leukaemic CD5+ve cells. 
More recently the presence of a greater percentage of CD19+ve malignant expressing 
intracellular IL-4 when compared to normal controls was also confirmed (Kay et al. 2001). It 
was also shown that CD8+ve T lymphocytes had an increased expression of intracellular IL-4 
compared to their normal counterparts (Kay et al. 2001 ). 
Thus the presence of cytokines detected in vitro varies from study to study. This may be due 
to many variable factors, such as incubation time, activation, type of culture media, presence 
of other cells or cytokines which may influence the results. However, a picture has emerged 
about the range of cytokines involved in autocrine or paracrine growth loops, with TNF, IL-l , 
IL-6, IL-7, JL-8 and IFN-y being found to be produced by B-lymphocytes from patients with 
B-CLL (Cordingley et al. 1988, Aqualines et al. 1991 and Rigley et al. 1991 ). It seems likely 
that, apart from JL-4, other cytokines are involved in cell-cell or cell-matrix interactions and 
may be important in preventing apoptosis of B-CLL cells in vivo (Dancescu et al. 1992 and 
Panayiotidis et al. 1993). Although it has been known for some time that IL-4 protects cells 
from death via apoptosis, little is known about the mechanism by which IL-4 exerts its effect 
(Mainou-Fowler et al. 1995). One way in which IL-4 protects malignant B-lymphocytes from 
apoptosis is by upregulating the expression of the anti-apoptotic gene bcl-2 (Dancescu et al. 
1992). It has been speculated that both Stat6 and PI 3-kinase pathways may not be needed for 
bcl-2/bcl-x induction by IL-4, suggesting involvement of an additional s ignal transduction 
pathway (Aronica et al. 2000). However, IL-4 deprivation induces apoptotic cell death but 
does not modulate bcl-2 or bcl-x expression (Rebollo et al. 2000). In this case, the role of the 
bcl-2 as a survival factor in the absence of IL-4 growth factor is taken over by bcl-3 (Rebollo 
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et al. 2000). IL-4 may protect against apoptosis via the insulin receptor substrate pathway and 
a second independent signalling pathway (Zamorano et al. 1996). 
The main action ofiL-4 on normal B-lymphocytes is to promote proliferation, increased MHC 
class II, CD23, CD40 antigen expression and the secretion of Ig by anti-IgM stimulated cells 
(Defrance et al. 1987, Rigley et al. 1991 ). Tt also enhances the activation of B-CLL cells via a 
selective up-regulation of CD54 (ICAMt) (Carlsson et al.1993). IL-4 abrogates B-CLL 
proliferation in response to TNF, IL-2 and low molecular weight B-lymphocyte growth factor 
and inhibits autocrine and paracrine TNF induced proliferation (Luo et al. 1991 ). It plays a 
particularly important role in the up-regulation of expression of one of the isoforms of the 
CD23 antigen, CD23 b, which is mainly found on B-CLL cells (Bonnefoy et al. 1995). In 8-
CLL patients, soluble CD23 levels provide additional prognostic information (Sarfati et al. 
1996). IL-4 can also protect B-CLL cells against anti-APO 1-induced apoptosis (Mainou-
Fowler et al. 1995). 
The increased intracellular IL-4 expression in B-CLL B- and T -lymphocytes found in this 
study can be explained in two ways. Firstly, B-CLL B-lymphocytes can secrete IL-4 in an 
autocrine fashion. Secondly, B-CLL T-lymphocytes can over-secrete IL-4 in a paracrine 
fashion, which is then internalised by the malignant 8-lymphocytes, either through IL-4 
receptors or in a non-receptor mediated fashion. Pre-incubation of B-CLL cells with anti-IL-4 
R antibody prior to intracellular staining did not influence the percentage of the cells 
expressing intracellular IL-4. Tills suggests that any paracrine IL-4 pathway may not require 
sigruficant IL-4R expression. 
6.1.2. Intracellular expression ofiL-4 in B-CLL and normal T lymphocytes 
The data from this study has shown a sigruficantly increased expression of intracellular IL-4 in 
B-CLL T-lymphocytes. Previous studies have reported a variety of abnormalities in the T-
lymphocyte compartment in B-CLL (Kay et al. 1979, Gale et a l. 1987). Untreated patients 
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have been shown to have a significant increase in T and NK cells, decreased T helper cells, 
increased T cytotoxic/suppresser cells and an inversion of the CD4 I CD8 ratio (Kay et al. 
1979, Vuillier et al. 1988 and Gale et al. 1987). The pattern of cytokine secretion by T-
lymphocytes is influenced not only by antigen but also by antigen presenting cells (Pharam, 
2000) and since accessory cells in B-CLL are predominantly malignant B-lymphocytes, they 
greatly alter the immune function ofT helper cells in vitro. In contrast, in normal individuals, 
the addition of antigen presenting cells, which are predominantly monocytes, resulted in a 
significant reduction in IL-4 (Decker et al. 1995). Multiple expansions of unique T cell clones 
may be derived in vivo from B-CLL tumour associated antigen stimulation (Farace et al. 
1994). Interestingly Mu and his eo-workers reported that freshly isolated CD4+ve and CD8+ 
ve T-lymphocytes from B-CLL patients had significantly elevated levels of intracellular IL-4 
(Mu et al. 1997). However, a recent study has shown that CD4+ve cells in B-CLL have a 
reduced expression of intracellular IL-4 and INF-y (Hill et al. 1999). An altered pattern oflL-4 
production was also found in PHA stimulated CD2+ve cel1s from patients with B-CLL 
(Reyes et al. 1998). 
Since studies of T-lymphocyte populations in B-CLL are sometimes conflicting and 
inconsistent, they may reflect the heterogeneity of the disease (Mu et al. 1997, Reys et al. 
1998). 
6.1.3. IL-4 receptor (IL-4R) expression in B-CLL and normal Band T lymphocytes 
IL-4 acts via high affinity receptors expressed on a wide range of hematopoietic and non-
hematopoietic cell lineages (RusseU et al. 1993). Activated T-lymphocytes express high levels 
ofiL-4R in response to IL-4 (Chromat et al. 1997). 
This study has demonstrated that 8-CLL patients have a greater percentage of CD3+ve T-
lymphocytes expressing surface IL-4 receptors than T -lymphocytes from normal individuals. 
However CD19+ve B-lymphocytes from patients with B-CLL did not show this difference. 
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This may be further evidence that a paracrine IL-4 pathway may not be involved in IL-4-
induced B-CLL B-lymphocyte survival. 
IL-4 responses are induced through the high affinity receptor that is composed of an IL-4Ra 
chain and a ye chain. The ye chain is a functional subunit of the receptors for interleukins, 2, 4, 
7, 9, and 15 and plays an important role in lymphoid development (Kondo et al. 1993, Russel 
et al. 1993, Noguchi et al. 1993 and Giri et al. 1994). Resting normal B-lymphocytes express 
on average 360 high affmity IL-4 receptors, and IL-4 may display different biological 
activities on resting and activated B-lymphocytes depending on the numbers of high affmity 
IL-4 receptors expressed (Zuber et al. 1990). Although the effect of IL-4 has been shown to 
be related to the expression of its receptor in so lid tumours and resting T- and B- lymphocytes 
(Ohara et al. 1988), the data from this thesis shows that pre-blocking with anti-IL-4R antibody 
does not effect intracellular expression ofiL-4. 
In vitro experiments have shown that receptor expression is not necessarily an essential 
requirement for responsiveness to cytokines (Taga et al. 1997). Many cytokines stimulate cells 
through a complex receptor structure, which may involve a chain or chains primarily involved 
in cytokine binding and another chain that transduces the signal (Taga et al. 1997). One study 
analysed cytokine receptor expression in various types of leukaemic cells, but failed to 
demonstrate a direct association between the leukaemia type and cytokine receptor expression 
(Zola et al. 1994). However this study did not include a comparison with normal control 
counterparts. In another study, the same group showed that when cells were stimulated with 
IL-4 they failed to proliferate (Zola et al. 1997). 
The significantly increased expression of IL-4 receptors on B-CLL T-lymphocytes could 
indicate an increased state of activation or a skew towards a Th2 response. 
258 
6.1.4. IL-4 protein secretion by B-CLL and normal cells 
Intracellular IL-4 expression studies demonstrated that there was a significant difference in IL-
4 production between PBMCs from patients with B-CLL and normal controls. In view of these 
results it was necessary to establish if PBMCs from patients with B-CLL were able to produce 
and release IL-4 and compared these results to normal controls. Several techniques can be 
used to measure the amount of cytokine secretion by stimulated cells. Enzyme-linked 
immunoabsorbent assay (ELISA) uses enzyme-labelled antibodies for detection of particular 
protein. Is a highly sensitive and specific assay and allows accurate measurements of very low 
protein levels (Bienvenue et al. 2000). Similarly enzyme-linked ImmunoSPOT (ELISPOT) or 
CellELISA can be used can be used to enumerate cytokine producing cells allowing detection 
of the protein of interest in the environment immediately surrounding the cell secreting it. In 
general this technique is more sensitive than sandwich ELISA and allows quantification of 
cytokines per cell basis (Bienvenue et aJ. 2000, Zhang et al. 200 I). Recently very novel 
technique was developed by Zhang. This technique termed IDAT (immuno-detection 
amplified by T7 RNA polymerase), combines the peotein binding abilities of an ant ibody with 
the sensitivity of nucleic acid amplification technique (Zhang et aJ. 200 I ). 
Hovewer, for the present study sandwich ELISA technique was used. Although expensive it 
allows very rapid quantification of PBMCs capacity to release IL-4 after mitogenic 
stimulation. 
When the PBMCs from B-CLL patients were stimulated for 48 hours with PHA or PWM, no 
measurable amount ofiL-4 protein was detected by ELISA after PWM stimulat ion and also in 
the majority of PHA-stimulated cells. In contrast all exept one normal control sample tested 
had measurable amouts of IL-4 after stimulation with PHA and PWM. It has been reported 
previously that B-CLL B-lymphocytes have an impaired proliferative response to mitogenic 
signals such as PWM (Catovsk:y et al. 1972, Karray et aJ. 1987). In addit ion, T -lymphocytes 
from B-CLL patients exhibit defective proliferative responses to PHA, however this response 
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was close to normal in patients with "smouldering B-CLL" (Gale et al. 1987, Prieto et al. 
1993). 
IL-4 on its own, displays anti-proliferative activity towards B-CLL cells. It inhibits autocrine 
and paracrine tumour necrosis factor (TNF) induced proliferation of B-CLL cells as well as 
spontaneous and TNF induced proliferation (van Kooten et al. 1992 and Reittie). Recombinant 
IL-4 profoundly inhibits the proliferative response of B-CLL cells to recombinant IL-2 
(Karray et al. 1988). A recent observation that apoptosis-inducing toxins stimulated 
intracellular IL-4 expression in normal PBMC with decreased level of anti-apoptotic bcl-2 
protein add additional complexity to the anti-apoptotic effect of IL-4 (Stein et al. 2000). 
The inability to detect a measurable amount of IL-4 protein in stimulated PBMCs from B-
CLL, despite the significant expression of intracellular IL-4 in both B and T lymphocytes is 
intriguing. It is possible that the IL-4 is secreted in an autocrine fashion by the B-CLL B-
lympocytes or in a paracrine fashion by the B-CLL T-lymphocytes and immediately taken up 
by the B-CLL B lymphocytes to be used for their own survival. This hypothesis was tested 
further by Western Blotting studies. Using a Western blotting technique incorporating 
enhanced chemiluminescence, the presence of a strongly positive IL-4 band in B-CLL T-
lymphocytes and very weakly positive bands in some B-CLL B-lymphocytes was found (data 
not shown). However, as with Northern blotting, Schena et al. were also unable to detect IL-4 
protein by Western blotting (1992). One problem with Western Blotting is that it require large 
amount of protein. The very weak presence ofiL-4 protein in some but not all purified B-CLL 
B-lymphocyte samples may be yet another indication of B-CLL heterogeneity These results 
may also indicate the presence of IL-4 protein internalised or bound to its receptor on 
malignant and normal B-lymphocytes. 
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6.2. ANALYSIS OF COMMON GAMMA CHAIN RELATED CYTOKINES BY 
NESTED RT-PCR 
To understand better the biology ofcytokines and the ability of the malignant and normal cells 
to produce cytokines, other techniques had to be applied. Several methods can be used to 
quantitate or semi-quantitated mRNA of the cytok:ines in question. Unfortunately Northern 
Blotting proved to be unsuccessful. The lack of positive results could be explained by a 
limited number ofiL-4 producing ceUs. However, the percentage ofCD19+ve cells expressing 
intracellular IL-4 was high in many patient samples. There is also a possibility that only a 
small number of mRNA copies were present in unstimulated ceUs or the prepared RNA was 
degraded ornot enough mRNA was present in the samples. RNA used in those experiments 
was a total RNA of each mRNA is only 1-2%. These results are in agreement with the study 
by Schena et al. in which they were unable to detect IL-4 mRNA using Northern blotting 
( 1992). In no other studies known to the author was this technique used to detect mRN A in 
malignant B-CLL cells. 
Other techniques such as Real-Time PCR, RNase Protection Assay, competetive PCR, RT-
PCR or nested RT-PCR are all designed to quantitate or semi-quantitate RNA in question 
(Giulietti et al. 2001 , Vet et al. 2002). 1-Iovewer many of them are relatively new and require 
specialized equipment not evalible at the time in our laboratory. cDNA arrays method is still 
limited in its use by cost consideration (Butcher, 1999). Therefore, a nested RT-PCR 
technique was used to further study the presence ofiL-4 mRNA in malignant B-lymphocytes, 
since initial question to be ansered was only the confirmation or absense of specific mRNA 
transcripts. RT-PCR has become an import.ant technique for the detection of mRNA. It is the 
most sensitive and the most flexible of the quantification methods and can be used to compare 
the Levels of mRNAs in differentsamles population, to descrirninate between closely related 
RNAs. However the sensitivity of this technique can be improved by using a nested RT-PCR 
(Haff et al. 1994). This is because fewer non-specific amplification products are produced, 
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which could otherwise interfere with interpretation of the data. ln addition, nested PCR lowers 
the threshold of target detection (Haff et al. 1994) as it is 10 000 times more sensitive than a 
single round of RT-PCR alone. Using a nested RT-PCR technique, the presence of mRNA 
transcripts of common gamma chain related cytokines were studied (section 2.12). To ensure 
the quality and the presense of equal amount of mRNA in aU tested samples beta-actin was 
aplied. Beta actin is expressed at moderately aboundant levels in most cell types. It was the 
first RN As to be used as a quantitive reference for RT -PCR assays (Bust in et al. 2000), despite 
the evidence that its levels vary widely. In addition , the presence of pseudogenes interferes 
with the interpretation of the results (Dirnhofer et al. 1995). In this study the presence of beta-
actin mRNA was confirmed only after first round of amplification not permiting using beta-
actin RT-PCR products to be used as a quantitive marker. 
6.2.1. Measurement of IL-2 wild type RT-PCR products 
The ftrst of the common ye cytokines studied was IL-2. The expression of IL-2 wild type 
mRNA was analysed in unstimulated B-and T-lymphocytes from B-CLL patients and normal 
controls. Wild type IL-2 RT-PCR products (amplification between exon 1 and 4) were 
significantly more abundant in patient compared to normal B-lymphocytes. In addition, when 
amplification was performed between exons 1 and 3, the density of wild type IL-2 RT-PCR 
product density was also significantly higher in patient B-lymphocyte samples than in controls 
In contrast however, there was no significant difference in the density of IL-2 RT-PCR 
products in T -lymphocytes between patients and controls. 
A previous study of the molecular expression of cytokines by normal and malignant B-
lymphocytes showed that IL-2 production was limited to the actively proliferating germinal 
centre B ceU blasts (Schena et al. 1992). Another study identified IL-8 mRNA transcripts but 
failed to identify IL-2, IL-3, IL-4, IL-5 and IL-7 (Di Celle et al. 1994). However leukaemic B-
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lymphocytes stimulated with PMA, ionomycin and Lipopolysaccharide can produce high 
amounts ofiL-2 protein for non-T cells (Mouzaki et al. 1995). 
The effect of IL-2 on apoptosis has also been well documented. Co-culture of normal and 
leukaemic B-lymphocytes with IL-2 results in proliferation and protection from apoptosis 
(Mainou-Fowler et al. 1995, Malkovska et al. 1987). This enhancement of B-lymphocyte 
viability and suppression of apoptosis was associated with a delay in the down regulation of 
the bcl-2 molecule (Tangye et al. 1997). IL-2 also enhances the production of tumour necrosis 
factor (TNF) and its receptor in activated B-CLL cells as well as expression of the CD23 type 
B antigen on mal ignant B-lymphocytes (Bonefoy et al. 1995). The CD23 molecule has been 
reported to play a role in normal B-lymphocyte proliferation and survival and TNF-a. is 
thought to be an autocrine growth factor for B-CLL. In B-CLL, soluble CD23 is significantly 
increased (Larsson et al. 1993, Fournier et al. 1992, and Fournier et al. 1995). The idea that in 
B-CLL a paracrine or autocrine system oflL-2 production and utilisation may occur has been 
supported by the findings of an IL-2 like factor (IL-2lt) by PHA stimulated leukaemic B cells 
and that IL-2 and IL-2lfwere able to use the same receptor (Giovarell i et al. 1988). 
Thus the presence of anti-apoptotic IL-2 mRNA in malignant B-lymphocytes but not in their 
normal counterparts may indicate another strong candidate the production of which can 
contribute to the survival of malignant B-lyrnphocytes. 
6.2.2. Measurement of lL-2 delta 2 RT -PCR products 
The next cytokine studied was IL-2 82, which is a splice variant of the wild type IL-2. The 
density ofiL-2 82 RT-PCR products was also found to be significantly higher in patient than 
in norrnal B-lymphocytes. Atarnas et a l. have shown that the IL-282 splice variant inhibited 
IL-2 eo-stimulation ofT-lymphocyte proliferation and cellular binding ofrecombinant IL-2 to 
high affinity I L-2 receptors. (1 997). Tills could be due to engagement of p and ye chains but 
not the a. chain of the IL-2R complex (Atamas et al. 1997). Thus the altered expression of a 
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wild type and alternatively splice variant protein may lead to disease (Glare et al. 1990 and 
Sakk:os et al. 1999). Since very little work has been performed to support results obtained in 
this thesis it can be speculated that the increased expression of the IL-2 splice variant mRNA 
transcripts in malignant B-lympbocytes may have regulatory effect on IL-2 wild type 
production. It was also shown that a positive significant correlation exists between IL-2 wild 
type rnRNA expression and its splice variant in patient and control T-lymphocytes samples but 
not in malignant and normal B-lymphocytes. In another words, increased expression of wild 
type of IL-2 leads to the increased expression of splice variant type. Thus malignant B-
lymphocyte may not be able to increase its IL-2 splice variant expression in response to IL-2 
wild type expression. 
6.2.3. Measurement of IL-4 wild type RT -PCR products 
The next cytokine belonging to the ye chain farruly is IL-4. When primers spanning exons 1 
and 4 were used, the density of wild type IL-4 RT-PCR product was greater in patient B-
lymphocytes than in controls but this did not reach statistical significance. When primers 
spanning exons I and 3 were used, the density of wild type IL-4 RT-PCR products was 
significantly higher in patient B-lymphocytes than in controls. Therefore this difference in IL-
4 wild type RT-PCR products when using different primers may be due to the fact that smaller 
size transcripts are much easier to identify or it may reflect the quality of the primers. 
There are conflicting reports about the expression ofiL-4 mRNA and protein by malignant B-
lymphocytes. In some studies, IL-4 mRNA or protein could not be demonstrated in the 
germinal centre and normal mantle zone B-lymphocytes or in B-CLL cell samples (Mertz et 
al. 1990, Di Celle et al. 1994). In another, 11 of 16 B-CLL patient malignant B-lymphocytes 
were shown to express IL-4 mRNA and this expression has been confirmed in normal B-
lymphocytes (Schena et al. 1992, Klein et al. 1996). 
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6.2.4. Measurement of IL-4 o2 m RNA transcripts 
IL-4 o2 is a splice variant of the wild type IL-4. The expression of IL-4 o2 RT -PCR products 
was significantly lower in patient T-lymphocytes than in controls but not significant when IL-
4o2 RT-PCR products from control and patient B-lymphocytes were compared. In addition a 
positive significant correlation was found between IL-4 wild type and IL-4 o2 RT-PCR 
products in patients B lymphocytes. This means that the expression of one type increases the 
expression of the other type. It is then difficult to explain why in patients T -lymphocytes the 
expression of the splice variant is significantly lover than in controls but the IL-4 intracellular 
level is significantly higher than in their normal counterparts (Kaminski et al. 1998 and Kay et 
al. 2001). 
A natural spliced variant ofiL-4, IL-4 o2 could represent yet another potential mechanism for 
the regulation of human IL-4 activity (Aim et al. 1996). In his study, the entire coding region 
ofiL-4o2 was detected in all PBMC tested as well as purified CD2+ve lymphocytes and was 
shown to increase after stimulation. However IL-4o2 RNA was expressed in PBMC at lower 
levels than IL-4 RNA. Additionally, IL-4 o2 was found to be expressed at much higher levels 
in thymocytes and bronchoalveolar lavage cells (Atarnas, et al. 1996). 
Recombinant IL-4o2 does not act as a co-stirnulator of T-lymphocyte proliferation but 
independently inhibits the action of recombinant IL-4 (Atamas et al. 1996). IL-4o2 is a widely 
expressed isoforrn in many cell types and its expression seems to be tissue dependent (Atamas 
at al 1996). Previous studies have shown that IL-4 o2 protein can inhibit the action of IL-4. 
This is thought to occur by competitive binding to the IL-4 receptor (Atamas et al 1996). It is 
known that protein variants formed by alternative splicing can inhibit the function of native 
protein (Kitamura et al. 1993). This is because alternative splicing generates structural and 
functional diversity of protein as welJ as differential expression in certain tissues (Boyd et al. 
1993 and Huang et al. 1993). 
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Promoters, enhancers and regulatory elements within the IL-4 gene have been studied 
successfully (Lee et al. 1994, Todd et al. 1993 and LiWeber et al. 1993). It was shown that a 
positive significant correlation exists between wild type and splice variant RT-PCR products 
in malignant B-lymphocytes only. Presence of alternative splicing of the IL-4 gene and the 
inter-relationship between IL-4 wild type and lL-4 82 RT-PCR product densities adds to the 
complexity of IL-4 regulation but this study does not provide any evidence to explain how this 
phenomenon can affect the proliferation or apoptosis of the cells. 
6.2.5. Measurement ofiL-7 RT-PCR products 
IL-7 is another important cytokine playing a role in B- and T -lymphocytes development and 
function and belongs to the ye chain receptor family. It is a stromal cell-derived growth factor 
(Welch et al. 1 989). Normal B-lymphocytes do not make detectable quantities of IL-7 mRNA 
(Hickman et al. 1990). In this study, the existence of IL-7 mRNA transcripts in B- and T-
lymphocytes of B-CLL patients and controls was detected. Patient B and T-lymphocyte 
samples had significantly increased mRNA transcripts when compared to their normal 
counterparts. This study also revealed several additional bands suggesting a number of 
additional spliced variants of IL-7 but attempts to sequence them proved to be inconclusive. 
The entire coding sequence for IL-7, as well as an alternatively spliced IL-7 mRNA lacking 
exon 4 (IL-784), was found to be transcribed in leukaemic B-lymphocytes but not in normal 
cells. Unexpected IL-7 amplification products were also found. Three additional spliced 
variants resulting from skipping of exon 3 and 5 or both in combination with exon 4, were 
demonstrated. They were named IL-783/4, IL-7'64/5 and IL-783/4/5. In addition three out-of-
frame spliced variants were identified: IL-7 (-56 bp exon2), IL-784 (-56 bp exon 2), and IL-7 
83/4/5 (-56bp exon 2), in which, in addition to exon skipping, 56bp of the 3' end of exon 2 
were omitted (Korte et al. 1999). The s ignificance of the spliced transcripts remains unknown. 
Malignant B-lymphocytes were also shown to express IL-7 receptors, suggesting that IL-7 
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could be relevant to the growth of leukaemic cells (Frishman et al. 1993). Some studies 
suggested that IL-7 could trigger proliferation in a variety of leukaemic cells, including CLL 
cells (Digel et al. 1991). In summary, B-CLL and control B-lymphocytes had a greater number 
of additional bands than T -lymphocytes. The existence of such a wide variety of spliced 
variants may be important for the regulation of IL-7 function and further studies are needed to 
investigate their involvement in the pathogenesis ofB-CLL. 
6.2.6. Measurement ofiL-9 RT-PCR products 
In this study, IL-9 nested RT-PCR products were not detected in B and T-lymphocytes 
separated from patients with B-CLL and normal controls. IL-9 is produced preferentially by 
Th2 lymphocytes and, although unstimulated freshly isolated PBMCs do not express IL-9 
mRNA, stimulation with PHA or anti-CD3 antibody has been shown to induce substantial 
expression of IL-9 in CD4 T -lymphocytes (Renauld et al. 1990). In addition, expression of IL-
9 has been shown to be restricted to the CD45RO+ve T-lymphocyte subset (memory cells) 
following stimulation with CD3 and CD28 (Houssiau et al. 1995). IL-9 expression is 
associated with HTL V -1, a retrovirus involved in adult T cell leukaemia and the existence of 
an IL-9-rnediated autocrine loop has been suggested for Hodgkin's disease (Kelleher et al. 
1991 and Renauld et al. 1995). 
It is therefore surprising that it was not possible to detect IL-9 products in normal T-
lymphocytes in this study. This could be due to number of reasons. Firstly, some faint bands 
were visible in patient Band T-lymphocytes and control T-lymphocytes after the first round of 
amplification. The results were negative in normal control B-lymphocytes. Secondly in 
unstimulated cells, IL-9 mRNA transcripts may be not very abundant. Lastly, despite many 
attempts to optimise IL-9 RT-PCR in this study, the optimal conditions for visualising IL-9 
products may not have been achieved. 
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6.2.7. Measurement ofiL-15 RT-PCR products 
IL-15 is another member of the ye chain receptor family. IL-15 RT-PCR products were found 
in all tested samples, but they were significantly higher in control than in patient T-
lymphocytes. Even though IL-15 mRNA IS constitutively expressed m 
monocytes/macrophages but not on human T- and B-lymphocytes (also on cell lines; Mt4, 
M9, C5966, Jurkat, Daudi, Raji and Ebstein-Barr virus-immorta)jsed B-cell clones) it can be 
upregulated by a variety of stimuli (Musso et al. 1999). In lymphocytes, IL-15 secretion is 
only found in pathological conditions such as chronic inflammation. Autocrine production of 
IL-15 was detected in myeloma cell lines as well as in cutaneous T -cell lymphoma (Tinhofer 
et al. 2000 and Asadullah et al. 2000). Constitutive gene expression of IL-15 was also found in 
bone marrow blasts from children with relapsed B-lymphocyte precursor acute lymphoblastic 
leukaemja (Kebelmann-Betzing et al. 2001 ). IL-15 has been found to be a potent survival 
factor in the prevention of spontaneous apoptosis but not CD95 induced apoptosis in CD8+ve 
and CD4+ve lymphocytes (Naora et al. 1999). IL-15 is not constitutively secreted and is 
possibly regulated at the transcriptional level (Onu et al. 1997). IL-15 has similar activities to 
IL-2. B-CLL cells stimulated with IL-15 plus thiorexm could be induced to proliferate. The 
stimulatory activity achieved by IL-15 was triggered through the IL-2 R system subunit since 
blocking the beta and gamma chains of the IL-2R resulted in decreased stimulatory activity of 
IL-15 (Trentin et al. 1996). IL-15 is able to trigger both proliferation and antibody production 
by normal B-lymphocytes, however this is acquired only after the B-lymphocytes have been 
pre-activated in vitro. In contrast, B-CLL cells are able to proliferate in response to IL-15 
regardless of in vitro preactivation. This activity appears to be related to the presence of the a 
and ye chain of the IL-2R system on malignant cells (Trentin et al. 1997). Both IL-15 and its 
receptor selectively regulate differentiation of slgM+, lgA- and IgM-, lgA+ B-1 cells (CD5 
expressing B cells) expressing IL-15R, into IgA-producing cells in mucosal tissues (Hiroi et 
al. 2000). IL-15 can enhance antibody-dependent cellular cytotoxjcity and natural killer (NK) 
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cell activity (Nguyen et al. 1998). It is also known that NK activity is impaired in B-CLL 
patients (Katrinakis et al. 1996). Thus decreased IL-15 mRNA transcripts in B-CLL T-
lymphocytes may have a negative effect on patients NK cell activity as well as antibody-
dependent cellular cytotoxicity which is already impaired by the lack of proper antibody 
producing B-lymphocytes. 
The presence of such strong IL- 15 rnRNA transcripts in B-and T-lymphocytes of patients and 
controls in this study is of interest, since mRNA transcripts have not been detected in these 
cells before. However using a nested RT-PCR technique, amplification ofvery small amounts 
of rnRNA is possible. The results obtained in this study were negative after the first round of 
amplification (data not shown). The intensive, and in many cases similar, density of the IL-15 
mRN A transcripts after a second round of amplification may be also explained by the plateaux 
effect and needs to be studied further. 
6.2.8. Measurement of ye chain and IL-4R a.RT-PCR products 
All the cytokines described above use the ye chain as part of their individual receptor. Thus 
studying the mRNA expression of this chain may shed some light on its role in cytokine 
regulation. Since IL-4 was the first cytokine looked at in this study, it was decided to also look 
for the presence ofiL-4R ~ chai.Q rnRNA transcripts. 
The analysis of full-length ye chain rnRNA transcripts showed that there was no significant 
difference between patient and control B- and T-lyrnphocytes. The ye chain is constitutively 
expressed on essentially all cells of hematopoietic origin. Some studies have shown that the ye 
chain is present in purified normal tonsil B-lymphocytes and in all B-CLL patients but at 
lower levels of expression compared with that found in HCL (Totero et al. 1995). The 
presence of ye transcripts only in immature leukaemic B-lyrnphocytes adds to the complexity 
of receptor systems in regulation of lymphoid cell development and function (Totero et al. 
1995). Two types of ye transcripts are expressed differing in their carboxyl terminal coding 
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regions. This newly identified transcript consists of a deletion of 72 nucleotides close to the 
3'-end of the open reading frame. The result is a loss of 24 amino acids, which includes a 
conserved tyrosine residue shared by several members of the cytokine receptor family (Shi et 
al. 1997). The importance of this new variant is as yet unknown. 
IL-4Ra mRNA transcripts were detected in all patient and control samples. However, no 
significant difference in RT-PCR product densities was found between patient and control B 
and T-lymphocytes. This study has also demonstrated that B-CLL patients have a greater 
percentage of CD3+ve T-lymphocytes expressing surface IL-4 receptors than T-lymphocytes 
from normal individuals. This discrepancy between the flow cytometric and RT -PCR results 
may come from the fact that flow cytometry only shows the percentage of lymphocytes 
expressing IL-4R but not the density of the receptor on their surface. However, this may be 
further evidence that a paracrine IL-4 pathway may not be involved in IL-4-induced B-CLL 
B-lyrnphocyte survival. 
6.3. MEASUREMENT OF IL-5 AND JL-13 RT-PCR PRODUCTS 
Finally, IL-5 and IL-13 were studied. The reason for this was that IL-5 was shown to act as a 
pro-apoptotic factor that acts on malignant B-CLL cells (Mainou-Fowler et al 1996). IL-13 
uses the IL-4R a chain as part of its own receptor and is also anti-apoptotic for malignant B 
cells (Tangye et al, 1997). 
A nested RT-PCR technique detected the presence ofiL-5 and IL- 13 mRNA transcripts in B-
and T-lyrnphocytes of B-CLL patients and normal controls but no significant difference was 
found between the corresponding samples. However, patient B-lymphocytes had more 
abundant IL-5 rnRNA transcripts when compared to normal B cells. Similarly to other 
cytokines, the secretion of IL-5 and IL-13 is associated with the Th2 cell subset and, in 
conjunction with IL-4, IL-5 and IL-13, are organised within 140 kb of DNA in humans (Kelly 
et al. 2000). Only one study looked for the presence of lL-5 rnRNA in B-CLL cells but was 
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unable to find any (di Celle et al. 1994). However the role of IL-5 in controlling B-CLL 
proliferation has been studied. In one study, B-CLL cells were found to have an impaired 
response to IL-5 (Hayes et al. 1993). This was evident by the lack oflgM production when IL-
5 was added to B-CLL cells. However, other studies have shown that IL-5 increased 
spontaneous apoptosis of B-CLL cells in a probably bcl-2 independent manner (Mainou-
Fowler et al. 1994, 1995). The detection of IL-5 transcripts in patient and control B-
lymphocytes in our study may be the result of using nested RT -PCR since the results obtained 
after the first round of amplification showed negative results with normal B-lymphocytes but 
positive bands with patient B lymphocytes. The question arises, if IL-5 plays a role as a pro-
apoptotic factor, why do the malignant B-lymphocytes have high density IL-5 m.RNA 
transcripts? This is difficult to explain unless the malignant cells have indeed impaired IL-5 
responses (Hayes et al. 1993). 
The role ofiL-13 in 8-CLL has also been tested, but the presence of mRNA transcripts in B-
CLL cells is not documented. Similarly to I L-2 and IL-4, IL-13 suppresses apoptosis of 
leukaemic CD5+ve B-lymphocytes and preserves the expression of bcl-2 (Tangye et al. 1997). 
IL-1 3 also inhibits IL-2 induced proliferation although this may dependent on the 
experimental conditions (Fluckinger et al. 1994). Similarly to IL-4, IL-13 enhances CD23 
expression as well as soluble CD23 secretion by B-CLL cells (Chaouchi et a l. 1996). Thus the 
presence of IL-13 mRNA transcripts at similar densities in both malignant and normal B-
lymphocytes, as well as patient and normal T -lymphocytes, is difficult to explain since I L-l3 
transcripts were faintly positive after a first round of amplification in the majority of B-CLL 
8-cell samples and completely negative in a ll normal B-lymphocyte samples (data not shown). 
One could speculate that similarly to IL-4, IL-13 secretion is tightly regulated and a small 
amount of protein is needed for the execution of its action. 
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6.3.1 Correlation between cytokine RT -PCR product density 
When all the molecular cytokine data were colated and analysed, a significant positive 
correlation was demonstrated between IL-2 and IL-4 RT-PCR product densities in B-CLL B-
and T -lymphocytes populations. In contrast, a significant negative correlation was found 
between IL-2 and IL-4 RT-PCR product densityies in normal T-lymphocyte samples. In 
addition, a significant correlation was found between IL-4 and IL-7 mRNA transcript densities 
in patient T-lymphocyte samples. 
The T -lymphocyte encounter with antigen leads to the development of a Th I or Th2 polarised 
subset (Mossmann, 1996). Th l cells produce IL-2 and INF-y, while Th2 cells produce IL-4, 
IL-5 and IL- 13 . It is possible that the negative correlation between IL-2 and IL-4RT-PCR 
product densities seen in normal T-lymphocytes is an indication ofT-lymphocyte polarisation. 
Contrary to normal T -lymphocytes, B and T -lymphocytes from patients with B-CLL displayed 
a positive correlation between the above cytokines. When mitogen (PHA and OKT3) 
stimulated T-lymphocytes were measured for their capacity to produce IL-2 and IL-4 protein, 
no correlation was found between the IL-2 and IL-4 protein levels, in particular the expected 
inverse correlation was not found (Cartwright et al. 2000). Thus the positive correlation shown 
between IL-2 and IL-4 RT-PCR product densities in patients with B-CLL may indicate that in 
malignant cells regulation of IL-4 and IL-2 rnRNA expression is deregulated when compared 
to normal cells. 
Although, no significant correlation was seen between IL-4 and IL-13 product densities, a 
noticeable positive trend was demonstrated in patient Band contro l T-lyrnphocytes. IL-4, IL-
13 and IL-5 are markers for the Th2 subset of effector T cells and are often expressed together 
(Kelly et al. 2000; Takemoto et al. 2000). It is therefore not surprising that activation of one 
cytokine induces the others. What is however surprising is that this pattern is seen in 
malignant B-lymphocytes. In this respect malignant B-lymphocytes are more similar in their 
behaviour and cytokine production to T than to B-lymphocytes. These positive and T-
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lymphocyte-like correlations of cytokines production may be important for malignant B-
lymphocyte survival. 
6.4. THE EFFECT OF ANTISENSE OLIGONUCLEOTIDES ON THE SURVIVAL OF 
B-CLL CELLS 
6.4.1 Measurement of proliferation and viability of B-CLL and normal cells by MTT 
assay 
In view of the fact that higher densities of IL-4 and IL-2 RT -PCR were demonstrated m 
malignant B lymphocytes it was decided to attempt to block these cytokines and their splice 
variants in an attempt to intefere with their anti-apoptototic effects. 
The MTT assay was used to investigate the proliferative abilities of B-CLL and normal 
control cells after the addition to the cultures of antisense oligonucleotide (ONs). 
Spectrophotometrically quantified changes in cell proliferation showed that the addition of IL-
2 and IL-4 antisense ONs decreased B-CLL cell viability compared to controls. However the 
experiments aiming to establish the optimal concentration of antisense ONs were not very 
consistent as far as the different ONs were concerned. Common methods for determining cell 
viability depend upon membrane integrity (e.g. trypan blue exclusion) or incorporation of 
nucleotides during cell proliferation (3H-thymidine). These methods are limited by their 
impracticality in processing large numbers of cell samples. The MTT assay provides a rapid 
and versatile method for assessing cell viability. Studies using the MTT assay showed 
excellent linearity between absorbance and leukaemic or other cell numbers viability (Alley et 
al. 1988 and Van de Loosdrecht et al. 1994). These were the reasons for using MTT assay in 
this study. However the MTT assay has drawbacks. Unless the experiment is performed using 
a pure cell population it is impossible to establish exactly which cell is undergoing 
proliferation or apoptosis. A more specific test was thus needed to answer these questions. 
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6.4.2 Measurement of apoptosis by Annexin V and Propidium iodide staining 
In this part of the study, flow cytometry was used to analyse the percentage of CD 19+ve and 
CD3+ve B-CLL and normal control cells undergoing apoptosis after incubation with antisense 
ONs. A series of antisense ONs were specially designed to attempt to suppress expression of 
IL-2 and IL-4 wild type and IL-2 and IL-4 spliced variant rnRNA transcripts. The results show 
that all cytokine specific antisense ONs and control antisense ONs are able to induce apoptosis 
in patient CD19+ve lymphocytes. Using IL-2b, IL-2c and IL-2d antisense ONs, the percentage 
of apoptotic double positive CD 19/ Annexin V cells was significantly increased. This increase 
in apoptosis coincided with the suppression of PHA-stirnulated IL-2 protein production after 
the addition of IL-2 and IL-4 ON, as measured by ELISA. However, IL-4 protein was 
increased after the addition of IL-4 antisense. Apoptosis was also unexpectedly induced by 
control antisense ONs. Since all the antisense were checked against GenBank Sequence Data 
to avoid similarity with any other human mRNA, this evidence suggests that increased 
apoptosis is at least partially due to a non specific effect of phosphorothioate oligonucleotides. 
However, it is also conceivable that IL-2 antisense ON has supressed an IL-2 autocrine ant-
apoptotic pathway. 
Since IL-2 has been shown to act as an anti-apoptotic cytokine for malignant B-lymphocytes, 
this "non-specific" effect of antisense ONs can be partially related to the decrease in IL-2 
expression. Most B-lymphocytes immortalised with EBV virus, as well as normal stimulated 
B-lymphocytes, can be induced to produce IL-2 protein (Mouzaki et al. 1995). Recently, 
human carcinoma cell lines have also been shown to constitutively express protein and mRN A 
for IL-2 in vivo and in vitro, attributed to the regulation of cel1 cycle progression and 
protection from apoptosis (Reichert et al. 2000). 
The concept of an increased or decreased balance between wild type mRNA and IL-4 spliced 
variant IL-4 82 comes from studies in type I diabetes as well as systemic sclerosis and stable 
asthma (Sakkos et al. 1999 and Glare et al. 1999). It has been suggested that these changes in 
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alternative splicing may lead to disease (Boyd et al. 1993). However, although successful 
usage of antisense to block IL-2 and IL-4 mRNA and in consequence JL-2 and IL-4 protein 
have been published, this is the first study to use antisense to block cytokine spliced variants at 
the exon-exon junction level. In view of the fact that IL-2 and IL-4 cytokines are able to 
prevent programmed cell death (Huang et al 1993, Panayiotidis et al. L 993), it seems logical to 
develop methods to modulate the secretion of IL-2 or IL-4 protein by malignant cells, which 
may in turn induce apoptosis. 
The concept behind the use of antisense is simple in that the ON is provided to inhibit the 
expression of a single gene product at the mRNA level. However evaluating the effect of 
antisense proved to be a very complicated procedure. Phosphorothioate antisense ONs are 
internalised and distributed in a manner, which is dependent on time, temperature, 
concentration, sequence and cell Line (Crooke et al. 1995). Lymphoid sub-populations also 
differ in their ability to uptake ONs. B-lymphocytes take up ONs one third more readily than 
T -lymphocytes and this uptake is increased with mitogenic stimulation (Krieg et al. 199 L ). 
One of the major concerns is that the body might recognise ant isense ONs as foreign and 
attack them. Yamamoto and his colleagues identified palindromic single-stranded 
immunostirnulatory DNA sequences including CpG (Cytosine-phosphate-Guanine) containing 
hexamers, 5' -GACGTC-3', 5' -AGCGCT-3' and 5'-AACGTT-3' and concluded that bacterial 
DNA containing these sequences can act ivate the immune system (Yamamoto et al. 1992 and 
Yarnamoto et al. 1994). Experiments have shown that ON fragments containing a two-base 
sequence, CpG, activated mammal ian B and natural killer cells in culture (Krieg et al. L 995). 
However this immune response was only triggered when the CpG sequence was un-
methylated. It is hypothesised that because the un-methylation is very common in bacterial 
DNA but not in mammalian DNA, un-methylated ON sequences may be seen as bacterial and 
stimulate an immune response (Wagner et al 1999, Stein 1996 and Engelhard et al. 1998). 
However, the antisense ONs used in this study did not contain CpG sequences. 
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The other common side effect of antisense ON treatment in animal models is a drop in the 
white blood cell count. Tllis side effect can be attributed to the inability of some antisense 
ONs to correctly bind to the target cell or tissue. They can bind to various proteins within the 
vicinity of the targeted region thus inhibiting production of certain crucial proteins important 
within the body (Ma et al. 1996, Tidd, 1992, Wagner 1994, Engelhard et al. 1998). 
Because ONs are negatively charged they can bind to other positively charged molecules. 
They are able to bind bovine serum albumin, receptor for platelet derived growth factor, the 
receptor for basic fibroblast growth factor, gp 120 protein of the human immunodeficiency 
virus as well as VEGF, PKC and protein tyrosine receptors including the epidermal growth 
factor receptors (Crooke et al 1996, Stein, 1995, Stein et al. 1993, Stein et al. 1994, Ma et al. 
1996, Ho et al. 1997, Stein et al 1996, Rockwell et al. 1997). All this happens in a sequence 
independent manner. It has been also reported to cause non-specific induction of tumour 
necrosis factor (Hartmann et al. 1996), induction of Sp 1 nuclear transcription factor binding 
activity (Crooke et al. 1996, Perez et al. 1994) and inhibition of transferrin receptor expression 
(Ho et al. 1991 ). ON-mediated Sp 1 protein induction has been shown to be rapid and 
independent of NF-kappa B activity (Perez et al. 1994). However non-specific effects of 
phosphorothioated ONs were usually encountered in the 20-50 ~LM range which is higher than 
the concentration used in this study. 
A series of experiments specially designed to determine whether various ONs, including 
phosphorothioated (sODNs) and phosphodiesters (ODNs), could activate human B-
lymphocytes directly have shown that sODNs were able to induce significant human B-
lymphocyte proliferation (Liang et al. 1996). Proliferating normal B-lymphocytes had 
increased expression of activation markers such as CD69, CD86 and CD25 and produced IgM, 
lgG and IgA in the absence of exogenous cytokines and T -lymphocytes (Liang et al. 1996). 
Another study has shown that when normal B-lymphocytes are exposed to antisense ONs, a 
large number of B-lymphocytes can be induced to express activation markers despite only a 
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modest degree of proliferation suggesting that many of the cells were initially activated, but 
few underwent clonal expansion (Liang et al. 2000). Furthermore, many of the originally 
activated B-lymphocytes underwent apoptosis rather than clonal expansion. Thus increased 
percentage of the CD 19+ve malignant lymphocytes after incubation with antisense ONs may 
be initially activated. 
6.4.3. The effect of antisense ONs on intracellular ll..-2 and ll..-4 expression 
In order to investigate the effect of ONs on B- and T -lymphocytes from patients with B-CLL, 
the CD19+ve and CD3+ve lymphocytes were stained fur the presence of intracellular IL-2 and 
IL-4. The results showed that the percentage of unstimulated CD 19+ve and CD3+ve 
lymphocytes expressing intracellular IL-2 and IL-4 decreased after incubation with IL-4c 
antisense ON. In contrast, in PMA-stimulated cells, the percentage of CD19+/IL-2+, 
CD3+/IL-2+ and CD3+/IL-4+ cells increased after incubation with IL-4c antisense ON. This 
increase in the percentage of double positive cells may indicate that PMA-stimulation can 
overcome suppressive ability ofiL-4c antisense ON. JL-4c antisense was specially designed to 
suppress IL-4 82 mRNA. Thus, influencing the percentage of the cells expressing IL-2 appears 
to be either a side effect of PTO-modified ONs or as a specific effect of a manipulation of IL-
4 expression. However if IL-4c antisense ON specifically inhibits the expression of IL-4 82 
mRN A and if a positive correlation exists between IL-4 wild type and IL-4 splice variant then 
possible reduction in IL-4 wild type protein should be seen. This observation is not supported 
by the increase in IL-4 protein level when PHA-stimulated B-CLL cells were incubated with 
IL-4c antisense ON. Thus the regulatory network that exists between cytokines and their 
splice variants is much more complicated and requires further studies. 
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6.5. FINAL CONCLUSION 
The results presented in this thesis firstly suggest that the presence of intracellular IL-4 in 
malignant B-lymphocytes may be a contributory factor in the pathogenesis of B-CLL. 
However, the question still remains as to the source of the IL-4. Attempts have been made to 
evaluate the presence of IL-2 and IL-4 protein and their mRNA transcripts using Western and 
Northern blotting technique (data not shown). However they were aboundand no conclusisve 
results were obtained. In addition Northern blotting aldough sensitive is not commonly used to 
detect low frequency transcripts. In addition higher quantity of oligo-dT separated mRNA are 
needed (RNA obtained from malignant and normal samplesin this thesis, represents total 
RNA). 
The discrepancy between the absence of protein as measured by ELISA (Kaminski et al. 1998) 
and Western blotting (data not shown) and the presence of mRNA transcripts in normal and 
malignant cells could be due to a number of reasons. Firstly, the cells may be unable to 
translate IL-4 mRNA into protein. Secondly, the protein may be labile and degraded faster in 
B-CLL compared to normal cells. Thirdly, the protein may be released and immediately bound 
to malignant B-lymphocytes in an autocrine fashion. Finally there may be a direct interaction 
between IL-4 and JL-4B2 transcripts that prevents the translation of the former into protein. 
The nested RT-PCR technique used, detected RT-PCR products of cytokines, normally not 
associated with B-lymphocytes (JL-2 and IL-4), to be significantly increased in malignant B-
lymphocytes. Other cytokines such as IL-7 and IL- 15 were signjficantly increased in B-CLL B 
and T-lymphocytes and normal T-lymphocytes respectively. The nested RT-PCR technique is 
very sensitive and can detect very small quantities of mRNA. Therefore, in addition to 
detecting mRNA from the cells of interest, there is a theoretical possibility of amplifying 
mRNA from small numbers of contaminating cells. 
In addition, there are djfferences in the expression of both JL-2 and IL-4 spliced variants that 
in turn might influence the expression of the wild type protein. The fact that many of these 
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cytokines are anti-apoptotic is likely to be of significant importance in the development and or 
survival of leukaemic B-lymphocytes. Identification of ways of manipulating or interfering 
with individual cytokines at either the protein or mRNA level could lead to new therapeutic 
modalities for B-CLL. 
The expression of typicaiJy T-lymphocyte rnRNA transcripts in malignant B-lymphocytes 
may provide additional information about the biology of those cells. It can be speculated that 
malignant B-lymphocytes represent a very specific subset of the B- lymphocyte population 
that, in the process of malignant change, manage to transcribe sets of genes normally active in 
T -lymphocytes. By doing so they might become self-regulatory and to a certain extent self-
sufficient. It is well known that aU malignant B-CLL cells are CD5+ve, a marker normally 
specific for T-lymphocytes and a minority subset of normal B-lymphocytes. Human CD5+ve 
B-lymphocytes are present in neonatal lymphoid tissue and their frequency decreases with 
age. In adu lts, CD5+ve B-lymphocytes are present in the germinal centre and mantle zone. 
The number of CD5+ve B-lymphocytes is increased in patients with autoimmune disorders 
and these cells, which are similar to those in CLL, may be induced to produce multi-specific 
autoantibodies. Some antigens are also able to activate CD5+ve cells (Dutra et al. 2000). 
However those B-lymphocytes are not malignant. In fact, when CD5+ve and CD5-ve cells 
were stimulated with surrogate T-dependent and T-independent signals they converged to 
indistinguishable phenotypes (Gagro et al. 2000). It is thus possible, that CD5+ve B-
lymphocytes are at the crossroads of B-cell malignancy and non-organ specific auto immunity 
(Youinou et al. 2000). In addition, there are cases of CD8+ve expression on B cells in chronic 
lymphocytic leukaemia (Islam et al. 2000). In retrospect, much more informative would be the 
investigation of pure populations of CD5+ve normal B-lymphocytes (I 0-30% in normal 
individual) compared with malignant CD5+ve B-lymphocytes. 
Finally, as already mentioned, the theory of antisense in suppressing expression of a particular 
gene is simple, but proving that this is a gene-specific event is much more difficult. Although 
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all IL-2 and IL-4 antisense ONs used in this study were able to increase the percentage of 
Annexin V/Propidium as well as CD19+ve/Annexin V positive cells as well as decrease the 
percentage of intracellular expression of IL-4 and IL-2 in CD3+ve and CD 19+ve cells, control 
antisense had a similar effect. The above effect was obtained without using cationic lipids as a 
carrier. Thus further studies using IL-2 and IL-4 antisense ONs need to be more specific in 
designing antisense, as well as further usage of cationic lipids as antisense carriers. Regardless 
ofthe fact that antisense ONs work via specific or non-specific mechanisms, they may be of 
potential therapeutic value in B-CLL. 
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6.6. FUTURE WORK 
In view of the possible therapeutic implications of the findings described in this thesis, and the 
fact that some of the results are in conflict with those of other authors, certain experiments 
need to be repeated. These include IL-2, IL-4 and IL-15 m.RNA expresion in B-CLL B and T 
lymphocytes. As mentioned above, it would be more informative to compare pure populations 
of CD5+ve normal and maliganant B-lymphocytes. In addition, it is necessary to select the 
most appropiate antisense ON as well as choosing optimal cariers. Once these have been 
determined, further experiments using these antisense ONs to intefere with the function of the 
IL-2, IL-4 and IL-15 should be carried out. Finally, to determine the functional effects of 
antisense ONs, further experiments need to be designed; eg measurement of apoptosis or bcl-2 
expression. 
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Appendix 1: Intracellular IL-4 expression in CD3+ and CD19+ lymphocytes from 
patients with 8-CLL and normal controls 
Number %CD1~/II.A+ % CD3+/IL-4+ Number %CD1~/IL-4+ %CD3+/llr4+ 
of of 
patients ( unstimulated) ( unstimuJated) controls ( unstimulated) ( unstimulated) 
(I) (ll) (Ill) (IV) 
1 30.0 21.6 1 5.1 2.2 
2 21.6 26.2 2 4.7 3.0 
3 28.8 13.5 3 5.4 1.8 
4 18.3 11.2 4 10.1 1.7 
5 53.8 5.4 5 9.9 4.2 
6 21.6 2.6 6 1.5 3.8 
7 14.8 7.2 7 6.8 3.4 
8 6.4 2.6 8 8.2 0.4 
9 17.4 3.2 9 11.9 1.0 
10 11.3 2.2 10 8.3 0.9 
Mean 22.4 9.6 7.2 2.2 
SD+/- SD+/- 13.1 SD+/- 8.5 SD+/- 3.1 SD+/-1.3 
Variable: Iilll Variable: ll/IV 
p=().03 p=().Ol 
The data is presented as the percentage of CD 19+ve and CD3+ve lymphocytes expressing intracellular IL-4. 
Unstimulated PBMCs were stained with anti-CD19 FITC and anti-IL-4 PE or anti-CD3 FITC and anti-IL-4 PE 
conjugated monoclonal antibodies and immediately analysed by flow cytometry. In each experiment if possible 
10,000 CD19+ve or CD3+ve lymphocytes were collected. IL=Lnterleukin, %=Percentage, SD=Standard 
deviation 
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Appendix 2: Surface IL-4R expression in CD19+ve and CD3+ve lympbocytes in patients 
with B-CLL and in normal controls 
Number %CD19+/ %CD3+/ Number of %CD19+/ % CD3+/ 
of IL-4R+ IL-4R+ controls IL-4R+ IL-4R+ 
patients (I) (Jl) (Ill) (IV) 
1 97.1 2.7 1 53 .0 1.1 
2 42.9 3.7 2 61.5 0.8 
3 28.2 0.6 3 82.5 0.6 
4 11.2 1.5 4 74.8 2.5 
5 70.5 6.8 5 64.9 0.8 
6 56.3 3.2 6 88.4 3.3 
7 70.0 3.5 7 69.1 1.4 
8 83.4 6. 1 8 69.6 1.8 
9 20.5 5.2 9 82.2 3.7 
10 96.9 7.8 10 41.6 1.0 
Mean 57.7 4.1 68.7 1.7 
SD+/- SD+/- 31.0 SD+/- 2.3 SD+/- 14.3 SD+/- 1.1 
Variable: IIIll Variable:fi/IV 
p=ns p=O.OOl 
The data is presented as the percentage ofCD I9+ve and CD3+ve lymphocytes expressing surfuce lL-4-R. Unstimulated 
PBMCs were stained with anti-CDI9 FITC and anti-ILAR PE or anti-CD3FITC and anti-JL..4R PE conjugated 
monoclonal antibodies and immediately analysed by flow cytometry. ln each individual experiment if possible I 0,000 
CD19+ve or CD3+ve lymphocytes were collected. 
%=Percentage, IL=Interleukin, SD=Standard deviation, ns=Not significant 
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Appendix 3: Densitometry results ofiL-4R a chain RT-PCR products 
IL-4 Receptor a chain 
Patients Controls 
B Lymphocytes T lymphocytes B lyrnphocytes T lyrnphocytes 
41.9 45.9 20.1 47.5 
46.6 48.6 43.0 47.9 
41.4 48.1 31.7 48.6 
41.4 42.4 35.9 43.0 
41.5 43.8 32.4 43.8 
40.4 49.4 39. 1 44.1 
38.4 41.8 41.7 44.2 
32.5 40.3 42.7 43.3 
38.6 45.2 
39.8 42.6 
Mean: 40.5 Mean: 45.0 Mean: 36.5 Mean: 45.0 
SO+/- 3.9 SO+/- 3.4 SO+/- 6.9 SD+/- 2.2 
Variable: B patients/ B control (t-test) p=ns 
B patients/ B control mean values ratio: l : 0.9 
Variable: T patients/ T controls (t-test) p=ns 
T patients/ T controls mean values ratio: 1 : 1 
Variable: B patients/ T patients (t-test) p--ns 
B patients/ T patients mean values ratio: l: 0.5 
Variable: 8 controls/ T controls (t-test) p=0.009 
B controls/ T controls mean values ratio: l : 1.2 
Appendix 3 shows the densitometry results of the IL-4R a chain RT-PCR product shown in Figure 3. 10. The 
Students t test was used to measure statistical significance. 
SD=Statistical significance, Mean=Mean optical density values, ns=Not significant 
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Appendix 4: Densitometry results ofyc receptor RT-PCR products 
Common gamma chain receptor 
Patients Controls 
B lymphocytes T lyrnphocytes B lymphocytes T lymphocytes 
1740.5 1601.3 2490.6 1749.3 
2343.0 2094.0 1381.0 2256.3 
2341.1 2060.6 1905.0 1003.9 
2547. 1 2164.9 1554.0 1404.3 
2413.3 1353.2 2214.3 2797.6 
2371.0 2372.2 1753.3 2275.3 
2619.5 2177.8 2604.3 2595.7 
2483.1 2024.0 2473.8 2027.4 
881 .2 2231 .2 2301.7 610.0 
830.9 2437.0 1575.9 22 12.3 
1860.2 2528.2 
Mean: 2039.2 Mean: 2094.9 Mean: 2025.4 Mean: 1893.2 
SD+/- 644.0 SO+/- 348. 1 SO+/- 446.2 SO+/- 699.7 
Variable: B patients/ B control (t-test) p=ns 
8 patients/ 8 control mean values ratio: 1 : 1 
Variable: T patients/ T controls (Hest) p=ns 
T patients/ T controls mean values ratio: 1:0.9 
Variable: 8 patients/ T patients (t-test) p=ns 
B patients/ T patients mean values ratio: 1: 1 
Variable: 8 controls/ T controls (t-test) p=ns 
B controls/ T controls mean values ratio: 1:0.9 
Appendix 4 shows the densitometry results of the IL-4R a chain RT-PCR product shown in Figure 5.6. The 
Students t test was used to measure statistical significance. 
SD=Statistical significance, Mean=Mean optical density values, ns=Not significant 
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Appendix 5: Densitometry results of the IL-2 RT -PCR products 
lL-2 (primers spanning exon 1 to 4) 
Patients Controls 
B lympho~es T lymphocytes B lymphocytes T lymphocytes 
1787.0 2272.9 51.2 1987.2 
59.7 254.5 42.9 1766.5 
77.1 2054.1 12.4 1843.7 
10.1 1589.2 21.8 1739.8 
75.5 0 53 .7 1793.2 
1428.7 82.2 10.0 2027.1 
1802.3 1734.0 0 1842.4 
75.5 1691 .2 13.3 252.8 
233.6 1745.8 49.1 191 6.6 
84.0 1860.5 66.4 2001.2 
102.7 136.3 
Mean: 521 .09 Mean: 1220.0 Mean: 22.9 Mean: 171 7.0 
S0 +/-747.0 SO+/- 894.5 SO+/- 18.71 SO+/- 524.3 
Variable: 8 patients/ B control (t-test) p=0.04 
B patients/ B control mean values ratio: 1 : 0.04 
Variable: T patients/ T controls (t-test) p=ns 
T patients/ T controls mean values ratio: 1: 1.4 
Variable: 8 patients/ T patients (t-test) p=0.35 
B patients/ T patients mean values ratio: 1: 2.3 
Variable: 8 controls/ T controls (t-test) p=0.002 
8 controls/ T controls mean values ratio: 1: 75 
Appendix 5 shows the densitometry results of the IL-4R a chain RT-PCR product shown in Figure 5.8. The 
Students t test was used to measure statist ical significance. 
SD=Statistical significance, Mean=Mean optical density values, n - Not significant 
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Appendix 6: Densitometry results ofiL-4 RT-PCR products 
IL-4 (primers spanning exon 1 to 4) 
Patients Controls 
B Lymphocytes T lymphocytes B Lymphocytes T lymphocytes 
416.7 404.9 5.2 3.6 
7.7 13.9 1.3 605.8 
205.0 181.6 7.1 399.5 
7.6 3.86 0 689.7 
26. 1 29.1 221.0 743.6 
89.3 43.7 13.7 4.8 
118.6 573.0 67.1 418.0 
32.8 487.6 18.0 193.1 
309.5 284.6 133.3 0 
141.2 673 .8 45.9 319.2 
45.2 36.7 
Mean: 127.2 Mean: 252.1 Mean: 51.3 Mean: 337.7 
SO+/- 133.9 SD+/- 249.6 SD+/- 72.6 SO+/- 284.5 
Variable: 8 patients/ 8 control (t-test) p=ns 
8 patients/ 8 control mean values ratio: I : 1 
Variable: T patients/ T controls (t-test) p=ns 
T patients/ T controls mean values ratio: 1: 0.9 
Variable: B patients/ T patients (t-test) p=ns 
8 patients/ T patients mean values ratio: I : 1 
Variable: B controls/ T controls (t-test) p=ns 
B controls/ T controls mean values ratio: 1: 0.9 
Appendix 6 shows the densitometry results of the 1L-4R a chain RT-PCR product shown in Figure 5.10. The 
Students t test was used to measure statistical significance. 
SD=Statistical significance, Mean= Mean optical density values, ns=Not significant 
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Appendix 7: Densitometry results of IL-7 RT -PCR products 
IL-7 
Patients Controls 
B lymphocytes T lymphocytes B Jyrnphocytes T lymphocytes 
2061.0 2171.2 12 18.9 1547.9 
2248.5 2111.0 934.5 225.4 
25 11.1 2844.2 423.8 20. 1 
465.1 800.2 1885.7 2250.2 
1335.4 3180.0 2610.8 971.7 
268.3 3103.1 11 3. 1 2827.3 
1244.9 3128.2 1092. 1 555.1 
1409.4 2975.0 2549.7 482.0 
1619.8 2743.6 1570.8 3349.7 
2693 .0 3229.5 0 2617.1 
1750.0 1000.0 
Mean: 1600.6 Mean: 2480.5 Mean: 1239.9 Mean: 1484.6 
SD+/- 772.8 SD+/- 868.9 SD+/- 925.5 SD+/- 1202.6 
Variable: 8 patients/ 8 control (t-test) p=0.03 
8 patients/ 8 control mean values ratio: l : 0.8 
Variable: T patients/ T controls (t-test) p=0.04 
T patients/ T controls mean values ratio: l : 0.6 
Variable: 8 patients/ T patients (t-test) p=0.02 
B patients/ T patients mean values ratio: l : L.6 
Variable: 8 controls/ T controls (t-test) p=ns 
B controls/ T controls mean values ratio: l : 1.2 
Appendix 7 shows the densitometry results of the IL-4R a chain RT-PCR product shown in Figure 5. 12. TI1e 
Students t test was used to measure statistical signi ficance. 
SD=Statistical s ign ificance, Mean=Mean optica l density values, ns=Not significant 
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A d' 8 D ,ppen IX : ensatometry resu ts o fiL-15 RT PCR d - pro ucts 
IL-15 
Patients Controls 
B lymphocytes T lymphocytes B lymphocytes T lymphocytes 
2293.6 1974.9 1813.5 2529.8 
1949.4 1702.2 1861.4 2470.6 
1886.6 1613.3 1788.1 2242.7 
1660.6 1618.9 1731.9 1698.4 
1990.7 1688.7 1823.8 2267.6 
1736.6 1730.3 1855.1 2290.4 
1746.0 1208.9 1739.5 2362.1 
1759.5 1603.5 1626.9 2506.4 
1964.2 1169.6 1626.4 2396.0 
1545.8 986.5 1905.1 2032.4 
1945.4 459.1 
Mean: 1861 .7 Mean: 1432.4 Mean: 1777.2 Mean: 2279.6 
SD+/- 201.1 SD+/- 433.9 SD+/- 95.4 SD+/- 251.9 
Variable: 8 patients/ B control (t-test) p=ns 
B patients/ B control mean values ratio: I : 1 
Variable: T patients/ T controls (t-test) p=O.OOI 
T patients/ T controls mean values ratio: 1: 0.6 
Variable: B patients/ T patients (t-test) p=0.007 
B patients/ T patients mean values ratio: 1: 1.8 
Variable: 8 controls/ T controls (t-test) p=OOOl 
B controls/ T controls mean values ratio: l : 1.3 
Appendix 8 shows the densitometry results of the IL-4R a chain RT-PCR product shown in Figure 5. 14. The 
Students t test was used to measure statistical significance. 
SD=Statistical significance, Mean=Mean optical density values, ns=Not significant 
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Appendix 9: Densitometry results of IL-2 and IL-2 B2 RT -PCR products 
IL-2 (primers spanning exon 1 to 3) 
IL-2 wild type band IL-2 spliced variant (B 2) band 
Patients Controls Patients Controls 
B lymph. T lymph. B lymph. T lymph. B lymph. T lymph. B lymph. T lymph. 
249.6 241.2 15.2 229.0 46.6 138.2 0 135.0 
215.9 67.2 31.3 240.4 0 0 0 123.6 
109.5 231 .5 45.2 238.5 0 65.9 0 70.1 
168.5 197.5 73.5 268.1 0 44.4 5.3 122.8 
96.3 142.9 53.5 202.1 21.8 5.3 0 121.9 
200.5 147.4 109.6 236.8 34.2 6.7 0 172.4 
217.3 274.4 81. 1 174.5 0 85.4 0 18.7 
138.9 216.3 91.4 180.1 0 41.1 0 22.2 
229.6 135.4 0 157.2 22.4 39.8 0 19.6 
21.4 225.9 29.2 30.3 0 0 0 0 
249.2 48.3 19.2 0 
Mean: Mean: Mean: Mean: Mean: Mean: Mean: Mean: 
172.4 175.3 53.0 195.7 13.1 38.8 0.53 80.6 
SO+/- SD+/- SD+/- SO+/- SD+/- SO+/- S0 +/-1.6 SD+/-61.7 
73.2 79.0 35.3 67.9 16.7 44.1 
t-test t-test 
Variable: B patients/ B controls p=0.0001 Variable: B patients/ B controls p=0.03 
Ratio: 1: 0.31 Ratio: 1: 0.04 
Variable: B patients IT patients p=ns Variable: B patients/T patients p=ns 
Ratio: 1 : 1 Ratio: 1: 3 
t-test t-test 
Variable: T patients/ T controls p=ns Variable: T patients/ T control p=ns 
Ratio: 1: 1.1 Ratio 1: 2 
Variable: B controls/ T controls p=0.001 Variable: B controls/T controls p=0.003 
Ratio: 1: 3.7 Ratio: 1 : 152 
Spearmans' correlation test 
Variable: B patients wild type/B patients splice variant p=ns 
Variable: T patients wild type/T patients splice variant r=761 p=0.006 
Variable: B controls wild type/B controls splice variant p=ns 
Variable: T controls wild type/T controls splice variant r=758 p=O.Ol 
Appendix 9 shows the densitometry results of the liA R a chain RT-PCR product shown in Figure 5. 19. The 
Students t test was used to measure statistical signi ficance. 
SD=Statistical significance, Mean=Mean opt ical density values, ns=Not significant, lymp=Lymphocytes 
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Appendix 10: Densitometry results of IL-4 and IL-4 B2 RT -PCR products 
IL-4 (primers spanning exon 1 to 3) 
IL-4 wild type band JL-4 spliced variant (IL-4 B2) band 
Patients Controls Patients Controls 
B lymph. T lymph. B lymph T lymph B lymph T lymph B lymph T lymph 
29.6 13 .5 19.0 18.5 12.9 1.9 9.5 24.3 
27.4 17.9 22.9 34.4 10.7 2.6 10.7 19.8 
28.9 37.1 20.0 20.5 10.4 3.1 12.9 12.1 
25.9 35.3 22.8 11.4 9.0 1.7 14.0 7.1 
23.9 10.9 10.3 1.0 
18.7 34.5 10.3 1.6 
31.9 32.6 13.8 1.8 
29.9 16.9 14.1 2.8 
Mean: Mean: Mean: Mean: Mean: Mean: Mean: Mean: 
27.0 24.8 21.2 21.2 11.4 2.1 11.8 15.8 
SD+/-4.1 SD+/- SD+/-1.9 SD+/-9.6 SD+/-1.9 SD+/-0.7 SD+/- SD+/-7.6 
10.9 2.0 
Variable: B patients/ B controls p=0.03 Variable: B patients/ B controls p=ns 
Ratio: l: 0.8 Ratio : 1 : 1 
Variable: B patients/T patients p=ns Variable: B patients/T patients p=O.OOI 
Ratio: 1: 0.9 Ratio : 1: 0.2 
Variable: T patients/ T controls p=ns Variable: T patients/ T controls p=O.OOOI 
Ratio: 1: 0.9 Ratio : 1: 7.6 
Variable: B controls/T controls p=ns Variable: B controlsff controls p=ns 
Ratio: 1: 1 Ratio : 1: 1.3 
Spearmans' correlation test 
Variable: B patients wild type/B patients splice variant r=874 p=0.005 
Variable: T patients wild type/T patients splice variant p=ns 
Variable: B controls wild type/B controls splice variant p=ns 
Variable: T controls wild type/T controls splice variant p=ns 
Appendix 10 shows the densitometry results of the LL-4R a chain RT-PCR product shown in Figure 5.21. The 
Students t test was used to measure statistical significance. 
SD=Statistical significance, Mean=Mean optica l density values, ns=Not significant, lymph=Lymphocytes 
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Appendix 11: Densitometry of IL-5 RT -PCR products 
IL-5 
Patients Controls 
B lyrnphocytes T lymphocytes B lymphocytes T lymphocytes 
885.9 1004.9 671.5 0 
148.0 774.8 61.5 974.5 
649.7 1058.7 335.7 8.8 
905.7 449.4 0 848.6 
16.7 116.3 666.3 0 
1012.5 0 790.7 910.2 
933.3 879.7 0 754.7 
872.9 764.2 630.3 0 
1173.0 610.5 854.0 917.7 
1018.5 1076.7 855.3 963.9 
1052.8 1013.7 
Mean: 788.0 Mean: 704.4 Mean: 486.2 Mean: 537.8 
SD+/-373.8 SD+/-374.8 SD+/-353.9 SD+/-465.0 
Variable: 8 patients/ 8 control (t-test) p=ns 
B patients/ 8 control mean values ratio: l : 1.6 
Variable: T patients/ T controls (t-test) p=ns 
T patients/ T controls mean values ratio: 1: 0.8 
Variable: 8 patients/ T patients (t-test) p=ns 
8 patients/ T patients mean values ratio: I: 0.9 
Variable: 8 controls/ T controls (t-test) p=ns 
8 controls/ T controls mean values ratio: l: 1.1 
Appendix 11 shows the densitometry results of the IL-4R a chain RT-PCR product shown in Figure 5.25. T11e 
Students t test was used to measure statistical s ignificance. 
SD=Statistical significance, Mean=Mean optical density values, ns=Not significant 
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Appendix 12: Densitometry of IL-13 RT -PCR products 
IL-13 
Patients Controls 
B lymphocytes T lyrnphocytes B lymphocytes T lymphocytes 
536.2 362.2 220.5 414.6 
39.4 428.8 466.6 477.2 
468.0 88.9 467.0 320.0 
309.7 439.3 34.8 520.7 
334.0 416.4 346.6 510.8 
350.2 419.3 350.9 211.5 
325.0 455.7 511 .9 306.3 
390.1 48.5 403.7 0 
196.0 190.6 152.1 361.9 
363.6 259.8 541.3 261.3 
296.8 289.9 
Mean: 328.2 Mean: 308.4 Mean: 349.5 Mean: 349.0 
S0+/- 130.6 S0+/-145.8 S0+/-166.0 S0+/-158.6 
Variable: B patients/ B control (t-test) p=ns 
B patients/ B control mean values ratio: I : 1 
Variable: T patients/ T controls (t-test) p=ns 
T patients/ T controls mean values ratio: 1: 1.1 
Variable: B patients/ T patients (t-test) p--us 
B patients/ T patients mean values ratio: 1: 0.9 
Variable: B controls/ T controls (t-test) p=ns 
8 controls/ T controls mean values ratio: 1: 1.1 
Appendix 12 shows the densitometry results of the IL-4R a chain RT -PCR product shown in Figure 5.27. The 
Students t test was used to measure statistical signjficance. 
SD=Statistical significance, Mean=Mean optical density va lues, ns=Not significant 
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Appendix 13: Flow cytometric analysis of tbe effect of PTO-modified IL-2 antisense ONs 
on unstimulated PBMCs separated from patients witb B-CLL 
Antisense 
Negative 
control 
IL-2c 
Mean 
fL-2a/IL-4a 
%CD19+ total 
66.5 
69.9 
57.5 
94.4 
80.4 
54.3 
69.5 
57.1 
81.9 
80.1 
%CD19+/A+ 
58.1 
50.8 
32.6 
34.1 
52.7 
61.5 
80.4 
51.8 
58.4 
57.4 
%PI+/A+ 
46.9 
17.0 
30.0 
15.9 
36.9 
46.6 
39.9 
32.4 
38.3 
Position of tbe individual antisense oligonucleotides 
Exon l Exon 3 Exon 4 Exon I 
IL-2b/rL-4b TL-2c/LL-4c IL-2d/IL-4d 
PBMCs isolated by density gradient centrifugation from five patients with B-CLL and from five normal controls 
were used. PBMCs were diluted in 5% FCS culture medium to a concentration of 0.5x I 06 and incubated for 48 
hours with PTO-modified IL-2 ONs at a total concentration of 3 x 2.5 f.1M in 24 well plates. Collected PBMCs 
were stained with anti-CDI9 PE, double stained with anti-CD19 PPJAnnexin V FITC (CDI9+/A+) and double 
stained with Propidium iodine/Annexin V FTTC (PI+/A+) and analysed immediately by flow cytometry. Ant.= 
Antisense, PI = Propidium iodine, A = Annexin V 
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Appendix 14: Flow cytometric analysis of the effect of PTO-modified IL-4 antisense ONs 
on unstimulated PBMCs separated from patients with 8-CLL 
Antisense %CD19 +total %CD19+/A+ %PI+/ A+ 
Negative 66.5 58.1 46.9 
control 69.9 50.8 17.0 
57.5 32.6 30.0 
94.4 34.1 15.9 
80.4 52.7 36.9 
Mean 73.5 45.6 27.4 
IL-4a 58.3 53.8 45.0 
75.0 79.3 9.6 
51.6 45.1 39.9 
95.4 48.2 22.4 
78.5 61.0 42.6 
Mean 71.7 57.6 31.9 
IL-4b 63.4 61.7 41.5 
66.5 63.8 45.0 
46.7 52.2 35.3 
72.0 45.9 22.3 
80.5 55.4 38.5 
Mean 65.8 55.8 36.5 
IL-4c 61.0 55.2 46.1 
74.0 75.8 48.1 
55.0 39.7 27.6 
77.4 57.6 34.7 
84.3 52.2 41.7 
Mean 70.3 56.0 39.6 
IL-4d 59.6 51.1 40.2 
66.8 48.1 33.1 
42.8 52.7 48.3 
74.2 50.3 17.7 
75.5 59.6 41.8 
Mean 63.7 52.3 36.2 
Control 63.6 65.9 50.5 
antisense 70.9 79.1 49.6 
41.1 61.6 -
71.5 57.9 32.8 
81.9 36.0 40.5 
Mean 65.8 60.0 43.3 
PBMCs isolated from five patients with 8-CLL and from five normal controls were used. PBMCs were diluted to 
a concentration of0.5xl06 and incubated for 48 hours with PTO-modified lL-4 ONs at a total concentration of 3 
x 2.5 J.IM in 24 well plates. PBMCs were stained with anti-CDI9 PE; double stained with anti-CDI9 PE/Annexin 
V FrTC (CDI9+/A+) and double stained with Annexin V FITC/Propidium Iodine (PI+/A+) and analysed 
immediately by flow cytometry. Ant.= Antisense, PI = Propidium iodide, A = Annexin V 
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Appendix 15: Flow cytometric analysis of the effect of PTO-modified IL-2 antisense ONs 
on unstimulated PBMCs separated from normal controls 
Antisense %CD19+ total %CD19+/A+ %PI +lA+ 
Negative 2.6 1.4 0.5 
control 7.8 3.3 4.8 
5.2 1.2 7.2 
7.2 1.7 3.6 
12.5 4.8 8.0 
Mean 7.0 2.4 4.8 
IL-2a 2.7 0.3 0.9 
5.7 3.4 6.4 
5.4 2.1 3.7 
6.6 2.2 3.5 
10.3 0.7 5.6 
Mean 6.1 1.7 4.0 
IL-2b 1.6 0.6 1.0 
4.8 6.4 8.4 
5.7 1.2 1.0 
7.0 1.4 5.3 
11.1 3.1 9.3 
Mean 6.0 2.5 5.0 
lL-2c 1.6 0.4 2.2 
5.8 3.1 8.6 
4.4 1.4 4.7 
6.9 2.0 6.7 
10.0 4.4 15.4 
Mean 5.7 2.2 7.5 
IL-2d 2.0 0.4 2.6 
7.8 3.1 6.5 
4.8 1.3 8.5 
7.8 1.0 4.7 
10.2 3.3 8.3 
Mean 6.4 1.8 6.1 
PBMCs from five nonnal controls were used. PBMCs were diluted in culture medium to a concentration of 
0.5XIOS/ml and incubated for 48 hours with different IL-2 PTO-modified antisense ONs in 24 well plates. 
Collected cells were stained with anti-CD 19 PE; double stained with anti-CD 19 PE and Annexin V FTTC 
(CD19+/A+) and double stained with Annexin V FITC and Propidium iodine (PI+/A+) and analysed by Aow 
cytometry. Ant.= Antisense, PI = Propidium Iodide, A = Annex.in V 
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Appendix 16: Flow cytometric analysis of the effect of PTO-modified IL-4 antisense ONs 
on unstimulated PBMCs separated from normal controls 
Antisense %CD19+ total %CD19+/A+ %PI+/ A+ 
fL-4a 2.2 0.3 0.9 
6.2 3.7 6.4 
5.2 0.6 2.8 
8.2 2.7 3.5 
10.7 2.0 7.3 
Mean 6.5 1.8 4.1 
IL-4b 3.3 0.3 2.4 
7.5 4.2 7.7 
5.5 1.3 1.5 
7.5 1.9 6.2 
10.0 1.7 5.3 
Mean 6.7 1.8 4.6 
IL-4c 2.5 0.4 2.4 
5.5 2.9 6.8 
5.2 1.1 2.4 
7.1 1.4 5.8 
9.2 2.5 6.3 
Mean 5.9 1.6 4.7 
LL-4d 1.9 0.5 3.4 
7.0 3.1 10.6 
8.4 2.1 2.6 
7.8 1.6 6.1 
12.0 3.7 12.0 
Mean 7.4 2.2 6.9 
Contro l 2.0 0.2 1.2 
antisense 4.0 2.8 6.5 
5.2 1.8 3.4 
7.2 2.1 4.4 
10.3 4.2 9.6 
Mean 5.7 2.2 5.0 
PBMCs isolated by density gradient centrifugation from normal controls were used. PBMCs were diluted in 5% 
FCS culture medium to a concentration of 0.5X I 05/ml. Cells were incubated for 48 hours with different IL-4 
PTO-modified anti sense ONs and control antisense ON. Collected cells were stained with anti-CD 19 PE, double 
stained with anti-CDI9 PE and Annexin V FITC (CDI9+/A+) and double stained with Annexin V FTTC and 
Propidium Iodine (PI) (PI+/ A+) and analysed by flow cytometry. 
Ant.= Antisense, PI = Propidium Iodide, A = Annexin V 
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Appendix 17: Flow cytometric analysis ofthe effect ofPTO-modified IL-2 and IL-4 
antisense ONs on unstimulated CD3+ve lymphocytes from normal controls 
Antisense %CD3+ %CD3+/A+ Antisense %CD3+ %CD3+/A+ 
Neg. control 47.2 3.5 Cont. ant. 42.2 4.4 
36.9 10.1 42.3 5.0 
31.9 0.6 38.9 4.8 
5l.8 8.3 46.2 14.4 
Mean 41.9 5.6 Mean 42.4 7.1 
lL-2a 45 .2 6.1 IL-4a 50.8 3.4 
32.7 8.7 38.8 5.8 
46.4 0.9 37.4 1.5 
24.0 3.6 48.2 7.0 
Mean 37.0 4.8 Mean 43.8 4.4 
IL-2b 46.6 5.9 IL-4-b 47.9 3.5 
35.5 6.5 34.1 7.7 
42.8 1.3 34.1 0.7 
41.9 9.0 46.8 10.6 
Mean 41.7 5.6 Mean 40.7 5.6 
IL-2c 50.5 3.6 IL-4c 47.7 1.9 
37.3 7.0 34.4 7.0 
39.7 2.5 41.2 1.7 
46.7 L0.2 53.2 8.3 
Mean 43.5 5.8 Mean 44.1 4.7 
IL-2d 45.7 10.2 IL-4<1 40.7 4.2 
36.4 5.8 35.9 9.7 
41.6 2.2 28.1 1.2 
51.7 6.3 39.9 8.5 
Mean 43.8 6.1 Mean 36.1 5.9 
PBMCs from normal healthy controls were incubated with various PTO-modified IL-2 and IL-4 antisense ONs at 
a concentration of 3x 2.5~ for 48 hours. After incubation, the PBMCs were stained with anti-CD3 PE 
monoclonal antibody or double stained with anti-CD3 PE and Annexin V FITC (CD3+/A+) and immediately 
analysed by flow cytometry. Ant.=Antisense, A = Annexin V, ONs=oligonucleotides 
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Appendix 18: Flow cytometric analysis of B-CLL PBMCs after addition of control, IL-2d 
PTO-modified and unmodified antisense ONs 
Antisense %CD19+ %CD19+/A+ %PI+/ A+ 
totaL 
Negative control 
81.0 13.3 1.7 
50.5 9.4 1.5 
87.3 3.2 0.4 
Mean 72.3 8.6 1.2 
IL-2d PTO modified ON 
81.9 13.0 2.9 
48.1 15.4 2.0 
87.3 1.2 2.2 
Mean 72.4 9.8 2.3 
IL-2d non-modified ON 
79.5 13.3 2.4 
41.8 20.1 3.6 
84.6 3.5 1.3 
Mean 68.3 12.3 2.4 
Control antisense 
80.7 14.3 2. 1 
57.9 2.0 4.6 
83.0 2.5 0.3 
Mean 73.8 6.2 2.3 
PBMCs from patients with B-CLL obtained following a Lymphoprep gradient separation were used. PBMCs 
were incubated with control antisense, unmodified LL-2d antisense ON and PTO-modified llr2d antisense ON 
for 48 hours. Antisense ONs were added at the concentration of3x2.51JM. 
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Appendix 19: Flow cytometric analysis of intraceUular IL-2 and IL-4 expression in 
unstimulated and PMA-stimulated CD19+ve and CD3+ve PBMCs from normal controls 
A) Normal control unstimulated PBMCs 
Antisense Time %CD19+/IL-4+ %CD19+/D.r2+ o/oCDJ+/IL-4+ %CD3+/D.r2+ 
Negative control 
2hr 6.8 0.3 26. 1 2.6 
4hr 0.6 0.1 23.3 0.1 
6hr 1.1 0.4 27.6 1.7 
llr4c antisence ON 
2hr 14.0 1.5 19.6 1.1 
4hr 0.1 0 12.7 0 
6br 0.4 0.1 9.4 1.0 
B) Normal control PBMCs -stimulated with PMA (20 ng/ml) 
Antisense Time %CD19+/IL-4+ %CD19+/D.r2+ %CD3+/IL-4+ %CD3+/IL-2+ 
Negative control 
2hr 2.7 4.7 22.2 47.4 
4hr 0.5 0.3 15.7 48.1 
6hr 2.8 0.7 50.6 57.7 
IL-4c antisense ON 
2hr 2.5 0.7 15.5 44.5 
4hr 0.1 0.3 18.8 54.0 
6hr 1.0 0.7 44.3 58.9 
Table A show the percentage ofCD19+ve cells expressing intracellular IL-2 and IL-4 after incubation with IL-4c 
antisense ON. Table B shows that incubation of PMA-stimulated PBMCs from nonnal controls with IL-4c 
antisense ON. 
Neg. cont.= Negative control, hr=Hours 
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Appendix 20: Flow cytometric analysis of unstimulated and PMA-stimulated CD19 and 
CD3+ve B-CLL cells expressing intracellular IL-2 and IL-4 
Unstimulated PBMCs from patients with B-CLL 
Antisense %CD 19+/IL-4+ %CD19+/IL-2+ %CD3+/IL-4+ %CD3+/IL-2+ 
Negaive 28.7 12.7 7.7 2.8 
control 4.5 1.8 1.0 0.1 
4.7 2.9 2.7 2.2 
3.3 1.0 0.4 0.6 
Mean 10.3 4.6 2.9 1.4 
IL-4c 0.4 0 0.5 0.1 
antisense ON 5.7 2.0 0.2 0 
5.7 2.6 2.6 3.9 
1.5 1.6 1.1 1.2 
Mean 3.3 1.5 1.1 1.1 
PMA-stimulated PBMCs from patients with B-CLL 
Antisense %CD 19+/IL-4+ %CD19+1IL-2+ %CD3+/IL4+ %CD3+/IL-2+ 
Negative 3.3 - 0.1 0.1 
control 9.9 7.4 0.3 0.7 
7.3 7.0 5.2 5.8 
5.7 5. 1 1.4 1.8 
Mean 6.5 6.5 1.7 2.1 
IL-4c 6.6 15.0 19.5 10.8 
antisense ON 8.7 - 0.4 0.8 
2.7 6.0 5.3 4.9 
6.2 5.9 1.6 1.7 
Mean 5.9 8.9 6.7 4.5 
Unstimulated and PMA-stimulated PBMCs from patients with 8-CLL were investigated for the percentage of CD3+ve 
and CD19+ve lymphocytes expressing intracellular lL-2 or IL-4 after incubation with JYfO-modified JL-4c antisense ON 
for 6 hours. 
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Appenix 21: ELISA readings ofPHA stimulated PBMCs isolated from patients with 8 -
CLL and incubated for 48 hours with IL-2 and IL-4 antisense ONs 
lL-2 ELISA readings (in pg) 
Patient Negative Control IL-2a IL-2b IL-2c IL-2d 
number control antisense 
I 4 1.85 9.02 40.41 23.57 14.44 51.77 
2 9.84 0.98 10.24 3.46 3.99 7.32 
3 22.61 0 7.76 0.98 3.99 13.7 1 
4 174.06 27.00 62.50 17.28 47.45 23.57 
Mean 62.09 9.25 30.23 11.32 17.47 24.09 
IL-4 ELTSA readings (in pg) 
Patient Negative Control IL-4a IL-4b IL-4c IL-4d 
number control antisense 
I 1.44 0. 14 1.92 1.27 0.65 2.00 
2 0 0.05 0.06 0.09 0.04 0.14 
3 1.10 0.62 1.03 1.68 0.93 2.31 
4 4.27 13.79 11 .65 9.62 7.64 11.0 I 
Mean 1.70 3.65 3.66 3.17 2.31 3.86 
PHA stimulated {JJ.lg/m I) PBMCs from four patients with 8-CLL were incubated for 48 hour with various PTO-
modified IL-2 and IL-4 antisense ONs as well as control antisense. 
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Appendix 22: Beta actin sequeocing results (Wilbur-Lipman DNA alignment) 
bacts.seq HSAC07 Index Number Len th Len th 
1>962 164>846 100.0 0 0 456 
----~~ 
v10 v20 v30 v40 v50 v60 " v70 v80 
GGGCGTGATGGTCGGCATGGG l CAGAAGGATTCCTATGTGGGCGACGAGGCCCAGAGCAAGAGAGGCATCCTCACCC TGA 
GGGCGTGATGGTGGGCATGGGiCAGAAGGATTCC TATGTGGGCGACGAGGCCCAGAGCAAGAGAGGCA TCC lCACCCTGA 
GGGCGTGATGGTGGGCATGGGT CAGAAGGATTCC TATGTGGGCGACGAGGCCCAGAGCAAGAGAGGCAl CC TCACCC TGA 
~ 1 70 ~ 180 ~ 1 90 ~200 - 210 - 220 -230 ~240 
v90 vlOO v ll O vl20 v130 v 140 v l50 v160 
AG TACC CC ATCGAGCACGGC AT CGT CACC AACTGGGACGACATGGAGAAAATCTGGCACC ACACC TTCTACAA TGAGC TG 
AGTACCCCAT GAGCACGGCATCGTCACCAAC TGGGACGACATGGA~AAAATC TGGCACCACACC ll C lACAATGAGCTG 
AGTACCCCAT CGAG CACGGCATCGl CACC AACTGGGACG ACAT GG AGAAAATCTGG CACC ACACCT I CTACAATGAGCTG 
~ 250 ~ 260 ~ 270 -280 ~ 290 - 300 - 3 10 - 320 
v 170 v l80 v 190 v200 v2 10 v220 v230 v240 
CGTGTGGCTCCCGAGGAGCACCCCGTGCTGC TGACCGAGGCCC CC CTGAACCCCAAGGCCAACCGCGAGAAGATGACCCA 
CGTG TGGCTCCCG AGGAGCAC CCCG TGCTGCTGACCGAGGCCCCCC TGAACCCC AAGGCCAACCGCGAGAAGAT GACC CA 
CG TGTGGC TCCCGAGGAGC ACCCCGTGCTGCTGAC CGAGGCCCCCCTGAACCCC AAGG CC AACCGCGAGAAGAlGACCCA 
· 330 · 340 · 350 - 360 ~ 370 - 380 ~380 ·qoo 
v250 v260 v270 v280 v290 v300 v3 10 v320 
GATCATGTTTGAGACCTTCAACACCCCAGCCATGTACGTTGCTATCCAGGCTGTGCTATCCCTGTACGCCTCTGGCCGTA 
GATCATGTTTGAGACCl l CAACACCCCAGCCATG TACGT TGCTATCCAGGCTGTGCTATCCCTGTACGCCTCTGGCCG T~ 
GATCATG TTTGAGACCTTCAACACCCCAGCCAT GT ACGTTGCTATCCAGGCTGTGCTATCCCTG l ACGCC TCTGGCCGTA 
· 410 · q2o ~ 430 ~ 440 ~ 450 - q6o ~ 4 70 ~ 480 
v330 v340 v350 v360 v370 v380 v390 v400 
CC AC TGGCATCGTGATGGACTCCGGTGACGGGGTCACCCACACTGTGCCCATCTACGAGGGGTATGCCCTCC CCCATGCC 
CC ACTGGCATCGTGATGGACTCCGG TGACGGGGTCACCCACACTGTGCCCATCTACGAGGGG TAlGCCCTCCCCCATGCC 
CCACTGGCATCGTGATGGAC TCCGGTGACGGGGTCACCCACACTGTGCCCATCTACGAGGGGTATGCCCTCCCCC ATGCC 
· q9o ~ soo ~ 5 1 0 ' 520 ~ 530 ~ 540 ~550 ~ 560 
v4 10 y42Q yq3q v440 v450 
AT CC l GCGTC l GqACC TGGCT QGCCGGG ACCTGACTGACTACC TCAlGAAGATCCl 
AT CC TGCGTCTGG ACC TGGCTGGCCGGG ACCTGACTGACTACCTC Al GAAGATCCT 
ATC CTGC4TC TGGACCTGQCTQGC CGG4ACCTGACTGACTACCTCATGAAGAT CC T 
~ o 7o -6ao ·6eo ~ 6oo ~610 
. bacta.seq _,__ HSAC07 Index Number 
1>1004 204>775 100.0 0 
---- --
th Len th _ ___ __,<....._ 
0 382 
v400 v390 v380 v370 v360 v350 v340 v330 
GGCGACGAGGCCCAGAGCAAGAGAGGCATCC TCACCC TGAAGTACCCCATCGAGCACGGCATCGT CACCAACTGGGACGA 
GGCGACGAGGCCCAGAGCAAGAGAG GC ATCC TCACCCTGAAGTACCCCAT CGAGCACGGCATCGTCACCAACTGGGACGA 
GG CGACGAGG CCC AGAGCAAGAGAGGCATCC TCACCCTGAAGTACCCCATCGAGCACGGCATCGT CACC AACTGGGACGA 
-2 10 ~ 220 -230 -240 ~250 - 260 .270 ~ 280 
v320 v3 10 v300 v290 v280 v270 v260 v250 
CATGGA GAAAAT CTGGCACC ACACC TTCTACAATGAGCTGCGTGT GGC TCCCGAGGAGC ACCCCGTGCTG CTGACCGAGG 
CATGGAGAAAATCTGGCACC ACACCTTCT ACAAT GAGCT GCGTGTGGCTCCCG AGGAG CACC CCGTGClGCTCACCGAGG 
CATGGAGAAAATCTGGCACCACACCTTCT ACAATGAGCTGCGTGTGGCTCCCGAGGAGCACCCCGTGCTGCTGACCGAGG 
-290 ~ 300 -3 10 - 320 ~ 330 - 340 ~350 ~360 
v2lJO v230 v220 v210 v200 v190 v 180 v170 
CCCCCCTGAACCCCAAGGCCAA CCGCGAGAAGAT GACCCAGATC ATGTTTGAGACC TT CAA CACCCCAGCCATGTACGTT 
CCCCCC TGAACCCCAAGGCCAACCGCGAGAAGATGACCCAGATCATG TTTGAGACC TTCAACACCCCAGCCATGTACGTT 
CCCC CC TGAACCCCAAGGCCAACCGCGAGAAGATGACC CAGATCA TGllTGAGACClTCAACACCCCAGCCA TGTACGTT 
· 370 · 3ao ~390 ~ 4oo ~ 410 · 420 ~ 4 30 - qqo 
v l60 v l 50 v iQO v 130 v 120 v l 10 v lOO v90 
GC TAI CC AGGCTG l GCT ATCCCTG TACGCCTCl GGCCGTACC ACT GGCATCGTGATGGACTCCGGTGACGGGGTCACCCA 
GCTATCC AGGCTG TGCT AT CCC TGTACGCC TCTGG CCGTACC ACTGGC AT CG TGA TGGACTCCGG TGACGGGG TCACCCA 
GCTATCC AGGC TGTGCTATCCCTGTACGCC TCTGG CCG TACCACTGGC Af CG TGATGGACTCCGG lGACGGGGTCACCCA 
· qso ~ q6o · q7o ~ 4 80 ~ 490 · 5oo ~ s 1 o · s2o 
v80 v70 v60 v50 v40 v30 
CAC TGTGCCC AT CTACGAGGGGTATGCCC TC CCCC AlGC CATCClGCG TCTGGACClGGC TG 
CACTGTGCCCATClACGAGGGGTATGCCCTCCCCCATGCCAl CC TGCGTCTGGACC TGGCTG 
CACTGTGCCC AlCTACGAGGGGTA TGCCC TC CCCC Al CCC AT CCl GCG fCfGGA CC TGGCTG 
·530 · s qo ~ 550 · s Bo · 570 - ~~r 
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· Appendix 23: llr2 wild type sequencing results (Wilbur-Lipman DNA alignment) 
Seq2 Similarity Gap Gap Consensus 
Len th ---=2s~·~se~q~------~H~U~M~IL~2_B __________ ~Inde~x ___ N __ um __ b_er ______ Le_n~g~t_h __ _ 
1>921 2880>3099 100.0 0 0 
-=---- --
147 
v 160 v l70 v l80 v 190 v200 v2 10 v220 v230 
AGGCCACAGAA CTGAAACATC TTCAGTGTCTAGAAGAAGAAC TCAAACCl CTGGAGGAAG TGC TAAA TTTAGC TCAAAGC 
AGGCCACAGAACTGAAACAT CTTC AGTGTC TAGAAGAAGAACTCAAA CCTCTGGAGGAAGTGCTAAATTTAGC TCAAAGC 
AGGCCACAGAAC TGAAACAT CTTCAG TGTCTAGAAGAAGAACTCAAACC TCTGGAGGAAGTGCTAAATI TAGCTCAAAGC 
~ 2880 ~2890 ~2900 ~29 10 ~2920 ~2930 ~2940 ~2950 
v240 v250 v260 v270 v280 v290 v300 
AAAAAC TT TCACT TAAGACCCAGGGACT TA ATC AG CAATATCAACGTAATAGTTCTGGAACTAAAGG 
AAAAACTl lCACTTAAGACCCAGGGACTTAATCAGCAATATCAACGTAATAGTTC TCCAACTAAAGG 
AAAAACTlTCACTlAAGACCCAGGGACT TAATCAG CAA TA TCAACGTAA TAGTTCTGGAACTAAAGG 
~2960 -2970 ~ 2980 -2990 ~3000 ~3010 ~ 3020 
Seq2 Similarity Gap Gap Consensus 
.-=-__ 2a_s_._se~---------H~U~M~I~L=2=B __________ ~In~d~e~x--~Number ____ ~L~e~n~th~ ___ L_e~ 
1>947 2880>3099 100.0 0 0 147 
---- ----
v220 v210 v200 v l90 v 180 v 170 v160 v150 
AGGCCACAGAACTGAAACATCTTCAGTGTCTAGAAGAAGAACTCAAACCTCTGGAGGAAGTGCTAAATlTAGCTCAAAGC 
AGG CCACAGAACTGAAACAT CT TCAG TGTCTAGAAGAAGAACTCAAACCTCTGGAGGAAGTGCTAAATTTAGCTCAAAGC 
AGGCCACAGAACTG AAACAT CT TCAGTG TCTAGAAGAAGAACTCAAACCTCTGGAGGAAG TG CTAAAT TT AG CTCAAAG C 
~2880 ~ 2890 - ~2900 ~29 10 -2920 ~2930 ~ 2940 - 2950 
v l40 v130 v 120 vllO v iOO v90 
AAAAACTTTCACTTAAGACCCAGGGACTTAATCAGCAATATCAACGTAATAGT TCTGGAACTAAAGG 
AAAAACTTTCAC TTAAGACCCAGGGACTTAATCAGC AATATCAACGTAATAG1 TCTGGAAC TAAAGG 
AAAAACTTT CACTTAAGACCC AGGGAC TTAATCAGCAATATCAACGTAATAGTTC TGGAACTAAAGG 
~ 2960 ~2970 ~ 2980 ~2990 ~ 3000 ~ 30 1 0 ~3020 
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Appendix 24: IL-2 delta 2 (IL-202) sequencing results (\Vilbur-Lipman DNA alignment) 
'il2ex1-3 (2) ex.SEQ HUMIL2 Index Number Length Len th 
1>903 509>681 100.0 0 0 116 
v260 v250 v240 v230 v220 v2 10 v200 v190 
CACTAAGTCTTGCAClTGTCACAAACAGTGCACCT AC TlCAAGTTCTACAAAGAAAACACAG CTACAACTGGAGCATTTA 
CACTAAGTCTTGCACTTGTCACAAACAGTGCACCTACTTCAAGTTCTACAAAG~AAACACAGCTACAACTGGAGCATTTA 
CACTAAGTCTTGCACTTGTCACAAACAGTGCACCTACTTCAAGTTCTACAAAGAAAACACAGCTACAACTGGAGCATTTA 
~s 1o ~ 520 ~530 ~sqo ~550 Asso ~570 Asao 
v180 v 170 v160 
CTGCTGGATTTACAGATGATTTTGAATGGAATTAAT 
CTGCTGGATTTACAGATGAT TTT GAATGGAATTAAT 
CTGCTGGATTTACAGATGAl fTTGAATGGAATTAA T 
~590 A600 ~6 10 A620 
il2ex 1-3 (2) .SEQ HUMIL2 
1>938 2974>4033 
Index Number Length 
98.3 0 0 
Length 
115 
v 170 v 180 v 190 v200 v2 10 v220 v230 v2QO 
AGGCCACAGAAC l GAAACATCTTCAGTGTCTAGAANAAGAACTCAAACC TNTGG AGGAAGTGCTAAA TTTAGC TCAAAGC 
AGGCCACAGAACTGAAACATCTTCAGTGTCTAGAA AAGAACTCAAA CC T TGGAGGAAGTGCTAAAT TTAGC TCAAAGC 
AGGCCACAGAACTGAAACATCTTCAGTGTCTAGAAGAAGAACTCAAAC CTC TGGAGGAAGTG CTAAATT TAGCTCAAAGC 
~3070 A3080 A3090 ~3100 ~3 1 10 ~3 1 20 ~ 3130 A31QO 
v250 v260 v270 
AAAAACTTT CACTTAAGACCC AGGGACT TAATCAG 
AAAAACTTTCACTTAAGAC CCAGGGACTTAATCAG 
AAAAACTll CACl l AAGA CCC AGGGACTTAAT CAG 
~ 3150 A3 160 A3170 A3 180 
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Appendix 25: IL-4 wild type sequencing results (Wilbur-Lipman DNA alignment) 
Seq1 
test1.seq 
Seq2 
HUMIL4 
Similarity Gap Gap Consensus 
Index Number Len th Len th 
1>357 144>614 _________ 99_.7 ______ ~0 ________ ~0 ______ ~3~5~0 
v lO v20 v30 v40 v50 v60 v70 v80 
CGATATCACCTTACAGGAGATCATCAAAACTT TGAACAGCC TCACAG AG CAGAAGACTC TG TGCACCGAGlTGACCGTAA 
CGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGCCTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAA 
CGATATCACCT TACAGGAGATCATCAAAACTT TGAACAGCCTCACAGAGCAGAAGAC TCTGTGCACCGAGlTGACCGTAA 
ft 150 ft 160 ft 170 ft180 ft 190 ft 200 ft2 10 ~220 
v90 v lOO v l 10 vl20 v l aO v l~O v l 50 v l60 
CAGACATCTTTGCTGCCTCCAAGAACACAACTGAGAAGGAAACCTTClGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC 
CAGACATCTTTGCTGCCTCCAAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC 
CAGACATCTTTGCTGCCTCCAAGAACACAACTG AGAAGGAAA CC TTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC 
ft230 ~2~0 ~250 ~260 ft270 ft280 ~290 ft300 
vl70 vlBO v 190 v200 v2 10 v220 v230 v240 
AGCCACCATGAGAAGGACACTCGCTGC CTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGCTGATCCGAT TCCT 
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGCTGATCCGATTCCT 
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGCTGATCCGATTCCT 
ft3 10 ft320 ~330 ft 3~0 ft3 50 -360 -370 - 380 
v250 v260 v270 v280 v290 v300 v310 v320 
GAAACGGCTCGANAGGAACCTCTGGGGCCTGGCGGGCT TGAATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGG 
GAAACGGCTCGA AGGAACCTCTGGGGCCTGGCGGGCTTGAATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGG 
GAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGC TTGAATTCC TGT CCTGTGAAGGAAGCCAACCAGAGTACGTTGG 
·390 · qoo ft 410 ft 420 ~430 - ~~40 ft 450 ft ll60 
v330 v340 v350 
AAAACTTCTTGGAAAGGC TA AAGACGATCA 
AAAACfTCTTGGAAAGGCTAAAGACGATCA 
AAAACTTCTTGGAAAGGCTAAAGACGATCA 
ft 470 ft 480 ft 490 
i14as.se 
Seq2 
HUMIL4 
Similarity 
Index 
Gap 
Number 
Gap 
Len th 
Consensus 
Len th 
- -- ---'----
1>315 118>575 99.7 0 0 306 
v3 10 v300 v290 v280 v270 v260 v250 v240 
GGCAACTTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAG CCTCACAGAGCAGAA 
GGCAACTTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGCC TCACAGAGCAGAA 
GGCAACTTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGCCTCACAGAGCAGAA 
- 1?.0 ft 130 ft 1QO · 150 ~ 160 ~ 1 70 ~ 180 ~ 190 
v230 v220 v2 10 v200 v 190 v180 v170 v l60 
GACTCTGTGCACCGAGTTGACCGTAACAGACATC TTTGCTGCCTCCAAGAACACAACTGAGAAGGAAA CTT CTGCAGGG 
GACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTCCAAGAACACAACTGAGAAGGAAACC TTCTGCAGGG 
GACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCC TCCAAGAACACAACTGAGAAGGAAACCTlCTGCAGGG 
-200 "2 10 ~220 ft230 - 240 ft250 ft 260 ft 270 
v l50 v lLIO v 130 v120 vl 10 v100 ~90 vBO 
CTGCGACTGTGC l CCGGCAG TTCTACAGCCACCATGAGAAGGACAClCGCTGCCTGGGTGCGACTGCACAG CAGTTCCAC 
CTGCGACTGTGCTCCGGCAGTTCTACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCC AC 
CTGCGACTGTGCTCCGGCAGTTCTACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCAC 
~ 280 ft 290 ·300 ~3 1 0 ft 320 ~330 · 3qo ft350 
v70 v60 v50 vLIO v30 v20 vlO 
AGGCACAAGCAGCTGAT CCG ATTCCTGAAACGGCTCGANAGGAACCTCTGGGG CC TGG GG GC TTG 
AGGCACAAGCAGCTGAl CCG AT TCCTGAAACGGCT CGA AGGAAC Cl CTGGGGCC TGGCGG GC TTG 
AGGCACAAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTClGGGGCCTGGCGGGCTTG 
"360 "370 ~ 380 ~390 ft tJQO "Li lO ft 420 
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Appendix 26: IL-4 delta 4 (IL-4 ~2) sequencing results (Wilbur-Lipman DNA alignment) 
_ex1#1 .seq HSIL4SV Index Number Length Length 
0 0 91 
------------------~-
91 75>210 100.0 
v lO v20 v30 vqQ v50 v60 v70 v80 
AGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGCCTCACAGAGCAGAAGAACACAACTGAGAAGGAAA 
AGTGCGA TATCACCTTACAGGAGATCAT CAAAAC TTTGAACAGCCTCACAGAGCAGAAGAACACAACTGAGAAGGAAA 
AGTGCGAT ATCACCTTACAGGAGATCATCAAAACTTTGAACAGCCTCACAGAGCAGAAGAACACAACTGAGAAGGAAA 
Rso Rgo Rtoo R11 0 R120 R130 R1qo · tso 
v90 
TTCTGCAGG 
TTCTGCAGG 
if TCTGCAGG 
R 160 
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Appendix 27: IL-~ sequencing results (Wilbur-Lipman alignment) 
.. j l5s.seq HUMIL5 Index Number Len th Len th 
1>101 7 1883>2075 100.0 0 0 129 
v80 v90 v l OO v110 v 120 v130 v1q0 v150 
CACCAACTGl GC ACTGAAGAAATC TTTCAGGGAATAGGCACACTGGAGAGTCAAACTGTGCAAGGGGGTACTGTGGAAAG 
CACC AA CTGlGCAC TGAAGAAATC TTTCAGGGAATAGG CACACTGGAGAGTCAAACTGTGCAAGGGGGTACTGTGGAAAG 
CACCAACTGlG CACTGAAGAAATCTTTCAGGGAATAGGCACACTGGAGAGTCAAACTGTGCAAGGGGGTACTGTGGAAAG 
~ 1 890 ~ 1 900 A19 10 A1920 
0
4 1930 " 19£t0 " 1950 A1960 
v l60 v l 70 v l80 v190 v200 
ACTATTCAAAAACTTGT CC TTAATAAAGAAATACATTGACGGCCAAAAA 
ACTATTCAAAAACTTGTCC TTAATAAAGAAATACATTGACGGCCAAAAA 
ACTATTCAAAAACTTGTCCTTAATAAAGAAATACATTGACGGCCAAAAA 
~ 1 970 ~ 1 980 " 1990 A2000 "2010 
il5as.seq HUMIL5 Index Number 
1>1001 1885>2074 86.5 0 
Length Length 
0 _ ___ 1=2~6 
v 150 v l qO =.. v 130 v120 v110 v iOO v90 v80 
CC AACTGNGCNCTGAANAAATCTTTCAGGGAATAGGC NCNCTGGANCCCCCAACTGNGCAANGGGGNACTGTGGAAANAC 
CCAACTG GC CTGAA AAATCTTTCAGGGAATAGGC C CTGGA C AACTG GCAA GGGG ACTGTGGAAA AC 
CCAACTGTGCACTGAAGAAATCTT TCAGGGAATAGGCACACTGGAGAGTCAAACTGTGCAAGGGGGTACTGTGGAAAGAC 
~ 1 890 Al900 ~ 1 910 A1920 Al930 " 19qo " 1950 Al960 
v70 v60 v50 vqo 
TATTCAAAAACTl GICC TTAATAAANAAANACAT TGGCGGCCAAAA 
TATTCAAAAAC TTG TCC TTAATAAA AAA ACAT TG CGGCCAAAA 
TATTCAAAAAClTGTCC TTAATAAAGAAATACAT TGACGGCCAAAA 
A1970 " 1980 " 1990 "2000 " 2010 
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Appendix 28: IL-7 sequencing results (Wilbur-Lipman alignment) 
il72a.s HUMIL7A 
279>1203 
Index Number Len th 
1 
Length 
617 1>941 99.4 1 
----
v6 10 v600 v590 v580 v570 v560 v550 v540 
TCGGCAACTCCGCGNAAAGACCAGGGTCCTGGGAGTGACTATGGNCGGlGAGAGCTTGCTCCTGCTCCAGliGCGGTCAT 
TCGGCAACTCCGCG AAGACCAGGG TCCTGGGAGTGACTATGG CGGTGAGAGCTTGCTCCTGCTCCAGTTGCGGT CAT 
TCGGCAACTCCGCGG-AAGA CCACGGTCCTGGGAGTGACTATGGGCGGTGAGAG CTTGCTCC TGCTCCAGTTGCGGT CAT 
~ 280 ~290 ~300 ~3 1 0 ~320 ~330 ~340 ~350 
v530 v520 v510 v500 v490 v480 vLI70 vll60 
CATGACTACGCCCGCCTCCCGCAGACCATGTTCCATGTTTCTTTTAGGTATATCTTTGGACTT CC TCCCCTGAT CCTTG T 
CATGAC TACGCCCGCCTCCCGCAGACCATGTT CCATGTTTCTTTTAGG TATATCTTTGGACTTCCTCCCCTGATCCTTG T 
CA TGACTACGCCCGCCTCCCGCAGACCATGf TCCATGTTTCTTT TAGG TATATCTTTGGACTTCCTCCCCTCATCCTTG T 
~360 ~ 370 ~ 3ao ~ 390 ~ qoo ~Li l O ~ LI20 - q3o 
v4 50 v440 vll30 v420 v4 10 vl!OO v390 v380 
TCTGTTGCCAGTAGCATCATCTGATTGTGATATTGAAGGTAAAGATGGCAAACAA TATGAGAGTGlTCTAA TGGl CAGC A 
TCTGTTGCCAGTAGCATCATCTGATTGTGATATTGAAGGTAAAGATGGCAAACAAl ATGAGAGTGTTCTAATGGTCAGCA 
TCTGTTGCCAGTAGCATCATCTGATTGTGATATTGAAGGTAAAGATGGCAAACAATATGAGAGTGTTCTAATGGT CAGCA 
~ 440 ~ 450 ~ 460 ~ 470 ~ 480 ~qgo ~ 500 -s lo 
v370 v360 v350 v3LIO v330 v320 v3 10 v300 
TCGATCAATTAT TGGACAGCAfGAAAGAAAT TGGTAGCAATTGCCTGAATAATGAATTTAACTTlllTAAAAGACATA TC 
TCGATCAATTATTGGACAGCATGAAAGAAATTGGTAGCAATTGCCTGAATAATGAATTTAACTTTTlfAAAAGACATAT C 
TCGATCAATTATTGGACAGCATGAAAGAAATTGGTAGCAATTGCCTGAATAATGAATTTAACTTTTTlAAAAGACATATC 
~ 520 ~ 530 ~ 540 ~550 ~ 560 ~570 ~580 ~ 590 
v290 v280 v270 v260 v250 v2LIO v230 v220 
TGTGATGCTAA TAAGGAAGGTATGTTTTTATTCCGlGCTGCTCGCAAGTlGAGGCAATTTCTTAAAATGAATAGCACTGG 
TGTGATG CTAATAAGGAAGGTATGTTTTTATTCCGTGCTGCTCGCAAGTTGAGGCAATTTCTTAAAATGAATAGCACT GG 
TGTGATGCTAA TAAGGAAGG TATGTTT f TATT CCGTGCTGCTCGCAAGTlGAGGCAATTTCTTAAAATGAAT AGCAC l GG 
~ 600 ~6 1 0 ~620 ~ 630 ~ 640 ~ 650 ~ 660 ~670 
v2 10 v200 v 190 v 180 v l70 v 160 v 150 vll!O 
TGATTTTGATCTCCACTTATTAAAAGTTTCAGAAGGCACAACAATACTGTTGAACTGCACTGGCCAGGTTAAAGGAAGAA 
TGATTTTGATCTCCACTTAT TAAAAGTTTCAGAAGGCACAACAATACTGTTGAAC TGCACTGGCCAGGTTAAAGGAAGAA 
TGATTTTGATCTCCACTTATTAAAAGTTTCAGAAGGCACAACAATACTG TTGAACTGCACTG GC CAGGTTAAAGGAAGAA 
~ 680 ~690 ~ 700 ~ 7 1 0 ~ 720 ~ 730 ~ 740 ~ 750 
vl30 v 120 v l lO vlOO v90 v80 v70 v60 
AACCAGCTGCCCTGGGTGAAGCCCAACCAACAAAGAGTTTGGAAGAAAATAAATCTTTAAAGGAACAGAAAAAACTGAA T 
AACCAGCTG CCCTGCGTGAAGCCCAACCAACAAAGAGTTTGGAAGAAAA TAAATCTTTAAAGGAACAGAAAAAACT GAAT 
AACCAGCTGC CCTGGGTGAAGCCCAA CCAACAAAGAGTTTGGAAGAAAAlAAATCTTTAAAGGAACAGAAAAAACTGAAT 
~76o ~ 770 ~ 780 ~ 790 ~8oo ~ 8 1 0 ~820 ~830 
v50 v40 v30 v20 v lO 
GACTTGlGTTTCCTAAAGAGACTATTACAAGAGATAAAAACTTGTTGGAATAAAATT 
GACTTGTGTTT CCTAAAGAGACT ATTACAAGAGATAAAAACTTGT l GGAATAAAATT 
GACTTGTGTTT CC TAAAGAGACTATTACAAGAGATAAAAACTTGTTGGAA TAAAAT T 
~ aqo ~850 ~ 860 ~870 A880 ~ ago 
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Appendix 29: IL-13 sequencing results (Wilbur-Lipman alignment) 
13s.se HUMIL 138 .~~---------------- Index Number Len th Len th 
1>929 2265>2422 100.0 _ 0 ____ 0 _ _ -- 8_1 
-----
v l OO v 110 v 120 vl30 vlQO v 150 v160 v170 
ATCAACGTGTCAGGCTGCAG TGCCATCGAGAAGACCCAGAGGATG~TGAGCGGATTCTGCCCGCACAAGGTCTCAGCTGG 
ATCAACGTGTCAGGCTGCAGTGCCATCGAGAAGACCCAGAGGATGCTGAGCGGATTClGCCCGCACAAGGTCT CAG CTGG 
ATCAACGTGTCAGGCTGCAGTGCCATCGAGAAGACCCAGAGGATGCTGAGCGGATTC1GCCCGCACAAGGTCTCAGCTGG 
~2290 A2300 A23 10 A2320 A2330 A23LIO A2350 A2360 
G 
c 
c 
A2370 
il13a.se 
1>218 
HUMIL138 Index Number Len th Len th 
2265>2422 100.0 -=0 ___ _ ..=_0 __ _ 8_!_ 
vlOO v90 v80 v70 v60 v50 vqo v30 
ATCAACGTGTCAGGCTGCAGTGCCATCGAGAAGACCCAGAGGATGCTGAGCGGATTCTGCCCGCACAAGGTCT CAGCTGG 
ATCAACGTGTCAGGCTGCAGTGCCAT CG AGAAGA CCCAGAGGATGCTGAGCGGATTCTGCCCCCACAACGTCTCAGCTGG 
ATCAACGTG TC AGGCTGCAGTGCCATCGAGAAGACCCAGAGGATGCTGAGCGGATT Cl CCCCGCAC AAGGTCT CAG CTCG 
A2290 A2300 A23 10 A2320 A2330 •23qo A2350 -2360 
G -
c 
G 
~2370 
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Appendix 30: IL-15 sequencing results (Wilbur-Lipman alignment) 
il15s.seq HSIL15MR2 Index Number Len th --~~~~~~~------
1>970 251>643 100.0 0 0 
vlOO v110 v 120 v 130 v 1QO v150 v 160 v170 
Length 
393 
GCTGT TTCAGTGCAGGGCTTCCTAAAACAGAAGCCAACTGGGTGAATGTAATAAGTGATTTGAAAAAAATTGAAGA TCTT 
GCTGTTTCAGTGCAGGGCTTCCTAAAACAGAAGCCAACTGGGTGAATGTAATAAGTGATT l GAAAAAAATlGAAGATCTT 
GCTGTTTCAGTGCAGGGCTTCCTAAAACAGAAGCCAACTGGGTGAATGTAATAAGTGATlTGAAAAAAATTGAAGATCTT 
~260 ~270 ~280 ~290 ~300 ~3 10 ~ 320 ~330 
v 180 v 190 v200 v2 10 v220 v230 v2QO v250 
ATTCAAl ClAlGCATATTGATGC l ACl fTATATACGGAAAGTGATG1TCACCCCAGT TGCAAAGTAACAGCAATGAAGTG 
ATTCAATCTATGCATATTGATGCTACTTTATATACGGAAAG TGATGTTCACCCCAGT TGCAAAGlAA CAGCAAfGAAGTG 
ATT CAATCTATGCATA TTGATGCTACTTTATATACGGAAAG TGATGTTCACCCCAGTTGCAAAGTAACAGCAAlGAAGTG 
~3 QO ~350 ~360 ~370 ~380 ~390 ~400 ~ Q 1 0 
v260 v270 v280 v290 v300 v310 v320 v330 
CTTTCTCTTGGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAG TATTCATGATACAGTAGAAAATCTGATCATCC 
CTTTCTCTlGGAGTTACAAGTTAl Tl CACTTGACTCCGGAGATGCAAGTA TTCATGATACAG TAGAAAATCTGAT CATC C 
CTTTCTCTTGGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAGTATTCATGATACAGTAGAAAATCTGATCATCC 
~ 420 ~ q3o ~440 ~450 ~ 460 ·q7o ~ 4ao ~q9o 
v3QO v350 v360 v370 v380 v390 v400 vQ10 
TAGCAAACAACAGTTTGTCTTCTAATGGGAATGTAACAGAATCTGGAlGCAAAGAATGTGAGGAACTGG AGGAAAAAAAT 
TAGCAAACAACAGTTTGT CT TCTAATGGGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAAClGGAGGAAAAAAAT 
TAGCAAACAACAG TTTGTCTTCTAATGGGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAA CTGGAGGAAAAAAAl 
~5oo ~5 1 0 ·520 ·530 ·5qo ~550 · s6o ~570 
vQ20 vQ30 v440 v450 vQ60 vQ70 v480 v490 
ATTAAAGAAi TTTTGCAGAGTTTTGTACATATTGTCCAAATGT TCATCAACACTTCTTGATTGCAATTGATTC 
AT TAAAGAATTTTTGCAGAGTTTTGTACATATTGTCCAAATGTTCATCAACACTTCTTGATTGCAATTGATTC 
ATTAAAGAAlTTTTGCAGAGTTT TGTAC ATATTGTCCAAATGTTCATCAACACTTCTTGAT TGCAATTGATT C 
·sao ~590 ·5oo ~6 1 0 ~620 ~ e3o ~6qo 
·jJ15a.se HSIL15MR2 Index Number Length 
1>974 251>643 100.0 0 0 
vq20 v4 10 vliOO v390 v380 v370 v360 v350 
Len th 
393 
GCTGTTlCAGTGCAGGG CT TCCTAAAACAGAAGCCAACTGGGTGAAlGlAATAAGTGATTTGAAAAAAA TTGAAGAT CTI 
GCTGTTTCAGTGCAGGGCTTCCTAAAACAGAAGCCAACTGGGTGAATGTAATAAGTGATTTGAAAAAAATTGAAGATCTT 
GCTGTTTCAGTGCAGGGCTTCCTAAAACAGAAGCCAACTGGGTGAATGTAATAAGTGATTTGAAAAAAATTGAAGATCTT 
~260 ~270 ~280 ~290 ~300 ~ 3 1 0 ~320 ~330 
v3qo v330 v320 v3 10 v300 v290 v280 · v270 
ATTCAAT CTATG CATATTGATGCTACTTTATATACGGAAAGTGATG TTC ACCCCAGlTGCAAAGTAACAGCAATGAA GTG 
AlTCAATClATGCATATTGATGCTACTT TATATACGGAAAGTGATGTTCACCCCAGTTG CAAAGTAACAGCAATGAAG TG 
ATTCAAl CTATGCATATTGATGCTACTTTATATACGGAAAGTGA TGTT CACCC CAGTTGCAAAGTAACAGCAATGAAG TG 
~ Jqo ~ 350 ~ 360 · 370 ·3ao ~390 ~ qoo ~ 41 0 
v260 v250 v2q0 v230 v220 v210 v200 v l90 
CTTTCTCTTGGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAGTATTCATGATACAGTAGAAAATCTGAlCATCC 
CllTClCTTGGAGTTACAAGT TAT l TCACTTGAGTCCGGAGATGCAAGTATTCATGATACAGTAGAAAATCTGATCATCC 
CTTTCTCTTGGAGTTACAAGTTATTTCACT TGAGTCCGGAGATGCAAGTATTCATGATACAGTAGAAAATCTGATCATCC 
~ q2o ~ qJo ~ qqo ~ qso ~ 460 ~ q7o · qao ~ 490 
v 180 v l70 v160 v 150 v1 QO v130 v120 v 11 0 
lAG CAAAC AACAGTlTGTCTT CTAATGGGAATGTAACAGAAT ClGGATGC AAAGAAT GTG AGGAACTGGAGGAAAAAAAl 
TAGCAAACAACAGTTT GTCTTCTAATGGGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAACTGGAGGAAAAAAA T 
TAGC AAACAACAGilT GTCTTCTAATGGGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAAClGGAGGAAAAAAAl 
~ 5oo ~ 5 1 0 ~ 520 ·530 ~ 5qo ·s5o ~560 ~ 570 
v lOO v90 v80 v70 v60 v50 vl!O v30 
ATTAAAGAAITTTTGCAGAGllllGlACATATTGTCCAAATGTTCAlCAACACTTCTTGATTGCAATlGATl C 
ATTAAAGAAlTl TTGCAGAGTTTTGTACATATTGTCCAAATGlT CAl CAACAClTC I TGATTGCAATTGAf l C 
ATTAAAGAA TTTlTGCAG AG l TTTGTACATATTGTCC AAATGT l CATCAACACTT CTlGATTGCAATTGAlT C 
· 5ao · s9o ~ 6oo ~6 1 0 ~ 620 ·e3o ~ 6qo 
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